VIOLIN Logo
VIOLIN Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

VIOLIN Curated References

Actinobacillus pleuropneumoniae

  1. Byrd et al., 1992: Byrd W, Harmon BG, Kadis S. Protective efficacy of conjugate vaccines against experimental challenge with porcine Actinobacillus pleuropneumoniae. Veterinary immunology and immunopathology. 1992; 34(3-4); 307-324. [PubMed: 1455686].
  2. Chen et al., 2012: Chen X, Xu Z, Li L, Chen H, Zhou R. Identification of conserved surface proteins as novel antigenic vaccine candidates of Actinobacillus pleuropneumoniae. Journal of microbiology (Seoul, Korea). 2012; 50(6); 978-986. [PubMed: 23274984].
  3. Chiang et al., 2009: Chiang CH, Huang WF, Huang LP, Lin SF, Yang WJ. Immunogenicity and protective efficacy of ApxIA and ApxIIA DNA vaccine against Actinobacillus pleuropneumoniae lethal challenge in murine model. Vaccine. 2009; 27(34); 4565-4570. [PubMed: 19520199].
  4. Chiers et al., 1998: Chiers K, van Overbeke I, De Laender P, Ducatelle R, Carel S, Haesebrouck F. Effects of endobronchial challenge with Actinobacillus pleuropneumoniae serotype 9 of pigs vaccinated with inactivated vaccines containing the Apx toxins. The Veterinary quarterly. 1998; 20(2); 65-69. [PubMed: 9563163].
  5. Chung et al., 2012: Chung JW, Küster-Schöck E, Gibbs BF, Jacques M, Coulton JW. Immunoproteomic analyses of outer membrane antigens of Actinobacillus pleuropneumoniae grown under iron-restricted conditions. Veterinary microbiology. 2012; 159(1-2); 187-194. [PubMed: 22541161].
  6. Haesebrouck et al., 2004: Haesebrouck F, Pasmans F, Chiers K, Maes D, Ducatelle R, Decostere A. Efficacy of vaccines against bacterial diseases in swine: what can we expect?. Veterinary microbiology. 2004; 100(3-4); 255-268. [PubMed: 15145504].
  7. Hu et al., 2015: Hu X, Yan H, Liu K, Hu J, Qi C, Yang J, Liu Y, Zhao J, Liu J. Identification and characterization of a novel stress-responsive outer membrane protein Lip40 from Actinobacillus pleuropneumoniae. BMC biotechnology. 2015; 15; 106. [PubMed: 26608465].
  8. Hur and Lee, 2014: Hur J, Lee JH. Optimization of immune strategy for a construct of Salmonella-delivered ApxIA, ApxIIA, ApxIIIA and OmpA antigens of Actinobacillus pleuropneumoniae for prevention of porcine pleuropneumonia using a murine model. Veterinary research communications. 2014; 38(1); 87-91. [PubMed: 24307459].
  9. Hur et al., 2016: Hur J, Eo SK, Park SY, Choi Y, Lee JH. Immunological study of an attenuated Salmonella Typhimurium expressing ApxIA, ApxIIA, ApxIIIA and OmpA of Actinobacillus pleuropneumoniae in a mouse model. The Journal of veterinary medical science. 2016; 77(12); 1693-1696. [PubMed: 26227587].
  10. Ingham et al., 2002: Ingham A, Zhang Y, Prideaux C. Attenuation of Actinobacillus pleuropneumoniae by inactivation of aroQ. Veterinary microbiology. 2002; 84(3); 263-273. [PubMed: 11731178].
  11. Kim et al., 2010: Kim JM, Jung DI, Eom YJ, Park SM, Yoo HS, Jang YS, Yang MS, Kim DH. Surface-displayed expression of a neutralizing epitope of ApxIIA exotoxin in Saccharomyces cerevisiae and oral administration of it for protective immune responses against challenge by Actinobacillus pleuropneumoniae. Bioscience, biotechnology, and biochemistry. 2010; 74(7); 1362-1367. [PubMed: 20622458].
  12. Lee et al., 2006: Lee KY, Kim DH, Kang TJ, Kim J, Chung GH, Yoo HS, Arntzen CJ, Yang MS, Jang YS. Induction of protective immune responses against the challenge of Actinobacillus pleuropneumoniae by the oral administration of transgenic tobacco plant expressing ApxIIA toxin from the bacteria. FEMS immunology and medical microbiology. 2006; 48(3); 381-389. [PubMed: 17054716].
  13. Li et al., 2008: Li L, Zhou R, Li T, Kang M, Wan Y, Xu Z, Chen H. Enhanced biofilm formation and reduced virulence of Actinobacillus pleuropneumoniae luxS mutant. Microbial pathogenesis. 2008; 45(3); 192-200. [PubMed: 18585450].
  14. Liu et al., 2007: Liu J, Chen X, Lin L, Tan C, Chen Y, Guo Y, Jin M, Guo A, Bei W, Chen H. Potential use an Actinobacillus pleuropneumoniae double mutant strain DeltaapxIICDeltaapxIVA as live vaccine that allows serological differentiation between vaccinated and infected animals. Vaccine. 2007; 25(44); 7696-7705. [PubMed: 17767980].
  15. Liu et al., 2011: Liu J, Chen Y, Yuan F, Hu L, Bei W, Chen H. Cloning, expression, and characterization of TonB2 from Actinobacillus pleuropneumoniae and potential use as an antigenic vaccine candidate and diagnostic marker. Canadian journal of veterinary research = Revue canadienne de recherche veterinaire. 2011; 75(3); 183-190. [PubMed: 22210994].
  16. Park et al., 2009: Park C, Ha Y, Kim S, Chae C, Ryu DY. Construction and characterization of an Actinobacillus pleuropneumoniae serotype 2 mutant lacking the Apx toxin secretion protein genes apxIIIB and apxIIID. The Journal of veterinary medical science / the Japanese Society of Veterinary Science. 2009; 71(10); 1317-1323. [PubMed: 19887737].
  17. Prideaux et al., 1998: Prideaux CT, Pierce L, Krywult J, Hodgson AL. Protection of mice against challenge with homologous and heterologous serovars of Actinobacillus pleuropneumoniae after live vaccination. Current microbiology. 1998; 37(5); 324-332. [PubMed: 9767712].
  18. Prideaux et al., 1999: Prideaux CT, Lenghaus C, Krywult J, Hodgson AL. Vaccination and protection of pigs against pleuropneumonia with a vaccine strain of Actinobacillus pleuropneumoniae produced by site-specific mutagenesis of the ApxII operon. Infection and immunity. 1999; 67(4); 1962-1966. [PubMed: 10085043].
  19. Shakarji et al., 2006: Shakarji L, Mikael LG, Srikumar R, Kobisch M, Coulton JW, Jacques M. Fhua and HgbA, outer membrane proteins of Actinobacillus pleuropneumoniae: their role as virulence determinants. Canadian journal of microbiology. 2006; 52(4); 391-396. [PubMed: 16699590].
  20. Shin et al., 2007: Shin SJ, Shin SW, Kang ML, Lee DY, Yang MS, Jang YS, Yoo HS. Enhancement of protective immune responses by oral vaccination with Saccharomyces cerevisiae expressing recombinant Actinobacillus pleuropneumoniae ApxIA or ApxIIA in mice. Journal of veterinary science. 2007; 8(4); 383-392. [PubMed: 17993753].
  21. Shin et al., 2013: Shin MK, Kang ML, Jung MH, Cha SB, Lee WJ, Kim JM, Kim DH, Yoo HS. Induction of protective immune responses against challenge of Actinobacillus pleuropneumoniae by oral administration with Saccharomyces cerevisiae expressing Apx toxins in pigs. Veterinary immunology and immunopathology. 2013; 151(1-2); 132-139. [PubMed: 23206402].
  22. ThePigSite Pig Health: Actinobacillus Pleuropneumonia (App) [http://www.thepigsite.com/pighealth/article/309/actinobacillus-pleuropneumonia-app]
  23. Tonpitak et al., 2002: Tonpitak W, Baltes N, Hennig-Pauka I, Gerlach GF. Construction of an Actinobacillus pleuropneumoniae serotype 2 prototype live negative-marker vaccine. Infection and immunity. 2002; 70(12); 7120-7125. [PubMed: 12438394].
  24. van and Frey, 2003: van den Bosch H, Frey J. Interference of outer membrane protein PalA with protective immunity against Actinobacillus pleuropneumoniae infections in vaccinated pigs. Vaccine. 2003; 21(25-26); 3601-3607. [PubMed: 12922088].
  25. Van et al., 2001: Van Overbeke I, Chiers K, Ducatelle R, Haesebrouck F. Effect of endobronchial challenge with Actinobacillus pleuropneumoniae serotype 9 of pigs vaccinated with a vaccine containing Apx toxins and transferrin-binding proteins. Journal of veterinary medicine. B, Infectious diseases and veterinary public health. 2001; 48(1); 15-20. [PubMed: 11254095].
  26. Xu et al., 2006: Xu F, Chen X, Shi A, Yang B, Wang J, Li Y, Guo X, Blackall PJ, Yang H. Characterization and immunogenicity of an apxIA mutant of Actinobacillus pleuropneumoniae. Veterinary microbiology. 2006; 118(3-4); 230-239. [PubMed: 16930871].
  27. Xu et al., 2007: Xu FZ, Shi AH, Chen XL, Yang B, Wang JL. [Construction and immunogenicity of an attenuated mutant of Actinobacillus pleuropneumoniae by insertional inactivation of apxIC]. Wei sheng wu xue bao = Acta microbiologica Sinica. 2007; 47(5); 923-927. [PubMed: 18062275].
  28. Zhang et al., 2016: Zhang F, Cao S, Zhu Z, Yang Y, Wen X, Chang YF, Huang X, Wu R, Wen Y, Yan Q, Huang Y, Ma X, Zhao Q. Immunoprotective Efficacy of Six <i>In vivo</i>-Induced Antigens against <i>Actinobacillus pleuropneumoniae</i> as Potential Vaccine Candidates in Murine Model. Frontiers in microbiology. 2016; 7; 1623. [PubMed: 27818646].
  29. Zhou et al., 2013: Zhou Y, Li L, Chen Z, Yuan H, Chen H, Zhou R. Adhesion protein ApfA of Actinobacillus pleuropneumoniae is required for pathogenesis and is a potential target for vaccine development. Clinical and vaccine immunology : CVI. 2013; 20(2); 287-294. [PubMed: 23269417].

Adenovirus

  1. Baden et al., 2014: Baden LR, Walsh SR, Seaman MS, Johnson JA, Tucker RP, Kleinjan JA, Gothing JA, Engelson BA, Carey BR, Oza A, Bajimaya S, Peter L, Bleckwehl C, Abbink P, Pau MG, Weijtens M, Kunchai M, Swann EM, Wolff M, Dolin R, Barouch DH. First-in-Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing HIV-1 Env (IPCAVD 002). The Journal of infectious diseases. 2014; ; . [PubMed: 24719474].
  2. FDA: Adenovirus Vaccine: FDA: Adenovirus Vaccine [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm247508.htm]
  3. Guo et al., 2021: Guo J, Zhang Y, Zhang Y, Zhang C, Zhu C, Xing M, Wang X, Zhou D. A bivalent live-attenuated vaccine candidate elicits protective immunity against human adenovirus types 4 and 7. Emerging microbes & infections. 2021; 10(1); 1947-1959. [PubMed: 34520320].
  4. Harrison, 2010: Harrison SC. Virology. Looking inside adenovirus. Science (New York, N.Y.). 2010; 329(5995); 1026-1027. [PubMed: 20798308].
  5. Kim et al., 2014: Kim E, Okada K, Beeler JA, Crim RL, Piedra PA, Gilbert BE, Gambotto A. Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model. Journal of virology. 2014; 88(9); 5100-5108. [PubMed: 24574396].
  6. Liu et al., 2018: Liu T, Zhou Z, Tian X, Liu W, Xu D, Fan Y, Liao J, Gu S, Li X, Zhou R. A recombinant trivalent vaccine candidate against human adenovirus types 3, 7, and 55. Vaccine. 2018; 36(16); 2199-2206. [PubMed: 29548605].
  7. Tompkins et al., 2007: Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerging infectious diseases. 2007; 13(3); 426-435. [PubMed: 17552096].

Aeromonas hydrophila

  1. Hernanz et al., 1998: Hernanz Moral C, Flaño del Castillo E, López Fierro P, Villena Cortés A, Anguita Castillo J, Cascón Soriano A, Sánchez Salazar M, Razquín Peralta B, Naharro Carrasco G. Molecular characterization of the Aeromonas hydrophila aroA gene and potential use of an auxotrophic aroA mutant as a live attenuated vaccine. Infection and immunity. 1998; 66(5); 1813-1821. [PubMed: 9573055].
  2. Liu et al., 2015: Liu L, Gong YX, Zhu B, Liu GL, Wang GX, Ling F. Effect of a new recombinant Aeromonas hydrophila vaccine on the grass carp intestinal microbiota and correlations with immunological responses. Fish & shellfish immunology. 2015; ; . [PubMed: 25862971].
  3. Mu et al., 2011: Mu W, Guan L, Yan Y, Liu Q, Zhang Y. A novel in vivo inducible expression system in Edwardsiella tarda for potential application in bacterial polyvalence vaccine. Fish & shellfish immunology. 2011; 31(6); 1097-1105. [PubMed: 21964456].
  4. Wiki: Aeromonas Hydrophila: Aeromonas Hydrophila [http://microbewiki.kenyon.edu/index.php/Aeromonas_Hydrophila]

Aeromonas salmonicida

  1. Bergh et al., 2013: Bergh PV, Burr SE, Benedicenti O, von Siebenthal B, Frey J, Wahli T. Antigens of the type-three secretion system of Aeromonas salmonicida subsp. salmonicida prevent protective immunity in rainbow trout. Vaccine. 2013; 31(45); 5256-5261. [PubMed: 24012573].
  2. Gudmundsdottir et al., 1997: BJARNHEIDUR K. GUDMUNDSDÓTTIR, BERGLJÓT MAGNADÓTTIR. Protection of Atlantic salmon (Salmo salarL.) against an experimental infection ofAeromonas salmonicidassp.achromogenes. Fish & shellfish immunology. 1997; 7(1); 55-69.
  3. Lund et al., 2003: Lund V, Espelid S, Mikkelsen H. Vaccine efficacy in spotted wolffish Anarhichas minor: relationship to molecular variation in A-layer protein of atypical Aeromonas salmonicida. Diseases of aquatic organisms. 2003; 56(1); 31-42. [PubMed: 14524499].
  4. Sundvold et al., 2010: Sundvold H, Ruyter B, Ostbye TK, Moen T. Identification of a novel allele of peroxisome proliferator-activated receptor gamma (PPARG) and its association with resistance to Aeromonas salmonicida in Atlantic salmon (Salmo salar). Fish & shellfish immunology. 2010; 28(2); 394-400. [PubMed: 20004720].
  5. USGS Fish Disease Leaflets: Furunculosis and Other Diseases Caused by Aeromonas Salmonicida [http://www.lsc.usgs.gov/fhb/leaflets/FHB66.pdf]
  6. Vaughan et al., 1993: Vaughan LM, Smith PR, Foster TJ. An aromatic-dependent mutant of the fish pathogen Aeromonas salmonicida is attenuated in fish and is effective as a live vaccine against the salmonid disease furunculosis. Infection and immunity. 1993; 61(5); 2172-2181. [PubMed: 8478107].
  7. Wiki: Aeromonas salmonicida: Aeromonas salmonicida [http://en.wikipedia.org/wiki/Aeromonas_salmonicida]

African horse sickness virus

  1. Castillo-Olivares et al., 2011: Castillo-Olivares J, Calvo-Pinilla E, Casanova I, Bachanek-Bankowska K, Chiam R, Maan S, Nieto JM, Ortego J, Mertens PP. A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model. PloS one. 2011; 6(1); e16503. [PubMed: 21298069].
  2. de et al., 2015: de la Poza F, Marín-López A, Castillo-Olivares J, Calvo-Pinilla E, Ortego J. Identification of CD8 T cell epitopes in VP2 and NS1 proteins of African horse sickness virus in IFNAR(-/-) mice. Virus research. 2015; 210; 149-153. [PubMed: 26272673].
  3. Guthrie et al., 2009: Guthrie AJ, Quan M, Lourens CW, Audonnet JC, Minke JM, Yao J, He L, Nordgren R, Gardner IA, Maclachlan NJ. Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus. Vaccine. 2009; 27(33); 4434-4438. [PubMed: 19490959].
  4. Manning et al., 2017: Manning NM, Bachanek-Bankowska K, Mertens PPC, Castillo-Olivares J. Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination. Vaccine. 2017; 35(44); 6024-6029. [PubMed: 28438410].
  5. O'Kennedy et al., 2022: O'Kennedy MM, Coetzee P, Koekemoer O, du Plessis L, Lourens CW, Kwezi L, du Preez I, Mamputha S, Mokoena NB, Rutkowska DA, Verschoor JA, Lemmer Y. Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR(-/-) mice. Vaccine. 2022; 40(35); 5160-5169. [PubMed: 35902279].
  6. Rutkowska et al., 2011: Rutkowska DA, Meyer QC, Maree F, Vosloo W, Fick W, Huismans H. The use of soluble African horse sickness viral protein 7 as an antigen delivery and presentation system. Virus research. 2011; 156(1-2); 35-48. [PubMed: 21195731].

African Swine Fever Virus

  1. Argilaguet et al., 2011: Argilaguet JM, Pérez-Martín E, Gallardo C, Salguero FJ, Borrego B, Lacasta A, Accensi F, Díaz I, Nofrarías M, Pujols J, Blanco E, Pérez-Filgueira M, Escribano JM, Rodríguez F. Enhancing DNA immunization by targeting ASFV antigens to SLA-II bearing cells. Vaccine. 2011; 29(33); 5379-5385. [PubMed: 21679736].
  2. Argilaguet et al., 2013: Argilaguet JM, Pérez-Martín E, López S, Goethe M, Escribano JM, Giesow K, Keil GM, Rodríguez F. BacMam immunization partially protects pigs against sublethal challenge with African swine fever virus. Antiviral research. 2013; 98(1); 61-65. [PubMed: 23428670].
  3. Borca et al., 2021: Borca MV, Ramirez-Medina E, Silva E, Vuono E, Rai A, Pruitt S, Espinoza N, Velazquez-Salinas L, Gay CG, Gladue DP. ASFV-G-∆I177L as an Effective Oral Nasal Vaccine against the Eurasia Strain of Africa Swine Fever. Viruses. 2021; 13(5); . [PubMed: 33925435].
  4. Burmakina et al., 2016: Burmakina G, Malogolovkin A, Tulman ER, Zsak L, Delhon G, Diel DG, Shobogorov NM, Morgunov YP, Morgunov SY, Kutish GF, Kolbasov D, Rock DL. African swine fever virus serotype-specific proteins are significant protective antigens for African swine fever. The Journal of general virology. 2016; 97(7); 1670-1675. [PubMed: 27114233].
  5. Chen et al., 2020: Chen W, Zhao D, He X, Liu R, Wang Z, Zhang X, Li F, Shan D, Chen H, Zhang J, Wang L, Wen Z, Wang X, Guan Y, Liu J, Bu Z. A seven-gene-deleted African swine fever virus is safe and effective as a live attenuated vaccine in pigs. Science China. Life sciences. 2020; 63(5); 623-634. [PubMed: 32124180].
  6. Giménez-Lirola et al., 2016: Giménez-Lirola LG, Mur L, Rivera B, Mogler M, Sun Y, Lizano S, Goodell C, Harris DL, Rowland RR, Gallardo C, Sánchez-Vizcaíno JM, Zimmerman J. Detection of African Swine Fever Virus Antibodies in Serum and Oral Fluid Specimens Using a Recombinant Protein 30 (p30) Dual Matrix Indirect ELISA. PloS one. 2016; 11(9); e0161230. [PubMed: 27611939].
  7. Heimerman et al., 2018: Heimerman ME, Murgia MV, Wu P, Lowe AD, Jia W, Rowland RR. Linear epitopes in African swine fever virus p72 recognized by monoclonal antibodies prepared against baculovirus-expressed antigen. Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc. 2018; 30(3); 406-412. [PubMed: 29327672].
  8. Lewis et al., 2000: Lewis T, Zsak L, Burrage TG, Lu Z, Kutish GF, Neilan JG, Rock DL. An African swine fever virus ERV1-ALR homologue, 9GL, affects virion maturation and viral growth in macrophages and viral virulence in swine. Journal of virology. 2000; 74(3); 1275-1285. [PubMed: 10627538].
  9. Lokhandwala et al., 2016: Lokhandwala S, Waghela SD, Bray J, Martin CL, Sangewar N, Charendoff C, Shetti R, Ashley C, Chen CH, Berghman LR, Mwangi D, Dominowski PJ, Foss DL, Rai S, Vora S, Gabbert L, Burrage TG, Brake D, Neilan J, Mwangi W. Induction of Robust Immune Responses in Swine by Using a Cocktail of Adenovirus-Vectored African Swine Fever Virus Antigens. Clinical and vaccine immunology : CVI. 2016; 23(11); 888-900. [PubMed: 27628166].
  10. McDowell et al., 2022: McDowell CD, Bold D, Trujillo JD, Meekins DA, Keating C, Cool K, Kwon T, Madden DW, Artiaga BL, Balaraman V, Ankhanbaatar U, Zayat B, Retallick J, Dodd K, Chung CJ, Morozov I, Gaudreault NN, Souza-Neto JA, Richt JA. Experimental Infection of Domestic Pigs with African Swine Fever Virus Isolated in 2019 in Mongolia. Viruses. 2022; 14(12); . [PubMed: 36560702].
  11. Sanchez-Vizcaino et al., 2012: Sanchez-Vizcaino JM, Mur L, Martinez-Lopez B. African Swine Fever: An Epidemiological Update. Transboundary and emerging diseases. 2012; ; . [PubMed: 22225967].

Allergy

  1. Ballantyne et al., 2007: Ballantyne SJ, Barlow JL, Jolin HE, Nath P, Williams AS, Chung KF, Sturton G, Wong SH, McKenzie AN. Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. The Journal of allergy and clinical immunology. 2007; 120(6); 1324-1331. [PubMed: 17889290].
  2. Bilsborough et al., 2008: Bilsborough J, Chadwick E, Mudri S, Ye X, Henderson WR Jr, Waggie K, Hebb L, Shin J, Rixon M, Gross JA, Dillon SR. TACI-Ig prevents the development of airway hyperresponsiveness in a murine model of asthma. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2008; 38(12); 1959-1968. [PubMed: 19037968].
  3. Chuang et al., 2006: Chuang YH, Suen JL, Chiang BL. Fas-ligand-expressing adenovirus-transfected dendritic cells decrease allergen-specific T cells and airway inflammation in a murine model of asthma. Journal of molecular medicine (Berlin, Germany). 2006; 84(7); 595-603. [PubMed: 16565865].
  4. Edwan and Agrawal, 2007: Edwan JH, Agrawal DK. Flt3-ligand plasmid prevents the development of pathophysiological features of chronic asthma in a mouse model. Immunologic research. 2007; 37(2); 147-159. [PubMed: 17695249].
  5. Eigenmann et al., 2008: Eigenmann PA, Asigbetse KE, Frossard CP. Avirulant Salmonella typhimurium strains prevent food allergy in mice. Clinical and experimental immunology. 2008; 151(3); 546-553. [PubMed: 18190606].
  6. Focke et al., 2001: Focke M, Mahler V, Ball T, Sperr WR, Majlesi Y, Valent P, Kraft D, Valenta R. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2001; 15(11); 2042-2044. [PubMed: 11511525].
  7. Gómez et al., 2008: Gómez S, Gamazo C, San Roman B, Ferrer M, Sanz ML, Espuelas S, Irache JM. Allergen immunotherapy with nanoparticles containing lipopolysaccharide from Brucella ovis. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2008; 70(3); 711-717. [PubMed: 18582571].
  8. Keane-Myers et al., 1998: Keane-Myers AM, Gause WC, Finkelman FD, Xhou XD, Wills-Karp M. Development of murine allergic asthma is dependent upon B7-2 costimulation. Journal of immunology (Baltimore, Md. : 1950). 1998; 160(2); 1036-1043. [PubMed: 9551945].
  9. Liu et al., 2009: Liu X, Li M, Wu Y, Zhou Y, Zeng L, Huang T. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochemical and biophysical research communications. 2009; 386(1); 181-185. [PubMed: 19508862].
  10. Maecker et al., 2001: Maecker HT, Hansen G, Walter DM, DeKruyff RH, Levy S, Umetsu DT. Vaccination with allergen-IL-18 fusion DNA protects against, and reverses established, airway hyperreactivity in a murine asthma model. Journal of immunology (Baltimore, Md. : 1950). 2001; 166(2); 959-965. [PubMed: 11145673].
  11. Nagashima et al., 2008: Nagashima O, Harada N, Usui Y, Yamazaki T, Yagita H, Okumura K, Takahashi K, Akiba H. B7-H3 contributes to the development of pathogenic Th2 cells in a murine model of asthma. Journal of immunology (Baltimore, Md. : 1950). 2008; 181(6); 4062-4071. [PubMed: 18768862].
  12. Peng et al., 2004: Peng HJ, Tsai LC, Su SN, Chang ZN, Shen HD, Chao PL, Kuo SW, Tsao IY, Hung MW. Comparison of different adjuvants of protein and DNA vaccination for the prophylaxis of IgE antibody formation. Vaccine. 2004; 22(5-6); 755-761. [PubMed: 14741169].
  13. Polte et al., 2006: Polte T, Foell J, Werner C, Hoymann HG, Braun A, Burdach S, Mittler RS, Hansen G. CD137-mediated immunotherapy for allergic asthma. The Journal of clinical investigation. 2006; 116(4); 1025-1036. [PubMed: 16528411].
  14. Simoes et al., 2008: Simoes DC, Vassilakopoulos T, Toumpanakis D, Petrochilou K, Roussos C, Papapetropoulos A. Angiopoietin-1 protects against airway inflammation and hyperreactivity in asthma. American journal of respiratory and critical care medicine. 2008; 177(12); 1314-1321. [PubMed: 18356565].
  15. Wang et al., 2008: Wang SY, Yang M, Xu XP, Qiu GF, Ma J, Wang SJ, Huang XX, Xu HX. Intranasal delivery of T-bet modulates the profile of helper T cell immune responses in experimental asthma. Journal of investigational allergology & clinical immunology : official organ of the International Association of Asthmology (INTERASMA) and Sociedad Latinoamericana de Alergia e Inmunologia. 2008; 18(5); 357-365. [PubMed: 18973099].
  16. Westritschnig et al., 2004: Westritschnig K, Focke M, Verdino P, Goessler W, Keller W, Twardosz A, Mari A, Horak F, Wiedermann U, Hartl A, Thalhamer J, Sperr WR, Valent P, Valenta R. Generation of an allergy vaccine by disruption of the three-dimensional structure of the cross-reactive calcium-binding allergen, Phl p 7. Journal of immunology (Baltimore, Md. : 1950). 2004; 172(9); 5684-5692. [PubMed: 15100313].
  17. Westritschnig et al., 2007: Westritschnig K, Linhart B, Focke-Tejkl M, Pavkov T, Keller W, Ball T, Mari A, Hartl A, Stöcklinger A, Scheiblhofer S, Thalhamer J, Ferreira F, Vieths S, Vogel L, Böhm A, Valent P, Valenta R. A hypoallergenic vaccine obtained by tail-to-head restructuring of timothy grass pollen profilin, Phl p 12, for the treatment of cross-sensitization to profilin. Journal of immunology (Baltimore, Md. : 1950). 2007; 179(11); 7624-7634. [PubMed: 18025208].
  18. Wiki: Allergy: Allergy [http://en.wikipedia.org/wiki/Allergy]

Arthritis

  1. Ho et al., 2006: Ho PP, Higgins JP, Kidd BA, Tomooka B, Digennaro C, Lee LY, de Vegvar HE, Steinman L, Robinson WH. Tolerizing DNA vaccines for autoimmune arthritis. Autoimmunity. 2006; 39(8); 675-682. [PubMed: 17178564].
  2. Mayo Clinic - Arthritis: Arthritis [http://www.mayoclinic.com/health/arthritis/DS01122]
  3. Quintana et al., 2002: Quintana FJ, Carmi P, Mor F, Cohen IR. Inhibition of adjuvant arthritis by a DNA vaccine encoding human heat shock protein 60. Journal of immunology (Baltimore, Md. : 1950). 2002; 169(6); 3422-3428. [PubMed: 12218165].
  4. Ragno et al., 1997: Ragno S, Colston MJ, Lowrie DB, Winrow VR, Blake DR, Tascon R. Protection of rats from adjuvant arthritis by immunization with naked DNA encoding for mycobacterial heat shock protein 65. Arthritis and rheumatism. 1997; 40(2); 277-283. [PubMed: 9041939].
  5. Santos-Junior et al., 2005: Santos-Junior RR, Sartori A, De Franco M, Filho OG, Coelho-Castelo AA, Bonato VL, Cabrera WH, Ibañez OM, Silva CL. Immunomodulation and protection induced by DNA-hsp65 vaccination in an animal model of arthritis. Human gene therapy. 2005; 16(11); 1338-1345. [PubMed: 16259568].
  6. Song et al., 2009: Song X, Liang F, Liu N, Luo Y, Xue H, Yuan F, Tan L, Sun Y, Xi C, Xi Y. Construction and characterization of a novel DNA vaccine that is potent antigen-specific tolerizing therapy for experimental arthritis by increasing CD4+CD25+Treg cells and inducing Th1 to Th2 shift in both cells and cytokines. Vaccine. 2009; 27(5); 690-700. [PubMed: 19095031].
  7. Xue et al., 2011: Xue H, Liang F, Liu N, Song X, Yuan F, Luo Y, Zhao X, Long J, Sun Y, Xi Y. Potent antirheumatic activity of a new DNA vaccine targeted to B7-2/CD28 costimulatory signaling pathway in autoimmune arthritis. Human gene therapy. 2011; 22(1); 65-76. [PubMed: 20695769].

Atherosclerosis

  1. Chyu et al., 2005: Chyu KY, Zhao X, Reyes OS, Babbidge SM, Dimayuga PC, Yano J, Cercek B, Fredrikson GN, Nilsson J, Shah PK. Immunization using an Apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E (-/-) mice. Biochemical and biophysical research communications. 2005; 338(4); 1982-1989. [PubMed: 16288717].
  2. Fredrikson et al., 2005: Fredrikson GN, Andersson L, Söderberg I, Dimayuga P, Chyu KY, Shah PK, Nilsson J. Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression. Autoimmunity. 2005; 38(2); 171-179. [PubMed: 16040338].
  3. Jan et al., 2010: Jan M, Meng S, Chen NC, Mai J, Wang H, Yang XF. Inflammatory and autoimmune reactions in atherosclerosis and vaccine design informatics. Journal of biomedicine & biotechnology. 2010; 2010; 459798. [PubMed: 20414374].

Avian Encephalomyelitis Virus

  1. AE-Poxine: AE-Poxine vaccine website [https://online.zoetis.com/US/EN/Products/Pages/AE_Poxine.aspx]
  2. Calneck, B. W., 2003: Bruce N. Calneck. Avian Encephalomyelitis. 271-281. Diseases of poultry, 11th ed. 2003. Iowa State University Press, Ames, IA.
  3. Marvil et al., 1999: Marvil P, Knowles NJ, Mockett AP, Britton P, Brown TD, Cavanagh D. Avian encephalomyelitis virus is a picornavirus and is most closely related to hepatitis A virus. The Journal of general virology. 1999; 80 ( Pt 3); 653-662. [PubMed: 10092005].

Avian Paramyxovirus

  1. Beck et al., 2003: Beck I, Gerlach H, Burkhardt E, Kaleta EF. Investigation of several selected adjuvants regarding their efficacy and side effects for the production of a vaccine for parakeets to prevent a disease caused by a paramyxovirus type 3. Vaccine. 2003; 21(9-10); 1006-1022. [PubMed: 12547615].
  2. Wiki: Avain paramyxovirus: Wiki: Avain paramyxovirus [http://en.wikipedia.org/wiki/Avian_paramyxovirus]

Avian pneumovirus

  1. Kapczynski and Sellers, 2003: Kapczynski DR, Sellers HS. Immunization of turkeys with a DNA vaccine expressing either the F or N gene of avian metapneumovirus. Avian diseases. 2003; 47(4); 1376-1383. [PubMed: 14708985].
  2. Merck Vet Manual: Avian Pneumovirus: Merck Vet Manual: Avian Pneumovirus [http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/206300.htm]

Avian Polyomavirus

  1. Merck Vet Manual: Avian Polyomavirus: Merck Vet Manual: Avian Polyomavirus [http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/170221.htm]
  2. Ritchie et al., 1996: Ritchie BW, Niagro FD, Latimer KS, Pritchard N, Campagnoli RP, Lukert PD. An inactivated avian polyomavirus vaccine is safe and immunogenic in various Psittaciformes. Vaccine. 1996; 14(12); 1103-1107. [PubMed: 8911004].

Avian Reovirus

  1. Avian Reovirus Infections: Avian Reovirus Infections [http://www.thepoultrysite.com/articles/96/avian-reovirus-infections]
  2. Wan et al., 2011: Wan J, Wang C, Wen X, Huang X, Ling S, Huang Y, Cao S. Immunogenicity of a DNA vaccine of Avian Reovirus orally delivered by attenuated Salmonella typhimurium. Research in veterinary science. 2011; 91(3); 382-383. [PubMed: 20947110].
  3. Wan et al., 2012: Wan J, Wen X, Huang X, Tang Y, Huang Y, Yan Q, Zhao Q, Cao S. Immunogenic analysis of two DNA vaccines of avian reovirus mediated by attenuated Salmonella typhimurium in chickens. Veterinary immunology and immunopathology. 2012; 147(3-4); 154-160. [PubMed: 22575372].
  4. Wu et al., 2005: Wu H, Williams Y, Gunn KS, Singh NK, Locy RD, Giambrone JJ. Yeast-derived sigma C protein-induced immunity against avian reovirus. Avian diseases. 2005; 49(2); 281-284. [PubMed: 16094835].

Babesia bovis

  1. Antonio et al., 2010: Antonio Alvarez J, Lopez U, Rojas C, Borgonio VM, Sanchez V, Castañeda R, Vargas P, Figueroa JV. Immunization of Bos taurus steers with Babesia bovis recombinant antigens MSA-1, MSA-2c and 12D3. Transboundary and emerging diseases. 2010; 57(1-2); 87-90. [PubMed: 20537116].
  2. Brown et al., 1993: Brown WC, Palmer GH, McElwain TF, Hines SA, Dobbelaere DA. Babesia bovis: characterization of the T helper cell response against the 42-kDa merozoite surface antigen (MSA-1) in cattle. Experimental parasitology. 1993; 77(1); 97-9110. [PubMed: 8344411].
  3. Brown et al., 1996: Brown WC, McElwain TF, Ruef BJ, Suarez CE, Shkap V, Chitko-McKown CG, Tuo W, Rice-Ficht AC, Palmer GH. Babesia bovis rhoptry-associated protein 1 is immunodominant for T helper cells of immune cattle and contains T-cell epitopes conserved among geographically distant B. bovis strains. Infection and immunity. 1996; 64(8); 3341-3350. [PubMed: 8757873].
  4. de and Combrink, 2006: de Waal DT, Combrink MP. Live vaccines against bovine babesiosis. Veterinary parasitology. 2006; 138(1-2); 88-96. [PubMed: 16504404].
  5. Ishizaki et al., 2017: Ishizaki T, Sivakumar T, Hayashida K, Takemae H, Tuvshintulga B, Munkhjargal T, Guswanto A, Igarashi I, Yokoyama N. Babesia bovis BOV57, a Theileria parva P67 homolog, is an invasion-related, neutralization-sensitive antigen. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases. 2017; 54; 138-145. [PubMed: 28668608].
  6. Norimine et al., 2004: Norimine J, Mosqueda J, Palmer GH, Lewin HA, Brown WC. Conservation of Babesia bovis small heat shock protein (Hsp20) among strains and definition of T helper cell epitopes recognized by cattle with diverse major histocompatibility complex class II haplotypes. Infection and immunity. 2004; 72(2); 1096-1106. [PubMed: 14742557].
  7. Terkawi et al., 2013: Terkawi MA, Ratthanophart J, Salama A, AbouLaila M, Asada M, Ueno A, Alhasan H, Guswanto A, Masatani T, Yokoyama N, Nishikawa Y, Xuan X, Igarashi I. Molecular characterization of a new Babesia bovis thrombospondin-related anonymous protein (BbTRAP2). PloS one. 2013; 8(12); e83305. [PubMed: 24349483].
  8. Wiki: Babesia bovis: Babesia bovis [http://en.wikipedia.org/wiki/Babesia_bovis]
  9. Wright et al., 1992: Wright IG, Casu R, Commins MA, Dalrymple BP, Gale KR, Goodger BV, Riddles PW, Waltisbuhl DJ, Abetz I, Berrie DA. The development of a recombinant Babesia vaccine. Veterinary parasitology. 1992; 44(1-2); 3-13. [PubMed: 1441189].

Babesia canis

  1. Moreau et al., 1989: Moreau Y, Vidor E, Bissuel G, Dubreuil N. Vaccination against canine babesiosis: an overview of field observations. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1989; 83 Suppl; 95-96. [PubMed: 2623757].
  2. Pet Education.com: Babesia canis: Babesia canis: The Cause of Piroplasmosis [http://www.peteducation.com/article.cfm?c=2+2101&aid=720]

Bacillus anthracis

  1. Balderas et al., 2016: Balderas MA, Nguyen CT, Terwilliger A, Keitel WA, Iniguez A, Torres R, Palacios F, Goulding CW, Maresso AW. Progress toward the Development of a NEAT Protein Vaccine for Anthrax Disease. Infection and immunity. 2016; 84(12); 3408-3422. [PubMed: 27647868].
  2. Bielinska et al., 2007: Bielinska AU, Janczak KW, Landers JJ, Makidon P, Sower LE, Peterson JW, Baker JR Jr. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infection and immunity. 2007; 75(8); 4020-4029. [PubMed: 17502384].
  3. Brey, 2005: Brey RN. Molecular basis for improved anthrax vaccines. Advanced drug delivery reviews. 2005 Jun 17; 57(9); 1266-92. [PubMed: 15935874].
  4. CDC, 2000: Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) [http://www.cdc.gov/mmwr/PDF/rr/rr4915.pdf]
  5. Chabot et al., 2004: Chabot DJ, Scorpio A, Tobery SA, Little SF, Norris SL, Friedlander AM. Anthrax capsule vaccine protects against experimental infection. Vaccine. 2004 Nov 15; 23(1); 43-7. [PubMed: 15519706].
  6. Chekanov et al., 2006: Chekanov AV, Remacle AG, Golubkov VS, Akatov VS, Sikora S, Savinov AY, Fugere M, Day R, Rozanov DV, Strongin AY. Both PA63 and PA83 are endocytosed within an anthrax protective antigen mixed heptamer: a putative mechanism to overcome a furin deficiency. Archives of biochemistry and biophysics. 2006 Feb 1; 446(1); 52-9. [PubMed: 16384550].
  7. Chitlaru et al., 2007: Chitlaru T, Gat O, Grosfeld H, Inbar I, Gozlan Y, Shafferman A. Identification of in vivo-expressed immunogenic proteins by serological proteome analysis of the Bacillus anthracis secretome. Infection and immunity. 2007; 75(6); 2841-2852. [PubMed: 17353282].
  8. Coeshott et al., 2004: Coeshott CM, Smithson SL, Verderber E, Samaniego A, Blonder JM, Rosenthal GJ, Westerink MA. Pluronic F127-based systemic vaccine delivery systems. Vaccine. 2004 Jun 23; 22(19); 2396-405. [PubMed: 15193401].
  9. Coker et al., 2003: Coker PR, Smith KL, Fellows PF, Rybachuck G, Kousoulas KG, Hugh-Jones ME. Bacillus anthracis virulence in Guinea pigs vaccinated with anthrax vaccine adsorbed is linked to plasmid quantities and clonality. Journal of clinical microbiology. 2003 Mar; 41(3); 1212-8. [PubMed: 12624053].
  10. Cui et al., 2006: Cui Z, Sloat BR. Topical immunization onto mouse skin using a microemulsion incorporated with an anthrax protective antigen protein-encoding plasmid. International journal of pharmaceutics. 2006 Jul 24; 317(2); 187-91. [PubMed: 16730934 ].
  11. FDA: Anthrax Vaccine Adsorbed: FDA: Anthrax Vaccine Adsorbed for Bacillus anthracis [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093863.htm]
  12. Flick-Smith et al., 2002: Flick-Smith HC, Walker NJ, Gibson P, Bullifent H, Hayward S, Miller J, Titball RW, Williamson ED. A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infection and immunity. 2002 Mar; 70(3); 1653-6. [PubMed: 11854261].
  13. Galloway et al., 2004: Galloway D, Liner A, Legutki J, Mateczun A, Barnewall R, Estep J. Genetic immunization against anthrax. Vaccine. 2004 Apr 16; 22(13-14); 1604-8. [PubMed: 15068841].
  14. Gat et al., 2005: Gat O, Mendelson I, Chitlaru T, Ariel N, Altboum Z, Levy H, Weiss S, Grosfeld H, Cohen S, Shafferman A. The solute-binding component of a putative Mn(II) ABC transporter (MntA) is a novel Bacillus anthracis virulence determinant. Molecular microbiology. 2005; 58(2); 533-551. [PubMed: 16194238].
  15. Glomski et al., 2007: Glomski IJ, Corre JP, Mock M, Goossens PL. Cutting Edge: IFN-gamma-producing CD4 T lymphocytes mediate spore-induced immunity to capsulated Bacillus anthracis. Journal of immunology (Baltimore, Md. : 1950). 2007 Mar 1; 178(5); 2646-50. [PubMed: 17312104 ].
  16. Gu et al., 1999: Gu ML, Leppla SH, Klinman DM. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine. 1999 Jan 28; 17(4); 340-4. [PubMed: 9987172].
  17. Hahn et al., 2004: Hahn UK, Alex M, Czerny CP, Bohm R, Beyer W. Protection of mice against challenge with Bacillus anthracis STI spores after DNA vaccination. International journal of medical microbiology : IJMM. 2004 Jul; 294(1); 35-44. [PubMed: 15293452].
  18. Hanna et al., 1999: Hanna PC, Ireland JA. Understanding Bacillus anthracis pathogenesis. Trends in microbiology. 1999 May; 7(5); 180-2. [PubMed: 10383221].
  19. Hermanson et al., 2004: Hermanson G, Whitlow V, Parker S, Tonsky K, Rusalov D, Ferrari M, Lalor P, Komai M, Mere R, Bell M, Brenneman K, Mateczun A, Evans T, Kaslow D, Galloway D, Hobart P. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proceedings of the National Academy of Sciences of the United States of America. 2004 Sep 14; 101(37); 13601-6. [PubMed: 15342913].
  20. Hirsh et al, 2004: Hirsh DC, Biberstrein EL.. Bacillus. . 170-174.. Veterinary Microbiology, 2nd Ed.. 2004. Blackwell Publishing, Ames, Iowa...
  21. Ivins et al., 1992: Ivins BE, Welkos SL, Little SF, Crumrine MH, Nelson GO. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infection and immunity. 1992; 60(2); 662-668. [PubMed: 1730501].
  22. Ivins et al., 1995: Ivins B, Fellows P, Pitt L, Estep J, Farchaus J, Friedlander A, Gibbs P. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine. 1995; 13(18); 1779-1784. [PubMed: 8701593].
  23. Klaschik et al., 2007: Klaschik S, Gursel I, Klinman DM. CpG-mediated changes in gene expression in murine spleen cells identified by microarray analysis. Molecular immunology. 2007 Feb; 44(6); 1095-104. [PubMed: 16930709].
  24. Klinman et al., 2004: Klinman DM, Xie H, Little SF, Currie D, Ivins BE. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine. 2004 Jul 29; 22(21-22); 2881-6. [PubMed: 15246624 ].
  25. Kutsenko et al., 2002: Kutsenko AS, Gizatullin RZ, Al-Amin AN, Wang F, Kvasha SM, Podowski RM, Matushkin YG, Gyanchandani A, Muravenko OV, Levitsky VG, Kolchanov NA, Protopopov AI, Kashuba VI, Kisselev LL, Wasserman W, Wahlestedt C, Zabarovsky ER. NotI flanking sequences: a tool for gene discovery and verification of the human genome. Nucleic acids research. 2002 Jul 15; 30(14); 3163-70. [PubMed: 12136098].
  26. Leppla et al., 2002: Leppla SH, Robbins JB, Schneerson R, Shiloach J. Development of an improved vaccine for anthrax. The Journal of clinical investigation. 2002 Jul; 110(2); 141-4. [PubMed: 12122102].
  27. Little et al., 1986: Little SF, Knudson GB. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infection and immunity. 1986 May; 52(2); 509-12. [PubMed: 3084385].
  28. Livingston et al., 2010: Livingston BD, Little SF, Luxembourg A, Ellefsen B, Hannaman D. Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques. Vaccine. 2010; 28(4); 1056-1061. [PubMed: 19896452].
  29. Luxembourg et al., 2008: Luxembourg A, Hannaman D, Nolan E, Ellefsen B, Nakamura G, Chau L, Tellez O, Little S, Bernard R. Potentiation of an anthrax DNA vaccine with electroporation. Vaccine. 2008; 26(40); 5216-5222. [PubMed: 18462850].
  30. McConnell et al., 2006: McConnell MJ, Hanna PC, Imperiale MJ. Cytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4. Infection and immunity. 2006; 74(2); 1009-1015. [PubMed: 16428747].
  31. Midha and Bhatnagar, 2009: Midha S, Bhatnagar R. Anthrax protective antigen administered by DNA vaccination to distinct subcellular locations potentiates humoral and cellular immune responses. European journal of immunology. 2009; 39(1); 159-177. [PubMed: 19130551].
  32. Mikshis et al., 2014: Mikshis NI, Popova PIu, Kudriavtseva OM, Semakova AP, Novikova LN, Kravtsov AL, Bugorkova SA, Shchukovskaia TN, Popov IuA, Kutyrev VV. [Immunogenicity and safety of a prototype chemical anthrax vaccine in laboratory animal models]. Zhurnal mikrobiologii, epidemiologii, i immunobiologii. 2014; (4); 22-30. [PubMed: 25286524].
  33. Mohamadzadeh et al., 2010: Mohamadzadeh M, Durmaz E, Zadeh M, Pakanati KC, Gramarossa M, Cohran V, Klaenhammer TR. Targeted expression of anthrax protective antigen by Lactobacillus gasseri as an anthrax vaccine. Future microbiology. 2010; 5(8); 1289-1296. [PubMed: 20722604].
  34. Osorio et al., 2009: Osorio M, Wu Y, Singh S, Merkel TJ, Bhattacharyya S, Blake MS, Kopecko DJ. Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge. Infection and immunity. 2009; 77(4); 1475-1482. [PubMed: 19179420].
  35. PathPort: Virginia Bioinformatics Institute [http://pathport.vbi.vt.edu/pathinfo/pathogens/Bacillus-anthracis_Info.shtml]
  36. Pittman et al., 2006: Pittman PR, Norris SL, Barrera Oro JG, Bedwell D, Cannon TL, McKee KT Jr. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine. 2006 Apr 24; 24(17); 3654-60. [PubMed: 16497418].
  37. Price et al., 2001: Price BM, Liner AL, Park S, Leppla SH, Mateczun A, Galloway DR. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infection and immunity. 2001 Jul; 69(7); 4509-15. [PubMed: 11401993].
  38. Rhie et al., 2003: Rhie GE, Roehrl MH, Mourez M, Collier RJ, Mekalanos JJ, Wang JY. A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proceedings of the National Academy of Sciences of the United States of America. 2003 Sep 16; 100(19); 10925-30. [PubMed: 12960361].
  39. Rhie et al., 2005: Rhie GE, Park YM, Chun JH, Yoo CK, Seong WK, Oh HB. Expression and secretion of the protective antigen of Bacillus anthracis in Bacillus brevis. FEMS immunology and medical microbiology. 2005; 45(2); 331-339. [PubMed: 16009541].
  40. Ribeiro et al., 2007: Ribeiro S, Rijpkema SG, Durrani Z, Florence AT. PLGA-dendron nanoparticles enhance immunogenicity but not lethal antibody production of a DNA vaccine against anthrax in mice. International journal of pharmaceutics. 2007; 331(2); 228-232. [PubMed: 17258876].
  41. Ribot et al., 2006: Ribot WJ, Powell BS, Ivins BE, Little SF, Johnson WM, Hoover TA, Norris SL, Adamovicz JJ, Friedlander AM, Andrews GP. Comparative vaccine efficacy of different isoforms of recombinant protective antigen against Bacillus anthracis spore challenge in rabbits. Vaccine. 2006 Apr 24; 24(17); 3469-76. [PubMed: 16519970].
  42. Riemenschneider et al., 2003: Riemenschneider J, Garrison A, Geisbert J, Jahrling P, Hevey M, Negley D, Schmaljohn A, Lee J, Hart MK, Vanderzanden L, Custer D, Bray M, Ruff A, Ivins B, Bassett A, Rossi C, Schmaljohn C. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine. 2003; 21(25-26); 4071-4080. [PubMed: 12922144].
  43. Schneerson et al., 2003: Schneerson R, Kubler-Kielb J, Liu TY, Dai ZD, Leppla SH, Yergey A, Backlund P, Shiloach J, Majadly F, Robbins JB. Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine. Proceedings of the National Academy of Sciences of the United States of America. 2003 Jul 22; 100(15); 8945-50. [PubMed: 12857944].
  44. Sloat and Cui, 2006: Sloat BR, Cui Z. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities. Pharmaceutical research. 2006; 23(6); 1217-1226. [PubMed: 16718616].
  45. Smith et al., 2006: Smith ME, Koser M, Xiao S, Siler C, McGettigan JP, Calkins C, Pomerantz RJ, Dietzschold B, Schnell MJ. Rabies virus glycoprotein as a carrier for anthrax protective antigen. Virology. 2006 Sep 30; 353(2); 344-56. [PubMed: 16820183].
  46. Spore vaccine: Anthrax Spore Vaccine [http://www.atozvetsupply.com/Anthrax-Vaccine-p/313-csav.htm]
  47. Tucker et al., 2003: Tucker SN, Lin K, Stevens S, Scollay R, Bennett MJ, Olson DC. Systemic and mucosal antibody responses following retroductal gene transfer to the salivary gland. Molecular therapy : the journal of the American Society of Gene Therapy. 2003; 8(3); 392-399. [PubMed: 12946312].
  48. Vilalta et al., 2005: Vilalta A, Mahajan RK, Hartikka J, Leamy V, Martin T, Rusalov D, Bozoukova V, Lalor P, Hall K, Kaslow DC, Rolland A. II. Cationic lipid-formulated plasmid DNA-based Bacillus anthracis vaccine: evaluation of plasmid DNA persistence and integration potential. Human gene therapy. 2005; 16(10); 1151-1156. [PubMed: 16218776].
  49. Wang et al., 2004: Wang TT, Fellows PF, Leighton TJ, Lucas AH. Induction of opsonic antibodies to the gamma-D-glutamic acid capsule of Bacillus anthracis by immunization with a synthetic peptide-carrier protein conjugate. FEMS immunology and medical microbiology. 2004 Apr 9; 40(3); 231-7. [PubMed: 15039099].
  50. Xie et al., 2005: Xie H, Gursel I, Ivins BE, Singh M, O'Hagan DT, Ulmer JB, Klinman DM. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infection and immunity. 2005 Feb; 73(2); 828-33. [PubMed: 15664922].

Bluetongue virus

  1. Boone et al., 2007: Boone JD, Balasuriya UB, Karaca K, Audonnet JC, Yao J, He L, Nordgren R, Monaco F, Savini G, Gardner IA, Maclachlan NJ. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine. 2007; 25(4); 672-678. [PubMed: 17059856].
  2. Bouet-Cararo et al., 2014: Bouet-Cararo C, Contreras V, Caruso A, Top S, Szelechowski M, Bergeron C, Viarouge C, Desprat A, Relmy A, Guibert JM, Dubois E, Thiery R, Bréard E, Bertagnoli S, Richardson J, Foucras G, Meyer G, Schwartz-Cornil I, Zientara S, Klonjkowski B. Expression of VP7, a Bluetongue virus group specific antigen by viral vectors: analysis of the induced immune responses and evaluation of protective potential in sheep. PloS one. 2014; 9(11); e111605. [PubMed: 25364822].
  3. Franceschi et al., 2011: Franceschi V, Capocefalo A, Calvo-Pinilla E, Redaelli M, Mucignat-Caretta C, Mertens P, Ortego J, Donofrio G. Immunization of knock-out α/β interferon receptor mice against lethal bluetongue infection with a BoHV-4-based vector expressing BTV-8 VP2 antigen. Vaccine. 2011; 29(16); 3074-3082. [PubMed: 21320537].
  4. Legisa et al., 2015: Legisa DM, Perez Aguirreburualde MS, Gonzalez FN, Marin-Lopez A, Ruiz V, Wigdorovitz A, Martinez-Escribano JA, Ortego J, Dus Santos MJ. An experimental subunit vaccine based on Bluetongue virus 4 VP2 protein fused to an antigen-presenting cells single chain antibody elicits cellular and humoral immune responses in cattle, guinea pigs and IFNAR(-/-) mice. Vaccine. 2015; 33(22); 2614-2619. [PubMed: 25858859].
  5. Maclachlan et al., 2009: Maclachlan NJ, Drew CP, Darpel KE, Worwa G. The pathology and pathogenesis of bluetongue. Journal of comparative pathology. 2009; 141(1); 1-16. [PubMed: 19476953].
  6. Perrin et al., 2007: Perrin A, Albina E, Bréard E, Sailleau C, Promé S, Grillet C, Kwiatek O, Russo P, Thiéry R, Zientara S, Cêtre-Sossah C. Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants. Vaccine. 2007; 25(37-38); 6774-6783. [PubMed: 17669563].
  7. Top et al., 2012: Top S, Foucras G, Deplanche M, Rives G, Calvalido J, Comtet L, Bertagnoli S, Meyer G. Myxomavirus as a vector for the immunisation of sheep: protection study against challenge with bluetongue virus. Vaccine. 2012; 30(9); 1609-1616. [PubMed: 22244980].
  8. Wang et al., 2013: Wang WS, Sun EC, Liu NH, Yang T, Xu QY, Qin YL, Zhao J, Feng YF, Li JP, Wei P, Zhang CY, Wu DL. Identification of three novel linear B-cell epitopes on the VP5 protein of BTV16. Veterinary microbiology. 2013; 162(2-4); 631-642. [PubMed: 23290575].
  9. Wiki: Bluetongue: Wiki: Bluetongue [http://en.wikipedia.org/wiki/Bluetongue]

Bordetella avium

  1. HealthGene Corp: Bordetella avium: D417 - Bordetella avium [http://www.healthgene.com/avian/d417.asp]
  2. Jackwood and Saif, 1985: Jackwood MW, Saif YM. Efficacy of a commercial turkey coryza vaccine (Art-Vax) in turkey poults. Avian diseases. 1985; 29(4); 1130-1139. [PubMed: 3833219].

Bordetella bronchiseptica

  1. Goodnow, 1980: Goodnow RA. Biology of Bordetella bronchiseptica. Microbiological reviews. 1980; 44(4); 722-738. [PubMed: 7010115].
  2. Mann et al., 2007: Mann P, Goebel E, Barbarich J, Pilione M, Kennett M, Harvill E. Use of a genetically defined double mutant strain of Bordetella bronchiseptica lacking adenylate cyclase and type III secretion as a live vaccine. Infection and immunity. 2007; 75(7); 3665-3672. [PubMed: 17452472].
  3. Mattoo et al., 2001: Mattoo S, Foreman-Wykert AK, Cotter PA, Miller JF. Mechanisms of Bordetella pathogenesis. Frontiers in bioscience : a journal and virtual library. 2001; 6; E168-186. [PubMed: 11689354].
  4. McArthur et al., 2003: McArthur JD, West NP, Cole JN, Jungnitz H, Guzmán CA, Chin J, Lehrbach PR, Djordjevic SP, Walker MJ. An aromatic amino acid auxotrophic mutant of Bordetella bronchiseptica is attenuated and immunogenic in a mouse model of infection. FEMS microbiology letters. 2003; 221(1); 7-16. [PubMed: 12694904].
  5. Nagano et al., 1988: Nagano H, Nakai T, Horiguchi Y, Kume K. Isolation and characterization of mutant strains of Bordetella bronchiseptica lacking dermonecrotic toxin-producing ability. Journal of clinical microbiology. 1988; 26(10); 1983-1987. [PubMed: 3182989].
  6. Register et al., 2007: Register KB, Sacco RE, Brockmeier SL. Immune response in mice and swine to DNA vaccines derived from the Pasteurella multocida toxin gene. Vaccine. 2007; 25(32); 6118-6128. [PubMed: 17590484].
  7. Scheiblhofer et al., 2003: Scheiblhofer S, Weiss R, Dürnberger H, Mostböck S, Breitenbach M, Livey I, Thalhamer J. A DNA vaccine encoding the outer surface protein C from Borrelia burgdorferi is able to induce protective immune responses. Microbes and infection / Institut Pasteur. 2003; 5(11); 939-946. [PubMed: 12941385].
  8. Stevenson and Roberts, 2002: Stevenson A, Roberts M. Use of a rationally attenuated Bordetella bronchiseptica as a live mucosal vaccine and vector for heterologous antigens. Vaccine. 2002; 20(17-18); 2325-2335. [PubMed: 12009288].

Bordetella pertussis

  1. Bruss and Siber, 2002: Bruss JB, Siber GR. Quantitative priming with inactivated pertussis toxoid vaccine in the aerosol challenge model. Infection and immunity. 2002; 70(8); 4600-4608. [PubMed: 12117973].
  2. Cainelli et al., 2007: Cainelli Gebara VC, Risoléo L, Lopes AP, Ferreira VR, Quintilio W, Lépine F, Silva WD, Raw I. Adjuvant and immunogenic activities of the 73kDa N-terminal alpha-domain of BrkA autotransporter and Cpn60/60kDa chaperonin of Bordetella pertussis. Vaccine. 2007; 25(4); 621-629. [PubMed: 17011680].
  3. Chen et al., 1998: Chen I, Finn TM, Yanqing L, Guoming Q, Rappuoli R, Pizza M. A recombinant live attenuated strain of Vibrio cholerae induces immunity against tetanus toxin and Bordetella pertussis tracheal colonization factor. Infection and immunity. 1998; 66(4); 1648-1653. [PubMed: 9529093].
  4. FDA: Adacel: FDA: Adacel [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172481.htm]
  5. FDA: Boostrix: FDA: Boostrix [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172925.htm]
  6. FDA: DAPTACEL: FDA: DAPTACEL [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm101572.htm]
  7. FDA: Infanrix: FDA: Infanrix [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm101568.htm]
  8. FDA: KINRIX: FDA: KINRIX vaccine information [https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM241453.pdf]
  9. FDA: Pediarix: FDA: Pediarix [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm146759.htm]
  10. FDA: Pentacel: FDA: Pentacel [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172502.htm]
  11. FDA: Quadracel: FDA: Quadracel vaccine information [https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM439903.pdf]
  12. FDA: Tripedia: FDA: Tripedia [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm101565.htm]
  13. Fennelly et al., 2008: Fennelly NK, Sisti F, Higgins SC, Ross PJ, van der Heide H, Mooi FR, Boyd A, Mills KH. Bordetella pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune responses. Infection and immunity. 2008; 76(3); 1257-1266. [PubMed: 18195025].
  14. Feunou et al., 2008: Feunou PF, Ismaili J, Debrie AS, Huot L, Hot D, Raze D, Lemoine Y, Locht C. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1. Vaccine. 2008; 26(45); 5722-5727. [PubMed: 18762220].
  15. GSK: Boostrix-Polio: GSK: Boostrix-Polio vaccine information [https://ca.gsk.com/media/589683/boostrix-polio.pdf]
  16. GSK: Infanrix-hexa: GSK: Infanrix-hexa vaccine information [http://ca.gsk.com/media/537989/infanrix-hexa.pdf]
  17. GSK: Infanrix-IPV: GSK: Infanrix-IPV vaccine information [http://ca.gsk.com/media/590851/infanrix-ipv.pdf]
  18. GSK: Infanrix-IPV/Hib: GSK: Infanrix-IPV/Hib vaccine information [http://ca.gsk.com/media/590970/infanrix-ipv-hib.pdf]
  19. Guiso et al., 1989: Guiso N, Rocancourt M, Szatanik M, Alonso JM. Bordetella adenylate cyclase is a virulence associated factor and an immunoprotective antigen. Microbial pathogenesis. 1989; 7(5); 373-380. [PubMed: 2622329].
  20. Kamachi et al., 2003: Kamachi K, Konda T, Arakawa Y. DNA vaccine encoding pertussis toxin S1 subunit induces protection against Bordetella pertussis in mice. Vaccine. 2003; 21(31); 4609-4615. [PubMed: 14575775].
  21. Kinnear et al., 2001: Kinnear SM, Marques RR, Carbonetti NH. Differential regulation of Bvg-activated virulence factors plays a role in Bordetella pertussis pathogenicity. Infection and immunity. 2001; 69(4); 1983-1993. [PubMed: 11254549].
  22. Komatsu et al., 2010: Komatsu E, Yamaguchi F, Abe A, Weiss AA, Watanabe M. Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model. Clinical and vaccine immunology : CVI. 2010; 17(5); 807-812. [PubMed: 20357056].
  23. Lee et al., 1999: Lee SF, March RJ, Halperin SA, Faulkner G, Gao L. Surface expression of a protective recombinant pertussis toxin S1 subunit fragment in Streptococcus gordonii. Infection and immunity. 1999; 67(3); 1511-1516. [PubMed: 10024603].
  24. Merkel et al., 1998: Merkel TJ, Stibitz S, Keith JM, Leef M, Shahin R. Contribution of regulation by the bvg locus to respiratory infection of mice by Bordetella pertussis. Infection and immunity. 1998; 66(9); 4367-4373. [PubMed: 9712789].
  25. Mielcarek et al., 2006: Mielcarek N, Debrie AS, Raze D, Quatannens J, Engle J, Goldman WE, Locht C. Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation. Vaccine. 2006; 24 Suppl 2; S2-54-5. [PubMed: 16823926].
  26. Nascimento et al., 2008: Nascimento IP, Dias WO, Quintilio W, Christ AP, Moraes JF, Vancetto MD, Ribeiro-Dos-Santos G, Raw I, Leite LC. Neonatal immunization with a single dose of recombinant BCG expressing subunit S1 from pertussis toxin induces complete protection against Bordetella pertussis intracerebral challenge. Microbes and infection / Institut Pasteur. 2008; 10(2); 198-202. [PubMed: 18248757].
  27. Novotny et al., 1985: Novotny P, Chubb AP, Cownley K, Montaraz JA, Beesley JE. Bordetella adenylate cyclase: a genus specific protective antigen and virulence factor. Developments in biological standardization. 1985; 61; 27-41. [PubMed: 2872113].
  28. Novotny et al., 1991: Novotny P, Chubb AP, Cownley K, Charles IG. Biologic and protective properties of the 69-kDa outer membrane protein of Bordetella pertussis: a novel formulation for an acellular pertussis vaccine. The Journal of infectious diseases. 1991; 164(1); 114-122. [PubMed: 2056199].
  29. Product Monograph: Adacel-Polio: Product Monograph: Adacel-Polio vaccine information [https://www.vaccineshoppecanada.com/document.cfm?file=adacel-polio_e.pdf]
  30. Product Monograph: Pediacel: Product Monograph: Pediacel vaccine information [https://www.vaccineshoppecanada.com/document.cfm?file=Pediacel_E.pdf]
  31. Roberts et al., 1990: Roberts M, Maskell D, Novotny P, Dougan G. Construction and characterization in vivo of Bordetella pertussis aroA mutants. Infection and immunity. 1990; 58(3); 732-739. [PubMed: 2407655].
  32. Salyers and Whitt., 2002: Abigail A. Salyers, Dixie D. Whitt. Bordetella pertussis. 263-73. Bacterial Pathogenesis: A Molecular Approach. 2002. ASM Press, Washington D.C. USA.
  33. Sato and Sato, 1984: Sato H, Sato Y. Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system. Infection and immunity. 1984; 46(2); 415-421. [PubMed: 6542069].
  34. Sukumar et al., 2007: Sukumar N, Mishra M, Sloan GP, Ogi T, Deora R. Differential Bvg phase-dependent regulation and combinatorial role in pathogenesis of two Bordetella paralogs, BipA and BcfA. Journal of bacteriology. 2007; 189(10); 3695-3704. [PubMed: 17351043].
  35. Wiki: Bordetella pertussis: Bordetella pertussis [http://en.wikipedia.org/wiki/Bordetella_pertussis]

Borna disease virus

  1. Hashimoto et al., 2003: Hashimoto Y, Chen HS, Cunningham C, Malik TH, Lai PK. Two major histocompatibility complex class I-restricted epitopes of the Borna disease virus p10 protein identified by cytotoxic T lymphocytes induced by DNA-based immunization. Journal of virology. 2003; 77(10); 6076-6081. [PubMed: 12719601].
  2. Hausmann et al., 2005: Hausmann J, Baur K, Engelhardt KR, Fischer T, Rziha HJ, Staeheli P. Vaccine-induced protection against Borna disease in wild-type and perforin-deficient mice. The Journal of general virology. 2005; 86(Pt 2); 399-403. [PubMed: 15659759].
  3. Henkel et al., 2005: Henkel M, Planz O, Fischer T, Stitz L, Rziha HJ. Prevention of virus persistence and protection against immunopathology after Borna disease virus infection of the brain by a novel Orf virus recombinant. Journal of virology. 2005; 79(1); 314-325. [PubMed: 15596826].

Borrelia burgdorferi

  1. Brandt et al., 2014: Brandt KS, Patton TG, Allard AS, Caimano MJ, Radolf JD, Gilmore RD. Evaluation of the Borrelia burgdorferi BBA64 protein as a protective immunogen in mice. Clinical and vaccine immunology : CVI. 2014; 21(4); 526-533. [PubMed: 24501342].
  2. Bryksin et al., 2005: Bryksin AV, Godfrey HP, Carbonaro CA, Wormser GP, Aguero-Rosenfeld ME, Cabello FC. Borrelia burgdorferi BmpA, BmpB, and BmpD proteins are expressed in human infection and contribute to P39 immunoblot reactivity in patients with Lyme disease. Clinical and diagnostic laboratory immunology. 2005; 12(8); 935-940. [PubMed: 16085911].
  3. Floden et al., 2013: Floden AM, Gonzalez T, Gaultney RA, Brissette CA. Evaluation of RevA, a fibronectin-binding protein of Borrelia burgdorferi, as a potential vaccine candidate for lyme disease. Clinical and vaccine immunology : CVI. 2013; 20(6); 892-899. [PubMed: 23595502].
  4. Hanson et al., 1998: Hanson MS, Cassatt DR, Guo BP, Patel NK, McCarthy MP, Dorward DW, Höök M. Active and passive immunity against Borrelia burgdorferi decorin binding protein A (DbpA) protects against infection. Infection and immunity. 1998; 66(5); 2143-2153. [PubMed: 9573101].
  5. Hanson et al., 2000: Hanson MS, Patel NK, Cassatt DR, Ulbrandt ND. Evidence for vaccine synergy between Borrelia burgdorferi decorin binding protein A and outer surface protein A in the mouse model of lyme borreliosis. Infection and immunity. 2000; 68(11); 6457-6460. [PubMed: 11035759].
  6. Labandeira-Rey et al., 2001: Labandeira-Rey M, Baker EA, Skare JT. VraA (BBI16) protein of Borrelia burgdorferi is a surface-exposed antigen with a repetitive motif that confers partial protection against experimental Lyme borreliosis. Infection and immunity. 2001; 69(3); 1409-1419. [PubMed: 11179306].
  7. Luke et al., 1997: Luke CJ, Carner K, Liang X, Barbour AG. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi. The Journal of infectious diseases. 1997; 175(1); 91-97. [PubMed: 8985201].
  8. Probert and LeFebvre, 1994: Probert WS, LeFebvre RB. Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen. Infection and immunity. 1994; 62(5); 1920-1926. [PubMed: 8168958].
  9. Sadziene et al., 1996: Sadziene A, Thompson PA, Barbour AG. A flagella-less mutant of Borrelia burgdorferi as a live attenuated vaccine in the murine model of Lyme disease. The Journal of infectious diseases. 1996; 173(5); 1184-1193. [PubMed: 8627071].
  10. Salyers and Whitt., 2002: Abigail A. Salyers, Dixie D. Whitt. The Spirochetes: Borrelia burgdorferi and Treponema pallidum. 187-199. Bacterial Pathogenesis: A Molecular Approach. 2002. ASM Press, Washington D.C. USA.
  11. Scheiblhofer et al., 2003: Scheiblhofer S, Weiss R, Dürnberger H, Mostböck S, Breitenbach M, Livey I, Thalhamer J. A DNA vaccine encoding the outer surface protein C from Borrelia burgdorferi is able to induce protective immune responses. Microbes and infection / Institut Pasteur. 2003; 5(11); 939-946. [PubMed: 12941385].
  12. Ulbrandt et al., 2001: Ulbrandt ND, Cassatt DR, Patel NK, Roberts WC, Bachy CM, Fazenbaker CA, Hanson MS. Conformational nature of the Borrelia burgdorferi decorin binding protein A epitopes that elicit protective antibodies. Infection and immunity. 2001; 69(8); 4799-4807. [PubMed: 11447153].
  13. Weiss et al., 1999: Weiss R, Dürnberger J, Mostböck S, Scheiblhofer S, Hartl A, Breitenbach M, Strasser P, Dorner F, Livey I, Crowe B, Thalhamer J. Improvement of the immune response against plasmid DNA encoding OspC of Borrelia by an ER-targeting leader sequence. Vaccine. 1999; 18(9-10); 815-824. [PubMed: 10580194].
  14. Wiki: B. burgdorferi: Wiki: Borrelia burgdorferi [http://en.wikipedia.org/wiki/Borrelia_burgdorferi]

Bovine coronavirus

  1. Liu et al., 2006: Liu L, Hägglund S, Hakhverdyan M, Alenius S, Larsen LE, Belák S. Molecular epidemiology of bovine coronavirus on the basis of comparative analyses of the S gene. Journal of clinical microbiology. 2006; 44(3); 957-960. [PubMed: 16517883].
  2. Nasiri et al., 2016: Nasiri K, Nassiri M, Tahmoorespur M, Haghparast A, Zibaee S. Design and Construction of Chimeric VP8-S2 Antigen for Bovine Rotavirus and Bovine Coronavirus. Advanced pharmaceutical bulletin. 2016; 6(1); 91-98. [PubMed: 27123423].

Bovine herpesvirus 1

  1. Babiuk et al., 1987: Babiuk LA, L'Italien J, van Drunen Littel-van den Hurk S, Zamb T, Lawman JP, Hughes G, Gifford GA. Protection of cattle from bovine herpesvirus type I (BHV-1) infection by immunization with individual viral glycoproteins. Virology. 1987; 159(1); 57-66. [PubMed: 3037783].
  2. Caselli et al., 2005: Caselli E, Boni M, Di Luca D, Salvatori D, Vita A, Cassai E. A combined bovine herpesvirus 1 gB-gD DNA vaccine induces immune response in mice. Comparative immunology, microbiology and infectious diseases. 2005; 28(2); 155-166. [PubMed: 15582691].
  3. Castrucci et al., 2004: Castrucci G, Ferrari M, Marchini C, Salvatori D, Provinciali M, Tosini A, Petrini S, Sardonini Q, Lo Dico M, Frigeri F, Amici A. Immunization against bovine herpesvirus-1 infection. Preliminary tests in calves with a DNA vaccine. Comparative immunology, microbiology and infectious diseases. 2004; 27(3); 171-179. [PubMed: 15001312].
  4. Cox et al., 1993: Cox GJ, Zamb TJ, Babiuk LA. Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA. Journal of virology. 1993; 67(9); 5664-5667. [PubMed: 8350420].
  5. Deshpande et al., 2002: Deshpande MS, Ambagala TC, Hegde NR, Hariharan MJ, Navaratnam M, Srikumaran S. Induction of cytotoxic T-lymphocytes specific for bovine herpesvirus-1 by DNA immunization. Vaccine. 2002; 20(31-32); 3744-3751. [PubMed: 12399204].
  6. Gao et al., 1994: Gao Y, Leary TP, Eskra L, Splitter GA. Truncated bovine herpesvirus-1 glycoprotein I (gpI) initiates a protective local immune response in its natural host. Vaccine. 1994; 12(2); 145-152. [PubMed: 8147097].
  7. Gogev et al., 2002: Gogev S, Vanderheijden N, Lemaire M, Schynts F, D'Offay J, Deprez I, Adam M, Eloit M, Thiry E. Induction of protective immunity to bovine herpesvirus type 1 in cattle by intranasal administration of replication-defective human adenovirus type 5 expressing glycoprotein gC or gD. Vaccine. 2002; 20(9-10); 1451-1465. [PubMed: 11818166].
  8. Gupta et al., 2001: Gupta PK, Saini M, Gupta LK, Rao VD, Bandyopadhyay SK, Butchaiah G, Garg GK, Garg SK. Induction of immune responses in cattle with a DNA vaccine encoding glycoprotein C of bovine herpesvirus-1. Veterinary microbiology. 2001; 78(4); 293-305. [PubMed: 11182496].
  9. Huang et al., 2005: Huang Y, Babiuk LA, van Drunen Littel-van den Hurk S. Immunization with a bovine herpesvirus 1 glycoprotein B DNA vaccine induces cytotoxic T-lymphocyte responses in mice and cattle. The Journal of general virology. 2005; 86(Pt 4); 887-898. [PubMed: 15784883].
  10. Kaashoek et al., 1994: Kaashoek MJ, Moerman A, Madić J, Rijsewijk FA, Quak J, Gielkens AL, van Oirschot JT. A conventionally attenuated glycoprotein E-negative strain of bovine herpesvirus type 1 is an efficacious and safe vaccine. Vaccine. 1994; 12(5); 439-444. [PubMed: 8023552].
  11. Kaashoek et al., 1995: Kaashoek MJ, Moerman A, Madić J, Weerdmeester K, Maris-Veldhuis M, Rijsewijk FA, van Oirschot JT. An inactivated vaccine based on a glycoprotein E-negative strain of bovine herpesvirus 1 induces protective immunity and allows serological differentiation. Vaccine. 1995; 13(4); 342-346. [PubMed: 7793128].
  12. Kaashoek et al., 1998: Kaashoek MJ, Rijsewijk FA, Ruuls RC, Keil GM, Thiry E, Pastoret PP, Van Oirschot JT. Virulence, immunogenicity and reactivation of bovine herpesvirus 1 mutants with a deletion in the gC, gG, gI, gE, or in both the gI and gE gene. Vaccine. 1998; 16(8); 802-809. [PubMed: 9627937].
  13. Khattar et al., 2010: Khattar SK, Collins PL, Samal SK. Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1. Vaccine. 2010; 28(18); 3159-3170. [PubMed: 20189484].
  14. Kit et al., 1985: Kit S, Qavi H, Gaines JD, Billingsley P, McConnell S. Thymidine kinase-negative bovine herpesvirus type 1 mutant is stable and highly attenuated in calves. Archives of virology. 1985; 86(1-2); 63-83. [PubMed: 2994602].
  15. Langellotti et al., 2011: Langellotti CA, Pappalardo JS, Quattrocchi V, Mongini C, Zamorano P. Induction of specific cytotoxic activity for bovine herpesvirus-1 by DNA immunization with different adjuvants. Antiviral research. 2011; 90(3); 134-142. [PubMed: 21443903].
  16. Petrini et al., 2011: Petrini S, Ramadori G, Corradi A, Borghetti P, Lombardi G, Villa R, Bottarelli E, Guercio A, Amici A, Ferrari M. Evaluation of safety and efficacy of DNA vaccines against bovine herpesvirus-1 (BoHV-1) in calves. Comparative immunology, microbiology and infectious diseases. 2011; 34(1); 3-10. [PubMed: 19906427].
  17. Pontarollo et al., 2002: Pontarollo RA, Babiuk LA, Hecker R, Van Drunen Littel-Van Den Hurk S. Augmentation of cellular immune responses to bovine herpesvirus-1 glycoprotein D by vaccination with CpG-enhanced plasmid vectors. The Journal of general virology. 2002; 83(Pt 12); 2973-2981. [PubMed: 12466473].
  18. Schrijver et al., 1997: Schrijver RS, Langedijk JP, Keil GM, Middel WG, Maris-Veldhuis M, Van Oirschot JT, Rijsewijk FA. Immunization of cattle with a BHV1 vector vaccine or a DNA vaccine both coding for the G protein of BRSV. Vaccine. 1997; 15(17-18); 1908-1916. [PubMed: 9413101].
  19. van et al., 1996: van Oirschot JT, Kaashoek MJ, Rijsewijk FA. Advances in the development and evaluation of bovine herpesvirus 1 vaccines. Veterinary microbiology. 1996; 53(1-2); 43-54. [PubMed: 9010997].
  20. van et al., 1997: van Drunen Littel-van den Hurk S, Tikoo SK, van den Hurk JV, Babiuk LA, Van Donkersgoed J. Protective immunity in cattle following vaccination with conventional and marker bovine herpesvirus-1 (BHV1) vaccines. Vaccine. 1997; 15(1); 36-44. [PubMed: 9041664].
  21. Wiki: Bovine herpesvirus 1: Bovine herpesvirus 1 [http://en.wikipedia.org/wiki/Bovine_herpesvirus_1]
  22. Zheng et al., 2005: Zheng C, Babiuk LA, van Drunen Littel-van den Hurk S. Bovine herpesvirus 1 VP22 enhances the efficacy of a DNA vaccine in cattle. Journal of virology. 2005; 79(3); 1948-1953. [PubMed: 15650221].

Bovine Leukemia virus

  1. Brillowska et al., 1999: Brillowska A, Dabrowski S, Rułka J, Kubiś P, Buzała E, Kur J. Protection of cattle against bovine leukemia virus (BLV) infection could be attained by DNA vaccination. Acta biochimica Polonica. 1999; 46(4); 971-976. [PubMed: 10824867].
  2. Kabeya et al., 1996: Kabeya H, Ohashi K, Ohishi K, Sugimoto C, Amanuma H, Onuma M. An effective peptide vaccine to eliminate bovine leukaemia virus (BLV) infected cells in carrier sheep. Vaccine. 1996; 14(12); 1118-1122. [PubMed: 8911007].
  3. Larsen et al., 2013: Larsen A, Gonzalez ET, Serena MS, Echeverría MG, Mortola E. Expression of p24 gag protein of bovine leukemia virus in insect cells and its use in immunodetection of the disease. Molecular biotechnology. 2013; 54(2); 475-483. [PubMed: 22829115].
  4. Suárez et al., 2022: Suárez Archilla G, Gutiérrez G, Camussone C, Calvinho L, Abdala A, Alvarez I, Petersen M, Franco L, Destefano G, Monti G, Jacques JR, Joris T, Willems L, Trono K. A safe and effective vaccine against bovine leukemia virus. Frontiers in immunology. 2022; 13; 980514. [PubMed: 36032174].
  5. Usui et al., 2003: Usui T, Konnai S, Tajima S, Watarai S, Aida Y, Ohashi K, Onuma M. Protective effects of vaccination with bovine leukemia virus (BLV) Tax DNA against BLV infection in sheep. The Journal of veterinary medical science / the Japanese Society of Veterinary Science. 2003; 65(11); 1201-1205. [PubMed: 14665749].
  6. Wiki: Bovine leukemia virus: Bovine leukemia virus [http://en.wikipedia.org/wiki/Bovine_leukemia_virus]

Bovine papillomavirus

  1. Avki et al., 2004: Avki S, Turutoglu H, Simsek A, Unsal A. Clinical and immunological effects of Newcastle disease virus vaccine on bovine papillomatosis. Veterinary immunology and immunopathology. 2004; 98(1-2); 9-16. [PubMed: 15127837].
  2. Jagu et al., 2011: Jagu S, Malandro N, Kwak K, Yuan H, Schlegel R, Palmer KE, Huh WK, Campo MS, Roden RB. A multimeric L2 vaccine for prevention of animal papillomavirus infections. Virology. 2011; 420(1); 43-50. [PubMed: 21920572].
  3. Módolo et al., 2017: Módolo DG, Araldi RP, Mazzuchelli-de-Souza J, Pereira A, Pimenta DC, Zanphorlin LM, Beçak W, Menossi M, de Cassia Stocco R, de Carvalho RF. Integrated analysis of recombinant BPV-1 L1 protein for the production of a bovine papillomavirus VLP vaccine. Vaccine. 2017; 35(12); 1590-1593. [PubMed: 28222997].
  4. Wiki: Bovine papillomavirus: Wiki: Bovine papillomavirus [http://en.wikipedia.org/wiki/Bovine_papillomavirus]

Bovine Parainfluenza 3 Virus (BPIV-3)

  1. Merck Vet Manual: Parainfluenza-3 Virus: Merck Veterinary Manual: Parainfluenza-3 Virus [http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/121210.htm]

Bovine Respiratory Syncytial Virus

  1. Blodörn et al., 2014: Blodörn K, Hägglund S, Fix J, Dubuquoy C, Makabi-Panzu B, Thom M, Karlsson P, Roque JL, Karlstam E, Pringle J, Eléouët JF, Riffault S, Taylor G, Valarcher JF. Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies. PloS one. 2014; 9(6); e100392. [PubMed: 24945377].
  2. Gershwin et al., 2017: Gershwin LJ, Behrens NE, McEligot HA, Carvallo-Chaigneau FR, Crum LT, Gunnarson BM, Corbeil LB. A recombinant subunit vaccine for bovine RSV and Histophilus somni protects calves against dual pathogen challenge. Vaccine. 2017; 35(15); 1954-1963. [PubMed: 28274639].
  3. Merck Vet Manual: BRSV: Merck Veterinary Manual-Bovine Respiratory Syncytial Virus [http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/121211.htm]
  4. Schmidt et al., 2002: Schmidt U, Beyer J, Polster U, Gershwin LJ, Buchholz UJ. Mucosal immunization with live recombinant bovine respiratory syncytial virus (BRSV) and recombinant BRSV lacking the envelope glycoprotein G protects against challenge with wild-type BRSV. Journal of virology. 2002; 76(23); 12355-12359. [PubMed: 12414977].
  5. Schrijver et al., 1997: Schrijver RS, Langedijk JP, Keil GM, Middel WG, Maris-Veldhuis M, Van Oirschot JT, Rijsewijk FA. Immunization of cattle with a BHV1 vector vaccine or a DNA vaccine both coding for the G protein of BRSV. Vaccine. 1997; 15(17-18); 1908-1916. [PubMed: 9413101].
  6. Taylor et al., 2005: Taylor G, Bruce C, Barbet AF, Wyld SG, Thomas LH. DNA vaccination against respiratory syncytial virus in young calves. Vaccine. 2005; 23(10); 1242-1250. [PubMed: 15652666].

Bovine viral diarrhea virus 1

  1. Beer et al., 2000: Beer M, Hehnen HR, Wolfmeyer A, Poll G, Kaaden OR, Wolf G. A new inactivated BVDV genotype I and II vaccine. An immunisation and challenge study with BVDV genotype I. Veterinary microbiology. 2000; 77(1-2); 195-208. [PubMed: 11042413].
  2. Mahony et al., 2015: Mahony D, Mody KT, Cavallaro AS, Hu Q, Mahony TJ, Qiao S, Mitter N. Immunisation of Sheep with Bovine Viral Diarrhoea Virus, E2 Protein Using a Freeze-Dried Hollow Silica Mesoporous Nanoparticle Formulation. PloS one. 2015; 10(11); e0141870. [PubMed: 26535891].
  3. Merck Vet Manual: Bovine Viral Diarrhea: Merck Vet Manual: Bovine Viral Diarrhea and Mucosal Disease Complex [http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/22103.htm]
  4. Petrini et al., 2011: Petrini S, Ramadori G, Corradi A, Borghetti P, Lombardi G, Villa R, Bottarelli E, Guercio A, Amici A, Ferrari M. Evaluation of safety and efficacy of DNA vaccines against bovine herpesvirus-1 (BoHV-1) in calves. Comparative immunology, microbiology and infectious diseases. 2011; 34(1); 3-10. [PubMed: 19906427].

Bovine viral diarrhea virus 2

  1. Liang et al., 2008: Liang R, van den Hurk JV, Landi A, Lawman Z, Deregt D, Townsend H, Babiuk LA, van Drunen Littel-van den Hurk S. DNA prime protein boost strategies protect cattle from bovine viral diarrhea virus type 2 challenge. The Journal of general virology. 2008; 89(Pt 2); 453-466. [PubMed: 18198376].
  2. Merck Vet Manual: Bovine Viral Diarrhea: Merck Vet Manual: Bovine Viral Diarrhea and Mucosal Disease Complex [http://www.merckmanuals.com/vet/digestive_system/intestinal_diseases_in_ruminants/intestinal_diseases_in_cattle.html#v3263133?qt=&sc=&alt=]
  3. van et al., 2013: van Drunen Littel-van den Hurk S, Lawman Z, Snider M, Wilson D, van den Hurk JV, Ellefsen B, Hannaman D. Two doses of bovine viral diarrhea virus DNA vaccine delivered by electroporation induce long-term protective immune responses. Clinical and vaccine immunology : CVI. 2013; 20(2); 166-173. [PubMed: 23220999].
  4. Zimmerman et al., 2006: Zimmerman AD, Boots RE, Valli JL, Chase CC. Evaluation of protection against virulent bovine viral diarrhea virus type 2 in calves that had maternal antibodies and were vaccinated with a modified-live vaccine. Journal of the American Veterinary Medical Association. 2006; 228(11); 1757-1761. [PubMed: 16740078].

Brucella spp.

  1. Abtahi et al., 2008: Abtahi H, Salmanian AH, Rafati S, Nejad GB, Saffari M, Ghazavi A, Mosayebi G. The profile of cytokines and IgG subclasses in BALB/c mice after immunization with Brucella ribosomal gene. Pakistan journal of biological sciences: PJBS. 2008; 11(21); 2472-2477. [PubMed: 19205266].
  2. Adone et al., 2005: Adone R, Ciuchini F, Marianelli C, Tarantino M, Pistoia C, Marcon G, Petrucci P, Francia M, Riccardi G, Pasquali P. Protective properties of rifampin-resistant rough mutants of Brucella melitensis. Infection and immunity. 2005; 73(7); 4198-4204. [PubMed: 15972510].
  3. Al-Mariri et al., 2001: Al-Mariri A, Tibor A, Mertens P, De Bolle X, Michel P, Godefroid J, Walravens K, Letesson JJ. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infection and immunity. 2001 Aug; 69(8); 4816-22. [PubMed: 11447155 ].
  4. Al-Mariri et al., 2001: Al-Mariri A, Tibor A, Mertens P, De Bolle X, Michel P, Godfroid J, Walravens K, Letesson JJ. Induction of immune response in BALB/c mice with a DNA vaccine encoding bacterioferritin or P39 of Brucella spp. Infection and immunity. 2001; 69(10); 6264-6270. [PubMed: 11553569].
  5. Al-Mariri et al., 2002: Al-Mariri A, Tibor A, Lestrate P, Mertens P, De Bolle X, Letesson JJ. Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen. Infection and immunity. 2002; 70(4); 1915-1923. [PubMed: 11895955].
  6. Arenas-Gamboa et al., 2008: Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Rice-Ficht AC. Immunization with a Single Dose of a Microencapsulated Brucella melitensis Mutant Enhances Protection Against Wild-type Challenge. Infection and immunity. 2008; ; . [PubMed: 18362129].
  7. Arenas-Gamboa et al., 2009: Arenas-Gamboa AM, Ficht TA, Davis DS, Elzer PH, Wong-Gonzalez A, Rice-Ficht AC. Enhanced immune response of red deer (Cervus elaphus) to live rb51 vaccine strain using composite microspheres. Journal of wildlife diseases. 2009; 45(1); 165-173. [PubMed: 19204345].
  8. Arenas-Gamboa et al., 2009: Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Gomez G, Rice-Ficht AC. The Brucella abortus S19 DeltavjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle. Infection and immunity. 2009; 77(2); 877-884. [PubMed: 19047401].
  9. Arenas-Gamboa et al., 2011: Arenas-Gamboa AM, Rice-Ficht AC, Kahl-McDonagh MM, Ficht TA. The protective efficacy and safety of 16M{Delta}mucR against intraperitoneal and aerosol challenge in BALB/c mice. Infection and immunity. 2011; ; . [PubMed: 21708998].
  10. Banai, 2002: Banai M. Control of small ruminant brucellosis by use of Brucella melitensis Rev.1 vaccine: laboratory aspects and field observations. Veterinary microbiology. 2002 Dec 20; 90(1-4); 497-519. [PubMed: 12414167].
  11. Bhattacharjee et al., 2002: Bhattacharjee AK, Van de Verg L, Izadjoo MJ, Yuan L, Hadfield TL, Zollinger WD, Hoover DL. Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane protein. Infection and immunity. 2002; 70(7); 3324-3329. [PubMed: 12065469].
  12. Bhattacharjee et al., 2006: Bhattacharjee AK, Izadjoo MJ, Zollinger WD, Nikolich MP, Hoover DL. Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine. Infection and immunity. 2006 Oct; 74(10); 5820-5. [PubMed: 16988260].
  13. Blasco et al., 1993: Blasco JM, Gamazo C, Winter AJ, Jimenez de Bagues MP, Marin C, Barberan M, Moriyon I, Alonso-Urmeneta B, Diaz R. Evaluation of whole cell and subcellular vaccines against Brucella ovis in rams. Veterinary immunology and immunopathology. 1993 Aug; 37(3-4); 257-70. [PubMed: 8236802].
  14. Bosseray, 1991: Bosseray N. Brucella melitensis Rev. 1 living attenuated vaccine: stability of markers, residual virulence and immunogenicity in mice. Biologicals : journal of the International Association of Biological Standardization. 1991 Oct; 19(4); 355-63. [PubMed: 1797046].
  15. Cassataro et al., 2002: Cassataro J, Velikovsky CA, Giambartolomei GH, Estein S, Bruno L, Cloeckaert A, Bowden RA, Spitz M, Fossati CA. Immunogenicity of the Brucella melitensis recombinant ribosome recycling factor-homologous protein and its cDNA. Vaccine. 2002; 20(11-12); 1660-1669. [PubMed: 11858876].
  16. Cassataro et al., 2004: Cassataro J, Pasquevich K, Bruno L, Wallach JC, Fossati CA, Baldi PC. Antibody reactivity to Omp31 from Brucella melitensis in human and animal infections by smooth and rough Brucellae. Clinical and diagnostic laboratory immunology. 2004 Jan; 11(1); 111-4. [PubMed: 14715555].
  17. Cassataro et al., 2005: Cassataro J, Velikovsky CA, de la Barrera S, Estein SM, Bruno L, Bowden R, Pasquevich KA, Fossati CA, Giambartolomei GH. A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response. Infection and immunity. 2005 Oct; 73(10); 6537-46. [PubMed: 16177328].
  18. Cassataro et al., 2007: Cassataro J, Pasquevich KA, Estein SM, Laplagne DA, Zwerdling A, de la Barrera S, Bowden R, Fossati CA, Giambartolomei GH, Goldbaum FA. A DNA vaccine coding for the quimera BLSOmp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination. Vaccine. 2007 Jun 12; ; . [PubMed: 17600596].
  19. Cassataro et al., 2007: Cassataro J, Pasquevich KA, Estein SM, Laplagne DA, Velikovsky CA, de la Barrera S, Bowden R, Fossati CA, Giambartolomei GH, Goldbaum FA. A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination. Vaccine. 2007 May 30; 25(22); 4437-46. [PubMed: 17442465].
  20. Cassataro et al., 2007: Cassataro J, Velikovsky CA, Bruno L, Estein SM, de la Barrera S, Bowden R, Fossati CA, Giambartolomei GH. Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding Brucella melitensis outer membrane protein 31 (Omp31) and recombinant Omp31 boosting. Clinical and vaccine immunology : CVI. 2007; 14(7); 869-874. [PubMed: 17428946].
  21. Cheville, 2000: Cheville NF. Development, testing and commercialization of a new brucellosis vaccine for cattle. Annals of the New York Academy of Sciences. 2000; 916; 147-53. [PubMed: 11193615].
  22. Cloeckaert et al., 2002: Cloeckaert A, Grayon M, Grepinet O. Identification of Brucella melitensis vaccine strain Rev.1 by PCR-RFLP based on a mutation in the rpsL gene. Vaccine. 2002 Jun 7; 20(19-20); 2546-50. [PubMed: 12057611].
  23. Cloeckaert et al., 2004: Cloeckaert A, Jacques I, Grilló MJ, Marín CM, Grayon M, Blasco JM, Verger JM. Development and evaluation as vaccines in mice of Brucella melitensis Rev.1 single and double deletion mutants of the bp26 and omp31 genes coding for antigens of diagnostic significance in ovine brucellosis. Vaccine. 2004; 22(21-22); 2827-2835. [PubMed: 15246618].
  24. Colby et al., 2002: Colby LA, Schurig GG, Elzer PH. An indirect ELISA to detect the serologic response of elk (Cervus elaphus nelsoni) inoculated with Brucella abortus strain RB51. Journal of wildlife diseases. 2002; 38(4); 752-759. [PubMed: 12528442].
  25. Commander et al., 2007: Commander NJ, Spencer SA, Wren BW, MacMillan AP. The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding Brucella melitensis 16M genes. Vaccine. 2007; 25(1); 43-54. [PubMed: 17049676].
  26. Cook et al., 2001: Cook WE, Williams ES, Thorne ET, Taylor SK, Anderson S. Safety of Brucella abortus strain RB51 in deer mice. Journal of wildlife diseases. 2001; 37(3); 621-625. [PubMed: 11504238].
  27. Corbel, 1997: Corbel MJ. Recent advances in brucellosis. Journal of medical microbiology. 1997 Feb; 46(2); 101-3. [PubMed: 9060868 ].
  28. Crawford et al., 1996: Crawford RM, Van De Verg L, Yuan L, Hadfield TL, Warren RL, Drazek ES, Houng HH, Hammack C, Sasala K, Polsinelli T, Thompson J, Hoover DL. Deletion of purE attenuates Brucella melitensis infection in mice. Infection and immunity. 1996; 64(6); 2188-2192. [PubMed: 8675325].
  29. Delpino et al., 2007a: Delpino MV, Estein SM, Fossati CA, Baldi PC. Partial protection against Brucella infection in mice by immunization with nonpathogenic alphaproteobacteria. Clinical and vaccine immunology : CVI. 2007; 14(10); 1296-1301. [PubMed: 17715332].
  30. Delpino et al., 2007b: Delpino MV, Estein SM, Fossati CA, Baldi PC, Cassataro J. Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice. Vaccine. 2007; 25(37-38); 6721-6729. [PubMed: 17686554].
  31. Drazek et al., 1995: Drazek ES, Houng HS, Crawford RM, Hadfield TL, Hoover DL, Warren RL. Deletion of purE attenuates Brucella melitensis 16M for growth in human monocyte-derived macrophages. Infection and immunity. 1995; 63(9); 3297-3301. [PubMed: 7642258].
  32. Edmonds et al., 2002: Edmonds MD, Cloeckaert A, Elzer PH. Brucella species lacking the major outer membrane protein Omp25 are attenuated in mice and protect against Brucella melitensis and Brucella ovis. Veterinary microbiology. 2002; 88(3); 205-221. [PubMed: 12151196].
  33. ELBERG and FAUNCE, 1957: ELBERG SS, FAUNCE K Jr. Immunization against Brucella infection. VI. Immunity conferred on goats by a nondependent mutant from a streptomycin-dependent mutant strain of Brucella melitensis. Journal of bacteriology. 1957; 73(2); 211-217. [PubMed: 13416171].
  34. Estein et al., 2003: Estein SM, Cassataro J, Vizcaino N, Zygmunt MS, Cloeckaert A, Bowden RA. The recombinant Omp31 from Brucella melitensis alone or associated with rough lipopolysaccharide induces protection against Brucella ovis infection in BALB/c mice. Microbes and infection / Institut Pasteur. 2003 Feb; 5(2); 85-93. [PubMed: 12650766].
  35. Estevan et al., 2006: Estevan M, Gamazo C, Grilló MJ, Del Barrio GG, Blasco JM, Irache JM. Experiments on a sub-unit vaccine encapsulated in microparticles and its efficacy against Brucella melitensis in mice. Vaccine. 2006; 24(19); 4179-4187. [PubMed: 16481077].
  36. Fernandes et al., 1996: Fernandes DM, Jiang X, Jung JH, Baldwin CL. Comparison of T cell cytokines in resistant and susceptible mice infected with virulent Brucella abortus strain 2308. FEMS immunology and medical microbiology. 1996 Dec 31; 16(3-4); 193-203. [PubMed: 9116636 ].
  37. Fu et al., 2012: Fu S, Xu J, Li X, Xie Y, Qiu Y, Du X, Yu S, Bai Y, Chen Y, Wang T, Wang Z, Yu Y, Peng G, Huang K, Huang L, Wang Y, Chen Z. Immunization of Mice with Recombinant Protein CobB or AsnC Confers Protection against Brucella abortus Infection. PloS one. 2012; 7(2); e29552. [PubMed: 22383953].
  38. Galindo et al., 2009: Galindo RC, Muñoz PM, de Miguel MJ, Marin CM, Blasco JM, Gortazar C, Kocan KM, de la Fuente J. Characterization of possible correlates of protective response against Brucella ovis infection in rams immunized with the B. melitensis Rev 1 vaccine. Vaccine. 2009; 27(23); 3039-3044. [PubMed: 19428917].
  39. Gee et al., 2005: Gee JM, Valderas MW, Kovach ME, Grippe VK, Robertson GT, Ng WL, Richardson JM, Winkler ME, Roop RM 2nd. The Brucella abortus Cu,Zn superoxide dismutase is required for optimal resistance to oxidative killing by murine macrophages and wild-type virulence in experimentally infected mice. Infection and immunity. 2005 May; 73(5); 2873-80. [PubMed: 15845493].
  40. Geong et al., 2000: Geong M, Robertson ID. Response of Bali cattle (Bos javanicus) to vaccination with Brucella abortus strain 19 in West Timor. Preventive veterinary medicine. 2000 Nov 16; 47(3); 177-86. [PubMed: 11058778].
  41. Goldbaum et al., 1999: Goldbaum FA, Velikovsky CA, Baldi PC, Mortl S, Bacher A, Fossati CA. The 18-kDa cytoplasmic protein of Brucella species --an antigen useful for diagnosis--is a lumazine synthase. Journal of medical microbiology. 1999 Sep; 48(9); 833-9. [PubMed: 10482294 ].
  42. Guilloteau et al., 2006: Guilloteau LA, Laroucau K, Olivier M, Grillo MJ, Marin CM, Verger JM, Blasco JM. Residual virulence and immunogenicity of CGV26 and CGV2631 B. melitensis Rev. 1 deletion mutant strains in sheep after subcutaneous or conjunctival vaccination. Vaccine. 2006; 24(17); 3461-3468. [PubMed: 16519974].
  43. Gupta et al., 2007: Gupta VK, Rout PK, Vihan VS. Induction of immune response in mice with a DNA vaccine encoding outer membrane protein (omp31) of Brucella melitensis 16M. Research in veterinary science. 2007; 82(3); 305-313. [PubMed: 17014873].
  44. Hamdy et al., 2002: Hamdy ME, El-Gibaly SM, Montasser AM. Comparison between immune responses and resistance induced in BALB/c mice vaccinated with RB51 and Rev. 1 vaccines and challenged with Brucella melitensis bv. 3. Veterinary microbiology. 2002; 88(1); 85-94. [PubMed: 12119140].
  45. He et al., 2001: He Y, Vemulapalli R, Zeytun A, Schurig GG. Induction of specific cytotoxic lymphocytes in mice vaccinated with Brucella abortus RB51. Infection and immunity. 2001 Sep; 69(9); 5502-8. [PubMed: 11500423 ].
  46. He et al., 2002: He Y, Vemulapalli R, Schurig GG. Recombinant Ochrobactrum anthropi expressing Brucella abortus Cu,Zn superoxide dismutase protects mice against B. abortus infection only after switching of immune responses to Th1 type. Infection and immunity. 2002 May; 70(5); 2535-43. [PubMed: 11953393].
  47. Hemmen et al., 1995: Hemmen F, Weynants V, Scarcez T, Letesson JJ, Saman E. Cloning and sequence analysis of a newly identified Brucella abortus gene and serological evaluation of the 17-kilodalton antigen that it encodes. Clinical and diagnostic laboratory immunology. 1995 May; 2(3); 263-7. [PubMed: 7664168 ].
  48. High et al., 2007: High KP, Prasad R, Marion CR, Schurig GG, Boyle SM, Sriranganathan N. Outcome and immune responses after Brucella abortus infection in young adult and aged mice. Biogerontology. 2007; 8(5); 583-593. [PubMed: 17653832].
  49. Hoover et al., 1999: Hoover DL, Crawford RM, Van De Verg LL, Izadjoo MJ, Bhattacharjee AK, Paranavitana CM, Warren RL, Nikolich MP, Hadfield TL. Protection of mice against brucellosis by vaccination with Brucella melitensis WR201(16MDeltapurEK). Infection and immunity. 1999; 67(11); 5877-5884. [PubMed: 10531243].
  50. Hu et al., 2010: Hu XD, Chen ST, Li JY, Yu DH, Yi-Zhang, Cai H. An IL-15 adjuvant enhances the efficacy of a combined DNA vaccine against Brucella by increasing the CD8+ cytotoxic T cell response. Vaccine. 2010; 28(12); 2408-2415. [PubMed: 20064480].
  51. Izadjoo et al., 2004: Izadjoo MJ, Bhattacharjee AK, Paranavitana CM, Hadfield TL, Hoover DL. Oral vaccination with Brucella melitensis WR201 protects mice against intranasal challenge with virulent Brucella melitensis 16M. Infection and immunity. 2004; 72(7); 4031-4039. [PubMed: 15213148].
  52. Jacques et al., 2007: Jacques I, Verger JM, Laroucau K, Grayon M, Vizcaino N, Peix A, Cortade F, Carreras F, Guilloteau LA. Immunological responses and protective efficacy against Brucella melitensis induced by bp26 and omp31 B. melitensis Rev.1 deletion mutants in sheep. Vaccine. 2007 Jan 15; 25(5); 794-805. [PubMed: 17070627].
  53. Januszewski et al., 2001: Januszewski MC, Olsen SC, McLean RG, Clark L, Rhyan JC. Experimental infection of nontarget species of rodents and birds with Brucella abortus strain RB51 vaccine. Journal of wildlife diseases. 2001; 37(3); 532-537. [PubMed: 11504226].
  54. Jensen and Halling, 2008: Jensen AE, Halling SM. Effect of polymyxin B and environmental conditions on isolation of Brucella species and the vaccine strain RB51. Comparative immunology, microbiology and infectious diseases. 2008; ; . [PubMed: 18814911].
  55. Jiménez et al., 1994: Jiménez de Bagüés MP, Elzer PH, Jones SM, Blasco JM, Enright FM, Schurig GG, Winter AJ. Vaccination with Brucella abortus rough mutant RB51 protects BALB/c mice against virulent strains of Brucella abortus, Brucella melitensis, and Brucella ovis. Infection and immunity. 1994; 62(11); 4990-4996. [PubMed: 7927779].
  56. Kahl-McDonagh and Ficht, 2006: Kahl-McDonagh MM, Ficht TA. Evaluation of protection afforded by Brucella abortus and Brucella melitensis unmarked deletion mutants exhibiting different rates of clearance in BALB/c mice. Infection and immunity. 2006; 74(7); 4048-4057. [PubMed: 16790778].
  57. Kahl-McDonagh et al., 2007: Kahl-McDonagh MM, Arenas-Gamboa AM, Ficht TA. Aerosol infection of BALB/c mice with Brucella melitensis and Brucella abortus and protective efficacy against aerosol challenge. Infection and immunity. 2007; 75(10); 4923-4932. [PubMed: 17664263].
  58. Ko et al., 2002: Ko J, Gendron-Fitzpatrick A, Ficht TA, Splitter GA. Virulence criteria for Brucella abortus strains as determined by interferon regulatory factor 1-deficient mice. Infection and immunity. 2002; 70(12); 7004-7012. [PubMed: 12438380].
  59. Kohler et al., 2002: Kohler S, Foulongne V, Ouahrani-Bettache S, Bourg G, Teyssier J, Ramuz M, Liautard JP. The analysis of the intramacrophagic virulome of Brucella suis deciphers the environment encountered by the pathogen inside the macrophage host cell. Proceedings of the National Academy of Sciences of the United States of America. 2002 Nov 26; 99(24); 15711-6. [PubMed: 12438693 ].
  60. Kurar and Splitter, 1997: Kurar E, Splitter GA. Nucleic acid vaccination of Brucella abortus ribosomal L7/L12 gene elicits immune response. Vaccine. 1997; 15(17-18); 1851-1857. [PubMed: 9413093].
  61. Laplagne et al., 2004: Laplagne DA, Zylberman V, Ainciart N, Steward MW, Sciutto E, Fossati CA, Goldbaum FA. Engineering of a polymeric bacterial protein as a scaffold for the multiple display of peptides. Proteins. 2004 Dec 1; 57(4); 820-8. [PubMed: 15390265].
  62. Leclerq et al., 2002: Leclerq S, Harms JS, Rosinha GM, Azevedo V, Oliveira SC. Induction of a th1-type of immune response but not protective immunity by intramuscular DNA immunisation with Brucella abortus GroEL heat-shock gene. Journal of medical microbiology. 2002; 51(1); 20-26. [PubMed: 11803949].
  63. Lee et al., 1999: Lee IK, Olsen SC, Kehrli M, Bolin CA. The adjuvant effect of a single dose of interleukin-12 on murine immune responses to live or killed Brucella abortus strain RB51. Canadian journal of veterinary research = Revue canadienne de recherche veterinaire. 1999; 63(4); 284-287. [PubMed: 10534009].
  64. Lee et al., 2001: Lee IK, Olsen SC, Bolin CA. Effects of exogenous recombinant interleukin-12 on immune responses and protection against Brucella abortus in a murine model. Canadian journal of veterinary research = Revue canadienne de recherche veterinaire. 2001; 65(4); 223-228. [PubMed: 11768128].
  65. Letesson et al., 1997: Letesson JJ, Tibor A, van Eynde G, Wansard V, Weynants V, Denoel P, Saman E. Humoral immune responses of Brucella-infected cattle, sheep, and goats to eight purified recombinant Brucella proteins in an indirect enzyme-linked immunosorbent assay. Clinical and diagnostic laboratory immunology. 1997 Sep; 4(5); 556-64. [PubMed: 9302205].
  66. Li, 1991: Li HZ. [A pathohistological study on experimental brucellosis in inbred mice]. Zhonghua bing li xue za zhi Chinese journal of pathology. 1991 Jun; 20(2); 134-6. [PubMed: 1914022 ].
  67. Longo et al., 2009: Longo M, Mallardo K, Montagnaro S, De Martino L, Gallo S, Fusco G, Galiero G, Guarino A, Pagnini U, Iovane G. Shedding of Brucella abortus rough mutant strain RB51 in milk of water buffalo (Bubalus bubalis). Preventive veterinary medicine. 2009; 90(1-2); 113-118. [PubMed: 19362381].
  68. Luo et al., 2006a: Luo DY, Li P, Xing L, Zhao GY, Shi W, Zhang SL, Wang XL. DNA vaccine encoding L7/L12-P39 of Brucella abortus induces protective immunity in BALB/c mice. Chinese medical journal. 2006 Feb 20; 119(4); 331-4. [PubMed: 16537031].
  69. Luo et al., 2006b: Luo D, Ni B, Li P, Shi W, Zhang S, Han Y, Mao L, He Y, Wu Y, Wang X. Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of Brucella abortus in BALB/c mice. Infection and immunity. 2006; 74(5); 2734-2741. [PubMed: 16622210].
  70. Makar et al., 1975: Makar AB, McMartin KE, Palese M, Tephly TR. Formate assay in body fluids: application in methanol poisoning. Biochemical medicine. 1975; 13(2); 117-126. [PubMed: 1].
  71. Mallick et al., 2007: Mallick AI, Singha H, Khan S, Anwar T, Ansari MA, Khalid R, Chaudhuri P, Owais M. Escheriosome-mediated delivery of recombinant ribosomal L7/L12 protein confers protection against murine brucellosis. Vaccine. 2007; 25(46); 7873-7884. [PubMed: 17931756].
  72. Martins et al., 2009: Martins H, Garin-Bastuji B, Lima F, Flor L, Pina Fonseca A, Boinas F. Eradication of bovine brucellosis in the Azores, Portugal-Outcome of a 5-year programme (2002-2007) based on test-and-slaughter and RB51 vaccination. Preventive veterinary medicine. 2009; 90(1-2); 80-89. [PubMed: 19439382].
  73. Montaraz et al., 1986: Montaraz JA, Winter AJ. Comparison of living and nonliving vaccines for Brucella abortus in BALB/c mice. Infection and immunity. 1986 Aug; 53(2); 245-51. [PubMed: 3089933 ].
  74. Moriyon et al., 2004: Moriyon I, Grillo MJ, Monreal D, Gonzalez D, Marin C, Lopez-Goni I, Mainar-Jaime RC, Moreno E, Blasco JM. Rough vaccines in animal brucellosis: structural and genetic basis and present status. Veterinary research. 2004 Jan-Feb; 35(1); 1-38. [PubMed: 15099501].
  75. Munoz-Montesino et al., 2004: Munoz-Montesino C, Andrews E, Rivers R, Gonzalez-Smith A, Moraga-Cid G, Folch H, Cespedes S, Onate AA. Intraspleen delivery of a DNA vaccine coding for superoxide dismutase (SOD) of Brucella abortus induces SOD-specific CD4+ and CD8+ T cells. Infection and immunity. 2004 Apr; 72(4); 2081-7. [PubMed: 15039330].
  76. Nol et al., 2009: Nol P, Olsen SC, Rhyan JC. Experimental infection of Richardson's ground squirrels (Spermophilus richardsonii) with attenuated and virulent strains of Brucella abortus. Journal of wildlife diseases. 2009; 45(1); 189-195. [PubMed: 19204348].
  77. Oliveira et al., 1994: Oliveira SC, Zhu Y, Splitter G. Sequences of the rplJL operon containing the L10 and L7/L12 genes from Brucella abortus. Gene. 1994 Mar 11; 140(1); 137-8. [PubMed: 8125331 ].
  78. Oliveira et al., 1996: Oliveira SC, Splitter GA. Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. Vaccine. 1996 Jul; 14(10); 959-62. [PubMed: 8873388 ].
  79. Olsen et al., 2004: Olsen SC, Rhyan J, Gidlewski T, Goff J, Stoffregen WC. Safety of Brucella abortus strain RB51 in black bears. Journal of wildlife diseases. 2004; 40(3); 429-433. [PubMed: 15465709].
  80. Olsen et al., 2007: Olsen SC, Waters WR, Stoffregen WS. An aerosolized Brucella spp. challenge model for laboratory animals. Zoonoses and public health. 2007; 54(8); 281-285. [PubMed: 17894637].
  81. Olsen et al., 2009: Olsen SC, Boyle SM, Schurig GG, Sriranganathan NN. Immune responses and protection against experimental challenge after vaccination of bison with Brucella abortus strain RB51 or RB51 overexpressing superoxide dismutase and glycosyltransferase genes. Clinical and vaccine immunology : CVI. 2009; 16(4); 535-540. [PubMed: 19176693].
  82. Onate et al., 2003: Onate AA, Cespedes S, Cabrera A, Rivers R, Gonzalez A, Munoz C, Folch H, Andrews E. A DNA vaccine encoding Cu,Zn superoxide dismutase of Brucella abortus induces protective immunity in BALB/c mice. Infection and immunity. 2003 Sep; 71(9); 4857-61. [PubMed: 12933826].
  83. Palmer et al., 1996: Palmer MV, Cheville NF, Tatum FM. Morphometric and histopathologic analysis of lymphoid depletion in murine spleens following infection with Brucella abortus strains 2308 or RB51 or an htrA deletion mutant. Veterinary pathology. 1996; 33(3); 282-289. [PubMed: 8740701].
  84. Paranavitana et al., 2005: Paranavitana C, Zelazowska E, Izadjoo M, Hoover D. Interferon-gamma associated cytokines and chemokines produced by spleen cells from Brucella-immune mice. Cytokine. 2005; 30(2); 86-92. [PubMed: 15804600].
  85. Parent et al., 2007: Parent MA, Goenka R, Murphy E, Levier K, Carreiro N, Golding B, Ferguson G, Roop RM 2nd, Walker GC, Baldwin CL. Brucella abortus bacA mutant induces greater pro-inflammatory cytokines than the wild-type parent strain. Microbes and infection / Institut Pasteur. 2007; 9(1); 55-62. [PubMed: 17196866].
  86. Pasquali et al., 2001: Pasquali P, Adone R, Gasbarre LC, Pistoia C, Ciuchini F. Mouse cytokine profiles associated with Brucella abortus RB51 vaccination or B. abortus 2308 infection. Infection and immunity. 2001; 69(10); 6541-6544. [PubMed: 11553603].
  87. Pasquali et al., 2003: Pasquali P, Rosanna A, Pistoia C, Petrucci P, Ciuchini F. Brucella abortus RB51 induces protection in mice orally infected with the virulent strain B. abortus 2308. Infection and immunity. 2003; 71(5); 2326-2330. [PubMed: 12704101].
  88. Pasquevich et al., 2009: Pasquevich KA, Estein SM, García Samartino C, Zwerdling A, Coria LM, Barrionuevo P, Fossati CA, Giambartolomei GH, Cassataro J. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection. Infection and immunity. 2009; 77(1); 436-445. [PubMed: 18981242].
  89. Poester et al., 2006: Poester FP, Gonçalves VS, Paixão TA, Santos RL, Olsen SC, Schurig GG, Lage AP. Efficacy of strain RB51 vaccine in heifers against experimental brucellosis. Vaccine. 2006; 24(25); 5327-5334. [PubMed: 16713034].
  90. Rajasekaran et al., 2008: Rajasekaran P, Seleem MN, Contreras A, Purwantini E, Schurig GG, Sriranganathan N, Boyle SM. Brucella abortus strain RB51 leucine auxotroph as an environmentally safe vaccine for plasmid maintenance and antigen overexpression. Applied and environmental microbiology. 2008; 74(22); 7051-7055. [PubMed: 18836016].
  91. Ramamoorthy et al., 2007: Ramamoorthy S, Sanakkayala N, Vemulapalli R, Duncan RB, Lindsay DS, Schurig GS, Boyle SM, Kasimanickam R, Sriranganathan N. Prevention of lethal experimental infection of C57BL/6 mice by vaccination with Brucella abortus strain RB51 expressing Neospora caninum antigens. International journal for parasitology. 2007; 37(13); 1521-1529. [PubMed: 17568587].
  92. Roop et al., 2004: Roop RM 2nd, Bellaire BH, Valderas MW, Cardelli JA. Adaptation of the Brucellae to their intracellular niche. Molecular microbiology. 2004 May; 52(3); 621-30. [PubMed: 15101970 ].
  93. Rosinha et al., 2002a: Rosinha GM, Freitas DA, Miyoshi A, Azevedo V, Campos E, Cravero SL, Rossetti O, Splitter G, Oliveira SC. Identification and characterization of a Brucella abortus ATP-binding cassette transporter homolog to Rhizobium meliloti ExsA and its role in virulence and protection in mice. Infection and immunity. 2002; 70(9); 5036-5044. [PubMed: 12183550].
  94. Rosinha et al., 2002b: Rosinha GM, Myioshi A, Azevedo V, Splitter GA, Oliveira SC. Molecular and immunological characterisation of recombinant Brucella abortus glyceraldehyde-3-phosphate-dehydrogenase, a T- and B-cell reactive protein that induces partial protection when co-administered with an interleukin-12-expressing plasmid in a DNA vaccine formulation. Journal of medical microbiology. 2002; 51(8); 661-671. [PubMed: 12171297].
  95. Schurig et al., 1991: Schurig GG, Roop RM 2nd, Bagchi T, Boyle S, Buhrman D, Sriranganathan N. Biological properties of RB51; a stable rough strain of Brucella abortus. Veterinary microbiology. 1991 Jul; 28(2); 171-88. [PubMed: 1908158].
  96. Schurig et al., 2002: Schurig GG, Sriranganathan N, Corbel MJ. Brucellosis vaccines: past, present and future. Veterinary microbiology. 2002 Dec 20; 90(1-4); 479-96. [PubMed: 12414166].
  97. Sislema-Egas et al., 2012: Sislema-Egas F, Céspedes S, Fernández P, Retamal-Díaz A, Sáez D, Oñate A. Evaluation of protective effect of DNA vaccines encoding the BAB1_0263 and BAB1_0278 open reading frames of Brucella abortus in BALB/c mice. Vaccine. 2012; 30(50); 7286-7291. [PubMed: 23026687].
  98. Stevens et al., 1994a: Stevens MG, Olsen SC, Pugh GW Jr. Lymphocyte proliferation in response to Brucella abortus 2308 or RB51 antigens in mice infected with strain 2308, RB51, or 19. Infection and immunity. 1994; 62(10); 4659-4663. [PubMed: 7927736].
  99. Stevens et al., 1994b: Stevens MG, Olsen SC, Pugh GW Jr, Palmer MV. Immune and pathologic responses in mice infected with Brucella abortus 19, RB51, or 2308. Infection and immunity. 1994 Aug; 62(8); 3206-12. [PubMed: 8039890].
  100. Stevens et al., 1995a: Stevens MG, Olsen SC, Pugh GW Jr. Comparison of spleen cell proliferation in response to Brucella abortus 2308 lipopolysaccharide or proteins in mice vaccinated with strain 19 or RB51. Infection and immunity. 1995; 63(8); 3199-3205. [PubMed: 7622248].
  101. Stevens et al., 1995b: Stevens MG, Olsen SC, Pugh GW Jr, Brees D. Comparison of immune responses and resistance to brucellosis in mice vaccinated with Brucella abortus 19 or RB51. Infection and immunity. 1995; 63(1); 264-270. [PubMed: 7806364].
  102. Stevens et al., 1996: Stevens MG, Olsen SC, Palmer MV, Pugh GW Jr. Immune responses and resistance to brucellosis in mice vaccinated orally with Brucella abortus RB51. Infection and immunity. 1996; 64(11); 4534-4541. [PubMed: 8890203].
  103. Stoffregen et al., 2006: Stoffregen WC, Olsen SC, Bricker BJ. Parenteral vaccination of domestic pigs with Brucella abortus strain RB51. American journal of veterinary research. 2006; 67(10); 1802-1808. [PubMed: 17014337].
  104. Suryanarayana et al., 2016: Suryanarayana N, Verma M, Thavachelvam K, Saxena N, Mankere B, Tuteja U, Hmuaka V. Generation of a novel chimeric PALFn antigen of Bacillus anthracis and its immunological characterization in mouse model. Applied microbiology and biotechnology. 2016; 100(19); 8439-8451. [PubMed: 27364624].
  105. Tibor et al., 1998: Tibor A, Jacques I, Guilloteau L, Verger JM, Grayon M, Wansard V, Letesson JJ. Effect of P39 gene deletion in live Brucella vaccine strains on residual virulence and protective activity in mice. Infection and immunity. 1998; 66(11); 5561-5564. [PubMed: 9784574].
  106. Tobias et al., 1992: Tobias L, Schurig GG, Cordes DO. Comparative behaviour of Brucella abortus strains 19 and RB51 in the pregnant mouse. Research in veterinary science. 1992; 53(2); 179-183. [PubMed: 1439207].
  107. Trant et al., 2010: Trant CG, Lacerda TL, Carvalho NB, Azevedo V, Rosinha GM, Salcedo SP, Gorvel JP, Oliveira SC. The Brucella abortus phosphoglycerate kinase mutant is highly attenuated and induces protection superior to that of vaccine strain 19 in immunocompromised and immunocompetent mice. Infection and immunity. 2010; 78(5); 2283-2291. [PubMed: 20194591].
  108. Ugalde et al., 2003: Ugalde JE, Comerci DJ, Leguizamón MS, Ugalde RA. Evaluation of Brucella abortus phosphoglucomutase (pgm) mutant as a new live rough-phenotype vaccine. Infection and immunity. 2003; 71(11); 6264-6269. [PubMed: 14573645].
  109. Velikovsky et al., 2002: Velikovsky CA, Cassataro J, Giambartolomei GH, Goldbaum FA, Estein S, Bowden RA, Bruno L, Fossati CA, Spitz M. A DNA vaccine encoding lumazine synthase from Brucella abortus induces protective immunity in BALB/c mice. Infection and immunity. 2002 May; 70(5); 2507-11. [PubMed: 11953389 ].
  110. Vemulapalli et al., 2000a: Vemulapalli R, He Y, Cravero S, Sriranganathan N, Boyle SM, Schurig GG. Overexpression of protective antigen as a novel approach to enhance vaccine efficacy of Brucella abortus strain RB51. Infection and immunity. 2000 Jun; 68(6); 3286-9. [PubMed: 10816475].
  111. Vemulapalli et al., 2000b: Vemulapalli R, He Y, Buccolo LS, Boyle SM, Sriranganathan N, Schurig GG. Complementation of Brucella abortus RB51 with a functional wboA gene results in O-antigen synthesis and enhanced vaccine efficacy but no change in rough phenotype and attenuation. Infection and immunity. 2000 Jul; 68(7); 3927-32. [PubMed: 10858205].
  112. Vemulapalli et al., 2004: Vemulapalli R, Contreras A, Sanakkayala N, Sriranganathan N, Boyle SM, Schurig GG. Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice. Veterinary microbiology. 2004 Sep 8; 102(3-4); 237-45. [PubMed: 15327798].
  113. Wang et al., 2011: Wang Y, Bai Y, Qu Q, Xu J, Chen Y, Zhong Z, Qiu Y, Wang T, Du X, Wang Z, Yu S, Fu S, Yuan J, Zhen Q, Yu Y, Chen Z, Huang L. The 16MΔvjbR as an ideal live attenuated vaccine candidate for differentiation between Brucella vaccination and infection. Veterinary microbiology. 2011; ; . [PubMed: 21530111].
  114. Winter et al., 1988: Winter AJ, Rowe GE, Duncan JR, Eis MJ, Widom J, Ganem B, Morein B. Effectiveness of natural and synthetic complexes of porin and O polysaccharide as vaccines against Brucella abortus in mice. Infection and immunity. 1988; 56(11); 2808-2817. [PubMed: 2844673].
  115. Winter et al., 1996: Winter AJ, Schurig GG, Boyle SM, Sriranganathan N, Bevins JS, Enright FM, Elzer PH, Kopec JD. Protection of BALB/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4. American journal of veterinary research. 1996 May; 57(5); 677-83. [PubMed: 8723881].
  116. Xin, 1986: Xin X. Orally administrable brucellosis vaccine: Brucella suis strain 2 vaccine. Vaccine. 1986; 4(4); 212-216. [PubMed: 3541425].
  117. Yang et al., 2006: Yang X, Becker T, Walters N, Pascual DW. Deletion of znuA virulence factor attenuates Brucella abortus and confers protection against wild-type challenge. Infection and immunity. 2006; 74(7); 3874-3879. [PubMed: 16790759].
  118. Yang et al., 2007: Yang X, Walters N, Robison A, Trunkle T, Pascual DW. Nasal immunization with recombinant Brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization. Vaccine. 2007; 25(12); 2261-2268. [PubMed: 17239499].
  119. Yu et al., 2007: Yu DH, Hu XD, Cai H. A combined DNA vaccine encoding BCSP31, SOD, and L7/L12 confers high protection against Brucella abortus 2308 by inducing specific CTL responses. DNA and cell biology. 2007 Jun; 26(6); 435-43. [PubMed: 17570767].
  120. Yu et al., 2007: Yu DH, Li M, Hu XD, Cai H. A combined DNA vaccine enhances protective immunity against Mycobacterium tuberculosis and Brucella abortus in the presence of an IL-12 expression vector. Vaccine. 2007; 25(37-38); 6744-6754. [PubMed: 17681650].

Burkholderia pseudomallei

  1. Breitbach et al., 2008: Breitbach K, Köhler J, Steinmetz I. Induction of protective immunity against Burkholderia pseudomallei using attenuated mutants with defects in the intracellular life cycle. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2008; 102 Suppl 1; S89-94. [PubMed: 19121696].
  2. Casey et al., 2016: Casey WT, Spink N, Cia F, Collins C, Romano M, Berisio R, Bancroft GJ, McClean S. Identification of an OmpW homologue in Burkholderia pseudomallei, a protective vaccine antigen against melioidosis. Vaccine. 2016; 34(23); 2616-2621. [PubMed: 27091689].
  3. Chen et al., 2006: Chen YS, Hsiao YS, Lin HH, Yen CM, Chen SC, Chen YL. Immunogenicity and anti-Burkholderia pseudomallei activity in Balb/c mice immunized with plasmid DNA encoding flagellin. Vaccine. 2006; 24(6); 750-758. [PubMed: 16169637].
  4. Druar et al., 2008: Druar C, Yu F, Barnes JL, Okinaka RT, Chantratita N, Beg S, Stratilo CW, Olive AJ, Soltes G, Russell ML, Limmathurotsakul D, Norton RE, Ni SX, Picking WD, Jackson PJ, Stewart DI, Tsvetnitsky V, Picking WL, Cherwonogrodzky JW, Ketheesan N, Peacock SJ, Wiersma EJ. Evaluating Burkholderia pseudomallei Bip proteins as vaccines and Bip antibodies as detection agents. FEMS immunology and medical microbiology. 2008; 52(1); 78-87. [PubMed: 17995960].
  5. Gourlay et al., 2015: Gourlay LJ, Thomas RJ, Peri C, Conchillo-Solé O, Ferrer-Navarro M, Nithichanon A, Vila J, Daura X, Lertmemongkolchai G, Titball R, Colombo G, Bolognesi M. From crystal structure to in silico epitope discovery in the Burkholderia pseudomallei flagellar hook-associated protein FlgK. The FEBS journal. 2015; 282(7); 1319-1333. [PubMed: 25645451].
  6. Haque et al., 2006: Haque A, Chu K, Easton A, Stevens MP, Galyov EE, Atkins T, Titball R, Bancroft GJ. A live experimental vaccine against Burkholderia pseudomallei elicits CD4+ T cell-mediated immunity, priming T cells specific for 2 type III secretion system proteins. The Journal of infectious diseases. 2006; 194(9); 1241-1248. [PubMed: 17041850].
  7. Harland et al., 2007: Harland DN, Chu K, Haque A, Nelson M, Walker NJ, Sarkar-Tyson M, Atkins TP, Moore B, Brown KA, Bancroft G, Titball RW, Atkins HS. Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis. Infection and immunity. 2007; 75(8); 4173-4180. [PubMed: 17517877].
  8. Harland et al., 2007: Harland DN, Chu K, Haque A, Nelson M, Walker NJ, Sarkar-Tyson M, Atkins TP, Moore B, Brown KA, Bancroft G, Titball RW, Atkins HS. Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis. Infection and immunity. 2007; 75(8); 4173-4180. [PubMed: 17517877].
  9. Nelson et al., 2004: Nelson M, Prior JL, Lever MS, Jones HE, Atkins TP, Titball RW. Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. Journal of medical microbiology. 2004; 53(Pt 12); 1177-1182. [PubMed: 15585494].
  10. Norris et al., 2011: Norris MH, Propst KL, Kang Y, Dow SW, Schweizer HP, Hoang TT. The Burkholderia pseudomallei {Delta}asd mutant exhibits attenuated intracellular infectivity and imparts protection against acute inhalation melioidosis in mice. Infection and immunity. 2011; ; . [PubMed: 21807903].
  11. Srilunchang et al., 2009: Srilunchang T, Proungvitaya T, Wongratanacheewin S, Strugnell R, Homchampa P. Construction and characterization of an unmarked aroC deletion mutant of Burkholderia pseudomallei strain A2. The Southeast Asian journal of tropical medicine and public health. 2009; 40(1); 123-130. [PubMed: 19323044].
  12. Tippayawat et al., 2009: Tippayawat P, Saenwongsa W, Mahawantung J, Suwannasaen D, Chetchotisakd P, Limmathurotsakul D, Peacock SJ, Felgner PL, Atkins HS, Titball RW, Bancroft GJ, Lertmemongkolchai G. Phenotypic and functional characterization of human memory T cell responses to Burkholderia pseudomallei. PLoS neglected tropical diseases. 2009; 3(4); e407. [PubMed: 19352426].
  13. Wiki: B. pseudomallei: Wiki: B. pseudomallei [http://en.wikipedia.org/wiki/Burkholderia_pseudomallei]
  14. Woo et al., 2001: Woo PC, Leung PK, Wong SS, Ho PL, Yuen KY. groEL encodes a highly antigenic protein in Burkholderia pseudomallei. Clinical and diagnostic laboratory immunology. 2001; 8(4); 832-836. [PubMed: 11427437].

Campylobacter fetus

  1. Thompson, 2002: Thompson SA. Campylobacter surface-layers (S-layers) and immune evasion. Annals of periodontology / the American Academy of Periodontology. 2002; 7(1); 43-53. [PubMed: 16013216].

Campylobacter jejuni

  1. Abimiku et al., 1989: Abimiku AG, Dolby JM, Borriello SP. Comparison of different vaccines and induced immune response against Campylobacter jejuni colonization in the infant mouse. Epidemiology and infection. 1989 Apr; 102(2); 271-80. [PubMed: 2703020 ].
  2. Abulreesh et al., 2006: Abulreesh HH, Paget TA, Goulder R. Campylobacter in waterfowl and aquatic environments: incidence and methods of detection. Environmental science & technology. 2006 Dec 1; 40(23); 7122-31. [PubMed: 17180958].
  3. Andrews, 1998: Andrews GP. The enteric Campylobacter: they are everywhere. Clinical laboratory science : journal of the American Society for Medical Technology. 1998 Sep-Oct; 11(5); 305-8. [PubMed: 10186956].
  4. Baqar et al., 1995a: Baqar S, Bourgeois AL, Schultheiss PJ, Walker RI, Rollins DM, Haberberger RL, Pavlovskis OR. Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates. Vaccine. 1995 Jan; 13(1); 22-8. [PubMed: 7539199].
  5. Baqar et al., 1995b: Baqar S, Applebee LA, Bourgeois AL. Immunogenicity and protective efficacy of a prototype Campylobacter killed whole-cell vaccine in mice. Infection and immunity. 1995 Sep; 63(9); 3731-5. [PubMed: 7642317].
  6. Baqar et al., 2008: Baqar S, Applebee LA, Gilliland TC Jr, Lee LH, Porter CK, Guerry P. Immunogenicity and protective efficacy of recombinant Campylobacter jejuni flagellum-secreted proteins in mice. Infection and immunity. 2008; 76(7); 3170-3175. [PubMed: 18426878].
  7. Buckley et al., 2010: Buckley AM, Wang J, Hudson DL, Grant AJ, Jones MA, Maskell DJ, Stevens MP. Evaluation of live-attenuated Salmonella vaccines expressing Campylobacter antigens for control of C. jejuni in poultry. Vaccine. 2010; 28(4); 1094-1105. [PubMed: 19853682].
  8. Burr et al., 2005: Burr DH, Rollins D, Lee LH, Pattarini DL, Walz SS, Tian JH, Pace JL, Bourgeois AL, Walker RI. Prevention of disease in ferrets fed an inactivated whole cell Campylobacter jejuni vaccine. Vaccine. 2005 Jul 29; 23(34); 4315-21. [PubMed: 16005742 ].
  9. Chintoan-Uta et al., 2015: Chintoan-Uta C, Cassady-Cain RL, Al-Haideri H, Watson E, Kelly DJ, Smith DG, Sparks NH, Kaiser P, Stevens MP. Superoxide dismutase SodB is a protective antigen against Campylobacter jejuni colonisation in chickens. Vaccine. 2015; 33(46); 6206-6211. [PubMed: 26458797].
  10. Dolby et al., 1986: Dolby JM, Newell DG. The protection of infant mice from colonization with Campylobacter jejuni by vaccination of the dams. The Journal of hygiene. 1986 Apr; 96(2); 143-51. [PubMed: 3701036 ].
  11. Engberg, 2006: Engberg J. Contributions to the epidemiology of Campylobacter infections. A review of clinical and microbiological studies. Danish medical bulletin. 2006 Nov; 53(4); 361-89. [PubMed: 17150145].
  12. Heimesaat et al., 2014: Heimesaat MM, Alutis M, Grundmann U, Fischer A, Tegtmeyer N, Böhm M, Kühl AA, Göbel UB, Backert S, Bereswill S. The role of serine protease HtrA in acute ulcerative enterocolitis and extra-intestinal immune responses during Campylobacter jejuni infection of gnotobiotic IL-10 deficient mice. Frontiers in cellular and infection microbiology. 2014; 4; 77. [PubMed: 24959425].
  13. Huang et al., 2007: Huang S, Sahin O, Zhang Q. Infection-induced antibodies against the major outer membrane protein of Campylobacter jejuni mainly recognize conformational epitopes. FEMS microbiology letters. 2007 Jul; 272(2); 137-43. [PubMed: 17521366].
  14. Huang et al., 2007: Huang S, Sahin O, Zhang Q. Infection-induced antibodies against the major outer membrane protein of Campylobacter jejuni mainly recognize conformational epitopes. FEMS microbiology letters. 2007; 272(2); 137-143. [PubMed: 17521366].
  15. Islam et al., 2010: Islam A, Raghupathy R, Albert MJ. Recombinant PorA, the major outer membrane protein of Campylobacter jejuni, provides heterologous protection in an adult mouse intestinal colonization model. Clinical and vaccine immunology : CVI. 2010; 17(11); 1666-1671. [PubMed: 20861330].
  16. Islam et al., 2010: Islam A, Raghupathy R, Albert MJ. Recombinant PorA, the major outer membrane protein of Campylobacter jejuni, provides heterologous protection in an adult mouse intestinal colonization model. Clinical and vaccine immunology : CVI. 2010; 17(11); 1666-1671. [PubMed: 20861330].
  17. Jagusztyn-Krynicka et al., 2004: Jagusztyn-Krynicka EK, Wyszynska A, Raczko A. New approaches to development of mucosal vaccine against enteric bacterial pathogens; preventing campylobacteriosis. Polish journal of microbiology / Polskie Towarzystwo Mikrobiologow = The Polish Society of Microbiologists. 2004; 53 Suppl; 7-15. [PubMed: 15787191].
  18. Khoury et al., 1995: Khoury CA, Meinersmann RJ. A genetic hybrid of the Campylobacter jejuni flaA gene with LT-B of Escherichia coli and assessment of the efficacy of the hybrid protein as an oral chicken vaccine. Avian diseases. 1995 Oct-Dec; 39(4); 812-20. [PubMed: 8719215 ].
  19. Kopecko, 1997: Kopecko DJ. Regulatory considerations for Campylobacter vaccine development. The Journal of infectious diseases. 1997 Dec; 176 Suppl 2; S189-91. [PubMed: 9396709].
  20. Lee et al., 1999: Lee LH, Burg E 3rd, Baqar S, Bourgeois AL, Burr DH, Ewing CP, Trust TJ, Guerry P. Evaluation of a truncated recombinant flagellin subunit vaccine against Campylobacter jejuni. Infection and immunity. 1999 Nov; 67(11); 5799-805. [PubMed: 10531231].
  21. Martin et al., 1999: Martin PR, Mulks MH. Cloning and characterization of a gene encoding an antigenic membrane protein from Actinobacillus pleuropneumoniae with homology to ABC transporters. FEMS immunology and medical microbiology. 1999 Aug 15; 25(3); 245-54. [PubMed: 10459579].
  22. Nelson et al., 2007: Nelson JM, Chiller TM, Powers JH, Angulo FJ. Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007 Apr 1; 44(7); 977-80. [PubMed: 17342653].
  23. Pawelec et al., 1997: Pawelec D, Rozynek E, Popowski J, Jagusztyn-Krynicka EK. Cloning and characterization of a Campylobacter jejuni 72Dz/92 gene encoding a 30 kDa immunopositive protein, component of the ABC transport system; expression of the gene in avirulent Salmonella typhimurium. FEMS immunology and medical microbiology. 1997 Oct; 19(2); 137-50. [PubMed: 9395059].
  24. Pawelec et al., 2000: Pawelec DP, Korsak D, Wyszynska AK, Rozynek E, Popowski J, Jagusztyn-Krynicka EK. Genetic diversity of the Campylobacter genes coding immunodominant proteins. FEMS microbiology letters. 2000 Apr 1; 185(1); 43-9. [PubMed: 10731605].
  25. Prokhorova et al., 2006: Prokhorova TA, Nielsen PN, Petersen J, Kofoed T, Crawford JS, Morsczeck C, Boysen A, Schrotz-King P. Novel surface polypeptides of Campylobacter jejuni as traveller's diarrhoea vaccine candidates discovered by proteomics. Vaccine. 2006 Sep 29; 24(40-41); 6446-55. [PubMed: 16824653].
  26. Rice et al., 1997: Rice BE, Rollins DM, Mallinson ET, Carr L, Joseph SW. Campylobacter jejuni in broiler chickens: colonization and humoral immunity following oral vaccination and experimental infection. Vaccine. 1997 Dec; 15(17-18); 1922-32. [PubMed: 9413103 ].
  27. Scott, 1997: Scott DA. Vaccines against Campylobacter jejuni. The Journal of infectious diseases. 1997 Dec; 176 Suppl 2; S183-8. [PubMed: 9396708].
  28. Shoaf-Sweeney et al., 2008: Shoaf-Sweeney KD, Larson CL, Tang X, Konkel ME. Identification of Campylobacter jejuni proteins recognized by maternal antibodies of chickens. Applied and environmental microbiology. 2008; 74(22); 6867-6875. [PubMed: 18805999].
  29. Sizemore et al., 2006: Sizemore DR, Warner B, Lawrence J, Jones A, Killeen KP. Live, attenuated Salmonella typhimurium vectoring Campylobacter antigens. Vaccine. 2006 May 1; 24(18); 3793-803. [PubMed: 16135393].
  30. Smibert, 1978: Smibert RM. The genus Campylobacter. Annual review of microbiology. 1978; 32; 673-709. [PubMed: 360978].
  31. Theoret et al., 2012: Theoret JR, Cooper KK, Zekarias B, Roland KL, Law BF, Curtiss R 3rd, Joens LA. The Campylobacter jejuni Dps homologue is important for in vitro biofilm formation and cecal colonization of poultry and may serve as a protective antigen for vaccination. Clinical and vaccine immunology : CVI. 2012; 19(9); 1426-1431. [PubMed: 22787197].
  32. Walker, 2005: Walker RI. Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries. Vaccine. 2005 May 16; 23(26); 3369-85. [PubMed: 15837361].
  33. Wallis, 2004: Wallis TS. Vaccination against salmonella, enterohaemorrhagic E. coli and Campylobacter in food-producing animals. Developments in biologicals. 2004; 119; 343-50. [PubMed: 15742645].
  34. White et al., 1997: White PL, Baker AR, James WO. Strategies to control Salmonella and Campylobacter in raw poultry products. Revue scientifique et technique (International Office of Epizootics). 1997 Aug; 16(2); 525-41. [PubMed: 9501366].
  35. Wilkinson et al., 2003: Wilkinson J, Rood D, Minior D, Guillard K, Darre M, Silbart LK. Immune response to a mucosally administered aflatoxin B1 vaccine. Poultry science. 2003 Oct; 82(10); 1565-72. [PubMed: 14601734].
  36. Wyszynska et al., 2004: Wyszynska A, Raczko A, Lis M, Jagusztyn-Krynicka EK. Oral immunization of chickens with avirulent Salmonella vaccine strain carrying C. jejuni 72Dz/92 cjaA gene elicits specific humoral immune response associated with protection against challenge with wild-type Campylobacter. Vaccine. 2004 Mar 29; 22(11-12); 1379-89. [PubMed: 15063560 ].
  37. Yeh et al., 2015: Yeh HY, Hiett KL, Line JE. Reactions of chicken sera to recombinant Campylobacter jejuni flagellar proteins. Archives of microbiology. 2015; 197(2); 353-358. [PubMed: 25413671].
  38. Zeng et al., 2009: Zeng X, Xu F, Lin J. Molecular, antigenic, and functional characteristics of ferric enterobactin receptor CfrA in Campylobacter jejuni. Infection and immunity. 2009; 77(12); 5437-5448. [PubMed: 19737895].
  39. Zheng et al., 2007: Zheng H, Cai FC, Zhong M, Deng B, Li X, Zhang XP. [Experimental study on the chitosan-DNA vaccines against campylobacter jejuni invasion]. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]. 2007; 41(5); 375-379. [PubMed: 18206008].

Canarypox virus

  1. Tulman et al., 2004: Tulman ER, Afonso CL, Lu Z, Zsak L, Kutish GF, Rock DL. The genome of canarypox virus. Journal of virology. 2004; 78(1); 353-366. [PubMed: 14671117].

Cancer

  1. Aarntzen et al., 2012: Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ, Croockewit AJ, de Wilt JH, van Rossum MM, Blokx WA, Jacobs JF, Duiveman-de Boer T, Schuurhuis DH, Mus R, Thielemans K, de Vries IJ, Figdor CG, Punt CJ, Adema GJ. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012; 18(19); 5460-5470. [PubMed: 22896657].
  2. Aarntzen et al., 2013: Aarntzen EH, Srinivas M, Bonetto F, Cruz LJ, Verdijk P, Schreibelt G, van de Rakt M, Lesterhuis WJ, van Riel M, Punt CJ, Adema GJ, Heerschap A, Figdor CG, Oyen WJ, de Vries IJ. Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013; 19(6); 1525-1533. [PubMed: 23382117].
  3. Abate-Daga et al., 2013: Abate-Daga D, Hanada K, Davis JL, Yang JC, Rosenberg SA, Morgan RA. Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. Blood. 2013; 122(8); 1399-1410. [PubMed: 23861247].
  4. Abkin et al., 2013: Abkin SV, Pankratova KM, Komarova EY, Guzhova IV, Margulis BA. Hsp70 chaperone-based gel composition as a novel immunotherapeutic anti-tumor tool. Cell stress & chaperones. 2013; 18(3); 391-396. [PubMed: 23233202].
  5. Adamina et al., 2010: Adamina M, Rosenthal R, Weber WP, Frey DM, Viehl CT, Bolli M, Huegli RW, Jacob AL, Heberer M, Oertli D, Marti W, Spagnoli GC, Zajac P. Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma. Molecular therapy : the journal of the American Society of Gene Therapy. 2010; 18(3); 651-659. [PubMed: 19935776].
  6. Adams et al., 2008: Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, Cruz CM, Angiulli A, Angiulli F, Ritter E, Holman RM, Shapiro RL, Berman RS, Berner N, Shao Y, Manches O, Pan L, Venhaus RR, Hoffman EW, Jungbluth A, Gnjatic S, Old L, Pavlick AC, Bhardwaj N. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. Journal of immunology (Baltimore, Md. : 1950). 2008; 181(1); 776-784. [PubMed: 18566444].
  7. Agarwala et al., 2004: Agarwala SS, Neuberg D, Park Y, Kirkwood JM. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer. 2004; 100(8); 1692-1698. [PubMed: 15073858].
  8. Ahlers et al., 1993: Ahlers JD, Pendleton CD, Dunlop N, Minassian A, Nara PL, Berzofsky JA. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations. Journal of immunology (Baltimore, Md. : 1950). 1993; 150(12); 5647-5665. [PubMed: 8515081].
  9. Ahlers et al., 2006: Ahlers CM, Camphausen K, Citrin D, Arlen PM, Gulley JL. A pilot trial of a carcinoembryonic antigen/ TRICOM-based vaccine and radiation to liver metastases in patients with carcinoembryonic antigen-positive solid tumors. Clinical colorectal cancer. 2006; 6(1); 72-75. [PubMed: 16796796].
  10. Ahmad et al., 2009: Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC. Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Molecular therapy : the journal of the American Society of Gene Therapy. 2009; 17(6); 1101-1108. [PubMed: 19337234].
  11. Ahmad et al., 2010: Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC. Optimised electroporation mediated DNA vaccination for treatment of prostate cancer. Genetic vaccines and therapy. 2010; 8(1); 1. [PubMed: 20181099].
  12. Akagi et al., 1997: Akagi J, Hodge JW, McLaughlin JP, Gritz L, Mazzara G, Kufe D, Schlom J, Kantor JA. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7. Journal of immunotherapy (Hagerstown, Md. : 1997). 1997; 20(1); 38-47. [PubMed: 9101412].
  13. Akbulut et al., 2010: Akbulut H, Tang Y, Akbulut KG, Maynard J, Deisseroth A. Addition of adenoviral vector targeting of chemotherapy to the MUC-1/ecdCD40L VPPP vector prime protein boost vaccine prolongs survival of mice carrying growing subcutaneous deposits of Lewis lung cancer cells. Gene therapy. 2010; 17(11); 1333-1340. [PubMed: 20596057].
  14. Alvarez et al., 2016: Alvarez RD, Huh WK, Bae S, Lamb LS Jr, Conner MG, Boyer J, Wang C, Hung CF, Sauter E, Paradis M, Adams EA, Hester S, Jackson BE, Wu TC, Trimble CL. A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3). Gynecologic oncology. 2016; 140(2); 245-252. [PubMed: 26616223].
  15. Alvarez-Salas, 2008: Alvarez-Salas LM. Amolimogene bepiplasmid, a DNA-based therapeutic encoding the E6 and E7 epitopes from HPV, for cervical and anal dysplasia. Current opinion in molecular therapeutics. 2008; 10(6); 622-628. [PubMed: 19051140].
  16. Alves et al., 2003: Alves PM, Faure O, Graff-Dubois S, Gross DA, Cornet S, Chouaib S, Miconnet I, Lemonnier FA, Kosmatopoulos K. EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. Cancer research. 2003; 63(23); 8476-8480. [PubMed: 14679012].
  17. Amin et al., 2015: Amin A, Dudek AZ, Logan TF, Lance RS, Holzbeierlein JM, Knox JJ, Master VA, Pal SK, Miller WH Jr, Karsh LI, Tcherepanova IY, DeBenedette MA, Williams WL, Plessinger DC, Nicolette CA, Figlin RA. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. Journal for immunotherapy of cancer. 2015; 3; 14. [PubMed: 25901286].
  18. Angsantikul et al., 2018: Angsantikul P, Fang RH, Zhang L. Toxoid Vaccination against Bacterial Infection Using Cell Membrane-Coated Nanoparticles. Bioconjugate chemistry. 2018; 29(3); 604-612. [PubMed: 29241006].
  19. Aragon-Ching et al., 2007: Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Frontiers in bioscience : a journal and virtual library. 2007; 12; 4957-4971. [PubMed: 17569623].
  20. Archer, Gary: PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma (PRiME) [https://clinicaltrials.gov/ct2/show/NCT03299309]
  21. Ardon et al., 2010: Ardon H, Van Gool S, Lopes IS, Maes W, Sciot R, Wilms G, Demaerel P, Bijttebier P, Claes L, Goffin J, Van Calenbergh F, De Vleeschouwer S. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. Journal of neuro-oncology. 2010; 99(2); 261-272. [PubMed: 20146084].
  22. Arlen et al., 2003: Arlen PM, Gulley JL, Palena C, Marshall J, Schlom J, Tsang KY. A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1. Journal of immunological methods. 2003; 279(1-2); 183-192. [PubMed: 12969559].
  23. Arlen et al., 2003: Arlen PM, Gulley JL, Tsang KY, Schlom J. Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer. Expert review of vaccines. 2003; 2(4); 483-493. [PubMed: 14711334].
  24. Arlen et al., 2007: Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, Feldman J, Poole DJ, Litzinger M, Steinberg SM, Jones E, Chen C, Marte J, Parnes H, Wright J, Dahut W, Schlom J, Gulley JL. Clinical safety of a viral vector based prostate cancer vaccine strategy. The Journal of urology. 2007; 178(4 Pt 1); 1515-1520. [PubMed: 17707059].
  25. Ascher et al., 1979: Ascher NL, Ahrenholz DH, Simmons RL, Weiblen B, Gomez L, Forstrom LA, Frick MP, Henke C, McCullough J. Indium 111 autologous tagged leukocytes in the diagnosis of intraperitoneal sepsis. Archives of surgery (Chicago, Ill. : 1960). 1979; 114(4); 386-392. [PubMed: 107925].
  26. Aspord et al., 2010: Aspord C, Charles J, Leccia MT, Laurin D, Richard MJ, Chaperot L, Plumas J. A novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells. PloS one. 2010; 5(5); e10458. [PubMed: 20454561].
  27. Aspord et al., 2012: Aspord C, Leccia MT, Salameire D, Laurin D, Chaperot L, Charles J, Plumas J. HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients. The Journal of investigative dermatology. 2012; 132(10); 2395-2406. [PubMed: 22696054].
  28. Atencio et al., 2006: Atencio IA, Grace M, Bordens R, Fritz M, Horowitz JA, Hutchins B, Indelicato S, Jacobs S, Kolz K, Maneval D, Musco ML, Shinoda J, Venook A, Wen S, Warren R. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial. Cancer gene therapy. 2006; 13(2); 169-181. [PubMed: 16082381].
  29. Avril et al., 2012: Avril T, Vauleon E, Hamlat A, Saikali S, Etcheverry A, Delmas C, Diabira S, Mosser J, Quillien V. Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells. Brain pathology (Zurich, Switzerland). 2012; 22(2); 159-174. [PubMed: 21790828].
  30. Ayyoub et al., 2001: Ayyoub M, Migliaccio M, Guillaume P, Liénard D, Cerottini JC, Romero P, Lévy F, Speiser DE, Valmori D. Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. European journal of immunology. 2001; 31(9); 2642-2651. [PubMed: 11536162].
  31. Backlund et al., 2022: Backlund CM, Holden RL, Moynihan KD, Garafola D, Farquhar C, Mehta NK, Maiorino L, Pham S, Iorgulescu JB, Reardon DA, Wu CJ, Pentelute BL, Irvine DJ. Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity. Proceedings of the National Academy of Sciences of the United States of America. 2022; 119(32); e2204078119. [PubMed: 35914154].
  32. Bae et al., 2009: Bae MY, Cho NH, Seong SY. Protective anti-tumour immune responses by murine dendritic cells pulsed with recombinant Tat-carcinoembryonic antigen derived from Escherichia coli. Clinical and experimental immunology. 2009; 157(1); 128-138. [PubMed: 19659778].
  33. Bae et al., 2012: Bae J, Smith R, Daley J, Mimura N, Tai YT, Anderson KC, Munshi NC. Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012; 18(17); 4850-4860. [PubMed: 22753586].
  34. Baghdadi et al., 2013: Baghdadi M, Nagao H, Yoshiyama H, Akiba H, Yagita H, Dosaka-Akita H, Jinushi M. Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. Cancer immunology, immunotherapy : CII. 2013; 62(4); 629-637. [PubMed: 23143694].
  35. Bahy et al., 2016: Bahy RH, Hamouda HM, Shahat AS, Yassin AS, Amin MA. Development and evaluation of a novel vaccine against prevalent invasive multi-drug resistant strains of Streptococcus pneumoniae. PeerJ. 2016; 4; e2737. [PubMed: 27917323].
  36. Baird et al., 2013: Baird JR, Byrne KT, Lizotte PH, Toraya-Brown S, Scarlett UK, Alexander MP, Sheen MR, Fox BA, Bzik DJ, Bosenberg M, Mullins DW, Turk MJ, Fiering S. Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge. Journal of immunology (Baltimore, Md. : 1950). 2013; 190(1); 469-478. [PubMed: 23225891].
  37. Baldueva et al., 2012: Baldueva IA, Novik AV, Moiseenko VM, Nekhaeva TL, Danilova AB, Danilov AO, Protsenko SA, Petrova TIu, UleÄ­skaia GI, Shchekina LA, Semenova AI, MikhaÄ­lichenko TD, Teletaeva GM, Zhabina AS, Volkov NV, Komarov IuI. [Phase II clinical trial of autologous dendritic cell vaccine with immunologic adjuvant in cutaneous melanoma patients]. Voprosy onkologii. 2012; 58(2); 212-221. [PubMed: 22774527].
  38. Balint et al., 2015: Balint JP, Gabitzsch ES, Rice A, Latchman Y, Xu Y, Messerschmidt GL, Chaudhry A, Morse MA, Jones FR. Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer. Cancer immunology, immunotherapy : CII. 2015; 64(8); 977-987. [PubMed: 25956394].
  39. Bartal and Robinson, 1987: Bartal AH, Robinson E. Novel approach to MER/BCG administration in cancer patients. Cancer investigation. 1987; 5(1); 1-5. [PubMed: 3580942].
  40. Barth et al., 2010: Barth RJ Jr, Fisher DA, Wallace PK, Channon JY, Noelle RJ, Gui J, Ernstoff MS. A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010; 16(22); 5548-5556. [PubMed: 20884622].
  41. Bartholomew et al., 2002: Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Experimental hematology. 2002; 30(1); 42-48. [PubMed: 11823036].
  42. Barton et al., 2021: Barton KN, Siddiqui F, Pompa R, Freytag SO, Khan G, Dobrosotskaya I, Ajlouni M, Zhang Y, Cheng J, Movsas B, Kwon D. Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancer. Molecular therapy oncolytics. 2021; 20; 94-9104. [PubMed: 33575474].
  43. Basak et al., 2000: Basak S, Eck S, Gutzmer R, Smith AJ, Birebent B, Purev E, Staib L, Somasundaram R, Zaloudik J, Li W, Jacob L, Mitchell E, Speicher D, Herlyn D. Colorectal cancer vaccines: antiidiotypic antibody, recombinant protein, and viral vector. Annals of the New York Academy of Sciences. 2000; 910; 237-252. [PubMed: 10911917].
  44. Battiwalla and Hematti, 2009: Battiwalla M, Hematti P. Mesenchymal stem cells in hematopoietic stem cell transplantation. Cytotherapy. 2009; 11(5); 503-515. [PubMed: 19728189].
  45. Baudard et al., 2007: Baudard M, Comte F, Conge AM, Mariano-Goulart D, Klein B, Rossi JF. Importance of [18F]fluorodeoxyglucose-positron emission tomography scanning for the monitoring of responses to immunotherapy in follicular lymphoma. Leukemia & lymphoma. 2007; 48(2); 381-388. [PubMed: 17325900].
  46. Baumgaertner et al., 2022: Baumgaertner P, Schmidt J, Costa-Nunes CM, Bordry N, Guillaume P, Luescher I, Speiser DE, Rufer N, Hebeisen M. CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity. Frontiers in immunology. 2022; 13; 973986. [PubMed: 36032094].
  47. Baxter et al., 2016: Baxter R, Hansen J, Timbol J, Pool V, Greenberg DP, Johnson DR, Decker MD. Post-licensure safety surveillance study of routine use of tetanus toxoid, reduced diphtheria toxoid and 5-component acellular pertussis vaccine. Human vaccines & immunotherapeutics. 2016; 12(11); 2742-2748. [PubMed: 27388557].
  48. Beachler et al., 2016: Beachler DC, Kreimer AR, Schiffman M, Herrero R, Wacholder S, Rodriguez AC, Lowy DR, Porras C, Schiller JT, Quint W, Jimenez S, Safaeian M, Struijk L, Schussler J, Hildesheim A, Gonzalez P. Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection. Journal of the National Cancer Institute. 2016; 108(1); . [PubMed: 26467666].
  49. Becker et al., 2010: Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, McNeel DG. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. Journal of immunotherapy (Hagerstown, Md. : 1997). 2010; 33(6); 639-647. [PubMed: 20551832].
  50. Bedke and Stenzl, 2013: Bedke J, Stenzl A. IMA901: a peptide vaccine in renal cell carcinoma. Expert opinion on investigational drugs. 2013; 22(10); 1329-1336. [PubMed: 23899354].
  51. Beebe et al., 2008: Beebe M, Qin M, Moi M, Wu S, Heiati H, Walker L, Newman M, Fikes J, Ishioka GY. Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy. Human vaccines. 2008; 4(3); 210-218. [PubMed: 18382135].
  52. Benagiano et al., 1973: Benagiano A, Firu P, Zarnea L. [Old and new methods in the prevention of dental caries]. Stomatologia. 1973; 20(1); 1-18. [PubMed: 4510871].
  53. Benteyn et al., 2013: Benteyn D, Van Nuffel AM, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A. Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). BioMed research international. 2013; 2013; 976383. [PubMed: 23509826].
  54. Benvenuti et al., 2000: Benvenuti F, Burrone OR, Efremov DG. Anti-idiotypic DNA vaccines for lymphoma immunotherapy require the presence of both variable region genes for tumor protection. Gene therapy. 2000; 7(7); 605-611. [PubMed: 10819576].
  55. Berd et al., 1997: Berd D, Maguire HC Jr, Schuchter LM, Hamilton R, Hauck WW, Sato T, Mastrangelo MJ. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997; 15(6); 2359-2370. [PubMed: 9196151].
  56. Berd et al., 2001: Berd D, Sato T, Cohn H, Maguire HC Jr, Mastrangelo MJ. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. International journal of cancer. 2001; 94(4); 531-539. [PubMed: 11745440].
  57. Berd et al., 2004: Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004; 22(3); 403-415. [PubMed: 14691123].
  58. Bergman et al., 2003: Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D, Wulderk M, Jeffers Y, Sadelain M, Hohenhaus AE, Segal N, Gregor P, Engelhorn M, Riviere I, Houghton AN, Wolchok JD. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003; 9(4); 1284-1290. [PubMed: 12684396].
  59. Berinstein et al., 2012: Berinstein NL, Karkada M, Morse MA, Nemunaitis JJ, Chatta G, Kaufman H, Odunsi K, Nigam R, Sammatur L, MacDonald LD, Weir GM, Stanford MM, Mansour M. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. Journal of translational medicine. 2012; 10; 156. [PubMed: 22862954].
  60. Berinstein et al., 2015: Berinstein NL, Karkada M, Oza AM, Odunsi K, Villella JA, Nemunaitis JJ, Morse MA, Pejovic T, Bentley J, Buyse M, Nigam R, Weir GM, MacDonald LD, Quinton T, Rajagopalan R, Sharp K, Penwell A, Sammatur L, Burzykowski T, Stanford MM, Mansour M. Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. Oncoimmunology. 2015; 4(8); e1026529. [PubMed: 26405584].
  61. Bernhardt et al., 2006: Bernhardt SL, Gjertsen MK, Trachsel S, Møller M, Eriksen JA, Meo M, Buanes T, Gaudernack G. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. British journal of cancer. 2006; 95(11); 1474-1482. [PubMed: 17060934].
  62. Bernstein et al., 2008: Bernstein MB, Chakraborty M, Wansley EK, Guo Z, Franzusoff A, Mostböck S, Sabzevari H, Schlom J, Hodge JW. Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells. Vaccine. 2008; 26(4); 509-521. [PubMed: 18155327].
  63. Bertino et al., 2013: Bertino P, Panigada M, Soprana E, Bianchi V, Bertilaccio S, Sanvito F, Rose AH, Yang H, Gaudino G, Hoffmann PR, Siccardi A, Carbone M. Fowlpox-based survivin vaccination for malignant mesothelioma therapy. International journal of cancer. 2013; 133(3); 612-623. [PubMed: 23335100].
  64. Berzofsky et al., 1991: Berzofsky JA, Pendleton CD, Clerici M, Ahlers J, Lucey DR, Putney SD, Shearer GM. Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types. The Journal of clinical investigation. 1991; 88(3); 876-884. [PubMed: 1715888].
  65. Berzofsky et al., 2001: Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nature reviews. Immunology. 2001; 1(3); 209-219. [PubMed: 11905830].
  66. Berzofsky et al., 2004: Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris JC. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. The Journal of clinical investigation. 2004; 113(11); 1515-1525. [PubMed: 15173875].
  67. Bettinotti et al., 2003: Bettinotti MP, Panelli MC, Ruppe E, Mocellin S, Phan GQ, White DE, Marincola FM. Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178. International journal of cancer. Journal international du cancer. 2003; 105(2); 210-216. [PubMed: 12673681].
  68. Bilgi et al., 1979: Bilgi C, Brown NE, McPherson TA, Lentle B. Pulmonary manifestations in patients with malignant melanoma during BCG immunotherapy. A preliminary report. Chest. 1979; 75(6); 685-687. [PubMed: 436519].
  69. Bjoern et al., 2016: Bjoern J, Iversen TZ, Nitschke NJ, Andersen MH, Svane IM. Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab. Cytotherapy. 2016; 18(8); 1043-1055. [PubMed: 27378345].
  70. Blalock et al., 2012: Blalock LT, Landsberg J, Messmer M, Shi J, Pardee AD, Haskell R, Vujanovic L, Kirkwood JM, Butterfield LH. Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. Oncoimmunology. 2012; 1(3); 287-357. [PubMed: 22737604].
  71. Boczkowski et al., 2009: Boczkowski D, Lee J, Pruitt S, Nair S. Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. Cancer gene therapy. 2009; 16(12); 900-911. [PubMed: 19498460].
  72. Boilesen et al., 2023: Boilesen DR, Neckermann P, Willert T, Müller MD, Schrödel S, Pertl C, Thirion C, Asbach B, Wagner R, Holst PJ. Efficacy and Synergy with Cisplatin of an Adenovirus Vectored Therapeutic E1E2E6E7 Vaccine against HPV Genome-Positive C3 Cancers in Mice. Cancer immunology research. 2023; 11(2); 261-275. [PubMed: 36534088].
  73. Bol et al., 2015: Bol KF, Figdor CG, Aarntzen EH, Welzen ME, van Rossum MM, Blokx WA, van de Rakt MW, Scharenborg NM, de Boer AJ, Pots JM, Olde Nordkamp MA, van Oorschot TG, Mus RD, Croockewit SA, Jacobs JF, Schuler G, Neyns B, Austyn JM, Punt CJ, Schreibelt G, de Vries IJ. Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients. Oncoimmunology. 2015; 4(8); e1019197. [PubMed: 26405571].
  74. Bollard et al., 2011: Bollard CM, Gottschalk S, Helen Huls M, Leen AM, Gee AP, Rooney CM. Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma. Cytotherapy. 2011; 13(5); 518-522. [PubMed: 21361747].
  75. Borch et al., 2016: Borch TH, Engell-Noerregaard L, Zeeberg Iversen T, Ellebaek E, Met Ö, Hansen M, Andersen MH, Thor Straten P, Svane IM. mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma. Oncoimmunology. 2016; 5(9); e1207842. [PubMed: 27757300].
  76. Borrello et al., 2009: Borrello IM, Levitsky HI, Stock W, Sher D, Qin L, DeAngelo DJ, Alyea EP, Stone RM, Damon LE, Linker CA, Maslyar DJ, Hege KM. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood. 2009; 114(9); 1736-1745. [PubMed: 19556425].
  77. Bowen et al., 2002: Bowen GP, Borgland SL, Lam M, Libermann TA, Wong NC, Muruve DA. Adenovirus vector-induced inflammation: capsid-dependent induction of the C-C chemokine RANTES requires NF-kappa B. Human gene therapy. 2002; 13(3); 367-379. [PubMed: 11860704].
  78. Braga et al., 2009: Braga CJ, Rittner GM, Muñoz Henao JE, Teixeira AF, Massis LM, Sbrogio-Almeida ME, Taborda CP, Travassos LR, Ferreira LC. Paracoccidioides brasiliensis vaccine formulations based on the gp43-derived P10 sequence and the Salmonella enterica FliC flagellin. Infection and immunity. 2009; 77(4); 1700-1707. [PubMed: 19204092].
  79. Bramante et al., 2014: Bramante S, Koski A, Kipar A, Diaconu I, Liikanen I, Hemminki O, Vassilev L, Parviainen S, Cerullo V, Pesonen SK, Oksanen M, Heiskanen R, Rouvinen-Lagerström N, Merisalo-Soikkeli M, Hakonen T, Joensuu T, Kanerva A, Pesonen S, Hemminki A. Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. International journal of cancer. 2014; 135(3); 720-730. [PubMed: 24374597].
  80. Braun et al., 2012: Braun M, Jandus C, Maurer P, Hammann-Haenni A, Schwarz K, Bachmann MF, Speiser DE, Romero P. Virus-like particles induce robust human T-helper cell responses. European journal of immunology. 2012; 42(2); 330-340. [PubMed: 22057679].
  81. Brayer et al., 2015: Brayer J, Lancet JE, Powers J, List A, Balducci L, Komrokji R, Pinilla-Ibarz J. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides. American journal of hematology. 2015; 90(7); 602-607. [PubMed: 25802083].
  82. Brockstedt et al., 2004: Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, Luckett W, Liu W, Cook DN, Portnoy DA, Dubensky TW Jr. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(38); 13832-13837. [PubMed: 15365184].
  83. Brockstedt et al., 2005: Brockstedt DG, Bahjat KS, Giedlin MA, Liu W, Leong M, Luckett W, Gao Y, Schnupf P, Kapadia D, Castro G, Lim JY, Sampson-Johannes A, Herskovits AA, Stassinopoulos A, Bouwer HG, Hearst JE, Portnoy DA, Cook DN, Dubensky TW Jr. Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nature medicine. 2005; 11(8); 853-860. [PubMed: 16041382].
  84. Broder et al., 2000: Broder H, Anderson A, Odesa SK, Kremen TJ, Liau LM. Recombinant adenovirus-transduced dendritic cell immunization in a murine model of central nervous system tumor. Neurosurgical focus. 2000; 9(6); e6. [PubMed: 16817689].
  85. Brooks et al., 2015: Brooks SE, Bonney SA, Lee C, Publicover A, Khan G, Smits EL, Sigurdardottir D, Arno M, Li D, Mills KI, Pulford K, Banham AH, van Tendeloo V, Mufti GJ, Rammensee HG, Elliott TJ, Orchard KH, Guinn BA. Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis. PloS one. 2015; 10(10); e0140483. [PubMed: 26492414].
  86. Brown et al., 2020: Brown TA 2nd, Mittendorf EA, Hale DF, Myers JW 3rd, Peace KM, Jackson DO, Greene JM, Vreeland TJ, Clifton GT, Ardavanis A, Litton JK, Shumway NM, Symanowski J, Murray JL, Ponniah S, Anastasopoulou EA, Pistamaltzian NF, Baxevanis CN, Perez SA, Papamichail M, Peoples GE. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence. Breast cancer research and treatment. 2020; 181(2); 391-401. [PubMed: 32323103].
  87. Brun et al., 2018: Brun JL, Rajaonarison J, Nocart N, Hoarau L, Brun S, Garrigue I. Targeted immunotherapy of high-grade cervical intra-epithelial neoplasia: Expectations from clinical trials. Molecular and clinical oncology. 2018; 8(2); 227-235. [PubMed: 29435283].
  88. Bu et al., 2024: Bu W, Kumar A, Board NL, Kim J, Dowdell K, Zhang S, Lei Y, Hostal A, Krogmann T, Wang Y, Pittaluga S, Marcotrigiano J, Cohen JI. Epstein-Barr virus gp42 antibodies reveal sites of vulnerability for receptor binding and fusion to B cells. Immunity. 2024; 57(3); 559-573.e6. [PubMed: 38479361].
  89. Buchan et al., 2005: Buchan S, Grønevik E, Mathiesen I, King CA, Stevenson FK, Rice J. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen. Journal of immunology (Baltimore, Md. : 1950). 2005; 174(10); 6292-6298. [PubMed: 15879128].
  90. Burke et al., 2012: Burke JM, Lamm DL, Meng MV, Nemunaitis JJ, Stephenson JJ, Arseneau JC, Aimi J, Lerner S, Yeung AW, Kazarian T, Maslyar DJ, McKiernan JM. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. The Journal of urology. 2012; 188(6); 2391-2397. [PubMed: 23088985].
  91. Burkhardt and Wu, 2013: Burkhardt UE, Wu CJ. Boosting leukemia-specific T cell responses in patients following stem cell transplantation. Oncoimmunology. 2013; 2(11); e26587. [PubMed: 24482749].
  92. Burkhardt et al., 2013: Burkhardt UE, Hainz U, Stevenson K, Goldstein NR, Pasek M, Naito M, Wu D, Ho VT, Alonso A, Hammond NN, Wong J, Sievers QL, Brusic A, McDonough SM, Zeng W, Perrin A, Brown JR, Canning CM, Koreth J, Cutler C, Armand P, Neuberg D, Lee JS, Antin JH, Mulligan RC, Sasada T, Ritz J, Soiffer RJ, Dranoff G, Alyea EP, Wu CJ. Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. The Journal of clinical investigation. 2013; 123(9); 3756-3765. [PubMed: 23912587].
  93. Butterfield et al., 2006: Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, Duran SD, Hernandez J, Seja E, Potter DM, McBride WH, Finn R, Glaspy JA, Economou JS. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006; 12(9); 2817-2825. [PubMed: 16675576].
  94. Butterfield et al., 2008: Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang JQ, Vu HT, Seja E, Oseguera DK, Potter DM, Glaspy JA, Economou JS, Ribas A. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. Journal of immunotherapy (Hagerstown, Md. : 1997). 2008; 31(3); 294-309. [PubMed: 18317358].
  95. Butterfield et al., 2014: Butterfield LH, Economou JS, Gamblin TC, Geller DA. Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients. Journal of translational medicine. 2014; 12; 86. [PubMed: 24708667].
  96. Byrne et al., 1983: Byrne MJ, Van Hazel G, Reynolds PM, Lemish WM, Holman CD. Adjuvant immunotherapy with BCG in stage II malignant melanoma. Journal of surgical oncology. 1983; 23(2); 114-116. [PubMed: 6343725].
  97. Cacciavillano et al., 2015: Cacciavillano W, Sampor C, Venier C, Gabri MR, de Dávila MT, Galluzzo ML, Guthmann MD, Fainboim L, Alonso DF, Chantada GL. A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies. Pediatric blood & cancer. 2015; 62(12); 2120-2124. [PubMed: 26154941].
  98. Cafri et al., 2020: Cafri G, Gartner JJ, Zaks T, Hopson K, Levin N, Paria BC, Parkhurst MR, Yossef R, Lowery FJ, Jafferji MS, Prickett TD, Goff SL, McGowan CT, Seitter S, Shindorf ML, Parikh A, Chatani PD, Robbins PF, Rosenberg SA. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. The Journal of clinical investigation. 2020; 130(11); 5976-5988. [PubMed: 33016924].
  99. Campbell et al., 2000: Campbell I, Moyana T, Carlsen S, Zheng C, Xiang J. Adenoviral transfer of xenogeneic MHC class I gene results in loss of tumorigenicity and inhibition of tumor growth. Cancer gene therapy. 2000; 7(1); 37-44. [PubMed: 10678354].
  100. Campisano et al., 2013: Campisano S, Mac Keon S, Gazzaniga S, Ruiz MS, Traian MD, Mordoh J, Wainstok R. Anti-melanoma vaccinal capacity of CD11c-positive and -negative cell populations present in GM-CSF cultures derived from murine bone marrow precursors. Vaccine. 2013; 31(2); 354-361. [PubMed: 23146677].
  101. Carbone et al., 2005: Carbone DP, Ciernik IF, Kelley MJ, Smith MC, Nadaf S, Kavanaugh D, Maher VE, Stipanov M, Contois D, Johnson BE, Pendleton CD, Seifert B, Carter C, Read EJ, Greenblatt J, Top LE, Kelsey MI, Minna JD, Berzofsky JA. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005; 23(22); 5099-5107. [PubMed: 15983396].
  102. Carpentier et al., 1998: Carpentier AF, Rosenfeld MR, Delattre JY, Whalen RG, Posner JB, Dalmau J. DNA vaccination with HuD inhibits growth of a neuroblastoma in mice. Clinical cancer research : an official journal of the American Association for Cancer Research. 1998; 4(11); 2819-2824. [PubMed: 9829748].
  103. Carreno et al., 2013: Carreno BM, Becker-Hapak M, Huang A, Chan M, Alyasiry A, Lie WR, Aft RL, Cornelius LA, Trinkaus KM, Linette GP. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. The Journal of clinical investigation. 2013; 123(8); 3383-3394. [PubMed: 23867552].
  104. Carter and Plosker, 2008: Carter NJ, Plosker GL. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2008; 22(5); 279-292. [PubMed: 18778110].
  105. Cassaday et al., 2007: Cassaday RD, Sondel PM, King DM, Macklin MD, Gan J, Warner TF, Zuleger CL, Bridges AJ, Schalch HG, Kim KM, Hank JA, Mahvi DM, Albertini MR. A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007; 13(2 Pt 1); 540-549. [PubMed: 17255276].
  106. Cassel et al., 1983: Cassel WA, Murray DR, Phillips HS. A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer. 1983; 52(5); 856-860. [PubMed: 6871827].
  107. Castel et al., 1991: Castel T, Estapé J, Viñolas N, Mascaró JM, Castro J, Vilalta A, Gratacós R, Daniels M, Palou J, Grau JJ. Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy. Dermatologica. 1991; 183(1); 25-30. [PubMed: 1769411].
  108. Chaise et al., 2008: Chaise C, Buchan SL, Rice J, Marquet J, Rouard H, Kuentz M, Vittes GE, Molinier-Frenkel V, Farcet JP, Stauss HJ, Delfau-Larue MH, Stevenson FK. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood. 2008; 112(7); 2956-2964. [PubMed: 18502835].
  109. Charoensit et al., 2008: Charoensit P, Kawakami S, Higuchi Y, Hashida M. Incorporation of all-trans retinoic acid into lipoplexes inhibits nuclear factor kappaB activation mediated liver injury induced by lipoplexes in mice. The journal of gene medicine. 2008; 10(1); 61-69. [PubMed: 18001002].
  110. Chen et al., 1994: Chen L, McGowan P, Ashe S, Johnston JV, Hellström I, Hellström KE. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Cancer research. 1994; 54(20); 5420-5423. [PubMed: 7522958].
  111. Chen et al., 1997: Chen K, Braun S, Lyman S, Fan Y, Traycoff CM, Wiebke EA, Gaddy J, Sledge G, Broxmeyer HE, Cornetta K. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer research. 1997; 57(16); 3511-3516. [PubMed: 9270021].
  112. Chen et al., 2012: Chen J, Zhang L, Wen W, Hao J, Zeng P, Qian X, Zhang Y, Yin Y. Induction of HCA587-specific antitumor immunity with HCA587 protein formulated with CpG and ISCOM in mice. PloS one. 2012; 7(10); e47219. [PubMed: 23071764].
  113. Chen et al., 2014: Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, Daphtary MM, Garrett-Mayer E, Davidson NE, Hirt K, Berg M, Uram JN, Dauses T, Fetting J, Duus EM, Atay-Rosenthal S, Ye X, Wolff AC, Stearns V, Jaffee EM, Emens LA. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer immunology research. 2014; 2(10); 949-961. [PubMed: 25116755].
  114. Chen et al., 2015: Chen JL, Dawoodji A, Tarlton A, Gnjatic S, Tajar A, Karydis I, Browning J, Pratap S, Verfaille C, Venhaus RR, Pan L, Altman DG, Cebon JS, Old LL, Nathan P, Ottensmeier C, Middleton M, Cerundolo V. NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus. International journal of cancer. 2015; 136(6); E590-601. [PubMed: 25081390].
  115. Chen et al., 2017: Chen J, Guo XZ, Li HY, Zhao JJ, Xu WD. Dendritic cells engineered to secrete anti-DcR3 antibody augment cytotoxic T lymphocyte response against pancreatic cancer in vitro. World journal of gastroenterology. 2017; 23(5); 817-829. [PubMed: 28223726].
  116. Chiappori et al., 2010: Chiappori AA, Soliman H, Janssen WE, Antonia SJ, Gabrilovich DI. INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert opinion on biological therapy. 2010; 10(6); 983-991. [PubMed: 20420527].
  117. Chick et al., 2021: Chick RC, Clifton GT, Hale DF, Vreeland TJ, Hickerson AT, Kemp Bohan PM, McCarthy PM, Litton JK, Alatrash G, Murthy RK, Qiao N, Philips A, Lukas J, Holmes JP, Mittendorf EA, Peoples GE. Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer. Clinical immunology (Orlando, Fla.). 2021; 225; 108679. [PubMed: 33485895].
  118. Chodon et al., 2014: Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014; 20(9); 2457-2465. [PubMed: 24634374].
  119. Choi et al., 2007: Choi Y, Jeon YH, Kang JH, Chung JK, Schmidt M, Kim AC. MIDGE/hNIS vaccination generates antigen-associated CD8+IFN-gamma+ T cells and enhances protective antitumor immunity. International journal of cancer. Journal international du cancer. 2007; 120(9); 1942-1950. [PubMed: 17266027].
  120. Chudley et al., 2012: Chudley L, McCann K, Mander A, Tjelle T, Campos-Perez J, Godeseth R, Creak A, Dobbyn J, Johnson B, Bass P, Heath C, Kerr P, Mathiesen I, Dearnaley D, Stevenson F, Ottensmeier C. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. Cancer immunology, immunotherapy : CII. 2012; ; . [PubMed: 22729556].
  121. Chung et al., 2022: Chung DJ, Sharma S, Rangesa M, DeWolf S, Elhanati Y, Perica K, Young JW. Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant. Blood advances. 2022; 6(5); 1547-1558. [PubMed: 35100339].
  122. Clark et al., 2009: Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. The New England journal of medicine. 2009; 361(25); 2424-2435. [PubMed: 19745215].
  123. Clarke et al., 1995: Clarke MF, Apel IJ, Benedict MA, Eipers PG, Sumantran V, González-García M, Doedens M, Fukunaga N, Davidson B, Dick JE, Minn AJ, Boise LH, Thompson CB, Wicha M, Núñez G. A recombinant bcl-x s adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells. Proceedings of the National Academy of Sciences of the United States of America. 1995; 92(24); 11024-11028. [PubMed: 7479929].
  124. Clerici et al., 1991: Clerici M, Lucey DR, Zajac RA, Boswell RN, Gebel HM, Takahashi H, Berzofsky JA, Shearer GM. Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. Journal of immunology (Baltimore, Md. : 1950). 1991; 146(7); 2214-2219. [PubMed: 1826020].
  125. Clinical trial NCT03544723: Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors [https://clinicaltrials.gov/ct2/show/NCT03544723]
  126. Clunie et al., 1980: Clunie GJ, Gough IR, Dury M, Furnival CM, Bolton PM. A trial of imidazole carboxamide and corynebacterium parvum in disseminated melanoma: clinical and immunologic results. Cancer. 1980; 46(3); 475-479. [PubMed: 6994866].
  127. Cochlovius et al., 1999: Cochlovius B, Linnebacher M, Zewe-Welschof M, Zöller M. Recombinant gp100 protein presented by dendritic cells elicits a T-helper-cell response in vitro and in vivo. International journal of cancer. 1999; 83(4); 547-554. [PubMed: 10508493].
  128. Cochlovius et al., 2002: Cochlovius B, Stassar MJ, Schreurs MW, Benner A, Adema GJ. Oral DNA vaccination: antigen uptake and presentation by dendritic cells elicits protective immunity. Immunology letters. 2002; 80(2); 89-96. [PubMed: 11750039].
  129. Cochran et al., 1981: Cochran AJ, Buyse ME, Lejeune FJ, Macher E, Revuz J, Rümke P. Adjuvant reactivity predicts survival in patients with "high-risk" primary malignant melanoma treated with systemic BCG. EORTC Malignant Melanoma Cooperative Group Writing Committee. International journal of cancer. Journal international du cancer. 1981; 28(5); 543-550. [PubMed: 7309294].
  130. Cohen and Rudin, 2001: Cohen EE, Rudin CM. ONYX-015. Onyx Pharmaceuticals. Current opinion in investigational drugs (London, England : 2000). 2001; 2(12); 1770-1775. [PubMed: 11892945].
  131. Cohen et al., 1978: Cohen MH, Jessup JM, Felix EL, Weese JL, Herberman RB. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene. Cancer. 1978; 41(6); 2456-2463. [PubMed: 657108].
  132. Cohen et al., 2005: Cohen CJ, Zheng Z, Bray R, Zhao Y, Sherman LA, Rosenberg SA, Morgan RA. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. Journal of immunology (Baltimore, Md. : 1950). 2005; 175(9); 5799-5808. [PubMed: 16237072].
  133. Cohen et al., 2006: Cohen AD, Diab A, Perales MA, Wolchok JD, Rizzuto G, Merghoub T, Huggins D, Liu C, Turk MJ, Restifo NP, Sakaguchi S, Houghton AN. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer research. 2006; 66(9); 4904-4912. [PubMed: 16651447].
  134. Connerotte et al., 2008: Connerotte T, Van Pel A, Godelaine D, Tartour E, Schuler-Thurner B, Lucas S, Thielemans K, Schuler G, Coulie PG. Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer research. 2008; 68(10); 3931-3940. [PubMed: 18483279].
  135. Conry et al., 2002: Conry RM, Curiel DT, Strong TV, Moore SE, Allen KO, Barlow DL, Shaw DR, LoBuglio AF. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002; 8(9); 2782-2787. [PubMed: 12231517].
  136. Cornelissen et al., 2016: Cornelissen R, Hegmans JP, Maat AP, Kaijen-Lambers ME, Bezemer K, Hendriks RW, Hoogsteden HC, Aerts JG. Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma. American journal of respiratory and critical care medicine. 2016; 193(9); 1023-1031. [PubMed: 26652184].
  137. Corrales-Rodriguez et al., 2011: Corrales-Rodriguez L, Blais N, Soulières D. Emepepimut-S for non-small cell lung cancer. Expert opinion on biological therapy. 2011; 11(8); 1091-1097. [PubMed: 21689064].
  138. Correa, 1988: Correa A. [Impressions in relation to periodontal tissue]. Revista de la Federacion Odontologica Colombiana. 1988; 38(164); 55-63. [PubMed: 3077513].
  139. Correale et al., 1998: Correale P, Walmsley K, Zaremba S, Zhu M, Schlom J, Tsang KY. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. Journal of immunology (Baltimore, Md. : 1950). 1998; 161(6); 3186-3194. [PubMed: 9743387].
  140. Correale et al., 2005: Correale P, Cusi MG, Del Vecchio MT, Aquino A, Prete SP, Tsang KY, Micheli L, Nencini C, La Placa M, Montagnani F, Terrosi C, Caraglia M, Formica V, Giorgi G, Bonmassar E, Francini G. Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. Journal of immunology (Baltimore, Md. : 1950). 2005; 175(2); 820-828. [PubMed: 16002679].
  141. Coveler et al., 2016: Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG. Algenpantucel-L immunotherapy in pancreatic adenocarcinoma. Immunotherapy. 2016; 8(2); 117-125. [PubMed: 26787078].
  142. Crum et al., 2004: Crum CP, Beach KJ, Hedley ML, Yuan L, Lee KR, Wright TC, Urban RG. Dynamics of human papillomavirus infection between biopsy and excision of cervical intraepithelial neoplasia: results from the ZYC101a protocol. The Journal of infectious diseases. 2004; 189(8); 1348-1354. [PubMed: 15073670].
  143. Culos and Cuellar, 2013: Culos KA, Cuellar S. Novel targets in the treatment of advanced melanoma: new first-line treatment options. The Annals of pharmacotherapy. 2013; 47(4); 519-526. [PubMed: 23548648].
  144. Curigliano et al., 2016: Curigliano G, Romieu G, Campone M, Dorval T, Duck L, Canon JL, Roemer-Becuwe C, Roselli M, Neciosup S, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF. A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer. Breast cancer research and treatment. 2016; 156(2); 301-310. [PubMed: 26975189].
  145. Currie and McElwain, 1975: Currie GA, McElwain TJ. Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study. British journal of cancer. 1975; 31(2); 143-156. [PubMed: 1164466].
  146. Czerniecki et al., 2007: Czerniecki BJ, Roses RE, Koski GK. Development of vaccines for high-risk ductal carcinoma in situ of the breast. Cancer research. 2007; 67(14); 6531-6534. [PubMed: 17638860].
  147. Czerniecki et al., 2007: Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, Nisenbaum H, Pasha T, Xu M, Fox KR, Weinstein S, Orel SG, Vonderheide R, Coukos G, DeMichele A, Araujo L, Spitz FR, Rosen M, Levine BL, June C, Zhang PJ. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer research. 2007; 67(4); 1842-1852. [PubMed: 17293384].
  148. Czerwinska et al., 2020: Czerwinska P, Rucinski M, Wlodarczyk N, Jaworska A, Grzadzielewska I, Gryska K, Galus L, Mackiewicz J, Mackiewicz A. Therapeutic melanoma vaccine with cancer stem cell phenotype represses exhaustion and maintains antigen-specific T cell stemness by up-regulating BCL6. Oncoimmunology. 2020; 9(1); 1710063. [PubMed: 32002306].
  149. D'Souza et al., 2016: D'Souza G, Westra WH, Wang SJ, van Zante A, Wentz A, Kluz N, Rettig E, Ryan WR, Ha PK, Kang H, Bishop J, Quon H, Kiess AP, Richmon JD, Eisele DW, Fakhry C. Differences in the Prevalence of Human Papillomavirus (HPV) in Head and Neck Squamous Cell Cancers by Sex, Race, Anatomic Tumor Site, and HPV Detection Method. JAMA oncology. 2016; ; . [PubMed: 27930766].
  150. Dalet et al., 2011: Dalet A, Stroobant V, Vigneron N, Van den Eynde BJ. Differences in the production of spliced antigenic peptides by the standard proteasome and the immunoproteasome. European journal of immunology. 2011; 41(1); 39-46. [PubMed: 21182075].
  151. Daley et al., 1978: Daley MJ, Gebel HM, Lynch RG. Idiotype-specific transplantation resistance to MOPC-315: abrogation by post-immunization thymectomy. Journal of immunology (Baltimore, Md. : 1950). 1978; 120(5); 1620-1624. [PubMed: 77876].
  152. Date et al., 1996: Date Y, Kimura A, Kato H, Sasazuki T. DNA typing of the HLA-A gene: population study and identification of four new alleles in Japanese. Tissue antigens. 1996; 47(2); 93-101. [PubMed: 8851721].
  153. Dauer et al., 2005: Dauer M, Herten J, Bauer C, Renner F, Schad K, Schnurr M, Endres S, Eigler A. Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells. Journal of immunotherapy (Hagerstown, Md. : 1997). 2005; 28(4); 332-342. [PubMed: 16000951].
  154. de et al., 2004: de Bono JS, Rha SY, Stephenson J, Schultes BC, Monroe P, Eckhardt GS, Hammond LA, Whiteside TL, Nicodemus CF, Cermak JM, Rowinsky EK, Tolcher AW. Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Annals of oncology : official journal of the European Society for Medical Oncology. 2004; 15(12); 1825-1833. [PubMed: 15550589].
  155. de et al., 2014: de Rosa F, Ridolfi L, Ridolfi R, Gentili G, Valmorri L, Nanni O, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Riccobon A, Parisi E, Romeo A, Turci L, Guidoboni M. Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study. Journal of translational medicine. 2014; 12; 209. [PubMed: 25053129].
  156. Deacon et al., 1982: Deacon SP, Langford DT, Shepherd WM, Knight PA. A comparative clinical study of Adsorbed Tetanus Vaccine and Adult-type Tetanus-Diphtheria Vaccine. The Journal of hygiene. 1982; 89(3); 513-519. [PubMed: 7153515].
  157. Deans and Moseley, 2000: Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Experimental hematology. 2000; 28(8); 875-884. [PubMed: 10989188].
  158. Delhem et al., 1998: Delhem N, Hadida F, Gorochov G, Carpentier F, de Cavel JP, Andréani JF, Autran B, Cesbron JY. Primary Th1 cell immunization against HIVgp160 in SCID-hu mice coengrafted with peripheral blood lymphocytes and skin. Journal of immunology (Baltimore, Md. : 1950). 1998; 161(4); 2060-2069. [PubMed: 9712080].
  159. DeMeritt et al., 2004: DeMeritt IB, Milford LE, Yurochko AD. Activation of the NF-kappaB pathway in human cytomegalovirus-infected cells is necessary for efficient transactivation of the major immediate-early promoter. Journal of virology. 2004; 78(9); 4498-4507. [PubMed: 15078930].
  160. Deng et al., 2018: Deng W, Lira V, Hudson TE, Lemmens EE, Hanson WG, Flores R, Barajas G, Katibah GE, Desbien AL, Lauer P, Leong ML, Portnoy DA, Dubensky TW Jr. Recombinant Listeria promotes tumor rejection by CD8+ T cell-dependent remodeling of the tumor microenvironment. Proceedings of the National Academy of Sciences of the United States of America. 2018; 115(32); 8179-8184. [PubMed: 30038013].
  161. Derré et al., 2016: Derré L, Cesson V, Lucca I, Cerantola Y, Valerio M, Fritschi U, Vlamopoulos Y, Burruni R, Legris AS, Dartiguenave F, Gharbi D, Martin V, Vaucher L, Speiser DE, Romero P, Jichlinski P, Nardelli-Haefliger D. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016; ; . [PubMed: 27521445].
  162. Desai et al., 2018: Desai S, Rathi N, Kawade A, Venkatramanan P, Kundu R, Lalwani SK, Dubey AP, Venkateswara Rao J, Narayanappa D, Ghildiyal R, Gogtay NJ, Venugopal P, Palkar S, Munshi R, Bavdekar A, Juvekar S, Ganguly N, Niyogi P, Uttam KG, Kondekar A, Kumbhar D, Mohanlal S, Agarwal MC, Shetty P, Antony K, Gunale B, Dharmadhikari A, Deshpande J, Nalavade U, Sharma D, Bansal A, Tang Y, Flores J, Kulkarni PS. Non-interference of Bovine-Human reassortant pentavalent rotavirus vaccine ROTASIIL® with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine. Vaccine. 2018; 36(37); 5519-5523. [PubMed: 30104114].
  163. Dessy et al., 2008: Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, Pinto LA, Wettendorff MA. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Human vaccines. 2008; 4(6); 425-434. [PubMed: 18948732].
  164. Dharmasena et al., 2016: Dharmasena MN, Feuille CM, Starke CE, Bhagwat AA, Stibitz S, Kopecko DJ. Development of an Acid-Resistant Salmonella Typhi Ty21a Attenuated Vector For Improved Oral Vaccine Delivery. PloS one. 2016; 11(9); e0163511. [PubMed: 27673328].
  165. Di et al., 2006: Di Pucchio T, Pilla L, Capone I, Ferrantini M, Montefiore E, Urbani F, Patuzzo R, Pennacchioli E, Santinami M, Cova A, Sovena G, Arienti F, Lombardo C, Lombardi A, Caporaso P, D'Atri S, Marchetti P, Bonmassar E, Parmiani G, Belardelli F, Rivoltini L. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer research. 2006; 66(9); 4943-4951. [PubMed: 16651452].
  166. Di et al., 2014: Di Y, Seymour L, Fisher K. Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood. Gene therapy. 2014; 21(4); 440-443. [PubMed: 24553347].
  167. Dijkgraaf et al., 2015: Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Nijman HW, van Poelgeest MI, van Erkel AR, Smit VT, Daemen TA, van der Hoeven JJ, Melief CJ, Welters MJ, Kroep JR, van der Burg SH. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget. 2015; 6(31); 32228-32243. [PubMed: 26334096].
  168. DiPaola et al., 2006: DiPaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E, Manson K, Schuetz T. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. Journal of translational medicine. 2006; 4; 1. [PubMed: 16390546].
  169. Disis et al., 2023: Disis ML, Dang Y, Coveler AL, Childs JS, Higgins DM, Liu Y, Zhou J, Mackay S, Salazar LG. A Phase I/II Trial of HER2 Vaccine-Primed Autologous T-Cell Infusions in Patients with Treatment Refractory HER2-Overexpressing Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023; 29(17); 3362-3371. [PubMed: 37093223].
  170. Downs-Canner et al., 2016: Downs-Canner S, Guo ZS, Ravindranathan R, Breitbach CJ, O'Malley ME, Jones HL, Moon A, McCart JA, Shuai Y, Zeh HJ, Bartlett DL. Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers. Molecular therapy : the journal of the American Society of Gene Therapy. 2016; 24(8); 1492-1501. [PubMed: 27203445].
  171. Drake, 2011: Drake CG. Update on prostate cancer vaccines. Cancer journal (Sudbury, Mass.). 2011; 17(5); 294-299. [PubMed: 21952278].
  172. Drugs R D, 2007: . INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201. Drugs in R&D. 2007; 8(3); 176-187. [PubMed: 17472413].
  173. Duan et al., 2007: Duan HF, Hu XW, Chen JL, Gao LH, Xi YY, Lu Y, Li JF, Zhao SR, Xu JJ, Chen HP, Chen W, Wu CT. Antitumor activities of TEM8-Fc: an engineered antibody-like molecule targeting tumor endothelial marker 8. Journal of the National Cancer Institute. 2007; 99(20); 1551-1555. [PubMed: 17925540].
  174. Duggan et al., 2016: Duggan MC, Jochems C, Donahue RN, Richards J, Karpa V, Foust E, Paul B, Brooks T, Tridandapani S, Olencki T, Pan X, Lesinski GB, Schlom J, Carson Iii WE. A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-?-2b in patients with CEA-expressing carcinomas. Cancer immunology, immunotherapy : CII. 2016; 65(11); 1353-1364. [PubMed: 27581603].
  175. Durán-Aniotz et al., 2013: Durán-Aniotz C, Segal G, Salazar L, Pereda C, Falcón C, Tempio F, Aguilera R, González R, Pérez C, Tittarelli A, Catalán D, Nervi B, Larrondo M, Salazar-Onfray F, López MN. The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses. Cancer immunology, immunotherapy : CII. 2013; 62(4); 761-772. [PubMed: 23242374].
  176. Eder et al., 2000: Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000; 6(5); 1632-1638. [PubMed: 10815880].
  177. Eger et al., 2016: Eger C, Siebert N, Seidel D, Zumpe M, Jüttner M, Brandt S, Müller HP, Lode HN. Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma. PloS one. 2016; 11(3); e0150479. [PubMed: 26967324].
  178. El-Domeiri et al., 1978: El-Domeiri AA, Das Gupta TK, Trippon M, Simo C, Sabet TY, Crispen R. Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma. Surgery, gynecology & obstetrics. 1978; 146(2); 230-232. [PubMed: 622668].
  179. Elias et al., 1997: Elias EG, Suter CM, Fabian DS. Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide. Journal of surgical oncology. 1997; 64(1); 17-22. [PubMed: 9040795].
  180. Elster et al., 2016: Elster JD, Krishnadas DK, Lucas KG. Dendritic cell vaccines: A review of recent developments and their potential pediatric application. Human vaccines & immunotherapeutics. 2016; 12(9); 2232-2239. [PubMed: 27245943].
  181. Embree et al., 2015: Embree J, Law B, Voloshen T, Tomovici A. Immunogenicity, safety, and antibody persistence at 3, 5, and 10 years postvaccination in adolescents randomized to booster immunization with a combined tetanus, diphtheria, 5-component acellular pertussis, and inactivated poliomyelitis vaccine administered with a hepatitis B virus vaccine concurrently or 1 month apart. Clinical and vaccine immunology : CVI. 2015; 22(3); 282-290. [PubMed: 25540274].
  182. Erbs et al., 2008: Erbs P, Findeli A, Kintz J, Cordier P, Hoffmann C, Geist M, Balloul JM. Modified vaccinia virus Ankara as a vector for suicide gene therapy. Cancer gene therapy. 2008; 15(1); 18-28. [PubMed: 17992203].
  183. Eschenburg et al., 2010: Eschenburg G, Stermann A, Preissner R, Meyer HA, Lode HN. DNA vaccination: using the patient's immune system to overcome cancer. Clinical & developmental immunology. 2010; 2010; 169484. [PubMed: 21197271].
  184. Escribà-Garcia et al., 2017: Escribà-Garcia L, Alvarez-Fernández C, Tellez-Gabriel M, Sierra J, Briones J. Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma. Journal of translational medicine. 2017; 15(1); 115. [PubMed: 28549432].
  185. Eton et al., 2010: Eton O, Ross MI, East MJ, Mansfield PF, Papadopoulos N, Ellerhorst JA, Bedikian AY, Lee JE. Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. Journal of translational medicine. 2010; 8; 9. [PubMed: 20109236].
  186. Fagerberg et al., 2014: Fagerberg L, Hallström BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Habuka M, Tahmasebpoor S, Danielsson A, Edlund K, Asplund A, Sjöstedt E, Lundberg E, Szigyarto CA, Skogs M, Takanen JO, Berling H, Tegel H, Mulder J, Nilsson P, Schwenk JM, Lindskog C, Danielsson F, Mardinoglu A, Sivertsson A, von Feilitzen K, Forsberg M, Zwahlen M, Olsson I, Navani S, Huss M, Nielsen J, Ponten F, Uhlén M. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Molecular & cellular proteomics : MCP. 2014; 13(2); 397-406. [PubMed: 24309898].
  187. Fakhrai et al., 2006: Fakhrai H, Mantil JC, Liu L, Nicholson GL, Murphy-Satter CS, Ruppert J, Shawler DL. Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer gene therapy. 2006; 13(12); 1052-1060. [PubMed: 16826191].
  188. Fang et al., 2009: Fang J, Lu Y, Ouyang K, Wu G, Zhang H, Liu Y, Chen Y, Lin M, Wang H, Jin L, Cao R, Roque RS, Zong L, Liu J, Li T. Specific antibodies elicited by a novel DNA vaccine targeting gastrin-releasing peptide inhibit murine melanoma growth in vivo. Clinical and vaccine immunology : CVI. 2009; 16(7); 1033-1039. [PubMed: 19458203].
  189. Faries et al., 2009: Faries MB, Hsueh EC, Ye X, Hoban M, Morton DL. Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009; 15(22); 7029-7035. [PubMed: 19903777].
  190. FDA: TICE BCG: FDA TICE BCG information [http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM163039.pdf]
  191. Felder et al., 2014: Felder M, Kapur A, Gonzalez-Bosquet J, Horibata S, Heintz J, Albrecht R, Fass L, Kaur J, Hu K, Shojaei H, Whelan RJ, Patankar MS. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Molecular cancer. 2014; 13; 129. [PubMed: 24886523].
  192. Felizardo et al., 2011: Felizardo TC, Wang JC, McGray RA, Evelegh C, Spaner DE, Fowler DH, Bramson JL, Medin JA. Differential immune responses mediated by adenovirus- and lentivirus-transduced DCs in a HER-2/neu overexpressing tumor model. Gene therapy. 2011; 18(10); 986-995. [PubMed: 21490686].
  193. Fenoglio et al., 2013: Fenoglio D, Traverso P, Parodi A, Tomasello L, Negrini S, Kalli F, Battaglia F, Ferrera F, Sciallero S, Murdaca G, Setti M, Sobrero A, Boccardo F, Cittadini G, Puppo F, Criscuolo D, Carmignani G, Indiveri F, Filaci G. A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. Cancer immunology, immunotherapy : CII. 2013; 62(6); 1041-1052. [PubMed: 23591981].
  194. Fenstermaker et al., 2016: Fenstermaker RA, Ciesielski MJ, Qiu J, Yang N, Frank CL, Lee KP, Mechtler LR, Belal A, Ahluwalia MS, Hutson AD. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer immunology, immunotherapy : CII. 2016; 65(11); 1339-1352. [PubMed: 27576783].
  195. Fenton et al., 1993: Fenton RG, Taub DD, Kwak LW, Smith MR, Longo DL. Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. Journal of the National Cancer Institute. 1993; 85(16); 1294-1302. [PubMed: 8340941].
  196. Ferguson et al., 2016: Ferguson PJ, Sykelyk A, Figueredo R, Koropatnick J. Synergistic cytotoxicity against human tumor cell lines by oncolytic adenovirus dl1520 (ONYX-015) and melphalan. Tumori. 2016; 102(1); 31-39. [PubMed: 26429639].
  197. Fernando et al., 1998: Fernando GJ, Stewart TJ, Tindle RW, Frazer IH. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model. Journal of immunology (Baltimore, Md. : 1950). 1998; 161(5); 2421-2427. [PubMed: 9725239].
  198. Fernando et al., 2010: Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, Palena C. The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. The Journal of clinical investigation. 2010; 120(2); 533-544. [PubMed: 20071775].
  199. Ferrara et al., 2009: Ferrara TA, Hodge JW, Gulley JL. Combining radiation and immunotherapy for synergistic antitumor therapy. Current opinion in molecular therapeutics. 2009; 11(1); 37-42. [PubMed: 19169958].
  200. Feyen et al., 2020: Feyen DAM, McKeithan WL, Bruyneel AAN, Spiering S, Hörmann L, Ulmer B, Zhang H, Briganti F, Schweizer M, Hegyi B, Liao Z, Pölönen RP, Ginsburg KS, Lam CK, Serrano R, Wahlquist C, Kreymerman A, Vu M, Amatya PL, Behrens CS, Ranjbarvaziri S, Maas RGC, Greenhaw M, Bernstein D, Wu JC, Bers DM, Eschenhagen T, Metallo CM, Mercola M. Metabolic Maturation Media Improve Physiological Function of Human iPSC-Derived Cardiomyocytes. Cell reports. 2020; 32(3); 107925. [PubMed: 32697997].
  201. Filipazzi et al., 2012: Filipazzi P, Pilla L, Mariani L, Patuzzo R, Castelli C, Camisaschi C, Maurichi A, Cova A, Rigamonti G, Giardino F, Di Florio A, Asioli M, Frati P, Sovena G, Squarcina P, Maio M, Danielli R, Chiarion-Sileni V, Villa A, Lombardo C, Tragni G, Santinami M, Parmiani G, Rivoltini L. Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012; 18(23); 6485-6496. [PubMed: 23032742].
  202. Finocchiaro and Glikin, 2012: Finocchiaro LM, Glikin GC. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up. Cancer gene therapy. 2012; 19(12); 852-861. [PubMed: 23059870].
  203. Firdaus et al., 2023: Firdaus FZ, Bartlett S, Hussein WM, Lu L, Wright Q, Huang W, Nahar UJ, Yang J, Khongkow M, Veitch M, Koirala P, Ruktanonchai UR, Monteiro MJ, Gonzalez Cruz JL, Stephenson RJ, Wells JW, Toth I, Skwarczynski M. Liposomal Formulations of a Polyleucine-Antigen Conjugate as Therapeutic Vaccines against Cervical Cancer. Pharmaceutics. 2023; 15(2); . [PubMed: 36839923].
  204. Fishman et al., 2008: Fishman M, Hunter TB, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo MJ, Noyes DR, Mahany JJ, Lee JH, Cantor A, Messina J, Seigne J, Pow-Sang J, Janssen W, Antonia SJ. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. Journal of immunotherapy (Hagerstown, Md. : 1997). 2008; 31(1); 72-80. [PubMed: 18157014].
  205. Flickinger et al., 2018: Flickinger JC Jr, Rodeck U, Snook AE. Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress. Vaccines. 2018; 6(3); . [PubMed: 30044426].
  206. Flores et al., 2007: Flores RM, Zakowski M, Venkatraman E, Krug L, Rosenzweig K, Dycoco J, Lee C, Yeoh C, Bains M, Rusch V. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2007; 2(10); 957-965. [PubMed: 17909360].
  207. Fontana et al., 2009: Fontana R, Bregni M, Cipponi A, Raccosta L, Rainelli C, Maggioni D, Lunghi F, Ciceri F, Mukenge S, Doglioni C, Colau D, Coulie PG, Bordignon C, Traversari C, Russo V. Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients. Blood. 2009; 113(8); 1651-1660. [PubMed: 19074732].
  208. Fotin-Mleczek et al., 2011: Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojki?-Zrna S, Probst J, Kallen KJ. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. Journal of immunotherapy (Hagerstown, Md. : 1997). 2011; 34(1); 1-15. [PubMed: 21150709].
  209. Fourcade et al., 2008: Fourcade J, Kudela P, Andrade Filho PA, Janjic B, Land SR, Sander C, Krieg A, Donnenberg A, Shen H, Kirkwood JM, Zarour HM. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. Journal of immunotherapy (Hagerstown, Md. : 1997). 2008; 31(8); 781-791. [PubMed: 18779741].
  210. Frank et al., 2020: Frank MJ, Khodadoust MS, Czerwinski DK, Haabeth OAW, Chu MP, Miklos DB, Advani RH, Alizadeh AA, Gupta NK, Maeda LS, Reddy SA, Laport GG, Meyer EH, Negrin RS, Rezvani AR, Weng WK, Sheehan K, Faham M, Okada A, Moore AH, Phillips DL, Wapnir IL, Brody JD, Levy R. Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. The Journal of experimental medicine. 2020; 217(9); . [PubMed: 32558897].
  211. Frankowski et al., 2004: Frankowski DJ, Raez J, Manners I, Winnik MA, Khan SA, Spontak RJ. Formation of dispersed nanostructures from poly(ferrocenyldimethylsilane-b-dimethylsiloxane) nanotubes upon exposure to supercritical carbon dioxide. Langmuir : the ACS journal of surfaces and colloids. 2004; 20(21); 9304-9314. [PubMed: 15461522].
  212. Freeman et al., 1995: Freeman SM, McCune C, Robinson W, Abboud CN, Abraham GN, Angel C, Marrogi A. The treatment of ovarian cancer with a gene modified cancer vaccine: a phase I study. Human gene therapy. 1995; 6(7); 927-939. [PubMed: 7578411].
  213. Freytag et al., 2013: Freytag SO, Barton KN, Zhang Y. Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer. Gene therapy. 2013; 20(12); 1131-1139. [PubMed: 23842593].
  214. Freytag et al., 2015: Freytag SO, Zhang Y, Siddiqui F. Preclinical toxicology of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for prostate cancer. Molecular therapy oncolytics. 2015; 2; . [PubMed: 26767191].
  215. Fritsch et al., 2014: Fritsch EF, Hacohen N, Wu CJ. Personal neoantigen cancer vaccines: The momentum builds. Oncoimmunology. 2014; 3; e29311. [PubMed: 25101225].
  216. Fromm et al., 2016: Fromm G, de Silva S, Giffin L, Xu X, Rose J, Schreiber TH. Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination. Cancer immunology research. 2016; 4(9); 766-778. [PubMed: 27364122].
  217. Fujio et al., 2015: Fujio K, Watanabe M, Ueki H, Li SA, Kinoshita R, Ochiai K, Futami J, Watanabe T, Nasu Y, Kumon H. A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment. Oncology reports. 2015; 33(4); 1585-1592. [PubMed: 25632844].
  218. Fulco et al., 2013: Fulco I, Largo RD, Miot S, Wixmerten A, Martin I, Schaefer DJ, Haug MD. Toward clinical application of tissue-engineered cartilage. Facial plastic surgery : FPS. 2013; 29(2); 99-105. [PubMed: 23564241].
  219. Fulco et al., 2014: Fulco I, Miot S, Haug MD, Barbero A, Wixmerten A, Feliciano S, Wolf F, Jundt G, Marsano A, Farhadi J, Heberer M, Jakob M, Schaefer DJ, Martin I. Engineered autologous cartilage tissue for nasal reconstruction after tumour resection: an observational first-in-human trial. Lancet (London, England). 2014; 384(9940); 337-346. [PubMed: 24726477].
  220. FUTURE II Study Group., 2007: . Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. The New England journal of medicine. 2007; 356(19); 1915-1927. [PubMed: 17494925].
  221. Gabri et al., 2016: Gabri MR, Cacciavillano W, Chantada GL, Alonso DF. Racotumomab for treating lung cancer and pediatric refractory malignancies. Expert opinion on biological therapy. 2016; 16(4); 573-578. [PubMed: 26903265].
  222. Gahéry-Ségard et al., 2003: Gahéry-Ségard H, Pialoux G, Figueiredo S, Igéa C, Surenaud M, Gaston J, Gras-Masse H, Lévy JP, Guillet JG. Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized. Journal of virology. 2003; 77(20); 11220-11231. [PubMed: 14512570].
  223. Gajdosik, 2014: Gajdosik Z. Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer. Drugs of today (Barcelona, Spain : 1998). 2014; 50(4); 301-307. [PubMed: 24918647].
  224. Gall et al., 2005: Gall JM, Davol PA, Grabert RC, Deaver M, Lum LG. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro. Experimental hematology. 2005; 33(4); 452-459. [PubMed: 15781336].
  225. Gao et al., 2014: Gao D, Li C, Xie X, Zhao P, Wei X, Sun W, Liu HC, Alexandrou AT, Jones J, Zhao R, Li JJ. Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. PloS one. 2014; 9(4); e93886. [PubMed: 24699863].
  226. Gao et al., 2016: Gao S, Zeng L, Zhang X, Wu Y, Cui J, Song Z, Sun X, Wang H, Yin Y, Xu W. Attenuated Streptococcus pneumoniae vaccine candidate SPY1 promotes dendritic cell activation and drives a Th1/Th17 response. Immunology letters. 2016; 179; 47-55. [PubMed: 27609353].
  227. Garcia et al., 2004: Garcia F, Petry KU, Muderspach L, Gold MA, Braly P, Crum CP, Magill M, Silverman M, Urban RG, Hedley ML, Beach KJ. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstetrics and gynecology. 2004; 103(2); 317-326. [PubMed: 14754702].
  228. Garcia-Hernandez et al., 2007: Garcia-Hernandez Mde L, Gray A, Hubby B, Kast WM. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer research. 2007; 67(3); 1344-1351. [PubMed: 17283172].
  229. Garcia-Hernandez et al., 2008: Garcia-Hernandez Mde L, Gray A, Hubby B, Klinger OJ, Kast WM. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer research. 2008; 68(3); 861-869. [PubMed: 18245488].
  230. Garfall and Stadtmauer, 2016: Garfall AL, Stadtmauer EA. Cellular and vaccine immunotherapy for multiple myeloma. Hematology. American Society of Hematology. Education Program. 2016; 2016(1); 521-527. [PubMed: 27913524].
  231. Garland et al., 2015: Garland SM, Cheung TH, McNeill S, Petersen LK, Romaguera J, Vazquez-Narvaez J, Bautista O, Shields C, Vuocolo S, Luxembourg A. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine. Vaccine. 2015; 33(48); 6855-6864. [PubMed: 26411885].
  232. Garland et al., 2022: Garland SM, Anagani M, Bhatla N, Chatterjee S, Lalwani S, Ross C, Group T, Lin J, Luxembourg A, Walia A, Tu Y. Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants. Human vaccines & immunotherapeutics. 2022; 18(6); 2105067. [PubMed: 35997582].
  233. Gathuru et al., 2005: Gathuru JK, Koide F, Ragupathi G, Adams JL, Kerns RT, Coleman TP, Livingston PO. Identification of DHBcAg as a potent carrier protein comparable to KLH for augmenting MUC1 antigenicity. Vaccine. 2005; 23(39); 4727-4733. [PubMed: 15978705].
  234. Gatson et al., 2016: Gatson NT, Weathers SP, de Groot JF. ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma. CNS oncology. 2016; 5(1); 11-26. [PubMed: 26670466].
  235. Germain and Margulies, 1993: Germain RN, Margulies DH. The biochemistry and cell biology of antigen processing and presentation. Annual review of immunology. 1993; 11; 403-450. [PubMed: 8476568].
  236. Geynisman et al., 2013: Geynisman DM, Zha Y, Kunnavakkam R, Aklilu M, Catenacci DV, Polite BN, Rosenbaum C, Namakydoust A, Karrison T, Gajewski TF, Kindler HL. A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma. Journal for immunotherapy of cancer. 2013; 1; 8. [PubMed: 24829746].
  237. Giaccone et al., 2005: Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, Thiberville L, D'addario G, Coens C, Rome LS, Zatloukal P, Masso O, Legrand C. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005; 23(28); 6854-6864. [PubMed: 16192577].
  238. Gomez et al., 2013: Gomez B, He L, Tsai YC, Wu TC, Viscidi RP, Hung CF. Creation of a Merkel cell polyomavirus small T antigen-expressing murine tumor model and a DNA vaccine targeting small T antigen. Cell & bioscience. 2013; 3(1); 29. [PubMed: 23856459].
  239. Gosavi et al., 2022: Gosavi D, Wower I, Beckmann IK, Hofacker IL, Wower J, Wolfinger MT, Sztuba-Solinska J. Insights into the secondary and tertiary structure of the Bovine Viral Diarrhea Virus Internal Ribosome Entry Site. RNA biology. 2022; 19(1); 496-506. [PubMed: 35380920].
  240. Greenberg et al., 2009: Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, Basser RL. Response to a monovalent 2009 influenza A (H1N1) vaccine. The New England journal of medicine. 2009; 361(25); 2405-2413. [PubMed: 19745216].
  241. Gribben et al., 2005: Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, Campos S, Gilligan TD, Richardson PG, Marshall B, Neuberg D, Nadler LM. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005; 11(12); 4430-4436. [PubMed: 15958627].
  242. Griguolo et al., 2019: Griguolo G, Pascual T, Dieci MV, Guarneri V, Prat A. Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. Journal for immunotherapy of cancer. 2019; 7(1); 90. [PubMed: 30922362].
  243. Grossmann et al., 1997: Grossmann ME, Brown MP, Brenner MK. Antitumor responses induced by transgenic expression of CD40 ligand. Human gene therapy. 1997; 8(16); 1935-1943. [PubMed: 9382959].
  244. Gruslova et al., 2015: Gruslova A, Cavazos DA, Miller JR, Breitbart E, Cohen YC, Bangio L, Yakov N, Soundararajan A, Floyd JR, Brenner AJ. VB-111: a novel anti-vascular therapeutic for glioblastoma multiforme. Journal of neuro-oncology. 2015; 124(3); 365-372. [PubMed: 26108658].
  245. Gu et al., 2010: Gu R, Shampang A, Nashar T, Patil M, Fuller DH, Ramsingh AI. Oral immunization with a live coxsackievirus/HIV recombinant induces gag p24-specific T cell responses. PloS one. 2010; 5(9); . [PubMed: 20824074].
  246. Guinn et al., 2001: Guinn BA, Bertram EM, DeBenedette MA, Berinstein NL, Watts TH. 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors. Cellular immunology. 2001; 210(1); 56-65. [PubMed: 11485353].
  247. Gulley et al., 2002: Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Michael Hamilton J. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. The Prostate. 2002; 53(2); 109-117. [PubMed: 12242725].
  248. Gulley et al., 2008: Gulley JL, Arlen PM, Tsang KY, Yokokawa J, Palena C, Poole DJ, Remondo C, Cereda V, Jones JL, Pazdur MP, Higgins JP, Hodge JW, Steinberg SM, Kotz H, Dahut WL, Schlom J. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008; 14(10); 3060-3069. [PubMed: 18483372].
  249. Guo et al., 2019: Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, Liu W, Storkus WJ, He Y, Liu Z, Bartlett DL. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. Journal for immunotherapy of cancer. 2019; 7(1); 6. [PubMed: 30626434].
  250. Gupta and Emens, 2010: Gupta R, Emens LA. GM-CSF-secreting vaccines for solid tumors: moving forward. Discovery medicine. 2010; 10(50); 52-60. [PubMed: 20670599].
  251. Gupta et al., 2006: Gupta V, Wang W, Sosnowski BA, Hofman FM, Chen TC. Fibroblast growth factor-2-retargeted adenoviral vector for selective transduction of primary glioblastoma multiforme endothelial cells. Neurosurgical focus. 2006; 20(4); E26. [PubMed: 16709032].
  252. Gupta et al., 2015: Gupta S, Termini JM, Rivas Y, Otero M, Raffa FN, Bhat V, Farooq A, Stone GW. A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model. Vaccine. 2015; 33(38); 4798-4806. [PubMed: 26241951].
  253. Gyurkocza et al., 2017: Gyurkocza B, Lazarus HM, Giralt S. Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy. Bone marrow transplantation. 2017; 52(8); 1083-1090. [PubMed: 28244979].
  254. Haight et al., 2000: Haight AE, Bowman LC, Ng CY, Vanin EF, Davidoff AM. Humoral response to vaccination with interleukin-2-expressing allogeneic neuroblastoma cells after primary therapy. Medical and pediatric oncology. 2000; 35(6); 712-715. [PubMed: 11107153].
  255. Hailemichael et al., 2013: Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, Greeley NR, Nitti G, Peng W, Liu C, Lou Y, Wang Z, Ma W, Rabinovich B, Sowell RT, Schluns KS, Davis RE, Hwu P, Overwijk WW. Persistent antigen at vaccination sites induces tumor-specific CD8⺠T cell sequestration, dysfunction and deletion. Nature medicine. 2013; 19(4); 465-472. [PubMed: 23455713].
  256. Halin et al., 2003: Halin C, Gafner V, Villani ME, Borsi L, Berndt A, Kosmehl H, Zardi L, Neri D. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer research. 2003; 63(12); 3202-3210. [PubMed: 12810649].
  257. Halperin et al., 2011: Halperin SA, McNeil S, Langley J, Blatter M, Dionne M, Embree J, Johnson R, Latiolais T, Meekison W, Noya F, Senders S, Zickler P, Johnson DR. Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose. Vaccine. 2011; 29(46); 8459-8465. [PubMed: 21803091].
  258. Halpern et al., 1992: Halpern SE, Dillman RO, Amox D, Hagan PL, Burks R, Dillman J, Perdikakis B, Merchant B, Frincke J, Schweighardt S. Detection of occult tumor using indium 111-labeled anticarcinoembryonic antigen antibodies. Archives of surgery (Chicago, Ill. : 1960). 1992; 127(9); 1094-1100. [PubMed: 1514913].
  259. Hanna, 2012: Hanna MG Jr. Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer. Human vaccines & immunotherapeutics. 2012; 8(8); 1156-1160. [PubMed: 22854664].
  260. Hannu et al., 2014: Hannu K, Johanna M, Ulf-HÃ¥kan S. KLK-targeted Therapies for Prostate Cancer. EJIFCC. 2014; 25(2); 207-218. [PubMed: 27683469].
  261. Hanwell et al., 2013: Hanwell DG, McNeil B, Visan L, Rodrigues L, Dunn P, Shewen PE, Macallum GE, Turner PV, Vogel TU. Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4. Journal of immunotherapy (Hagerstown, Md. : 1997). 2013; 36(4); 238-247. [PubMed: 23603858].
  262. Hardwick et al., 2018: Hardwick NR, Frankel P, Ruel C, Kilpatrick J, Tsai W, Kos F, Kaltcheva T, Leong L, Morgan R, Chung V, Tinsley R, Eng M, Wilczynski S, Ellenhorn JDI, Diamond DJ, Cristea M. p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018; 24(6); 1315-1325. [PubMed: 29301826].
  263. Harrop et al., 2006: Harrop R, Ryan MG, Myers KA, Redchenko I, Kingsman SM, Carroll MW. Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated. Cancer immunology, immunotherapy : CII. 2006; 55(9); 1081-1090. [PubMed: 16311730].
  264. Harzstark and Small, 2007: Harzstark AL, Small EJ. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge). Expert opinion on biological therapy. 2007; 7(8); 1275-1280. [PubMed: 17696825].
  265. Hawkins et al., 2002: Hawkins WG, Gold JS, Blachere NE, Bowne WB, Hoos A, Lewis JJ, Houghton AN. Xenogeneic DNA immunization in melanoma models for minimal residual disease. The Journal of surgical research. 2002; 102(2); 137-143. [PubMed: 11796010].
  266. He et al., 1997: He Z, He YS, Kim Y, Chu L, Ohmstede C, Biron KK, Coen DM. The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines. Journal of virology. 1997; 71(1); 405-411. [PubMed: 8985364].
  267. He et al., 2013: He X, Wang J, Zhao F, Chen D, Chen J, Zhang H, Yang C, Liu Y, Dou J. ESAT-6-gpi DNA vaccine augmented the specific antitumour efficacy induced by the tumour vaccine B16F10-ESAT-6-gpi/IL-21 in a mouse model. Scandinavian journal of immunology. 2013; 78(1); 69-78. [PubMed: 23679337].
  268. He et al., 2014: He Y, Hong Y, Mizejewski GJ. Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects. Immunotherapy. 2014; 6(6); 725-736. [PubMed: 25041030].
  269. Hegmans et al., 2005: Hegmans JP, Hemmes A, Aerts JG, Hoogsteden HC, Lambrecht BN. Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. American journal of respiratory and critical care medicine. 2005; 171(10); 1168-1177. [PubMed: 15764728].
  270. Hegmans et al., 2010: Hegmans JP, Veltman JD, Lambers ME, de Vries IJ, Figdor CG, Hendriks RW, Hoogsteden HC, Lambrecht BN, Aerts JG. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. American journal of respiratory and critical care medicine. 2010; 181(12); 1383-1390. [PubMed: 20167848].
  271. Heimberger et al., 2003: Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003; 9(11); 4247-4254. [PubMed: 14519652].
  272. Heiser et al., 2002: Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. The Journal of clinical investigation. 2002; 109(3); 409-417. [PubMed: 11828001].
  273. Henz et al., 1996: Henz BM, Macher E, Bröcker EB, Suciu S, Steerenberg PA, Jung E, Rümke P. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781). Dermatology (Basel, Switzerland). 1996; 193(2); 105-109. [PubMed: 8884144].
  274. Herbert et al., 2010: Herbert N, Haferkamp A, Schmitz-Winnenthal HF, Zöller M. Concomitant tumor and autoantigen vaccination supports renal cell carcinoma rejection. Journal of immunology (Baltimore, Md. : 1950). 2010; 185(2); 902-916. [PubMed: 20548033].
  275. Hersey et al., 1986: Hersey P, Edwards A, D'Alessandro G, MacDonald M. Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. II. Effects on cell mediated cytotoxicity and leucocyte dependent antibody activity: immunological effects of VMCL in melanoma patients. Cancer immunology, immunotherapy : CII. 1986; 22(3); 221-231. [PubMed: 3460702].
  276. Hersey et al., 2002: Hersey P, Coates AS, McCarthy WH, Thompson JF, Sillar RW, McLeod R, Gill PG, Coventry BJ, McMullen A, Dillon H, Simes RJ. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002; 20(20); 4181-4190. [PubMed: 12377961].
  277. Hersey et al., 2005: Hersey P, Menzies SW, Coventry B, Nguyen T, Farrelly M, Collins S, Hirst D, Johnson H. Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma. Cancer immunology, immunotherapy : CII. 2005; 54(3); 208-218. [PubMed: 15449035].
  278. Hersey, 1992: Hersey P. Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma. World journal of surgery. 1992; 16(2); 251-260. [PubMed: 1561807].
  279. Higashihara et al., 2014: Higashihara Y, Kato J, Nagahara A, Izumi K, Konishi M, Kodani T, Serizawa N, Osada T, Watanabe S. Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer. International journal of oncology. 2014; 44(3); 662-668. [PubMed: 24398900].
  280. Hillman et al., 2017: Hillman GG, Reich LA, Rothstein SE, Abernathy LM, Fountain MD, Hankerd K, Yunker CK, Rakowski JT, Quemeneur E, Slos P. Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen. Journal for immunotherapy of cancer. 2017; 5; 4. [PubMed: 28116088].
  281. Hirschowitz et al., 1998: Hirschowitz EA, Leonard S, Song W, Ferris B, Leopold PL, Lewis JJ, Bowne WB, Wang S, Houghton AN, Crystal RG. Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma. Gene therapy. 1998; 5(7); 975-983. [PubMed: 9813669].
  282. Hirschowitz et al., 2004: Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J. Autologous dendritic cell vaccines for non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004; 22(14); 2808-2815. [PubMed: 15254048].
  283. Hirschowitz et al., 2006: Hirschowitz EA, Hiestand DM, Yannelli JR. Vaccines for lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2006; 1(1); 93-104. [PubMed: 17409835].
  284. Hirschowitz et al., 2011: Hirschowitz EA, Mullins A, Prajapati D, Baeker T, Kloecker G, Foody T, Damron K, Love C, Yannelli JR. Pilot study of 1650-G: a simplified cellular vaccine for lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011; 6(1); 169-173. [PubMed: 21150468].
  285. Ho et al., 2022: Ho VT, Kim HT, Brock J, Galinsky I, Daley H, Reynolds C, Weber A, Pozdnyakova O, Severgnini M, Nikiforow S, Cutler C, Koreth J, Alyea EP, Antin JH, Gooptu M, Romee R, Shapiro R, Chen YB, Rosenblatt J, Avigan D, Hodi FS, Dranoff G, Wu CJ, Ritz J, Soiffer RJ. GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. Blood advances. 2022; 6(7); 2183-2194. [PubMed: 34807983].
  286. Hodge et al., 1999: Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer research. 1999; 59(22); 5800-5807. [PubMed: 10582702].
  287. Hodge et al., 2003: Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J. Vaccine therapy of established tumors in the absence of autoimmunity. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003; 9(5); 1837-1849. [PubMed: 12738742].
  288. Hodge et al., 2008: Hodge JW, Guha C, Neefjes J, Gulley JL. Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park, N.Y.). 2008; 22(9); 1064-1070. [PubMed: 18777956].
  289. Hodi, 2010: Hodi FS. Overcoming immunological tolerance to melanoma: Targeting CTLA-4. Asia-Pacific journal of clinical oncology. 2010; 6 Suppl 1; S16-23. [PubMed: 20482528].
  290. Hofman et al., 2010: Hofman FM, Stathopoulos A, Kruse CA, Chen TC, Schijns VE. Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells. Anti-cancer agents in medicinal chemistry. 2010; 10(6); 462-470. [PubMed: 20879986].
  291. Holmberg and Sandmaier, 2001: Holmberg LA, Sandmaier BM. Theratope vaccine (STn-KLH). Expert opinion on biological therapy. 2001; 1(5); 881-891. [PubMed: 11728222].
  292. Holt et al., 2011: Holt GE, Podack ER, Raez LE. Immunotherapy as a strategy for the treatment of non-small-cell lung cancer. Therapy (London, England : 2004). 2011; 8(1); 43-54. [PubMed: 21359153].
  293. Hong et al., 1993: Hong WK, Lippman SM, Wolf GT. Recent advances in head and neck cancer--larynx preservation and cancer chemoprevention: the Seventeenth Annual Richard and Hinda Rosenthal Foundation Award Lecture. Cancer research. 1993; 53(21); 5113-5120. [PubMed: 8221647].
  294. Hoogsteder et al., 2014: Hoogsteder PH, Kotz D, van Spiegel PI, Viechtbauer W, van Schayck OC. Efficacy of the nicotine vaccine 3'-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial. Addiction (Abingdon, England). 2014; 109(8); 1252-1259. [PubMed: 24894625].
  295. Hossain et al., 2019: Hossain MK, Vartak A, Sucheck SJ, Wall KA. Liposomal Fc Domain Conjugated to a Cancer Vaccine Enhances Both Humoral and Cellular Immunity. ACS omega. 2019; 4(3); 5204-5208. [PubMed: 30949616].
  296. Hsueh and Morton, 2003: Hsueh EC, Morton DL. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Seminars in cancer biology. 2003; 13(6); 401-407. [PubMed: 15001158].
  297. Hsueh et al., 2002: Hsueh EC, Essner R, Foshag LJ, Ollila DW, Gammon G, O'Day SJ, Boasberg PD, Stern SL, Ye X, Morton DL. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002; 20(23); 4549-4554. [PubMed: 12454111].
  298. https://clinicaltrials.gov/study/NCT00134082: Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma [https://clinicaltrials.gov/study/NCT00134082]
  299. Hu et al., 2021: Hu Z, Leet DE, Allesøe RL, Oliveira G, Li S, Luoma AM, Liu J, Forman J, Huang T, Iorgulescu JB, Holden R, Sarkizova S, Gohil SH, Redd RA, Sun J, Elagina L, Giobbie-Hurder A, Zhang W, Peter L, Ciantra Z, Rodig S, Olive O, Shetty K, Pyrdol J, Uduman M, Lee PC, Bachireddy P, Buchbinder EI, Yoon CH, Neuberg D, Pentelute BL, Hacohen N, Livak KJ, Shukla SA, Olsen LR, Barouch DH, Wucherpfennig KW, Fritsch EF, Keskin DB, Wu CJ, Ott PA. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nature medicine. 2021; 27(3); 515-525. [PubMed: 33479501].
  300. Hu et al., 2022: Hu JL, Omofoye OA, Rudnick JD, Kim S, Tighiouart M, Phuphanich S, Wang H, Mazer M, Ganaway T, Chu RM, Patil CG, Black KL, Shiao SL, Wang R, Yu JS. A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022; 28(4); 689-696. [PubMed: 34862245].
  301. Huang et al., 2012: Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, Madan RA, Gulley JL, Schlom J. Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood. 2012; 120(15); 3030-3038. [PubMed: 22932804].
  302. Huebener et al., 2008: Huebener N, Fest S, Strandsby A, Michalsky E, Preissner R, Zeng Y, Gaedicke G, Lode HN. A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity. Molecular cancer therapeutics. 2008; 7(7); 2241-2251. [PubMed: 18645033].
  303. Hui et al., 2013: Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, Ho R, Wong WL, Wilson S, Johnson BF, Edwards C, Stocken DD, Rickinson AB, Steven NM, Chan AT. Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer research. 2013; 73(6); 1676-1688. [PubMed: 23348421].
  304. Hung et al., 2008: Hung CF, Wu TC, Monie A, Roden R. Antigen-specific immunotherapy of cervical and ovarian cancer. Immunological reviews. 2008; 222; 43-69. [PubMed: 18363994].
  305. Hunter-Craig et al., 1970: Hunter-Craig I, Newton KA, Westbury G, Lacey BW. Use of vaccinia virus in the treatment of metastatic malignant melanoma. British medical journal. 1970; 2(5708); 512-515. [PubMed: 4913781].
  306. Hutchins et al., 2017: Hutchins LF, Makhoul I, Emanuel PD, Pennisi A, Siegel ER, Jousheghany F, Guo X, Pashov AD, Monzavi-Karbassi B, Kieber-Emmons T. Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects. Oncotarget. 2017; 8(58); 99161-99178. [PubMed: 29228761].
  307. Hutson et al., 2008: Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. The oncologist. 2008; 13(10); 1084-1096. [PubMed: 18838439].
  308. Ibrahim et al., 2013: Ibrahim NK, Murray JL, Zhou D, Mittendorf EA, Sample D, Tautchin M, Miles D. Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial. Journal of Cancer. 2013; 4(7); 577-584. [PubMed: 23983823].
  309. Iinuma et al., 2014: Iinuma H, Fukushima R, Inaba T, Tamura J, Inoue T, Ogawa E, Horikawa M, Ikeda Y, Matsutani N, Takeda K, Yoshida K, Tsunoda T, Ikeda T, Nakamura Y, Okinaga K. Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. Journal of translational medicine. 2014; 12; 84. [PubMed: 24708624].
  310. Illiano et al., 2016: Illiano E, Bissa M, Paolini F, Zanotto C, De Giuli Morghen C, Franconi R, Radaelli A, Venuti A. Prime-boost therapeutic vaccination in mice with DNA/DNA or DNA/Fowlpox virus recombinants expressing the Human Papilloma Virus type 16 E6 and E7 mutated proteins fused to the coat protein of Potato virus X. Virus research. 2016; 225; 82-90. [PubMed: 27664839].
  311. Insaidoo et al., 2011: Insaidoo FK, Borbulevych OY, Hossain M, Santhanagopolan SM, Baxter TK, Baker BM. Loss of T cell antigen recognition arising from changes in peptide and major histocompatibility complex protein flexibility: implications for vaccine design. The Journal of biological chemistry. 2011; 286(46); 40163-40173. [PubMed: 21937447].
  312. Irie et al., 2004: Irie RF, Ollila DW, O'Day S, Morton DL. Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer immunology, immunotherapy : CII. 2004; 53(2); 110-117. [PubMed: 14564483].
  313. Ishizaki et al., 2006: Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006; 12(19); 5841-5849. [PubMed: 17020992].
  314. James et al., 2014: James BR, Anderson KG, Brincks EL, Kucaba TA, Norian LA, Masopust D, Griffith TS. CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma. Cancer immunology, immunotherapy : CII. 2014; 63(11); 1213-1227. [PubMed: 25143233].
  315. Jamshed et al., 2016: Jamshed S, Walsh EE, Dimitroff LJ, Santelli JS, Falsey AR. Improved immunogenicity of high-dose influenza vaccine compared to standard-dose influenza vaccine in adult oncology patients younger than 65 years receiving chemotherapy: A pilot randomized clinical trial. Vaccine. 2016; 34(5); 630-635. [PubMed: 26721330].
  316. Jha et al., 2012: Jha G, Miller JS, Curtsinger JM, Zhang Y, Mescher MF, Dudek AZ. Randomized Phase II Study of IL-2 With or Without an Allogeneic Large Multivalent Immunogen Vaccine for the Treatment of Stage IV Melanoma. American journal of clinical oncology. 2012; ; . [PubMed: 23241505].
  317. Jia et al., 2017: Jia YY, Tan WJ, Duan FF, Pan ZM, Chen X, Yin YL, Jiao XA. A Genetically Modified attenuated Listeria Vaccine Expressing HPV16 E7 Kill Tumor Cells in Direct and Antigen-Specific Manner. Frontiers in cellular and infection microbiology. 2017; 7; 279. [PubMed: 28706878].
  318. Jiménez-Cervantes et al., 1994: Jiménez-Cervantes C, Solano F, Kobayashi T, Urabe K, Hearing VJ, Lozano JA, García-Borrón JC. A new enzymatic function in the melanogenic pathway. The 5,6-dihydroxyindole-2-carboxylic acid oxidase activity of tyrosinase-related protein-1 (TRP1). The Journal of biological chemistry. 1994; 269(27); 17993-18000. [PubMed: 8027058].
  319. Johnson et al., 2006: Johnson LE, Frye TP, Arnot AR, Marquette C, Couture LA, Gendron-Fitzpatrick A, McNeel DG. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine. 2006; 24(3); 293-303. [PubMed: 16115700].
  320. Johnson et al., 2007: Johnson LE, Frye TP, Chinnasamy N, Chinnasamy D, McNeel DG. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. Cancer immunology, immunotherapy : CII. 2007; 56(6); 885-895. [PubMed: 17102977].
  321. Johnson et al., 2009: Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, VanWaes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM, Rosenberg SA. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009; 114(3); 535-546. [PubMed: 19451549].
  322. Jones et al., 1996: Jones RC, Kelley M, Gupta RK, Nizze JA, Yee R, Leopoldo Z, Qi K, Stern S, Morton DL. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model. Annals of surgical oncology. 1996; 3(5); 437-445. [PubMed: 8876885].
  323. Ju et al., 2022: Ju M, Fan J, Zou Y, Yu M, Jiang L, Wei Q, Bi J, Hu B, Guan Q, Song X, Dong M, Wang L, Yu L, Wang Y, Kang H, Xin W, Zhao L. Computational Recognition of a Regulatory T-cell-specific Signature With Potential Implications in Prognosis, Immunotherapy, and Therapeutic Resistance of Prostate Cancer. Frontiers in immunology. 2022; 13; 807840. [PubMed: 35812443].
  324. Juric et al., 2010: Juric D, Mahovli? V, Rajhvajn S, Ovanin-Raki? A, Skopljanac-Macina L, Barisi? A, Proji? IS, Babi? D, Susa M, Corusi? A, Oreskovi? S. Liquid-based cytology--new possibilities in the diagnosis of cervical lesions. Collegium antropologicum. 2010; 34(1); 19-24. [PubMed: 20432728].
  325. Juszczyk et al., 1987: Juszczyk Z, Szydlo W, Jakubów H, Ziecik S. [Ultrasonographic control of the positioning of the catheter and intracardiac electrode]. Polski tygodnik lekarski (Warsaw, Poland : 1960). 1987; 42(10); 309-311. [PubMed: 03299309].
  326. Kaczanowska et al., 2024: Kaczanowska S, Murty T, Alimadadi A, Contreras CF, Duault C, Subrahmanyam PB, Reynolds W, Gutierrez NA, Baskar R, Wu CJ, Michor F, Altreuter J, Liu Y, Jhaveri A, Duong V, Anbunathan H, Ong C, Zhang H, Moravec R, Yu J, Biswas R, Van Nostrand S, Lindsay J, Pichavant M, Sotillo E, Bernstein D, Carbonell A, Derdak J, Klicka-Skeels J, Segal JE, Dombi E, Harmon SA, Turkbey B, Sahaf B, Bendall S, Maecker H, Highfill SL, Stroncek D, Glod J, Merchant M, Hedrick CC, Mackall CL, Ramakrishna S, Kaplan RN. Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer cell. 2024; 42(1); 35-51.e8. [PubMed: 38134936].
  327. Kafi et al., 2009: Kafi K, Betting DJ, Yamada RE, Bacica M, Steward KK, Timmerman JM. Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines. Molecular immunology. 2009; 46(3); 448-456. [PubMed: 19046770].
  328. Kakudo et al., 2013: Kakudo N, Tanaka Y, Morimoto N, Ogawa T, Kushida S, Hara T, Kusumoto K. Adipose-derived regenerative cell (ADRC)-enriched fat grafting: optimal cell concentration and effects on grafted fat characteristics. Journal of translational medicine. 2013; 11; 254. [PubMed: 24107489].
  329. Kalli et al., 2013: Kalli F, Machiorlatti R, Battaglia F, Parodi A, Conteduca G, Ferrera F, Proietti M, Tardito S, Sanguineti M, Millo E, Fenoglio D, De Palma R, Inghirami G, Filaci G. Comparative analysis of cancer vaccine settings for the selection of an effective protocol in mice. Journal of translational medicine. 2013; 11; 120. [PubMed: 23663506].
  330. Kalli et al., 2018: Kalli KR, Block MS, Kasi PM, Erskine CL, Hobday TJ, Dietz A, Padley D, Gustafson MP, Shreeder B, Puglisi-Knutson D, Visscher DW, Mangskau TK, Wilson G, Knutson KL. Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018; 24(13); 3014-3025. [PubMed: 29545464].
  331. Kamata et al., 2002: Kamata M, Denda-Nagai K, Kubota N, Aida S, Takeda K, Irimura T. Vaccination of mice with MUC1 cDNA suppresses the development of lung metastases. Clinical & experimental metastasis. 2002; 19(8); 689-696. [PubMed: 12553374].
  332. Kampf et al., 2007: Kampf G, Steinmann J, Rabenau H. Suitability of vaccinia virus and bovine viral diarrhea virus (BVDV) for determining activities of three commonly-used alcohol-based hand rubs against enveloped viruses. BMC infectious diseases. 2007; 7; 5. [PubMed: 17291338].
  333. Kamran et al., 2016: Kamran N, Calinescu A, Candolfi M, Chandran M, Mineharu Y, Asad AS, Koschmann C, Nunez FJ, Lowenstein PR, Castro MG. Recent advances and future of immunotherapy for glioblastoma. Expert opinion on biological therapy. 2016; 16(10); 1245-1264. [PubMed: 27411023].
  334. Kandalaft et al., 2013: Kandalaft LE, Powell DJ Jr, Chiang CL, Tanyi J, Kim S, Bosch M, Montone K, Mick R, Levine BL, Torigian DA, June CH, Coukos G. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology. 2013; 2(1); e22664. [PubMed: 23482679].
  335. Kanehira et al., 2007: Kanehira M, Harada Y, Takata R, Shuin T, Miki T, Fujioka T, Nakamura Y, Katagiri T. Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene. 2007; 26(44); 6448-6455. [PubMed: 17452976].
  336. Kantoff et al., 2010: Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England journal of medicine. 2010; 363(5); 411-422. [PubMed: 20818862].
  337. Kaplan et al., 2006: Kaplan CD, Krüger JA, Zhou H, Luo Y, Xiang R, Reisfeld RA. A novel DNA vaccine encoding PDGFRbeta suppresses growth and dissemination of murine colon, lung and breast carcinoma. Vaccine. 2006; 24(47-48); 6994-7002. [PubMed: 17050049].
  338. Karamitros et al., 2018: Karamitros D, Stoilova B, Aboukhalil Z, Hamey F, Reinisch A, Samitsch M, Quek L, Otto G, Repapi E, Doondeea J, Usukhbayar B, Calvo J, Taylor S, Goardon N, Six E, Pflumio F, Porcher C, Majeti R, Göttgens B, Vyas P. Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells. Nature immunology. 2018; 19(1); 85-97. [PubMed: 29167569].
  339. Karkada et al., 2010: Karkada M, Weir GM, Quinton T, Sammatur L, MacDonald LD, Grant A, Liwski R, Juskevicius R, Sinnathamby G, Philip R, Mansour M. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses. Journal of immunotherapy (Hagerstown, Md. : 1997). 2010; 33(3); 250-261. [PubMed: 20445345].
  340. Karyampudi and Ghosh, 2008: Karyampudi L, Ghosh SK. Mycobacterial HSP70 as an adjuvant in the design of an idiotype vaccine against a murine lymphoma. Cellular immunology. 2008; 254(1); 74-80. [PubMed: 18715553].
  341. Kass et al., 2001: Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer research. 2001; 61(1); 206-214. [PubMed: 11196163].
  342. Kato, 2014: Kato Y. [Efficacy of WT1 peptide-/MUC-1 peptide-pulsed dendritic cell therapy in 313 patients with a wide range of cancers]. Gan to kagaku ryoho. Cancer & chemotherapy. 2014; 41(10); 1280-1282. [PubMed: 25335717].
  343. Kaufman et al., 2008: Kaufman HL, Lenz HJ, Marshall J, Singh D, Garett C, Cripps C, Moore M, von Mehren M, Dalfen R, Heim WJ, Conry RM, Urba WJ, Benson AB 3rd, Yu M, Caterini J, Kim-Schulze S, Debenedette M, Salha D, Vogel T, Elias I, Berinstein NL. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008; 14(15); 4843-4849. [PubMed: 18676757].
  344. Kawakami et al., 1994: Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proceedings of the National Academy of Sciences of the United States of America. 1994; 91(9); 3515-3519. [PubMed: 8170938].
  345. Kawakami et al., 1994: Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proceedings of the National Academy of Sciences of the United States of America. 1994; 91(14); 6458-6462. [PubMed: 8022805].
  346. Kawakami et al., 1994: Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. The Journal of experimental medicine. 1994; 180(1); 347-352. [PubMed: 7516411].
  347. Keehn et al., 2016: Keehn A, Gartrell B, Schoenberg MP. Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer. Future oncology (London, England). 2016; 12(23); 2673-2682. [PubMed: 27609194].
  348. Keller et al., 2015: Keller M, Ebstein F, Bürger E, Textoris-Taube K, Gorny X, Urban S, Zhao F, Dannenberg T, Sucker A, Keller C, Saveanu L, Krüger E, Rothkötter HJ, Dahlmann B, Henklein P, Voigt A, Kuckelkorn U, Paschen A, Kloetzel PM, Seifert U. The proteasome immunosubunits, PA28 and ER-aminopeptidase 1 protect melanoma cells from efficient MART-126-35 -specific T-cell recognition. European journal of immunology. 2015; 45(12); 3257-3268. [PubMed: 26399368].
  349. Kelsen et al., 2007: Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007; 25(24); 3719-3725. [PubMed: 17704421].
  350. Kemp et al., 2011: Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, Porras C, Schiller JT, Lowy DR, Herrero R, Pinto LA. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine. 2011; 29(11); 2011-2014. [PubMed: 21241731].
  351. Keskin et al., 2019: Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, Shukla SA, Hu Z, Li L, Le PM, Allesøe RL, Richman AR, Kowalczyk MS, Abdelrahman S, Geduldig JE, Charbonneau S, Pelton K, Iorgulescu JB, Elagina L, Zhang W, Olive O, McCluskey C, Olsen LR, Stevens J, Lane WJ, Salazar AM, Daley H, Wen PY, Chiocca EA, Harden M, Lennon NJ, Gabriel S, Getz G, Lander ES, Regev A, Ritz J, Neuberg D, Rodig SJ, Ligon KL, Suvà ML, Wucherpfennig KW, Hacohen N, Fritsch EF, Livak KJ, Ott PA, Wu CJ, Reardon DA. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019; 565(7738); 234-239. [PubMed: 30568305].
  352. Khan et al., 2015: Khan MI, Pach A 3rd, Khan GM, Bajracharya D, Sahastrabuddhe S, Bhutta W, Tahir R, Soofi S, Thapa CB, Joshi N, Puri MK, Shrestha P, Upreti SR, Clemens JD, Bhutta Z, Ochiai RL. Typhoid vaccine introduction: An evidence-based pilot implementation project in Nepal and Pakistan. Vaccine. 2015; 33 Suppl 3; C62-67. [PubMed: 25937612].
  353. Kharfan-Dabaja et al., 2012: Kharfan-Dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH, Wloch MK, Guterwill DF, Smith LR, Rolland AP, Kenney RT. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Infectious diseases. 2012; 12(4); 290-299. [PubMed: 22237175].
  354. Khong et al., 2004: Khong HT, Yang JC, Topalian SL, Sherry RM, Mavroukakis SA, White DE, Rosenberg SA. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. Journal of immunotherapy (Hagerstown, Md. : 1997). 2004; 27(6); 472-477. [PubMed: 15534491].
  355. Kim and Liau, 2010: Kim W, Liau LM. Dendritic cell vaccines for brain tumors. Neurosurgery clinics of North America. 2010; 21(1); 139-157. [PubMed: 19944973].
  356. Kim and Sin, 2005: Kim MS, Sin JI. Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model. Immunology. 2005; 116(2); 255-266. [PubMed: 16162274].
  357. Kim et al., 2000: Kim SK, Ragupathi G, Cappello S, Kagan E, Livingston PO. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Vaccine. 2000; 19(4-5); 530-537. [PubMed: 11027818].
  358. Kim et al., 2001: Kim JJ, Yang JS, Nottingham LK, Tang W, Dang K, Manson KH, Wyand MS, Wilson DM, Weiner DB. Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen. Oncogene. 2001; 20(33); 4497-4506. [PubMed: 11494145].
  359. Kim et al., 2001: Kim JJ, Yang JS, Dang K, Manson KH, Weiner DB. Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001; 7(3 Suppl); 882s-889s. [PubMed: 11300487].
  360. Kim et al., 2008: Kim SG, Park MY, Kim CH, Sohn HJ, Kim HS, Park JS, Kim HJ, Oh ST, Kim TG. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination. Vaccine. 2008; 26(50); 6433-6440. [PubMed: 18812201].
  361. Kim et al., 2014: Kim TJ, Jin HT, Hur SY, Yang HG, Seo YB, Hong SR, Lee CW, Kim S, Woo JW, Park KS, Hwang YY, Park J, Lee IH, Lim KT, Lee KH, Jeong MS, Surh CD, Suh YS, Park JS, Sung YC. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nature communications. 2014; 5; 5317. [PubMed: 25354725].
  362. Kim et al., 2015: Kim JH, Lee JO, Kim N, Lee HJ, Lee YW, Kim HI, Kim SJ, Park SH, Kim HS. Paclitaxel suppresses the viability of breast tumor MCF7 cells through the regulation of EF1α and FOXO3a by AMPK signaling. International journal of oncology. 2015; 47(5); 1874-1880. [PubMed: 26397839].
  363. Kim et al., 2016: Kim SW, Goedegebuure P, Gillanders WE. Mammaglobin-A is a target for breast cancer vaccination. Oncoimmunology. 2016; 5(2); e1069940. [PubMed: 27057470].
  364. Kim et al., 2016: Kim H, Seo EH, Lee SH, Kim BJ. The Telomerase-Derived Anticancer Peptide Vaccine GV1001 as an Extracellular Heat Shock Protein-Mediated Cell-Penetrating Peptide. International journal of molecular sciences. 2016; 17(12); . [PubMed: 27941629].
  365. Kim et al., 2019: Kim KH, Kim CS, Kim HM, Kim JD, Ma SH, Kim DH, Hwang PH, Han JW, Lee TJ, Kim JH, Karkada N, Mesaros N, Sohn WY, Kim JH. Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course in healthy Korean infants: phase III, randomized study. Human vaccines & immunotherapeutics. 2019; 15(2); 317-326. [PubMed: 30431387].
  366. Kim et al., 2023: Kim JY, Yang DW, Kim S, Choi JG. Retrospective Analysis of the Clinical Characteristics of Patients with Breast Cancer Treated with Telomerase Peptide Immunotherapy Combined with Cytotoxic Chemotherapy. Breast cancer (Dove Medical Press). 2023; 15; 955-966. [PubMed: 38146419].
  367. Kitawaki et al., 2011: Kitawaki T, Kadowaki N, Fukunaga K, Kasai Y, Maekawa T, Ohmori K, Itoh T, Shimizu A, Kuzushima K, Kondo T, Ishikawa T, Uchiyama T. Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia. Experimental hematology. 2011; 39(4); 424-433.e2. [PubMed: 21216276].
  368. Ko et al., 2009: Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R, Finke JH. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009; 15(6); 2148-2157. [PubMed: 19276286].
  369. Kobayashi et al., 2006: Kobayashi H, Nagato T, Aoki N, Sato K, Kimura S, Tateno M, Celis E. Defining MHC class II T helper epitopes for WT1 tumor antigen. Cancer immunology, immunotherapy : CII. 2006; 55(7); 850-860. [PubMed: 16220325].
  370. Kobayashi et al., 2017: Kobayashi Y, Sakura T, Miyawaki S, Toga K, Sogo S, Heike Y. A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia. Cancer immunology, immunotherapy : CII. 2017; 66(7); 851-863. [PubMed: 28321480].
  371. Koido et al., 2000: Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. Journal of immunology (Baltimore, Md. : 1950). 2000; 165(10); 5713-5719. [PubMed: 11067929].
  372. Kolarić et al., 1979: Kolarić K, Malenica B, Roth A. A preliminary report of a pilot trial in adjuvant chemotherapy of primary melanoma. Tumori. 1979; 65(2); 229-236. [PubMed: 462575].
  373. Komatsu et al., 2013: Komatsu N, Jackson HM, Chan KF, Oveissi S, Cebon J, Itoh K, Chen W. Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein. Molecular immunology. 2013; 54(3-4); 465-471. [PubMed: 23454162].
  374. Kong et al., 2018: Kong Z, Wang Y, Ma W. Vaccination in the immunotherapy of glioblastoma. Human vaccines & immunotherapeutics. 2018; 14(2); 255-268. [PubMed: 29087782].
  375. Koski et al., 2012: Koski GK, Koldovsky U, Xu S, Mick R, Sharma A, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Czerniecki BJ. A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. Journal of immunotherapy (Hagerstown, Md. : 1997). 2012; 35(1); 54-65. [PubMed: 22130160].
  376. Kouiavskaia et al., 2009: Kouiavskaia DV, Berard CA, Datena E, Hussain A, Dawson N, Klyushnenkova EN, Alexander RB. Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer. Journal of immunotherapy (Hagerstown, Md. : 1997). 2009; 32(6); 655-666. [PubMed: 19483644].
  377. Kozłowska et al., 2013: Kozłowska A, Mackiewicz J, Mackiewicz A. Therapeutic gene modified cell based cancer vaccines. Gene. 2013; 525(2); 200-207. [PubMed: 23566846].
  378. Krishnadas et al., 2015: Krishnadas DK, Shusterman S, Bai F, Diller L, Sullivan JE, Cheerva AC, George RE, Lucas KG. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. Cancer immunology, immunotherapy : CII. 2015; 64(10); 1251-1260. [PubMed: 26105625].
  379. Krown et al., 1978: Krown SE, Hilal EY, Pinsky CM, Hirshaut Y, Wanebo HJ, Hansen JA, Huvos AG, Oettgen HF. Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma. Cancer. 1978; 42(6); 2648-2660. [PubMed: 728866].
  380. Kruit et al., 2013: Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob JJ, Becker JC, Spatz A, Eggermont AM, Louahed J, Lehmann FF, Brichard VG, Keilholz U. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013; 31(19); 2413-2420. [PubMed: 23715572].
  381. Kuai et al., 2020: Kuai R, Singh PB, Sun X, Xu C, Najafabadi AH, Scheetz L, Yuan W, Xu Y, Hong H, Keskin DB, Wu CJ, Jain R, Schwendeman A, Moon JJ. Robust anti-tumor T cell response with efficient intratumoral infiltration by nanodisc cancer immunotherapy. Advanced therapeutics. 2020; 3(9); . [PubMed: 38317797].
  382. Kubuschok et al., 2000: Kubuschok B, Cochlovius C, Jung W, Schmits R, Trümper L, Hartmann F, Renner C, Pfreundschuh M. Gene-modified spontaneous Epstein-Barr virus-transformed lymphoblastoid cell lines as autologous cancer vaccines: mutated p21 ras oncogene as a model. Cancer gene therapy. 2000; 7(9); 1231-1240. [PubMed: 11023195].
  383. Kudela et al., 2011: Kudela P, Sun Z, Fourcade J, Janjic B, Kirkwood JM, Maillere B, Zarour HM. Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1. Journal of immunology (Baltimore, Md. : 1950). 2011; 186(1); 312-322. [PubMed: 21131422].
  384. Kurtzberg et al., 2020: Kurtzberg J, Abdel-Azim H, Carpenter P, Chaudhury S, Horn B, Mahadeo K, Nemecek E, Neudorf S, Prasad V, Prockop S, Quigg T, Satwani P, Cheng A, Burke E, Hayes J, Skerrett D. A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2020; 26(5); 845-854. [PubMed: 32018062].
  385. Kwiatkowska-Borowczyk et al., 2018: Kwiatkowska-Borowczyk E, CzerwiÅ„ska P, Mackiewicz J, Gryska K, Kazimierczak U, Tomela K, PrzybyÅ‚a A, KozÅ‚owska AK, Galus Å, Kwinta Å, Dondajewska E, GÄ…bka-Buszek A, Å»akowska M, Mackiewicz A. Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients. Oncoimmunology. 2018; 7(11); e1509821. [PubMed: 30377573].
  386. Kyriakopoulos et al., 2020: Kyriakopoulos CE, Eickhoff JC, Ferrari AC, Schweizer MT, Wargowski E, Olson BM, McNeel DG. Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020; 26(19); 5162-5171. [PubMed: 32513836].
  387. Kyte et al., 2016: Kyte JA, Aamdal S, Dueland S, Sæbøe-Larsen S, Inderberg EM, Madsbu UE, Skovlund E, Gaudernack G, Kvalheim G. Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells. Oncoimmunology. 2016; 5(11); e1232237. [PubMed: 27999747].
  388. La et al., 2012: La Rosa C, Longmate J, Lacey SF, Kaltcheva T, Sharan R, Marsano D, Kwon P, Drake J, Williams B, Denison S, Broyer S, Couture L, Nakamura R, Dadwal S, Kelsey MI, Krieg AM, Diamond DJ, Zaia JA. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. The Journal of infectious diseases. 2012; 205(8); 1294-1304. [PubMed: 22402037].
  389. La et al., 2017: La Rosa C, Longmate J, Martinez J, Zhou Q, Kaltcheva TI, Tsai W, Drake J, Carroll M, Wussow F, Chiuppesi F, Hardwick N, Dadwal S, Aldoss I, Nakamura R, Zaia JA, Diamond DJ. MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults. Blood. 2017; 129(1); 114-125. [PubMed: 27760761].
  390. Lacy et al., 2009: Lacy MQ, Mandrekar S, Dispenzieri A, Hayman S, Kumar S, Buadi F, Dingli D, Litzow M, Wettstein P, Padley D, Kabat B, Gastineau D, Rajkumar SV, Gertz MA. Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. American journal of hematology. 2009; 84(12); 799-802. [PubMed: 19899131].
  391. Lange et al., 2013: Lange S, Lampe J, Bossow S, Zimmermann M, Neubert W, Bitzer M, Lauer UM. A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma. Human gene therapy. 2013; 24(5); 554-564. [PubMed: 23550539].
  392. Lattanzi et al., 2018: Lattanzi M, Han J, Moran U, Utter K, Tchack J, Sabado RL, Berman R, Shapiro R, Huang HH, Osman I, Bhardwaj N, Pavlick AC. Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis. Journal for immunotherapy of cancer. 2018; 6(1); 38. [PubMed: 29773080].
  393. Lauer et al., 2018: Lauer UM, Schell M, Beil J, Berchtold S, Koppenhöfer U, Glatzle J, Königsrainer A, Möhle R, Nann D, Fend F, Pfannenberg C, Bitzer M, Malek NP. Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018; 24(18); 4388-4398. [PubMed: 29773661].
  394. Lawatscheck et al., 2007: Lawatscheck R, Aleksaite E, Schenk JA, Micheel B, Jandrig B, Holland G, Sasnauskas K, Gedvilaite A, Ulrich RG. Chimeric polyomavirus-derived virus-like particles: the immunogenicity of an inserted peptide applied without adjuvant to mice depends on its insertion site and its flanking linker sequence. Viral immunology. 2007; 20(3); 453-460. [PubMed: 17931115].
  395. Lazarus et al., 2005: Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR Jr, Moseley AB, Bacigalupo A. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2005; 11(5); 389-398. [PubMed: 15846293].
  396. Le et al., 2012: Le DT, Dubenksy TW Jr, Brockstedt DG. Clinical development of Listeria monocytogenes-based immunotherapies. Seminars in oncology. 2012; 39(3); 311-322. [PubMed: 22595054].
  397. Le et al., 2013: Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA Jr, Donehower RC, Jaffee EM, Laheru DA. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. Journal of immunotherapy (Hagerstown, Md. : 1997). 2013; 36(7); 382-389. [PubMed: 23924790].
  398. Lee et al., 2005: Lee J, Fassnacht M, Nair S, Boczkowski D, Gilboa E. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer research. 2005; 65(23); 11156-11163. [PubMed: 16322266].
  399. Lee et al., 2007: Lee ST, Neelapu SS, Kwak LW. Therapeutic vaccine for lymphoma. Yonsei medical journal. 2007; 48(1); 1-10. [PubMed: 17326239].
  400. Lee et al., 2017: Lee JM, Lee MH, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE, Schaue D, Wang G, Rosen F, Yanagawa J, Walser TC, Lin Y, Park SJ, Adams S, Marincola FM, Tumeh PC, Abtin F, Suh R, Reckamp KL, Lee G, Wallace WD, Lee S, Zeng G, Elashoff DA, Sharma S, Dubinett SM. Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017; 23(16); 4556-4568. [PubMed: 28468947].
  401. Lee et al., 2018: Lee SJ, Kim HJ, Huh YM, Kim IW, Jeong JH, Kim JC, Kim JD. Functionalized Magnetic PLGA Nanospheres for Targeting and Bioimaging of Breast Cancer. Journal of nanoscience and nanotechnology. 2018; 18(3); 1542-1547. [PubMed: 29448628].
  402. Leitner et al., 2003: Leitner WW, Hwang LN, deVeer MJ, Zhou A, Silverman RH, Williams BR, Dubensky TW, Ying H, Restifo NP. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nature medicine. 2003; 9(1); 33-39. [PubMed: 12496961].
  403. Leitner et al., 2004: Leitner WW, Hwang LN, Bergmann-Leitner ES, Finkelstein SE, Frank S, Restifo NP. Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. Vaccine. 2004; 22(11-12); 1537-1544. [PubMed: 15063579].
  404. Leslie et al., 2007: Leslie MC, Zhao YJ, Lachman LB, Hwu P, Wu GJ, Bar-Eli M. Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis. Gene therapy. 2007; 14(4); 316-323. [PubMed: 17024104].
  405. Lesterhuis et al., 2006: Lesterhuis WJ, de Vries IJ, Schuurhuis DH, Boullart AC, Jacobs JF, de Boer AJ, Scharenborg NM, Brouwer HM, van de Rakt MW, Figdor CG, Ruers TJ, Adema GJ, Punt CJ. Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. Annals of oncology : official journal of the European Society for Medical Oncology. 2006; 17(6); 974-980. [PubMed: 16600979].
  406. Li et al., 2013: Li L, Yang G, Ren C, Tanimoto R, Hirayama T, Wang J, Hawke D, Kim SM, Lee JS, Goltsov AA, Park S, Ittmann MM, Troncoso P, Thompson TC. Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2. Molecular oncology. 2013; 7(3); 484-496. [PubMed: 23333597].
  407. Li et al., 2016: Li Y, Li RC, Ye Q, Li C, Liu YP, Ma X, Li Y, Zhao H, Chen X, Assudani D, Karkada N, Han HH, Van Der Meeren O, Mesaros N. Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b conjugate vaccine (DTPa-IPV/Hib) administered in Chinese infants. Human vaccines & immunotherapeutics. 2016; ; 1-11. [PubMed: 27768515].
  408. Li et al., 2017: Li J, Chen J, Li X, Qian Y. Vaccination efficacy with marrow mesenchymal stem cell against cancer was enhanced under simulated microgravity. Biochemical and biophysical research communications. 2017; 485(3); 606-613. [PubMed: 28238782].
  409. Li et al., 2021: Li T, Zhao L, Yang Y, Wang Y, Zhang Y, Guo J, Chen G, Qin P, Xu B, Ma B, Zhang F, Shang Y, Li Q, Zhang K, Yuan D, Feng C, Ma Y, Liu Z, Tian Z, Li H, Wang S, Gao Q. T Cells Expanded from PD-1(+) Peripheral Blood Lymphocytes Share More Clones with Paired Tumor-Infiltrating Lymphocytes. Cancer research. 2021; 81(8); 2184-2194. [PubMed: 33408117].
  410. Liao et al., 2006: Liao JC, Gregor P, Wolchok JD, Orlandi F, Craft D, Leung C, Houghton AN, Bergman PJ. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer immunity. 2006; 6; 8. [PubMed: 16626110].
  411. Lieberman et al., 1975: Lieberman R, Wybran J, Epstein W. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma. Cancer. 1975; 35(3); 756-777. [PubMed: 234295].
  412. Lienard et al., 2009: Lienard D, Avril MF, Le Gal FA, Baumgaertner P, Vermeulen W, Blom A, Geldhof C, Rimoldi D, Pagliusi S, Romero P, Dietrich PY, Corvaia N, Speiser DE. Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant. Journal of immunotherapy (Hagerstown, Md. : 1997). 2009; 32(8); 875-883. [PubMed: 19752746].
  413. Lilleby et al., 2017: Lilleby W, Gaudernack G, Brunsvig PF, Vlatkovic L, Schulz M, Mills K, Hole KH, Inderberg EM. Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer. Cancer immunology, immunotherapy : CII. 2017; 66(7); 891-901. [PubMed: 28391357].
  414. Lin et al., 2016: Lin HC, Chao YH, Wu KH, Yen TY, Hsu YL, Hsieh TH, Wei HM, Wu JL, Muo CH, Hwang KP, Peng CT, Lin CC, Li TC. Increased risk of herpes zoster in children with cancer: A nationwide population-based cohort study. Medicine. 2016; 95(30); e4037. [PubMed: 27472677].
  415. Lindencrona et al., 2004: Lindencrona JA, Preiss S, Kammertoens T, Schüler T, Piechocki M, Wei WZ, Seliger B, Blankenstein T, Kiessling R. CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. International journal of cancer. Journal international du cancer. 2004; 109(2); 259-264. [PubMed: 14750178].
  416. Lindsey et al., 2006: Lindsey KR, Gritz L, Sherry R, Abati A, Fetsch PA, Goldfeder LC, Gonzales MI, Zinnack KA, Rogers-Freezer L, Haworth L, Mavroukakis SA, White DE, Steinberg SM, Restifo NP, Panicali DL, Rosenberg SA, Topalian SL. Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006; 12(8); 2526-2537. [PubMed: 16638862].
  417. Lipton et al., 1983: Lipton A, Harvey HA, Lawrence B, Gottlieb R, Kukrika M, Dixon R, Graham W, Miller S, Heckard R, Schelzel D, White DS. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma. Cancer. 1983; 51(1); 57-60. [PubMed: 6821809].
  418. Lipton et al., 1991: Lipton A, Harvey HA, Balch CM, Antle CE, Heckard R, Bartolucci AA. Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991; 9(7); 1151-1156. [PubMed: 2045856].
  419. Liu et al., 2011: Liu Y, Tian X, Leitner WW, Aldridge ME, Zheng J, Yu Z, Restifo NP, Weiss R, Scheiblhofer S, Xie C, Sun R, Cheng G, Zeng G. Polymeric structure and host Toll-like receptor 4 dictate immunogenicity of NY-ESO-1 antigen in vivo. The Journal of biological chemistry. 2011; 286(43); 37077-37084. [PubMed: 21900253].
  420. Liu et al., 2013: Liu H, Geng S, Feng C, Xie X, Wu B, Chen X, Zou Q, Wang S, Cui J, Xing R, Li W, Lu Y, Wang B. A DNA vaccine targeting p42.3 induces protective antitumor immunity via eliciting cytotoxic CD8+T lymphocytes in a murine melanoma model. Human vaccines & immunotherapeutics. 2013; 9(10); 2196-2202. [PubMed: 24051432].
  421. Liu et al., 2017: Liu Z, Yang Y, Zhang X, Wang H, Xu W, Wang H, Xiao F, Bai Z, Yao H, Ma X, Jin L, Wu C, Seth P, Zhang Z, Wang L. An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation. Human gene therapy. 2017; 28(8); 667-680. [PubMed: 28530155].
  422. Lladser et al., 2010: Lladser A, Ljungberg K, Tufvesson H, Tazzari M, Roos AK, Quest AF, Kiessling R. Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma. Cancer immunology, immunotherapy : CII. 2010; 59(1); 81-92. [PubMed: 19526360].
  423. Lo et al., 2005: Lo HW, Day CP, Hung MC. Cancer-specific gene therapy. Advances in genetics. 2005; 54; 235-255. [PubMed: 16096014].
  424. Lode et al., 2000: Lode HN, Pertl U, Xiang R, Gaedicke G, Reisfeld RA. Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma. Medical and pediatric oncology. 2000; 35(6); 641-646. [PubMed: 11107137].
  425. LoGuidice et al., 2016: LoGuidice A, Houlihan A, Deans R. Multipotent adult progenitor cells on an allograft scaffold facilitate the bone repair process. Journal of tissue engineering. 2016; 7; 2041731416656148. [PubMed: 27493716].
  426. Lohmueller et al., 2016: Lohmueller JJ, Sato S, Popova L, Chu IM, Tucker MA, Barberena R, Innocenti GM, Cudic M, Ham JD, Cheung WC, Polakiewicz RD, Finn OJ. Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential. Scientific reports. 2016; 6; 31740. [PubMed: 27545199].
  427. Longenecker et al., 1993: Longenecker BM, Reddish M, Koganty R, MacLean GD. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant. Annals of the New York Academy of Sciences. 1993; 690; 276-291. [PubMed: 7690215].
  428. Lopes et al., 2006: Lopes L, Fletcher K, Ikeda Y, Collins M. Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy. Cancer immunology, immunotherapy : CII. 2006; 55(8); 1011-1016. [PubMed: 16311731].
  429. Loskog et al., 2004: Loskog A, Dzojic H, Vikman S, Ninalga C, Essand M, Korsgren O, Totterman TH. Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor Microenvironment. Journal of immunology (Baltimore, Md. : 1950). 2004; 172(11); 7200-7205. [PubMed: 15153545].
  430. Lotem et al., 2004: Lotem M, Shiloni E, Pappo I, Drize O, Hamburger T, Weitzen R, Isacson R, Kaduri L, Merims S, Frankenburg S, Peretz T. Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. British journal of cancer. 2004; 90(4); 773-780. [PubMed: 14970852].
  431. Lotem et al., 2009: Lotem M, Machlenkin A, Hamburger T, Nissan A, Kadouri L, Frankenburg S, Gimmon Z, Elias O, David IB, Kuznetz A, Shiloni E, Peretz T. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009; 15(15); 4968-4977. [PubMed: 19602547].
  432. Lu et al., 2006: Lu Y, Xu LC, Parker N, Westrick E, Reddy JA, Vetzel M, Low PS, Leamon CP. Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugate-targeted immunotherapy in hapten-immunized mice. Molecular cancer therapeutics. 2006; 5(12); 3258-3267. [PubMed: 17172429].
  433. Lu et al., 2009: Lu Y, Klein PJ, Westrick E, Xu LC, Santhapuram HK, Bloomfield A, Howard SJ, Vlahov IR, Ellis PR, Low PS, Leamon CP. Strategy to prevent drug-related hypersensitivity in folate-targeted hapten immunotherapy of cancer. The AAPS journal. 2009; 11(3); 628-638. [PubMed: 19728104].
  434. Lu et al., 2016: Lu S, Ren J, Li Q, Jiang Z, Chen Y, Xu K, Ruan B, Yang S, Xie T, Yang L, Li J, Yao J. Effects of hepatitis B vaccine boosters on anti-HBs-negative children after primary immunization. Human vaccines & immunotherapeutics. 2016; ; 0. [PubMed: 27905821].
  435. Lubaroff et al., 2009: Lubaroff DM, Konety BR, Link B, Gerstbrein J, Madsen T, Shannon M, Howard J, Paisley J, Boeglin D, Ratliff TL, Williams RD. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009; 15(23); 7375-7380. [PubMed: 19920098].
  436. Lutz et al., 2011: Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, Sugar E, Piantadosi S, Cameron JL, Solt S, Onners B, Tartakovsky I, Choi M, Sharma R, Illei PB, Hruban RH, Abrams RA, Le D, Jaffee E, Laheru D. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Annals of surgery. 2011; 253(2); 328-335. [PubMed: 21217520].
  437. Luxembourg et al., 2015: Luxembourg A, Moreira ED Jr, Samakoses R, Kim KH, Sun X, Maansson R, Moeller E, Christiano S, Chen J. Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine. Human vaccines & immunotherapeutics. 2015; 11(6); 1306-1312. [PubMed: 26086587].
  438. Luxembourg et al., 2015: Luxembourg A, Brown D, Bouchard C, Giuliano AR, Iversen OE, Joura EA, Penny ME, Restrepo JA, Romaguera J, Maansson R, Moeller E, Ritter M, Chen J. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine. Human vaccines & immunotherapeutics. 2015; 11(6); 1313-1322. [PubMed: 25912208].
  439. Ly et al., 2013: Ly LV, Sluijter M, van der Burg SH, Jager MJ, van Hall T. Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma. Journal of immunology (Baltimore, Md. : 1950). 2013; 190(1); 489-496. [PubMed: 23203930].
  440. Ma et al., 2012: Ma Y, Xu YC, Tang L, Zhang Z, Wang J, Wang HX. Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Experimental hematology & oncology. 2012; 1(1); 11. [PubMed: 23210562].
  441. MacGregor et al., 1977: MacGregor AB, Falk RE, Landi S, Ambus U, Samuel ES, Langer B. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin. Canadian journal of surgery. Journal canadien de chirurgie. 1977; 20(1); 25-30. [PubMed: 832200].
  442. Mahipal et al., 2019: Mahipal A, Ejadi S, Gnjatic S, Kim-Schulze S, Lu H, Ter Meulen JH, Kenney R, Odunsi K. First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1. Cancer immunology, immunotherapy : CII. 2019; 68(7); 1211-1222. [PubMed: 31069460].
  443. Mahmud et al., 2018: Mahmud SM, Bozat-Emre S, Mostaço-Guidolin LC, Marrie RA. Registry Cohort Study to Determine Risk for Multiple Sclerosis after Vaccination for Pandemic Influenza A(H1N1) with Arepanrix, Manitoba, Canada. Emerging infectious diseases. 2018; 24(7); 1267-1274. [PubMed: 29912696].
  444. Mahoney et al., 2019: Mahoney KM, Shukla SA, Patsoukis N, Chaudhri A, Browne EP, Arazi A, Eisenhaure TM, Pendergraft WF 3rd, Hua P, Pham HC, Bu X, Zhu B, Hacohen N, Fritsch EF, Boussiotis VA, Wu CJ, Freeman GJ. A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Cancer immunology, immunotherapy : CII. 2019; 68(3); 421-432. [PubMed: 30564891].
  445. Mailliard et al., 2004: Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer research. 2004; 64(17); 5934-5937. [PubMed: 15342370].
  446. Mandl et al., 1998: Mandl S, Sigal LJ, Rock KL, Andino R. Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen. Proceedings of the National Academy of Sciences of the United States of America. 1998; 95(14); 8216-8221. [PubMed: 9653167].
  447. Manegold and Thatcher, 2007: Manegold C, Thatcher N. Survival improvement in thoracic cancer: progress from the last decade and beyond. Lung cancer (Amsterdam, Netherlands). 2007; 57 Suppl 2; S3-5. [PubMed: 17686443].
  448. Manley et al., 2011: Manley CA, Leibman NF, Wolchok JD, Rivière IC, Bartido S, Craft DM, Bergman PJ. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine. 2011; 25(1); 94-99. [PubMed: 21143299].
  449. Maraskovsky et al., 2004: Maraskovsky E, Sjölander S, Drane DP, Schnurr M, Le TT, Mateo L, Luft T, Masterman KA, Tai TY, Chen Q, Green S, Sjölander A, Pearse MJ, Lemonnier FA, Chen W, Cebon J, Suhrbier A. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004; 10(8); 2879-2890. [PubMed: 15102697].
  450. Marshall et al., 2005: Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R, Hodge JW, Doren S, Grosenbach DW, Hwang J, Fox E, Odogwu L, Park S, Panicali D, Schlom J. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005; 23(4); 720-731. [PubMed: 15613691].
  451. Marshall, 2003: Marshall J. Carcinoembryonic antigen-based vaccines. Seminars in oncology. 2003; 30(3 Suppl 8); 30-36. [PubMed: 12881810].
  452. Maruyama et al., 2000: Maruyama H, Zaloudik J, Li W, Sperlagh M, Koido T, Somasundaram R, Scheck S, Prewett M, Herlyn D. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine. Cancer immunology, immunotherapy : CII. 2000; 49(3); 123-132. [PubMed: 10881691].
  453. Mastelic-Gavillet et al., 2019: Mastelic-Gavillet B, Balint K, Boudousquie C, Gannon PO, Kandalaft LE. Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results. Frontiers in immunology. 2019; 10; 766. [PubMed: 31031762].
  454. Matheson and Goa, 2000: Matheson AJ, Goa KL. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection. Paediatric drugs. 2000; 2(2); 139-159. [PubMed: 10937466].
  455. Mattarollo et al., 2013: Mattarollo SR, Steegh K, Li M, Duret H, Foong Ngiow S, Smyth MJ. Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells. Immunology and cell biology. 2013; 91(1); 105-114. [PubMed: 23090488].
  456. Mazumder et al., 2017: Mazumder S, Johnson JM, Swank V, Dvorina N, Martelli E, Ko J, Tuohy VK. Primary Immunoprevention of Epithelial Ovarian Carcinoma by Vaccination against the Extracellular Domain of Anti-Müllerian Hormone Receptor II. Cancer prevention research (Philadelphia, Pa.). 2017; 10(11); 612-624. [PubMed: 29093011].
  457. Mazumder et al., 2022: Mazumder S, Swank V, Dvorina N, Johnson JM, Tuohy VK. Formulation of an ovarian cancer vaccine with the squalene-based AddaVax adjuvant inhibits the growth of murine epithelial ovarian carcinomas. Clinical and experimental vaccine research. 2022; 11(2); 163-172. [PubMed: 35799868].
  458. McCaffery et al., 1996: McCaffery M, Yao TJ, Williams L, Livingston PO, Houghton AN, Chapman PB. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clinical cancer research : an official journal of the American Association for Cancer Research. 1996; 2(4); 679-686. [PubMed: 9816218].
  459. McCormick et al., 2016: McCormick KA, Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG. Pancreatic cancer: Update on immunotherapies and algenpantucel-L. Human vaccines & immunotherapeutics. 2016; 12(3); 563-575. [PubMed: 26619245].
  460. McKenzie et al., 1998: McKenzie IF, Apostolopoulos V, Lees C, Xing PX, Lofthouse S, Osinski C, Popovski V, Acres B, Pietersz G. Oxidised mannan antigen conjugates preferentially stimulate T1 type immune responses. Veterinary immunology and immunopathology. 1998; 63(1-2); 185-190. [PubMed: 9656453].
  461. McKenzie et al., 2004: McKenzie T, Liu Y, Fanale M, Swisher SG, Chada S, Hunt KK. Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells. Surgery. 2004; 136(2); 437-442. [PubMed: 15300212].
  462. McNeel et al., 2009: McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC, Wilding G. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009; 27(25); 4047-4054. [PubMed: 19636017].
  463. McNeil et al., 2007: McNeil SA, Noya F, Dionne M, Predy G, Meekison W, Ojah C, Ferro S, Mills EL, Langley JM, Halperin SA. Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults. Vaccine. 2007; 25(17); 3464-3474. [PubMed: 17270320].
  464. Mehendale et al., 2008: Mehendale S, van Lunzen J, Clumeck N, Rockstroh J, Vets E, Johnson PR, Anklesaria P, Barin B, Boaz M, Kochhar S, Lehrman J, Schmidt C, Peeters M, Schwarze-Zander C, Kabamba K, Glaunsinger T, Sahay S, Thakar M, Paranjape R, Gilmour J, Excler JL, Fast P, Heald AE. A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. AIDS research and human retroviruses. 2008; 24(6); 873-880. [PubMed: 18544020].
  465. Meleshko et al., 2017: Meleshko AN, Petrovskaya NA, Savelyeva N, Vashkevich KP, Doronina SN, Sachivko NV. Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma. Human vaccines & immunotherapeutics. 2017; 13(6); 1-6. [PubMed: 28272989].
  466. Melssen et al., 2019: Melssen MM, Petroni GR, Chianese-Bullock KA, Wages NA, Grosh WW, Varhegyi N, Smolkin ME, Smith KT, Galeassi NV, Deacon DH, Gaughan EM, Slingluff CL Jr. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients. Journal for immunotherapy of cancer. 2019; 7(1); 163. [PubMed: 31248461].
  467. Meng et al., 2001: Meng WS, Butterfield LH, Ribas A, Dissette VB, Heller JB, Miranda GA, Glaspy JA, McBride WH, Economou JS. alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer research. 2001; 61(24); 8782-8786. [PubMed: 11751399].
  468. Mevorach et al., 2014: Mevorach D, Zuckerman T, Reiner I, Shimoni A, Samuel S, Nagler A, Rowe JM, Or R. Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014; 20(1); 58-65. [PubMed: 24140121].
  469. Meyer et al., 2005: Meyer RG, Britten CM, Siepmann U, Petzold B, Sagban TA, Lehr HA, Weigle B, Schmitz M, Mateo L, Schmidt B, Bernhard H, Jakob T, Hein R, Schuler G, Schuler-Thurner B, Wagner SN, Drexler I, Sutter G, Arndtz N, Chaplin P, Metz J, Enk A, Huber C, Wölfel T. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer immunology, immunotherapy : CII. 2005; 54(5); 453-467. [PubMed: 15627214].
  470. MFGS-MOv18-gamma: Retroviral Vector MFGS-MOv18-gamma [https://www.ncbi.nlm.nih.gov/medgen/271119]
  471. Miguel et al., 2012: Miguel A, Herrero MJ, Sendra L, Botella R, Algás R, Sánchez M, Aliño SF. Comparative antitumor effect of preventive versus therapeutic vaccines employing B16 melanoma cells genetically modified to express GM-CSF and B7.2 in a murine model. Toxins. 2012; 4(11); 1058-1081. [PubMed: 23202306].
  472. Miguel et al., 2013: Miguel A, Herrero MJ, Sendra L, Botella R, Algás R, Sánchez M, Aliño SF. Comparative antitumor effect among GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccines. Cancer gene therapy. 2013; 20(10); 576-581. [PubMed: 23969885].
  473. Miller et al., 2014: Miller MJ, Foy KC, Overholser JP, Nahta R, Kaumaya PT. HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells. Oncoimmunology. 2014; 3(11); e956012. [PubMed: 25941588].
  474. Millman and Pagliuca, 2017: Millman JR, Pagliuca FW. Autologous Pluripotent Stem Cell-Derived β-Like Cells for Diabetes Cellular Therapy. Diabetes. 2017; 66(5); 1111-1120. [PubMed: 28507211].
  475. Mincheff et al., 2000: Mincheff M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Altankova I, Georgiev G, Petrov S, Meryman HT. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. European urology. 2000; 38(2); 208-217. [PubMed: 10895014].
  476. Mincheff et al., 2006: Mincheff M, Zoubak S, Makogonenko Y. Immune responses against PSMA after gene-based vaccination for immunotherapy-A: results from immunizations in animals. Cancer gene therapy. 2006; 13(4); 436-444. [PubMed: 16276349].
  477. Mitchell et al., 1994: Mitchell MS, Jakowatz J, Harel W, Dean G, Stevenson L, Boswell WD, Groshen S. Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994; 12(2); 402-411. [PubMed: 8113848].
  478. Mitchell et al., 2015: Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair SK, Congdon KL, Reap EA, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE 2nd, Coan A, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, Sampson JH. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015; 519(7543); 366-369. [PubMed: 25762141].
  479. Mitchell et al., 2018: Mitchell D, Chintala S, Dey M. Plasmacytoid dendritic cell in immunity and cancer. Journal of neuroimmunology. 2018; 322; 63-73. [PubMed: 30049538].
  480. Mittelman et al., 1995: Mittelman A, Chen GZ, Wong GY, Liu C, Hirai S, Ferrone S. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 1995; 1(7); 705-713. [PubMed: 9816036].
  481. Mittendorf et al., 2011: Mittendorf EA, Alatrash G, Xiao H, Clifton GT, Murray JL, Peoples GE. Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials. Expert review of vaccines. 2011; 10(6); 755-774. [PubMed: 21692698].
  482. Miyauchi et al., 2011: Miyauchi M, Murata M, Shibuya K, Koga-Yamakawa E, Uenishi Y, Kusunose N, Sunagawa M, Yano I, Kashiwazaki Y. Arabino-mycolates derived from cell-wall skeleton of Mycobacterium bovis BCG as a prominent structure for recognition by host immunity. Drug discoveries & therapeutics. 2011; 5(3); 130-135. [PubMed: 22466242].
  483. Miyauchi et al., 2012: Miyauchi M, Murata M, Fukushima A, Sato T, Nakagawa M, Fujii T, Koseki N, Chiba N, Kashiwazaki Y. Optimization of cell-wall skeleton derived from Mycobacterium bovis BCG Tokyo 172 (SMP-105) emulsion in delayed-type hypersensitivity and antitumor models. Drug discoveries & therapeutics. 2012; 6(4); 218-225. [PubMed: 23006993].
  484. Mizote et al., 2014: Mizote Y, Uenaka A, Isobe M, Wada H, Kakimi K, Saika T, Kita S, Koide Y, Oka M, Nakayama E. Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients. Vaccine. 2014; 32(8); 957-964. [PubMed: 24397899].
  485. Moehler et al., 2019: Moehler M, Heo J, Lee HC, Tak WY, Chao Y, Paik SW, Yim HJ, Byun KS, Baron A, Ungerechts G, Jonker D, Ruo L, Cho M, Kaubisch A, Wege H, Merle P, Ebert O, Habersetzer F, Blanc JF, Rosmorduc O, Lencioni R, Patt R, Leen AM, Foerster F, Homerin M, Stojkowitz N, Lusky M, Limacher JM, Hennequi M, Gaspar N, McFadden B, De Silva N, Shen D, Pelusio A, Kirn DH, Breitbach CJ, Burke JM. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). Oncoimmunology. 2019; 8(8); 1615817. [PubMed: 31413923].
  486. Mohammadzadeh et al., 2018: Mohammadzadeh M, Shirmohammadi M, Ghojazadeh M, Nikniaz L, Raeisi M, Aghdas SAM. Dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis. Prostate international. 2018; 6(4); 119-125. [PubMed: 30505813].
  487. Mohanty et al., 2007: Mohanty K, Saha A, Pal S, Mallick P, Chatterjee SK, Foon KA, Bhattacharya-Chatterjee M. Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu. Breast cancer research and treatment. 2007; 104(1); 1-11. [PubMed: 17004107].
  488. Mohn et al., 2018: Mohn KG, Smith I, Sjursen H, Cox RJ. Immune responses after live attenuated influenza vaccination. Human vaccines & immunotherapeutics. 2018; 14(3); 571-578. [PubMed: 28933664].
  489. Mordoh et al., 2013: Mordoh J, Tapia IJ, Barrio MM. A word of caution: do not wake sleeping dogs; micrometastases of melanoma suddenly grew after progesterone treatment. BMC cancer. 2013; 13; 132. [PubMed: 23510193].
  490. Moreira et al., 2016: Moreira ED Jr, Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, Bosch FX, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Qi H, Hyatt D, Martin J, Moeller E, Ritter M, Baudin M, Luxembourg A. Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials. Pediatrics. 2016; 138(2); . [PubMed: 27422279].
  491. Morera et al., 2008: Morera Y, Bequet-Romero M, Ayala M, Lamdán H, Agger EM, Andersen P, Gavilondo JV. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants. Angiogenesis. 2008; 11(4); 381-393. [PubMed: 19034678].
  492. Morera et al., 2017: Morera Y, Sánchez J, Bequet-Romero M, Selman-Housein KH, de la Torre A, Hernández-Bernal F, Martín Y, Garabito A, Piñero J, Bermúdez C, de la Torre J, Ayala M, Gavilondo JV. Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine. Vaccine. 2017; 35(28); 3582-3590. [PubMed: 28536029].
  493. Morris et al., 2000: Morris JC, Ramsey WJ, Wildner O, Muslow HA, Aguilar-Cordova E, Blaese RM. A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV.RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma. Human gene therapy. 2000; 11(3); 487-503. [PubMed: 10697123].
  494. Morse et al., 2010: Morse MA, Hobeika AC, Osada T, Berglund P, Hubby B, Negri S, Niedzwiecki D, Devi GR, Burnett BK, Clay TM, Smith J, Lyerly HK. An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. The Journal of clinical investigation. 2010; 120(9); 3234-3241. [PubMed: 20679728].
  495. Morse et al., 2013: Morse MA, Chaudhry A, Gabitzsch ES, Hobeika AC, Osada T, Clay TM, Amalfitano A, Burnett BK, Devi GR, Hsu DS, Xu Y, Balcaitis S, Dua R, Nguyen S, Balint JP Jr, Jones FR, Lyerly HK. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer immunology, immunotherapy : CII. 2013; 62(8); 1293-1301. [PubMed: 23624851].
  496. Morse et al., 2013: Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hobeika AC, Osada T, Onaitis M, Clary BM, Hsu D, Devi GR, Bulusu A, Annechiarico RP, Chadaram V, Clay TM, Lyerly HK. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Annals of surgery. 2013; 258(6); 879-886. [PubMed: 23657083].
  497. Morton et al., 1992: Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Annals of surgery. 1992; 216(4); 463-482. [PubMed: 1417196].
  498. Mosaheb et al., 2020: Mosaheb MM, Dobrikova EY, Brown MC, Yang Y, Cable J, Okada H, Nair SK, Bigner DD, Ashley DM, Gromeier M. Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. Nature communications. 2020; 11(1); 524. [PubMed: 31988324].
  499. Mota et al., 2023: Mota I, Patrucco E, Mastini C, Mahadevan NR, Thai TC, Bergaggio E, Cheong TC, Leonardi G, Karaca-Atabay E, Campisi M, Poggio T, Menotti M, Ambrogio C, Longo DL, Klaeger S, Keshishian H, Sztupinszki ZM, Szallasi Z, Keskin DB, Duke-Cohan JS, Reinhold B, Carr SA, Wu CJ, Moynihan KD, Irvine DJ, Barbie DA, Reinherz EL, Voena C, Awad MM, Blasco RB, Chiarle R. ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer. Nature cancer. 2023; 4(7); 1016-1035. [PubMed: 37430060].
  500. Motta et al., 2001: Motta I, André F, Lim A, Tartaglia J, Cox WI, Zitvogel L, Angevin E, Kourilsky P. Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells. Journal of immunology (Baltimore, Md. : 1950). 2001; 167(3); 1795-1802. [PubMed: 11466405].
  501. Moulton et al., 2002: Moulton HM, Yoshihara PH, Mason DH, Iversen PL, Triozzi PL. Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002; 8(7); 2044-2051. [PubMed: 12114402].
  502. Movahedin et al., 2017: Movahedin M, Brooks TM, Supekar NT, Gokanapudi N, Boons GJ, Brooks CL. Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigen. Glycobiology. 2017; 27(7); 677-687. [PubMed: 28025250].
  503. Mpendo et al., 2015: Mpendo J, Mutua G, Nyombayire J, Ingabire R, Nanvubya A, Anzala O, Karita E, Hayes P, Kopycinski J, Dally L, Hannaman D, Egan MA, Eldridge JH, Syvertsen K, Lehrman J, Rasmussen B, Gilmour J, Cox JH, Fast PE, Schmidt C. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults. PloS one. 2015; 10(8); e0134287. [PubMed: 26252526].
  504. Muderspach et al., 2000: Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V, Weber J. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000; 6(9); 3406-3416. [PubMed: 10999722].
  505. Mullane et al., 2013: Mullane KM, Winston DJ, Wertheim MS, Betts RF, Poretz DM, Camacho LH, Pergam SA, Mullane MR, Stek JE, Sterling TM, Zhao Y, Manoff SB, Annunziato PW. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. The Journal of infectious diseases. 2013; 208(9); 1375-1385. [PubMed: 23908479].
  506. Muthumani et al., 2017: Muthumani K, Marnin L, Kudchodkar SB, Perales-Puchalt A, Choi H, Agarwal S, Scott VL, Reuschel EL, Zaidi FI, Duperret EK, Wise MC, Kraynyak KA, Ugen KE, Sardesai NY, Joseph Kim J, Weiner DB. Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody. Cancer immunology, immunotherapy : CII. 2017; 66(12); 1577-1588. [PubMed: 28819703].
  507. Nagabhushan et al., 2007: Nagabhushan TL, Maneval DC, Benedict WF, Wen SF, Ihnat PM, Engler H, Connor RJ. Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer. Cytokine & growth factor reviews. 2007; 18(5-6); 389-394. [PubMed: 17692556].
  508. Nagayama et al., 2010: Nagayama H, Matsumoto K, Isoo N, Ohno H, Takahashi N, Nakaoka T, Shinozaki M, Watanabe M, Inoue Y, Nagamura F, Oyaizu N, Yamashita N. Gastrointestinal bleeding during anti-angiogenic peptide vaccination in combination with gemcitabine for advanced pancreatic cancer. Clinical journal of gastroenterology. 2010; 3(6); 307-317. [PubMed: 26190488].
  509. Nagorsen et al., 2004: Nagorsen D, Servis C, Lévy N, Provenzano M, Dudley ME, Marincola FM, Lévy F. Proteasomal cleavage does not determine immunogenicity of gp100-derived peptides gp100 209-217 and gp100 209-217T210M. Cancer immunology, immunotherapy : CII. 2004; 53(9); 817-824. [PubMed: 15133631].
  510. Narayanan et al., 2004: Narayanan K, Jaramillo A, Benshoff ND, Campbell LG, Fleming TP, Dietz JR, Mohanakumar T. Response of established human breast tumors to vaccination with mammaglobin-A cDNA. Journal of the National Cancer Institute. 2004; 96(18); 1388-1396. [PubMed: 15367572].
  511. Nasser et al., 2020: Nasser R, Rakedzon S, Dickstein Y, Mousa A, Solt I, Peterisel N, Feldman T, Neuberger A. Are all vaccines safe for the pregnant traveller? A systematic review and meta-analysis. Journal of travel medicine. 2020; 27(2); . [PubMed: 31616947].
  512. Nau, 2015: Nau JY. [Zona vaccine, molecular screening of lung cancer]. Revue medicale suisse. 2015; 11(477); 1258-1259. [PubMed: 26211288].
  513. NCBI, 2023: E1M184V peptide, HIV vaccine peptide CID 24204505 [https://pubchem.ncbi.nlm.nih.gov/compound/24204505]
  514. NCIt: C48373: NCIt vaccine ‘Alpha Fetoprotein Plasmid DNA Vaccine’ [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48373]
  515. NCIT_C100099: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C100099]
  516. NCIT_C101094: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C101094]
  517. NCIT_C101262: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C101262]
  518. NCIT_C101777: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C101777]
  519. NCIT_C101891: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C101891]
  520. NCIT_C101892: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C101892]
  521. NCIT_C102541: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C102541]
  522. NCIT_C102751: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C102751]
  523. NCIT_C102753: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C102753]
  524. NCIT_C102782: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C102782]
  525. NCIT_C102787: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C102787]
  526. NCIT_C102879: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C102879]
  527. NCIT_C102978: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C102978]
  528. NCIT_C102982: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C102982]
  529. NCIT_C103192: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C103192]
  530. NCIT_C103823: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C103823]
  531. NCIT_C103830: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C103830]
  532. NCIT_C104419: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C104419]
  533. NCIT_C104734: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C104734]
  534. NCIT_C104737: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C104737]
  535. NCIT_C104738: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C104738]
  536. NCIT_C104743: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C104743]
  537. NCIT_C104747: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C104747]
  538. NCIT_C105806: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C105806]
  539. NCIT_C106242: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C106242]
  540. NCIT_C106257: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C106257]
  541. NCIT_C107159: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C107159]
  542. NCIT_C107169: Allogeneic HLA-A2/4-1BB ligand-expressing Melanoma Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C107169]
  543. NCIT_C107243: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C107243]
  544. NCIT_C107243: PEP-CMV Vaccine (Code C107243) [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C107243]
  545. NCIT_C107685: BC-819 Plasmid/Polyethylenimine Complex [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C107685]
  546. NCIT_C111036: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C111036]
  547. NCIT_C111037: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C111037]
  548. NCIT_C111688: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C111688]
  549. NCIT_C111900: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C111900]
  550. NCIT_C111903: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C111903]
  551. NCIT_C111991: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C111991]
  552. NCIT_C111998: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C111998]
  553. NCIT_C112005: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C112005]
  554. NCIT_C112206: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C112206]
  555. NCIT_C1126: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1126]
  556. NCIT_C113174: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C113174]
  557. NCIT_C113296: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C113296]
  558. NCIT_C113432: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C113432]
  559. NCIT_C113432: NY-ESO-1/GLA-SE Vaccine ID-G305 (Code C113432) [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C113432]
  560. NCIT_C113647: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C113647]
  561. NCIT_C113651: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C113651]
  562. NCIT_C113653: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C113653]
  563. NCIT_C113786: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C113786]
  564. NCIT_C113794: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C113794]
  565. NCIT_C113807: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C113807]
  566. NCIT_C114285: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C114285]
  567. NCIT_C114289: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C114289]
  568. NCIT_C114293: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C114293]
  569. NCIT_C114295: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C114295]
  570. NCIT_C114380: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C114380]
  571. NCIT_C114385: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C114385]
  572. NCIT_C114496: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C114496]
  573. NCIT_C114755: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C114755]
  574. NCIT_C114990: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C114990]
  575. NCIT_C115101: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C115101]
  576. NCIT_C115105: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C115105]
  577. NCIT_C115106: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C115106]
  578. NCIT_C1159: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1159]
  579. NCIT_C115976: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C115976]
  580. NCIT_C116067: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116067]
  581. NCIT_C116321: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116321]
  582. NCIT_C116331: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116331]
  583. NCIT_C116332: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116332]
  584. NCIT_C116709: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116709]
  585. NCIT_C116733: Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C116733]
  586. NCIT_C116736: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116736]
  587. NCIT_C116740: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116740]
  588. NCIT_C116777: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116777]
  589. NCIT_C116847: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116847]
  590. NCIT_C116848: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116848]
  591. NCIT_C116868: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116868]
  592. NCIT_C116879: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116879]
  593. NCIT_C116880: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116880]
  594. NCIT_C116888: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116888]
  595. NCIT_C116893: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116893]
  596. NCIT_C116913: Total Tumor RNA-loaded Dendritic Cell Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C116913]
  597. NCIT_C116920: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116920]
  598. NCIT_C117235: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C117235]
  599. NCIT_C117725: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C117725]
  600. NCIT_C118364: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C118364]
  601. NCIT_C11845: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C11845]
  602. NCIT_C118851: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C118851]
  603. NCIT_C118852: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C118852]
  604. NCIT_C11915: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C11915]
  605. NCIT_C119614: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C119614]
  606. NCIT_C119616: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C119616]
  607. NCIT_C119617: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C119617]
  608. NCIT_C119664: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C119664]
  609. NCIT_C119745: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C119745]
  610. NCIT_C119759: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C119759]
  611. NCIT_C120039: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C120039]
  612. NCIT_C120118: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C120118]
  613. NCIT_C120129: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C120129]
  614. NCIT_C120183: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C120183]
  615. NCIT_C121544: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C121544]
  616. NCIT_C121570: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C121570]
  617. NCIT_C121640: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C121640]
  618. NCIT_C121777: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C121777]
  619. NCIT_C121848: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C121848]
  620. NCIT_C121856: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C121856]
  621. NCIT_C121947: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C121947]
  622. NCIT_C122396: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C122396]
  623. NCIT_C122399: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C122399]
  624. NCIT_C122402: Autologous Oxidized Ovarian Tumor Cell Lysate Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C122402]
  625. NCIT_C122678: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C122678]
  626. NCIT_C123283: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C123283]
  627. NCIT_C123378: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C123378]
  628. NCIT_C123381: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C123381]
  629. NCIT_C123918: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C123918]
  630. NCIT_C123919: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C123919]
  631. NCIT_C123921: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C123921]
  632. NCIT_C123923: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C123923]
  633. NCIT_C123928: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C123928]
  634. NCIT_C123930: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C123930]
  635. NCIT_C124054: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C124054]
  636. NCIT_C124652: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C124652]
  637. NCIT_C125631: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C125631]
  638. NCIT_C125692: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C125692]
  639. NCIT_C126797: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C126797]
  640. NCIT_C127125: NY-ESO-1/PRAME/MAGE-A3/WT-1 Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C127125]
  641. NCIT_C127910: pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C127910]
  642. NCIT_C129522: Autologous Bladder Cell Carcinoma RNAs/CD40L RNA Electroporated Autologous Matured Dendritic Cells [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C129522]
  643. NCIT_C129935: Personalized Peptide Cancer Vaccine NEO-PV-01 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C129935]
  644. NCIT_C1325: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1325]
  645. NCIT_C132684: H3.3K27M-specific Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C132684]
  646. NCIT_C141422: Neoantigen-loaded Autologous Dendritic Cell Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C141422]
  647. NCIT_C143034: Adenoviral Brachyury Vaccine ETBX-051 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C143034]
  648. NCIT_C143035: Adenoviral MUC1 Vaccine ETBX-061 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C143035]
  649. NCIT_C143059: Prime Cancer Vaccine MVA-BN-CV301 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C143059]
  650. NCIT_C1455: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1455]
  651. NCIT_C1479: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1479]
  652. NCIT_C148144: Oral Therapeutic Vaccine V3-X [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148144]
  653. NCIT_C148146: PD-L1 Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148146]
  654. NCIT_C148154: PD-L1/IDO Peptide Vaccine IO102-103 [https://ncithesaurus.nci.nih.gov/ncitbrowser/pages/home.jsf]
  655. NCIT_C148214: Autologous AML/Dendritic Cell Fusion Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148214]
  656. NCIT_C148239: mRNA-based Personalized Cancer Vaccine NCI-4650 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148239]
  657. NCIT_C148539: HPV E6/E7-encoding Semliki Forest Virus Vaccine Vvax001 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148539]
  658. NCIT_C150471: Personalized Synthetic Long Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C150471]
  659. NCIT_C153334: Allogeneic GM-CSF-secreting Lethally Irradiated Pancreatic Tumor Cell Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C153334]
  660. NCIT_C154278: Colorectal Cancer Peptide Vaccine PolyPEPI1018 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C154278]
  661. NCIT_C156067: Autologous CMV-pp65-flLAMP mRNA Loaded Dendritic Cell Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C156067]
  662. NCIT_C158480: Autologous Dendritic Cell/Myeloma Fusion Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C158480]
  663. NCIT_C159498: IDO Peptide Vaccine IO102 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C159498]
  664. NCIT_C159540: Oral Cancer Vaccine V3-OVA [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C159540]
  665. NCIT_C162186: mRNA-derived KRAS-targeted Vaccine V941 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C162186]
  666. NCIT_C162250: Autologous mDC3 Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C162250]
  667. NCIT_C1633: Polyvalent Melanoma Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1633]
  668. NCIT_C1643: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1643]
  669. NCIT_C1648: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1648]
  670. NCIT_C165508: Neoantigen Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C165508]
  671. NCIT_C1690: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1690]
  672. NCIT_C170932: Anti-HER2/HER3 Dendritic Cell Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C170932]
  673. NCIT_C173525: Multi-epitope HER2 Peptide Vaccine TPIV100 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C173525]
  674. NCIT_C175590: ESR1 Peptides/GM-CSF/Montanide ISA Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C175590]
  675. NCIT_C178432: Autologous Total Tumor mRNA and CMV-pp65-flLAMP mRNA Loaded Liposome Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C178432]
  676. NCIT_C179254: Personalized Peptides-loaded Autologous Dendritic Cell Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C179254]
  677. NCIT_C179595: TLR1/2 Agonist Pam3Cys-GDPKHPKSF [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C179595]
  678. NCIT_C179670: Autologous CMV-pp65-LAMP mRNA Loaded Monocyte Vaccine MT-201-GBM [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C179670]
  679. NCIT_C180518: ALVAC gp100 Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C180518]
  680. NCIT_C1830: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1830]
  681. NCIT_C187131: P30-linked EphA2/CMV pp65/Survivin Peptide Vaccine P30-EPS [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C187131]
  682. NCIT_C192174: Prodencel [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C192174]
  683. NCIT_C1977: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1977]
  684. NCIT_C1978: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1978]
  685. NCIT_C1979: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1979]
  686. NCIT_C1980: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1980]
  687. NCIT_C1981: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1981]
  688. NCIT_C1982: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1982]
  689. NCIT_C1983: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1983]
  690. NCIT_C1985: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1985]
  691. NCIT_C1986: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1986]
  692. NCIT_C1987: Dendritic Cell Tumor Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1987]
  693. NCIT_C1988: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1988]
  694. NCIT_C1988: Dendritic Cell Tumor Cell Lysate Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1988]
  695. NCIT_C199632: Autologous Vaccine-enhanced Ex Vivo Activated Cancer Neoantigens-specific T-cells TVI-Brain-1 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C199632]
  696. NCIT_C200465: RAS Peptide Cancer Vaccine TG01 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C200465]
  697. NCIT_C2023: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2023]
  698. NCIT_C2055: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2055]
  699. NCIT_C2057: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2057]
  700. NCIT_C2060: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2060]
  701. NCIT_C2063: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2063]
  702. NCIT_C2195: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2195]
  703. NCIT_C2204: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2204]
  704. NCIT_C2205: BCR-ABL Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C2205]
  705. NCIT_C2214: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2214]
  706. NCIT_C2227: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2227]
  707. NCIT_C2232: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2232]
  708. NCIT_C2235: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2235]
  709. NCIT_C2235: PR1 Leukemia Peptide Vaccine (Code C2235) [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2235]
  710. NCIT_C2236: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2236]
  711. NCIT_C2237: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2237]
  712. NCIT_C2241: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2241]
  713. NCIT_C2339: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2339]
  714. NCIT_C2341: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2341]
  715. NCIT_C2382: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2382]
  716. NCIT_C2384: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2384]
  717. NCIT_C2403: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2403]
  718. NCIT_C2419: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2419]
  719. NCIT_C2423: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2423]
  720. NCIT_C2424: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2424]
  721. NCIT_C2426: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2426]
  722. NCIT_C2428: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2428]
  723. NCIT_C2430: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2430]
  724. NCIT_C2433: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2433]
  725. NCIT_C2436: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2436]
  726. NCIT_C2438: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2438]
  727. NCIT_C2439: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2439]
  728. NCIT_C2442: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2442]
  729. NCIT_C2445: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2445]
  730. NCIT_C2464: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2464]
  731. NCIT_C2465: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2465]
  732. NCIT_C2468: Tetanus Peptide Melanoma Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C2468]
  733. NCIT_C2471: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2471]
  734. NCIT_C2473: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2473]
  735. NCIT_C2474: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2474]
  736. NCIT_C2485: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2485]
  737. NCIT_C2492: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2492]
  738. NCIT_C2493: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2493]
  739. NCIT_C2497: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2497]
  740. NCIT_C2501: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2501]
  741. NCIT_C2510: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2510]
  742. NCIT_C2512: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2512]
  743. NCIT_C2520: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2520]
  744. NCIT_C2521: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2521]
  745. NCIT_C2531: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2531]
  746. NCIT_C2534: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2534]
  747. NCIT_C2540: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2540]
  748. NCIT_C2545: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2545]
  749. NCIT_C2569: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2569]
  750. NCIT_C2576: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2576]
  751. NCIT_C2606: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2606]
  752. NCIT_C2619: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2619]
  753. NCIT_C2620: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2620]
  754. NCIT_C2622: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2622]
  755. NCIT_C2628: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2628]
  756. NCIT_C2637: MVF-HER-2(628-647)-CRL 1005 Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C2637]
  757. NCIT_C2640: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2640]
  758. NCIT_C2643: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2643]
  759. NCIT_C26444: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26444]
  760. NCIT_C26445: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26445]
  761. NCIT_C26446: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26446]
  762. NCIT_C26449: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26449]
  763. NCIT_C26450: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26450]
  764. NCIT_C2648: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2648]
  765. NCIT_C2650: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2650]
  766. NCIT_C2657: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2657]
  767. NCIT_C2660: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2660]
  768. NCIT_C26645: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26645]
  769. NCIT_C2666: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2666]
  770. NCIT_C2667: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2667]
  771. NCIT_C26680: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26680]
  772. NCIT_C26681: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26681]
  773. NCIT_C2674: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2674]
  774. NCIT_C2675: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2675]
  775. NCIT_C2680: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2680]
  776. NCIT_C2686: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2686]
  777. NCIT_C2709: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2709]
  778. NCIT_C2710: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2710]
  779. NCIT_C2718: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2718]
  780. NCIT_C2732: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2732]
  781. NCIT_C2740: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2740]
  782. NCIT_C2741: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2741]
  783. NCIT_C2742: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2742]
  784. NCIT_C2743: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2743]
  785. NCIT_C2746: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2746]
  786. NCIT_C2754: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2754]
  787. NCIT_C2757: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2757]
  788. NCIT_C2760: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2760]
  789. NCIT_C2761: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2761]
  790. NCIT_C2762: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2762]
  791. NCIT_C2763: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2763]
  792. NCIT_C2764: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2764]
  793. NCIT_C2766: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2766]
  794. NCIT_C2767: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2767]
  795. NCIT_C2771: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2771]
  796. NCIT_C2772: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2772]
  797. NCIT_C2773: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2773]
  798. NCIT_C2774: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2774]
  799. NCIT_C2775: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2775]
  800. NCIT_C2776: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2776]
  801. NCIT_C2781: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2781]
  802. NCIT_C2783: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2783]
  803. NCIT_C2786: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2786]
  804. NCIT_C2787: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2787]
  805. NCIT_C2798: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2798]
  806. NCIT_C2805: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2805]
  807. NCIT_C2806: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2806]
  808. NCIT_C2807: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2807]
  809. NCIT_C2809: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2809]
  810. NCIT_C2811: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2811]
  811. NCIT_C2814: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2814]
  812. NCIT_C2815: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2815]
  813. NCIT_C2816: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2816]
  814. NCIT_C2821: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2821]
  815. NCIT_C2822: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2822]
  816. NCIT_C2824: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2824]
  817. NCIT_C2830: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2830]
  818. NCIT_C28330: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28330]
  819. NCIT_C28503: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28503]
  820. NCIT_C28549: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28549]
  821. NCIT_C28550: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28550]
  822. NCIT_C28551: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28551]
  823. NCIT_C28682: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28682]
  824. NCIT_C28775: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28775]
  825. NCIT_C28776: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28776]
  826. NCIT_C28780: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28780]
  827. NCIT_C28784: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28784]
  828. NCIT_C28810: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28810]
  829. NCIT_C28860: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28860]
  830. NCIT_C28877: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28877]
  831. NCIT_C28878: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28878]
  832. NCIT_C29065: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29065]
  833. NCIT_C29068: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29068]
  834. NCIT_C29086: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29086]
  835. NCIT_C29088: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29088]
  836. NCIT_C29090: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29090]
  837. NCIT_C29091: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29091]
  838. NCIT_C29112: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29112]
  839. NCIT_C29187: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29187]
  840. NCIT_C29192: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29192]
  841. NCIT_C29316: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29316]
  842. NCIT_C29317: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29317]
  843. NCIT_C29334: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29334]
  844. NCIT_C29337: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29337]
  845. NCIT_C29338: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29338]
  846. NCIT_C29338: PSA:154-163(155L) Peptide Vaccine (Code C29338) [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29338]
  847. NCIT_C29401: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29401]
  848. NCIT_C29402: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29402]
  849. NCIT_C29409: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29409]
  850. NCIT_C29476: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29476]
  851. NCIT_C29555: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29555]
  852. NCIT_C29558: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29558]
  853. NCIT_C29559: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29559]
  854. NCIT_C29560: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29560]
  855. NCIT_C29561: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29561]
  856. NCIT_C29563: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29563]
  857. NCIT_C29564: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29564]
  858. NCIT_C29566: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29566]
  859. NCIT_C29778: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29778]
  860. NCIT_C29785: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29785]
  861. NCIT_C29786: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29786]
  862. NCIT_C29908: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29908]
  863. NCIT_C29910: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29910]
  864. NCIT_C29918: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29918]
  865. NCIT_C29945: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29945]
  866. NCIT_C29982: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29982]
  867. NCIT_C30000: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C30000]
  868. NCIT_C37448: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C37448]
  869. NCIT_C37515: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C37515]
  870. NCIT_C38117: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38117]
  871. NCIT_C38119: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38119]
  872. NCIT_C38121: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38121]
  873. NCIT_C38122: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38122]
  874. NCIT_C38123: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38123]
  875. NCIT_C38124: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38124]
  876. NCIT_C38132: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38132]
  877. NCIT_C38587: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38587]
  878. NCIT_C38681: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38681]
  879. NCIT_C38695: Multi-epitope Melanoma Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C38695]
  880. NCIT_C38700: Melanoma Helper Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C38700]
  881. NCIT_C38708: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38708]
  882. NCIT_C38715: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38715]
  883. NCIT_C38720: Transgenic Lymphocyte Immunization Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C38720]
  884. NCIT_C38761: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38761]
  885. NCIT_C48368: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48368]
  886. NCIT_C48371: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48371]
  887. NCIT_C48372: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48372]
  888. NCIT_C48373: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48373]
  889. NCIT_C48376: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48376]
  890. NCIT_C48377: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48377]
  891. NCIT_C48390: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48390]
  892. NCIT_C48391: GM.CD40L Cell Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C48391]
  893. NCIT_C48392: HER-2-neu, CEA Peptides, GM-CSF, Montanide ISA-51 Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C48392]
  894. NCIT_C48393: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48393]
  895. NCIT_C48394: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48394]
  896. NCIT_C48395: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48395]
  897. NCIT_C48396: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48396]
  898. NCIT_C48410: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48410]
  899. NCIT_C48411: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48411]
  900. NCIT_C48412: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48412]
  901. NCIT_C48414: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48414]
  902. NCIT_C48418: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48418]
  903. NCIT_C48419: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48419]
  904. NCIT_C48465: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48465]
  905. NCIT_C48632: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48632]
  906. NCIT_C48637: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48637]
  907. NCIT_C48638: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48638]
  908. NCIT_C48639: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48639]
  909. NCIT_C48640: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48640]
  910. NCIT_C48816: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48816]
  911. NCIT_C49023: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49023]
  912. NCIT_C49042: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49042]
  913. NCIT_C49063: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49063]
  914. NCIT_C49064: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49064]
  915. NCIT_C49082: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49082]
  916. NCIT_C49087: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49087]
  917. NCIT_C49177: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49177]
  918. NCIT_C49275: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49275]
  919. NCIT_C49289: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49289]
  920. NCIT_C49290: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49290]
  921. NCIT_C51978: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C51978]
  922. NCIT_C52190: GM-K562 Cell Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C52190]
  923. NCIT_C53290: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53290]
  924. NCIT_C53410: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53410]
  925. NCIT_C53443: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C53443]
  926. NCIT_C61073: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61073]
  927. NCIT_C61076: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61076]
  928. NCIT_C61077: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61077]
  929. NCIT_C61082: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61082]
  930. NCIT_C61087: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61087]
  931. NCIT_C61088: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61088]
  932. NCIT_C61098: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61098]
  933. NCIT_C61146: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61146]
  934. NCIT_C61309: Bcr-Abl (b2a2)-Derived Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C61309]
  935. NCIT_C61310: Bcr-Abl (b3a2)-Derived Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C61310]
  936. NCIT_C61327: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61327]
  937. NCIT_C61434: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61434]
  938. NCIT_C61442: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61442]
  939. NCIT_C61495: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61495]
  940. NCIT_C61592: Hodgkin's Antigens-GM-CSF-Expressing Cell Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C61592]
  941. NCIT_C62452: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62452]
  942. NCIT_C62478: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62478]
  943. NCIT_C62479: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62479]
  944. NCIT_C62527: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62527]
  945. NCIT_C62531: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62531]
  946. NCIT_C62756: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62756]
  947. NCIT_C62767: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62767]
  948. NCIT_C62768: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62768]
  949. NCIT_C62775: MAGE-A1, Her-2/neu, FBP Peptides Cancer Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C62775]
  950. NCIT_C62801: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62801]
  951. NCIT_C64635: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C64635]
  952. NCIT_C64773: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C64773]
  953. NCIT_C64785: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C64785]
  954. NCIT_C64846: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C64846]
  955. NCIT_C66972: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C66972]
  956. NCIT_C66985: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C66985]
  957. NCIT_C67082: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C67082]
  958. NCIT_C67085: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C67085]
  959. NCIT_C67086: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C67086]
  960. NCIT_C67089: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C67089]
  961. NCIT_C67098: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C67098]
  962. NCIT_C68839: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C68839]
  963. NCIT_C68842: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C68842]
  964. NCIT_C68999: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C68999]
  965. NCIT_C69000: Sialyl Lewis-Keyhole Limpet Hemocyanin Conjugate Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C69000]
  966. NCIT_C69076: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C69076]
  967. NCIT_C70644: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C70644]
  968. NCIT_C70674: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C70674]
  969. NCIT_C70968: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C70968]
  970. NCIT_C70985: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C70985]
  971. NCIT_C71036: Autologous Follicular Lymphoma-Derived Idiotype Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C71036]
  972. NCIT_C71162: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C71162]
  973. NCIT_C71520: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C71520]
  974. NCIT_C71526: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C71526]
  975. NCIT_C71533: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C71533]
  976. NCIT_C71723: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C71723]
  977. NCIT_C71741: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C71741]
  978. NCIT_C71748: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C71748]
  979. NCIT_C71757: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C71757]
  980. NCIT_C71758: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C71758]
  981. NCIT_C71760: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C71760]
  982. NCIT_C71761: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C71761]
  983. NCIT_C73438: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C73438]
  984. NCIT_C73995: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C73995]
  985. NCIT_C73997: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C73997]
  986. NCIT_C73998: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C73998]
  987. NCIT_C73999: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C73999]
  988. NCIT_C74000: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74000]
  989. NCIT_C74015: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74015]
  990. NCIT_C74016: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74016]
  991. NCIT_C74023: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74023]
  992. NCIT_C74036: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74036]
  993. NCIT_C74042: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74042]
  994. NCIT_C74056: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74056]
  995. NCIT_C74057: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74057]
  996. NCIT_C74063: Mixed Bacteria Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C74063]
  997. NCIT_C74064: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74064]
  998. NCIT_C74066: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74066]
  999. NCIT_C74070: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74070]
  1000. NCIT_C74087: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74087]
  1001. NCIT_C74088: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74088]
  1002. NCIT_C74089: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74089]
  1003. NCIT_C74090: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74090]
  1004. NCIT_C76227: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C76227]
  1005. NCIT_C77858: Human Monoclonal Antibody B11-hCG Beta Fusion Protein CDX-1307 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C77858]
  1006. NCIT_C77863: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C77863]
  1007. NCIT_C77867: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C77867]
  1008. NCIT_C77869: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C77869]
  1009. NCIT_C77874: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C77874]
  1010. NCIT_C77877: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C77877]
  1011. NCIT_C77878: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C77878]
  1012. NCIT_C77895: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C77895]
  1013. NCIT_C77900: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C77900]
  1014. NCIT_C77907: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C77907]
  1015. NCIT_C77909: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C77909]
  1016. NCIT_C77910: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C77910]
  1017. NCIT_C78193: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78193]
  1018. NCIT_C78448: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78448]
  1019. NCIT_C78466: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78466]
  1020. NCIT_C78487: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78487]
  1021. NCIT_C78489: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78489]
  1022. NCIT_C78819: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78819]
  1023. NCIT_C78820: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78820]
  1024. NCIT_C78821: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78821]
  1025. NCIT_C78830: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78830]
  1026. NCIT_C78832: LV.IL-2/B7.1-Transduced AML Blast Vaccine RFUSIN2-AML1 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C78832]
  1027. NCIT_C78861: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78861]
  1028. NCIT_C78862: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78862]
  1029. NCIT_C78865: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78865]
  1030. NCIT_C79799: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C79799]
  1031. NCIT_C79832: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C79832]
  1032. NCIT_C79833: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C79833]
  1033. NCIT_C79842: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C79842]
  1034. NCIT_C80055: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C80055]
  1035. NCIT_C80834: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C80834]
  1036. NCIT_C82352: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82352]
  1037. NCIT_C82361: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82361]
  1038. NCIT_C82371: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82371]
  1039. NCIT_C82381: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82381]
  1040. NCIT_C82388: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82388]
  1041. NCIT_C82407: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82407]
  1042. NCIT_C82416: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82416]
  1043. NCIT_C82417: MUC1 Peptide-Poly-ICLC Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C82417]
  1044. NCIT_C82420: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82420]
  1045. NCIT_C82420: P53-Synthetic Long Peptides Vaccine (Code C82420) [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C82420]
  1046. NCIT_C82654: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82654]
  1047. NCIT_C82661: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82661]
  1048. NCIT_C82675: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82675]
  1049. NCIT_C82688: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82688]
  1050. NCIT_C84755: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C84755]
  1051. NCIT_C84844: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C84844]
  1052. NCIT_C84845: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C84845]
  1053. NCIT_C84854: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C84854]
  1054. NCIT_C85445: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85445]
  1055. NCIT_C85450: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85450]
  1056. NCIT_C85451: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85451]
  1057. NCIT_C85452: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85452]
  1058. NCIT_C85456: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85456]
  1059. NCIT_C85462: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85462]
  1060. NCIT_C85463: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85463]
  1061. NCIT_C85464: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85464]
  1062. NCIT_C85466: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85466]
  1063. NCIT_C85470: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85470]
  1064. NCIT_C85479: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85479]
  1065. NCIT_C87436: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C87436]
  1066. NCIT_C88279: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C88279]
  1067. NCIT_C88288: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C88288]
  1068. NCIT_C88289: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C88289]
  1069. NCIT_C88320: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C88320]
  1070. NCIT_C88326: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C88326]
  1071. NCIT_C88334: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C88334]
  1072. NCIT_C88341: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C88341]
  1073. NCIT_C90540: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90540]
  1074. NCIT_C90542: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90542]
  1075. NCIT_C90555: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90555]
  1076. NCIT_C90558: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90558]
  1077. NCIT_C90560: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90560]
  1078. NCIT_C90569: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90569]
  1079. NCIT_C90570: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90570]
  1080. NCIT_C90571: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90571]
  1081. NCIT_C90572: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90572]
  1082. NCIT_C90592: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90592]
  1083. NCIT_C91076: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91076]
  1084. NCIT_C91077: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91077]
  1085. NCIT_C91085: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91085]
  1086. NCIT_C91373: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91373]
  1087. NCIT_C91373: Adenoviral Vector Ad5-CEA(6D) Vaccine [ttps://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C91373]
  1088. NCIT_C91377: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91377]
  1089. NCIT_C91378: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91378]
  1090. NCIT_C91379: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91379]
  1091. NCIT_C91380: Melanoma TRP2 CTL Epitope Vaccine SCIB1 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C91380]
  1092. NCIT_C91707: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91707]
  1093. NCIT_C91710: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91710]
  1094. NCIT_C91714: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91714]
  1095. NCIT_C91715: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91715]
  1096. NCIT_C91716: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91716]
  1097. NCIT_C91717: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91717]
  1098. NCIT_C91718: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91718]
  1099. NCIT_C91719: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91719]
  1100. NCIT_C91722: 4-Peptide Melanoma Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C91722]
  1101. NCIT_C92573: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C92573]
  1102. NCIT_C94210: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C94210]
  1103. NCIT_C94215: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C94215]
  1104. NCIT_C94216: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C94216]
  1105. NCIT_C94217: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C94217]
  1106. NCIT_C94218: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C94218]
  1107. NCIT_C95024: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95024]
  1108. NCIT_C95211: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95211]
  1109. NCIT_C95212: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95212]
  1110. NCIT_C95213: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95213]
  1111. NCIT_C95705: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95705]
  1112. NCIT_C95722: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95722]
  1113. NCIT_C95727: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95727]
  1114. NCIT_C95741: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95741]
  1115. NCIT_C95751: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95751]
  1116. NCIT_C95759: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95759]
  1117. NCIT_C95771: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95771]
  1118. NCIT_C96041: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C96041]
  1119. NCIT_C96042: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C96042]
  1120. NCIt_C96042: NA-17/MAGE-3.A2/NY-ESO-1 Peptide Vaccine (Code C96042) [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C96042]
  1121. NCIT_C96391: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C96391]
  1122. NCIT_C96392: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C96392]
  1123. NCIT_C96393: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C96393]
  1124. NCIT_C96397: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C96397]
  1125. NCIT_C96398: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C96398]
  1126. NCIT_C96399: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C96399]
  1127. NCIT_C96402: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C96402]
  1128. NCIT_C96405: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C96405]
  1129. NCIT_C96519: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C96519]
  1130. NCIT_C96737: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C96737]
  1131. NCIT_C96738: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C96738]
  1132. NCIT_C96739: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C96739]
  1133. NCIT_C97034: Pentavalent KLH Conjugate Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C97034]
  1134. NCIT_C97122: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C97122]
  1135. NCIT_C97123: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C97123]
  1136. NCIT_C97126: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C97126]
  1137. NCIT_C97127: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C97127]
  1138. NCIT_C97265: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C97265]
  1139. NCIT_C97344: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C97344]
  1140. NCIT_C97665: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C97665]
  1141. NCIT_C97666: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C97666]
  1142. NCIT_C97951: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C97951]
  1143. NCIT_C97951: Maveropepimut-S (Code C97951) [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C97951]
  1144. NCIT_C98287: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C98287]
  1145. NCIT_C99116: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C99116]
  1146. NCIT_C99129: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C99129]
  1147. NCIT_C99228: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C99228]
  1148. NCIT_C99378: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C99378]
  1149. NCIT_C99902: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C99902]
  1150. NCIT_C99903: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C99903]
  1151. NCT00000105: Vaccination With Tetanus and KLH to Assess Immune Responses [https://clinicaltrials.gov/study/NCT00000105]
  1152. NCT00001386: [https://clinicaltrials.gov/ct2/show/NCT00001386]
  1153. NCT00001512: [https://clinicaltrials.gov/ct2/show/NCT00001512]
  1154. NCT00001561: [https://clinicaltrials.gov/ct2/show/NCT00001561]
  1155. NCT00001564: [https://clinicaltrials.gov/ct2/show/NCT00001564]
  1156. NCT00001564: [https://clinicaltrials.gov/show/NCT00001564/]
  1157. NCT00001565: [https://clinicaltrials.gov/ct2/show/NCT00001565]
  1158. NCT00001703: [https://clinicaltrials.gov/show/NCT00001703/]
  1159. NCT00001705: [https://clinicaltrials.gov/ct2/show/NCT00001705]
  1160. NCT00001827: p53 Vaccine for Ovarian Cancer [https://clinicaltrials.gov/ct2/show/NCT00001827]
  1161. NCT00002505: Tumor Cell Vaccine in Treating Patients With Advanced Cancer [https://clinicaltrials.gov/study/NCT00002505]
  1162. NCT00002637: Biological Therapy in Treating Patients With Prostate Cancer [https://clinicaltrials.gov/study/NCT00002637]
  1163. NCT00002767: [https://clinicaltrials.gov/ct2/show/NCT00002767]
  1164. NCT00002787: [https://clinicaltrials.gov/ct2/show/NCT00002787?term=Autologous+Immunoglobulin+Idiotype-Keyhole+Limpet+Hemocyanin+Conjugate+Vaccine&rank=1]
  1165. NCT00002817: [https://clinicaltrials.gov/show/NCT00002817/]
  1166. NCT00002916: [https://clinicaltrials.gov/ct2/show/NCT00002916]
  1167. NCT00002960: [https://clinicaltrials.gov/ct2/show/NCT00002960?term=Recombinant+Adenovirus+p53+SCH+58500&rank=1]
  1168. NCT00003023: [https://clinicaltrials.gov/ct2/show/NCT00003023]
  1169. NCT00003167: [https://clinicaltrials.gov/ct2/show/NCT00003167]
  1170. NCT00003184: [https://clinicaltrials.gov/ct2/show/NCT00003184]
  1171. NCT00003556: [https://clinicaltrials.gov/ct2/show/NCT00003556?term=Canarypox-hIL-12+Melanoma+Vaccine&rank=1]
  1172. NCT00003556: [https://clinicaltrials.gov/ct2/show/NCT00003556?term=ALVAC-hB7.1&rank=1]
  1173. NCT00003638: [https://clinicaltrials.gov/ct2/show/NCT00003638]
  1174. NCT00003761: [https://clinicaltrials.gov/ct2/show/NCT00003761?term=Recombinant+Vaccinia+DF3%2FMUC1+Vaccine&rank=1]
  1175. NCT00003871: [https://clinicaltrials.gov/ct2/show/NCT00003871?term=FOWLVAC&rank=1]
  1176. NCT00003871: [https://clinicaltrials.gov/ct2/show/NCT00003871?term=Fowlpox+Vaccine&rank=1]
  1177. NCT00003877: [https://clinicaltrials.gov/show/NCT00003877/]
  1178. NCT00003895: [https://clinicaltrials.gov/ct2/show/NCT00003895]
  1179. NCT00004032: [https://clinicaltrials.gov/ct2/show/NCT00004032]
  1180. NCT00004052: Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia [https://clinicaltrials.gov/study/NCT00004052]
  1181. NCT00004104: Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma [https://clinicaltrials.gov/study/NCT00004104]
  1182. NCT00004156: [https://clinicaltrials.gov/ct2/show/NCT00004156?term=MUC1-KLH+Vaccine%2FQS21&rank=1]
  1183. NCT00004184: [https://clinicaltrials.gov/ct2/show/NCT00004184]
  1184. NCT00004211: [https://clinicaltrials.gov/ct2/show/NCT00004211]
  1185. NCT00004604: [https://clinicaltrials.gov/ct2/show/NCT00004604]
  1186. NCT00004880: Vaccine Therapy in Treating Patients With Advanced Kidney Cancer [https://clinicaltrials.gov/study/NCT00004880]
  1187. NCT00004918: [https://clinicaltrials.gov/show/NCT00004918/]
  1188. NCT00005039: [https://clinicaltrials.gov/show/NCT00005039/]
  1189. NCT00005039: [https://clinicaltrials.gov/ct2/show/NCT00005039?term=Recombinant+Fowlpox-Prostate+Specific+Antigen+Vaccine&rank=1]
  1190. NCT00005057: [https://clinicaltrials.gov/ct2/show/NCT00005057]
  1191. NCT00005629: [https://clinicaltrials.gov/ct2/show/NCT00005629]
  1192. NCT00006041: [https://clinicaltrials.gov/ct2/show/NCT00006041?term=MUC1-KLH+Conjugate+Vaccine&rank=1]
  1193. NCT00006066: [https://clinicaltrials.gov/ct2/show/NCT00006066]
  1194. NCT00006106: [https://clinicaltrials.gov/ct2/show/NCT00006106?term=ONYX-015&rank=1]
  1195. NCT00006106: ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer [https://clinicaltrials.gov/ct2/show/NCT00006106]
  1196. NCT00006216: [https://clinicaltrials.gov/ct2/show/NCT00006216]
  1197. NCT00006243: [https://clinicaltrials.gov/ct2/show/NCT00006243?term=MART-1%3A27-35+Peptide&rank=1]
  1198. NCT00006352: [https://clinicaltrials.gov/ct2/show/NCT00006352]
  1199. NCT00006470: [https://clinicaltrials.gov/ct2/show/NCT00006470]
  1200. NCT00007826: [https://clinicaltrials.gov/ct2/show/NCT00007826]
  1201. NCT00008099: [https://clinicaltrials.gov/ct2/show/NCT00008099?term=MUC1+Antigen%2FSB+AS-2&rank=1]
  1202. NCT00015977: [https://clinicaltrials.gov/ct2/show/NCT00015977]
  1203. NCT00016146: [https://clinicaltrials.gov/ct2/show/NCT00016146?term=MUC-2-Globo+H-KLH+Conjugate+Vaccine&rank=2]
  1204. NCT00017537: Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer [https://clinicaltrials.gov/study/NCT00017537]
  1205. NCT00019006: [https://clinicaltrials.gov/show/NCT00019006/]
  1206. NCT00019110: [https://clinicaltrials.gov/ct2/show/NCT00019110]
  1207. NCT00019383: [https://clinicaltrials.gov/show/NCT00019383/]
  1208. NCT00019591: Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer [https://clinicaltrials.gov/ct2/show/NCT00019591]
  1209. NCT00019734: [https://clinicaltrials.gov/show/NCT00019734/]
  1210. NCT00019890: [https://clinicaltrials.gov/ct2/show/NCT00019890]
  1211. NCT00019916: [https://clinicaltrials.gov/ct2/show/NCT00019916?term=p53+Peptide+Vaccine&rank=1]
  1212. NCT00020475: [https://clinicaltrials.gov/ct2/show/NCT00020475?term=MART-1%3A26-35+%2827L%29&rank=1]
  1213. NCT00022438: [https://clinicaltrials.gov/show/NCT00022438/]
  1214. NCT00023647: [https://clinicaltrials.gov/show/NCT00023647]
  1215. NCT00028431: Novel Adjuvants for Peptide-Based Melanoma Vaccines [https://clinicaltrials.gov/ct2/show/NCT00028431]
  1216. NCT00028431: Novel Adjuvants for Peptide-Based Melanoma Vaccines [https://clinicaltrials.gov/study/NCT00028431]
  1217. NCT00028496: [https://clinicaltrials.gov/ct2/show/NCT00028496?term=Recombinant+Fowlpox-CEA%286D%29%2FTRICOM+Vaccine&rank=1]
  1218. NCT00030693: [https://clinicaltrials.gov/ct2/show/NCT00030693?term=Recombinant+Fowlpox-B7.1+Vaccine&rank=1]
  1219. NCT00030823: [https://clinicaltrials.gov/ct2/show/NCT00030823?term=Globo-H-GM2-Lewis-y-MUC1-32%28aa%29-sTn%28c%29-TF%28c%29-Tn%28c%29-KLH+Conjugate+Vaccine&rank=1]
  1220. NCT00031564: [https://clinicaltrials.gov/ct2/show/NCT00031564]
  1221. NCT00033228: [https://clinicaltrials.gov/show/NCT00033228]
  1222. NCT00033748: [https://clinicaltrials.gov/ct2/show/NCT00033748]
  1223. NCT00038415: A Phase I/​II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach [https://clinicaltrials.gov/study/NCT00038415]
  1224. NCT00039325: [https://clinicaltrials.gov/ct2/show/NCT00039325]
  1225. NCT00039325: [https://clinicaltrials.gov/ct2/show/NCT00039325?term=MART-1+Adenovirus+Vaccine&rank=1]
  1226. NCT00040170: [https://clinicaltrials.gov/show/NCT00040170/]
  1227. NCT00048386: Neuroblastoma Vaccine for Treatment of High-Risk Neuroblastoma After Chemotherapy (CYCHE2) [https://clinicaltrials.gov/study/NCT00048386]
  1228. NCT00049218: [https://clinicaltrials.gov/ct2/show/NCT00049218]
  1229. NCT00054535: [https://clinicaltrials.gov/ct2/show/NCT00054535?term=Recombinant+Fowlpox-Tyrosinase+Vaccine&rank=1]
  1230. NCT00056134: Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma [https://clinicaltrials.gov/study/NCT00056134]
  1231. NCT00057915: [https://clinicaltrials.gov/ct2/show/NCT00057915]
  1232. NCT00058747: [https://clinicaltrials.gov/ct2/show/NCT00058747]
  1233. NCT00061035: Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma [https://clinicaltrials.gov/study/NCT00061035]
  1234. NCT00062907: [https://clinicaltrials.gov/ct2/show/NCT00062907?term=Recombinant+Adenovirus+L523S+Vaccine&rank=1]
  1235. NCT00062907: [https://clinicaltrials.gov/show/NCT00062907]
  1236. NCT00066404: [https://clinicaltrials.gov/ct2/show/NCT00066404?term=Recombinant+Adenovirus-hIFN-beta&rank=1]
  1237. NCT00069940: [https://clinicaltrials.gov/show/NCT00069940/]
  1238. NCT00071942: [https://clinicaltrials.gov/show/NCT00071942/]
  1239. NCT00071981: [https://clinicaltrials.gov/ct2/show/NCT00071981]
  1240. NCT00071981: Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma [https://clinicaltrials.gov/study/NCT00071981]
  1241. NCT00072085: [https://clinicaltrials.gov/ct2/show/NCT00072085]
  1242. NCT00072137: [https://clinicaltrials.gov/ct2/show/NCT00072137?term=Recombinant+Fowlpox+GM-CSF+Vaccine+Adjuvant&rank=1]
  1243. NCT00074295: [https://clinicaltrials.gov/ct2/show/NCT00074295]
  1244. NCT00078494: [https://clinicaltrials.gov/ct2/show/NCT00078494?term=LMP-2%3A340-349+Peptide+Vaccine&rank=1]
  1245. NCT00078520: [https://clinicaltrials.gov/ct2/show/NCT00078520]
  1246. NCT00080353: [https://clinicaltrials.gov/ct2/show/NCT00080353?term=Recombinant+Fowlpox-gp100p209&rank=1]
  1247. NCT00081848: [https://clinicaltrials.gov/show/NCT00081848/]
  1248. NCT00085189: Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma [https://clinicaltrials.gov/study/NCT00085189]
  1249. NCT00085462: [https://clinicaltrials.gov/ct2/show/NCT00085462?term=gp100-Fowlpox+Vaccine&rank=1]
  1250. NCT00087373: [https://clinicaltrials.gov/ct2/show/NCT00087373?term=Recombinant+Fowlpox-TRICOM+Vaccine&rank=1]
  1251. NCT00089778: [https://clinicaltrials.gov/ct2/show/NCT00089778]
  1252. NCT00090480: Vaccine Treatment for Advanced Breast Cancer [https://clinicaltrials.gov/study/NCT00090480]
  1253. NCT00091104: [https://clinicaltrials.gov/ct2/show/NCT00091104]
  1254. NCT00091273: [https://clinicaltrials.gov/ct2/show/NCT00091273]
  1255. NCT00091286: Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer [https://clinicaltrials.gov/study/NCT00091286]
  1256. NCT00092534: [https://clinicaltrials.gov/ct2/show/NCT00092534]
  1257. NCT00093548: [https://clinicaltrials.gov/show/NCT00093548]
  1258. NCT00094653: MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/​MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma [https://clinicaltrials.gov/study/NCT00094653]
  1259. NCT00096629: [https://clinicaltrials.gov/show/NCT00096629]
  1260. NCT00098917: [https://clinicaltrials.gov/ct2/show/NCT00098917]
  1261. NCT00100971: [https://clinicaltrials.gov/ct2/show/NCT00100971]
  1262. NCT00101101: Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma [https://clinicaltrials.gov/study/NCT00101101]
  1263. NCT00101166: Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma [https://clinicaltrials.gov/study/NCT00101166]
  1264. NCT00101309: [https://clinicaltrials.gov/ct2/show/NCT00101309]
  1265. NCT00103142: [https://clinicaltrials.gov/show/NCT00103142/]
  1266. NCT00105053: Vaccine Treatment for Hormone Refractory Prostate Cancer [https://clinicaltrials.gov/study/NCT00105053]
  1267. NCT00107159: [https://clinicaltrials.gov/ct2/show/NCT00107159]
  1268. NCT00108732: [https://clinicaltrials.gov/ct2/show/NCT00108732?term=Fowlpox-PSA-TRICOM+Vaccine&rank=1]
  1269. NCT00108875: [https://clinicaltrials.gov/ct2/show/NCT00108875?term=Survivin+Peptide+Vaccine&rank=2]
  1270. NCT00109655: [https://clinicaltrials.gov/ct2/show/NCT00109655?term=CG0070&rank=1]
  1271. NCT00109655: Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure [https://clinicaltrials.gov/ct2/show/NCT00109655]
  1272. NCT00109811: [https://clinicaltrials.gov/show/NCT00109811/]
  1273. NCT00110526: [https://clinicaltrials.gov/ct2/show/NCT00110526]
  1274. NCT00112957: [https://clinicaltrials.gov/show/NCT00112957/]
  1275. NCT00112957: [https://clinicaltrials.gov/ct2/show/NCT00112957?term=rF-NY-ESO-1&rank=1]
  1276. NCT00116363: [https://clinicaltrials.gov/ct2/show/NCT00116363]
  1277. NCT00116467: [https://clinicaltrials.gov/ct2/show/NCT00116467]
  1278. NCT00116597: [https://clinicaltrials.gov/show/NCT00116597/]
  1279. NCT00121173: [https://clinicaltrials.gov/show/NCT00121173]
  1280. NCT00128661: [https://clinicaltrials.gov/ct2/show/NCT00128661]
  1281. NCT00136903: [https://clinicaltrials.gov/show/NCT00136903]
  1282. NCT00140738: [https://clinicaltrials.gov/show/NCT00140738/]
  1283. NCT00145145: [https://clinicaltrials.gov/ct2/show/NCT00145145?term=MAGE-3.A1&rank=1]
  1284. NCT00145158: [https://clinicaltrials.gov/ct2/show/NCT00145158?term=Peptides%2FMontanide+ISA-51&rank=1]
  1285. NCT00146835: [https://clinicaltrials.gov/ct2/show/NCT00146835]
  1286. NCT00148928: Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA [https://clinicaltrials.gov/study/NCT00148928]
  1287. NCT00197860: [https://clinicaltrials.gov/ct2/show/NCT00197860]
  1288. NCT00199836: A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer [https://clinicaltrials.gov/ct2/show/NCT00199836]
  1289. NCT00199849: [https://clinicaltrials.gov/show/NCT00199849]
  1290. NCT00199849: NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine [https://clinicaltrials.gov/ct2/show/NCT00199849]
  1291. NCT00203866: [https://clinicaltrials.gov/ct2/show/NCT00203866]
  1292. NCT00203892: [https://clinicaltrials.gov/ct2/show/NCT00203892]
  1293. NCT00217373: [https://clinicaltrials.gov/show/NCT00217373/]
  1294. NCT00217373: Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) [https://clinicaltrials.gov/ct2/show/NCT00217373]
  1295. NCT00227474: [https://clinicaltrials.gov/show/NCT00227474/]
  1296. NCT00257465: [https://clinicaltrials.gov/ct2/show/NCT00257465]
  1297. NCT00257738: [https://clinicaltrials.gov/ct2/show/NCT00257738?term=MAGE-A3+Peptide+Vaccine&rank=1]
  1298. NCT00264732: [https://clinicaltrials.gov/show/NCT00264732]
  1299. NCT00267085: Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease [https://clinicaltrials.gov/study/NCT00267085]
  1300. NCT00273910: [https://clinicaltrials.gov/ct2/show/NCT00273910]
  1301. NCT00278200: [https://clinicaltrials.gov/ct2/show/NCT00278200]
  1302. NCT00285259: [https://clinicaltrials.gov/show/NCT00285259]
  1303. NCT00298298: [https://clinicaltrials.gov/ct2/show/NCT00298298]
  1304. NCT00300612: Vaccine Treatment for Advanced Malignant Melanoma [https://clinicaltrials.gov/study/NCT00300612]
  1305. NCT00301093: Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia [https://clinicaltrials.gov/study/NCT00301093]
  1306. NCT00304096: [https://clinicaltrials.gov/show/NCT00304096/]
  1307. NCT00305760: Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer [https://clinicaltrials.gov/study/NCT00305760]
  1308. NCT00306566: [https://clinicaltrials.gov/ct2/show/NCT00306566?term=Melan-A+VLP+Vaccine&rank=1]
  1309. NCT00307229: [https://clinicaltrials.gov/ct2/show/NCT00307229]
  1310. NCT00312286: [https://clinicaltrials.gov/ct2/show/NCT00312286]
  1311. NCT00313508: [https://clinicaltrials.gov/ct2/show/NCT00313508]
  1312. NCT00323557: [https://clinicaltrials.gov/ct2/show/NCT00323557?term=Streptococcus+pneumoniae+Vaccine&rank=1]
  1313. NCT00329368: [https://clinicaltrials.gov/ct2/show/NCT00329368?term=KLH-FITC&rank=1]
  1314. NCT00343109: Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer [https://clinicaltrials.gov/study/NCT00343109]
  1315. NCT00345293: Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer [https://clinicaltrials.gov/ct2/show/NCT00345293]
  1316. NCT00361296: Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes [https://clinicaltrials.gov/study/NCT00361296]
  1317. NCT00373217: Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer [https://clinicaltrials.gov/study/NCT00373217]
  1318. NCT00379977: [https://clinicaltrials.gov/ct2/show/NCT00379977?term=Haemophilus+Influenzae+B+Vaccine&rank=4]
  1319. NCT00381875: [https://clinicaltrials.gov/ct2/show/NCT00381875]
  1320. NCT00389610: [https://clinicaltrials.gov/ct2/show/NCT00389610]
  1321. NCT00393029: [https://clinicaltrials.gov/ct2/show/NCT00393029]
  1322. NCT00398073: [https://clinicaltrials.gov/show/NCT00398073]
  1323. NCT00399529: [https://clinicaltrials.gov/ct2/show/NCT00399529]
  1324. NCT00404339: [https://clinicaltrials.gov/ct2/show/NCT00404339]
  1325. NCT00405327: [https://clinicaltrials.gov/ct2/show/NCT00405327]
  1326. NCT00405327: A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation [https://clinicaltrials.gov/study/NCT00405327]
  1327. NCT00411749: [https://clinicaltrials.gov/ct2/show/NCT00411749?term=V501&rank=1]
  1328. NCT00418574: [https://clinicaltrials.gov/ct2/show/NCT00418574]
  1329. NCT00423254: [https://clinicaltrials.gov/show/NCT00423254/]
  1330. NCT00423254: [https://clinicaltrials.gov/show/NCT00423254]
  1331. NCT00433914: [https://clinicaltrials.gov/ct2/show/NCT00433914]
  1332. NCT00436254: [https://clinicaltrials.gov/show/NCT00436254]
  1333. NCT00442130: Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination [https://clinicaltrials.gov/study/NCT00442130]
  1334. NCT00450619: [https://clinicaltrials.gov/ct2/show/NCT00450619?term=TRICOM+Vaccine&rank=1]
  1335. NCT00455221: Safety Assessment of a Multipeptide-gene Vaccine in CML [https://clinicaltrials.gov/study/NCT00455221]
  1336. NCT00457249: [https://clinicaltrials.gov/ct2/show/NCT00457249?term=DECAVAC&rank=1]
  1337. NCT00458653: [https://clinicaltrials.gov/ct2/show/NCT00458653]
  1338. NCT00458679: [https://clinicaltrials.gov/ct2/show/NCT00458679]
  1339. NCT00466726: Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (CML0206) [https://clinicaltrials.gov/study/NCT00466726]
  1340. NCT00470379: [https://clinicaltrials.gov/ct2/show/NCT00470379?term=NY-ESO-1b+Peptide+Vaccine&rank=1]
  1341. NCT00470574: Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer [https://clinicaltrials.gov/study/NCT00470574]
  1342. NCT00471133: [https://clinicaltrials.gov/show/NCT00471133]
  1343. NCT00477906: [https://clinicaltrials.gov/ct2/show/NCT00477906]
  1344. NCT00478062: Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma [https://clinicaltrials.gov/study/NCT00478062]
  1345. NCT00480025: [https://clinicaltrials.gov/ct2/show/NCT00480025?term=GSK1572932A&rank=1]
  1346. NCT00482027: [https://clinicaltrials.gov/ct2/show/NCT00482027]
  1347. NCT00493545: [https://clinicaltrials.gov/show/NCT00493545/]
  1348. NCT00499577: [https://clinicaltrials.gov/ct2/show/NCT00499577?term=hTERT+I540%2FR572Y%2FD988Y+Multipeptide+Vaccine&rank=1]
  1349. NCT00499577: [https://clinicaltrials.gov/show/NCT00499577/]
  1350. NCT00505063: [https://clinicaltrials.gov/show/NCT00505063]
  1351. NCT00505271: Safety and Efficacy Study Using Rexin-G for Breast Cancer [https://clinicaltrials.gov/ct2/show/NCT00505271]
  1352. NCT00505713: [https://clinicaltrials.gov/show/NCT00505713]
  1353. NCT00509288: [https://clinicaltrials.gov/ct2/show/NCT00509288]
  1354. NCT00509496: [https://clinicaltrials.gov/ct2/show/NCT00509496]
  1355. NCT00510133: [https://clinicaltrials.gov/ct2/show/NCT00510133]
  1356. NCT00514072: [https://clinicaltrials.gov/ct2/show/NCT00514072]
  1357. NCT00515528: Vaccination Plus Ontak in Patients With Metastatic Melanoma [https://clinicaltrials.gov/study/NCT00515528]
  1358. NCT00516685: [https://clinicaltrials.gov/show/NCT00516685/]
  1359. NCT00521261: [https://clinicaltrials.gov/show/NCT00521261/]
  1360. NCT00523159: [https://clinicaltrials.gov/show/NCT00523159/]
  1361. NCT00524277: [https://clinicaltrials.gov/ct2/show/NCT00524277]
  1362. NCT00530140: Idiotypic Vaccination for Follicular Lymphoma Patients (FLIDVAX2006) [https://clinicaltrials.gov/study/NCT00530140]
  1363. NCT00534209: [https://clinicaltrials.gov/ct2/show/NCT00534209]
  1364. NCT00551187: [https://clinicaltrials.gov/ct2/show/NCT00551187]
  1365. NCT00574977: [https://clinicaltrials.gov/show/NCT00574977]
  1366. NCT00580060: [https://clinicaltrials.gov/show/NCT00580060]
  1367. NCT00589186: [https://clinicaltrials.gov/ct2/show/NCT00589186]
  1368. NCT00610311: Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma [https://clinicaltrials.gov/study/NCT00610311]
  1369. NCT00612001: [https://clinicaltrials.gov/ct2/show/NCT00612001]
  1370. NCT00612222: [https://clinicaltrials.gov/ct2/show/NCT00612222?term=ALVAC-MART-1+Vaccine&rank=1]
  1371. NCT00613509: [https://clinicaltrials.gov/ct2/show/NCT00613509?term=ALVAC%282%29+Melanoma+Multi-antigen+Vaccine&rank=1]
  1372. NCT00616135: [https://clinicaltrials.gov/show/NCT00616135/]
  1373. NCT00616291: [https://clinicaltrials.gov/ct2/show/NCT00616291?term=NY-ESO-1%2FLAGE-1+Peptide+Vaccine&rank=1]
  1374. NCT00616291: Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer [https://clinicaltrials.gov/ct2/show/NCT00616291]
  1375. NCT00616720: [https://clinicaltrials.gov/ct2/show/NCT00616720]
  1376. NCT00623831: A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen [https://clinicaltrials.gov/study/NCT00623831]
  1377. NCT00624182: [https://clinicaltrials.gov/show/NCT00624182/]
  1378. NCT00625755: A Phase I/​II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma [https://clinicaltrials.gov/study/NCT00625755]
  1379. NCT00626015: [https://clinicaltrials.gov/ct2/show/NCT00626015?term=PEP-3-KLH&rank=1]
  1380. NCT00626483: Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia (REGULATe) [https://clinicaltrials.gov/study/NCT00626483]
  1381. NCT00629057: [https://clinicaltrials.gov/show/NCT00629057/]
  1382. NCT00632333: Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer [https://clinicaltrials.gov/ct2/show/NCT00632333]
  1383. NCT00633724: [https://clinicaltrials.gov/ct2/show/NCT00633724?term=HLA-A*2402-Restricted+VEGFR1+VEGFR2&rank=3]
  1384. NCT00639925: [https://clinicaltrials.gov/show/NCT00639925/]
  1385. NCT00654030: [https://clinicaltrials.gov/ct2/show/NCT00654030]
  1386. NCT00655785: Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2) [https://clinicaltrials.gov/ct2/show/NCT00655785]
  1387. NCT00660101: [https://clinicaltrials.gov/ct2/show/NCT00660101]
  1388. NCT00660101: Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer [https://clinicaltrials.gov/study/NCT00660101]
  1389. NCT00669136: [https://clinicaltrials.gov/ct2/show/NCT00669136]
  1390. NCT00669734: [https://clinicaltrials.gov/ct2/show/NCT00669734?term=Falimarev&rank=2]
  1391. NCT00674791: [https://clinicaltrials.gov/ct2/show/NCT00674791?term=IMT-1012+Immunotherapeutic+Vaccine&rank=1]
  1392. NCT00676507: [https://clinicaltrials.gov/ct2/show/NCT00676507]
  1393. NCT00677859: [https://clinicaltrials.gov/show/NCT00677859/]
  1394. NCT00681421: [https://clinicaltrials.gov/ct2/show/NCT00681421]
  1395. NCT00681577: Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer [https://clinicaltrials.gov/ct2/show/NCT00681577]
  1396. NCT00683670: Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma [https://clinicaltrials.gov/study/NCT00683670]
  1397. NCT00684294: Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer (Auto TAG) [https://clinicaltrials.gov/study/NCT00684294]
  1398. NCT00685412: [https://clinicaltrials.gov/show/NCT00685412]
  1399. NCT00694551: [https://clinicaltrials.gov/show/NCT00694551/]
  1400. NCT00698711: [https://clinicaltrials.gov/ct2/show/NCT00698711?term=MUC-2-KLH+Vaccine&rank=1]
  1401. NCT00703222: [https://clinicaltrials.gov/ct2/show/NCT00703222]
  1402. NCT00716495: [https://clinicaltrials.gov/ct2/show/NCT00716495]
  1403. NCT00722839: [https://clinicaltrials.gov/ct2/show/NCT00722839?term=PADRE-CMV+Fusion+Peptide+Vaccine&rank=1]
  1404. NCT00722839: [https://clinicaltrials.gov/show/NCT00722839/]
  1405. NCT00725283: [https://clinicaltrials.gov/show/NCT00725283/]
  1406. NCT00726739: [https://clinicaltrials.gov/ct2/show/NCT00726739]
  1407. NCT00727441: [https://clinicaltrials.gov/ct2/show/NCT00727441]
  1408. NCT00727441: Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery [https://clinicaltrials.gov/study/NCT00727441]
  1409. NCT00753415: [https://clinicaltrials.gov/ct2/show/NCT00753415?term=V934%2FV935&rank=1]
  1410. NCT00784524: [https://clinicaltrials.gov/ct2/show/NCT00784524]
  1411. NCT00791570: [https://clinicaltrials.gov/ct2/show/NCT00791570?]
  1412. NCT00793208: [https://clinicaltrials.gov/ct2/show/NCT00793208]
  1413. NCT00798629: [https://clinicaltrials.gov/ct2/show/NCT00798629?term=gp100+Adenovirus+Vaccine&rank=1]
  1414. NCT00798629: [https://clinicaltrials.gov/ct2/show/NCT00798629]
  1415. NCT00807781: [https://clinicaltrials.gov/show/NCT00807781]
  1416. NCT00809250: Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation [https://clinicaltrials.gov/study/NCT00809250]
  1417. NCT00831467: [https://clinicaltrials.gov/show/NCT00831467/]
  1418. NCT00831753: [https://clinicaltrials.gov/ct2/show/NCT00831753]
  1419. NCT00836199: [https://clinicaltrials.gov/ct2/show/NCT00836199?term=NicVax&rank=1]
  1420. NCT00836407: Ipilimumab +/​- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer [https://clinicaltrials.gov/study/NCT00836407]
  1421. NCT00840931: Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS) [https://clinicaltrials.gov/study/NCT00840931]
  1422. NCT00844506: [https://clinicaltrials.gov/ct2/show/NCT00844506?term=P53-Synthetic+Long+Peptides+Vaccine&rank=1]
  1423. NCT00849290: [https://clinicaltrials.gov/ct2/show/NCT00849290]
  1424. NCT00859729: [https://clinicaltrials.gov/show/NCT00859729]
  1425. NCT00868114: Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer [https://clinicaltrials.gov/study/NCT00868114]
  1426. NCT00868595: [https://clinicaltrials.gov/ct2/show/NCT00868595]
  1427. NCT00874588: [https://clinicaltrials.gov/ct2/show/NCT00874588?term=HLA-A*2402-Restricted+VEGFR1+Peptide+Vaccine&rank=2]
  1428. NCT00880464: [https://clinicaltrials.gov/ct2/show/NCT00880464]
  1429. NCT00886613: [https://clinicaltrials.gov/show/NCT00886613]
  1430. NCT00890110: [https://clinicaltrials.gov/ct2/show/NCT00890110]
  1431. NCT00891137: [https://clinicaltrials.gov/show/NCT00891137/]
  1432. NCT00895466: [https://clinicaltrials.gov/ct2/show/NCT00895466]
  1433. NCT00897923: [https://clinicaltrials.gov/show/NCT00897923/]
  1434. NCT00900809: [https://clinicaltrials.gov/show/NCT00900809/]
  1435. NCT00900809: QUILT-3.018: Neukoplastâ„¢ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia [https://clinicaltrials.gov/ct2/show/NCT00900809]
  1436. NCT00911560: Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma [https://clinicaltrials.gov/study/NCT00911560]
  1437. NCT00923195: [https://clinicaltrials.gov/ct2/show/NCT00923195]
  1438. NCT00923351: Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma [https://clinicaltrials.gov/study/NCT00923351]
  1439. NCT00924092: Open Label Phase I Study to Evaluate the Safety and Tolerability of Vaccine (GI-6207) Consisting of Whole, Heat-Killed Recombinant Saccharomyces Cerevisiae Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-Expressing Carcinoma [https://clinicaltrials.gov/ct2/show/NCT00924092]
  1440. NCT00927381: [https://clinicaltrials.gov/ct2/show/NCT00927381]
  1441. NCT00928902: Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma (MEL36) [https://clinicaltrials.gov/study/NCT00928902]
  1442. NCT00935597: [https://clinicaltrials.gov/ct2/show/NCT00935597]
  1443. NCT00937183: [https://clinicaltrials.gov/ct2/show/NCT00937183]
  1444. NCT00938223: Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma (MEL39) [https://clinicaltrials.gov/study/NCT00938223]
  1445. NCT00943722: [https://clinicaltrials.gov/ct2/show/NCT00943722]
  1446. NCT00944580: [https://clinicaltrials.gov/ct2/show/NCT00944580?term=MAGE-A1%2FMAGE-A3%2FNY-ESO-1+Peptides+Vaccine&rank=2]
  1447. NCT00972309: [https://clinicaltrials.gov/show/NCT00972309/]
  1448. NCT00978107: [https://clinicaltrials.gov/show/NCT00978107/]
  1449. NCT00978913: [https://clinicaltrials.gov/ct2/show/NCT00978913]
  1450. NCT00986609: MUC1 Vaccine for Triple-negative Breast Cancer [https://clinicaltrials.gov/study/NCT00986609]
  1451. NCT00988559: [https://clinicaltrials.gov/show/NCT00988559]
  1452. NCT01008813: [https://clinicaltrials.gov/ct2/show/NCT01008813]
  1453. NCT01016548: [https://clinicaltrials.gov/show/NCT01016548]
  1454. NCT01022346: [https://clinicaltrials.gov/show/NCT01022346/]
  1455. NCT01045460: [https://clinicaltrials.gov/ct2/show/NCT01045460]
  1456. NCT01047345: [https://clinicaltrials.gov/ct2/show/NCT01047345]
  1457. NCT01048151: [https://clinicaltrials.gov/ct2/show/NCT01048151?term=Golnerminogene+Pradenovec&rank=1]
  1458. NCT01058850: [https://clinicaltrials.gov/ct2/show/NCT01058850?]
  1459. NCT01064375: [https://clinicaltrials.gov/show/NCT01064375]
  1460. NCT01066390: [https://clinicaltrials.gov/ct2/show/NCT01066390]
  1461. NCT01081223: Phase I/​II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma [https://clinicaltrials.gov/study/NCT01081223]
  1462. NCT01082198: [https://clinicaltrials.gov/ct2/show/NCT01082198]
  1463. NCT01088789: [https://clinicaltrials.gov/ct2/show/NCT01088789]
  1464. NCT01094496: A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study) [https://clinicaltrials.gov/study/NCT01094496]
  1465. NCT01094548: [https://clinicaltrials.gov/ct2/show/NCT01094548]
  1466. NCT01095848: [https://clinicaltrials.gov/ct2/show/NCT01095848]
  1467. NCT01096602: Blockade of PD-1 in Conjunction With the Dendritic Cell/​AML Vaccine Following Chemotherapy Induced Remission [https://clinicaltrials.gov/study/NCT01096602]
  1468. NCT01143545: [https://clinicaltrials.gov/ct2/show/NCT01143545]
  1469. NCT01146262: [https://clinicaltrials.gov/ct2/show/NCT01146262]
  1470. NCT01147965: [https://clinicaltrials.gov/ct2/show/NCT01147965]
  1471. NCT01171729: [https://clinicaltrials.gov/ct2/show/NCT01171729]
  1472. NCT01174082: Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant [https://clinicaltrials.gov/study/NCT01174082]
  1473. NCT01176461: [https://clinicaltrials.gov/ct2/show/NCT01176461]
  1474. NCT01176462: [https://clinicaltrials.gov/ct2/show/NCT01176462]
  1475. NCT01189383: IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma [https://clinicaltrials.gov/study/NCT01189383]
  1476. NCT01209871: Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma [https://clinicaltrials.gov/study/NCT01209871]
  1477. NCT01213472: [https://clinicaltrials.gov/ct2/show/NCT01213472]
  1478. NCT01216436: [https://clinicaltrials.gov/ct2/show/NCT01216436]
  1479. NCT01219348: [https://clinicaltrials.gov/ct2/show/NCT01219348?term=IDO+Peptide+Vaccine&rank=1]
  1480. NCT01220128: [https://clinicaltrials.gov/show/NCT01220128/]
  1481. NCT01241162: Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma [https://clinicaltrials.gov/study/NCT01241162]
  1482. NCT01241682: [https://clinicaltrials.gov/ct2/show/NCT01241682]
  1483. NCT01242618: [https://clinicaltrials.gov/show/NCT01242618/]
  1484. NCT01250470: [https://clinicaltrials.gov/ct2/show/NCT01250470?term=Montanide+ISA-51%2FSurvivin+Peptide+Vaccine&rank=1]
  1485. NCT01253837: [https://clinicaltrials.gov/ct2/show/NCT01253837]
  1486. NCT01265368: [https://clinicaltrials.gov/ct2/show/NCT01265368]
  1487. NCT01270503: [https://clinicaltrials.gov/ct2/show/NCT01270503?term=Menactra&rank=1]
  1488. NCT01280552: [https://clinicaltrials.gov/ct2/show/NCT01280552]
  1489. NCT01307618: [https://clinicaltrials.gov/ct2/show/NCT01307618?term=NA17.A2&rank=2]
  1490. NCT01307618: Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma [https://clinicaltrials.gov/ct2/show/NCT01307618]
  1491. NCT01308294: [https://clinicaltrials.gov/ct2/show/NCT01308294?term=Melan-A%2FMAGE-3.DP4+Peptide+Vaccine&rank=1]
  1492. NCT01312376: Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer [https://clinicaltrials.gov/study/NCT01312376]
  1493. NCT01322802: [https://clinicaltrials.gov/show/NCT01322802]
  1494. NCT01334047: [https://clinicaltrials.gov/ct2/show/NCT01334047]
  1495. NCT01334060: [https://clinicaltrials.gov/show/NCT01334060]
  1496. NCT01349647: Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid [https://clinicaltrials.gov/study/NCT01349647]
  1497. NCT01353222: [https://clinicaltrials.gov/ct2/show/NCT01353222]
  1498. NCT01380600: [https://clinicaltrials.gov/show/NCT01380600]
  1499. NCT01398124: [https://clinicaltrials.gov/ct2/show/NCT01398124]
  1500. NCT01400672: [https://clinicaltrials.gov/ct2/show/NCT01400672]
  1501. NCT01405521: [https://clinicaltrials.gov/ct2/show/NCT01405521?term=Ty21a&rank=2]
  1502. NCT01413087: Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC-BC-819) [https://clinicaltrials.gov/study/NCT01413087]
  1503. NCT01437280: [https://clinicaltrials.gov/ct2/show/NCT01437280?term=CGTG-102&rank=1]
  1504. NCT01453361: [https://clinicaltrials.gov/show/NCT01453361]
  1505. NCT01488188: [https://clinicaltrials.gov/ct2/show/NCT01488188]
  1506. NCT01498328: [https://clinicaltrials.gov/ct2/show/NCT01498328]
  1507. NCT01525017: [https://clinicaltrials.gov/ct2/show/NCT01525017]
  1508. NCT01526473: [https://clinicaltrials.gov/ct2/show/NCT01526473?term=AVX901&rank=1]
  1509. NCT01536054: [https://clinicaltrials.gov/ct2/show/NCT01536054?term=ALVAC%282%29-NY-ESO-1+%28M%29%2FTRICOM+Vaccine&rank=1]
  1510. NCT01556789: [https://clinicaltrials.gov/ct2/show/NCT01556789?term=ONT-10&rank=1]
  1511. NCT01559597: [https://clinicaltrials.gov/ct2/show/NCT01559597?term=Tetanus+Toxoid+Vaccine&rank=3]
  1512. NCT01598454: [https://clinicaltrials.gov/ct2/show/NCT01598454]
  1513. NCT01606241: [https://clinicaltrials.gov/ct2/show/NCT01606241?term=FR+Alpha+Peptide+Vaccine&rank=1]
  1514. NCT01621542: [https://clinicaltrials.gov/show/NCT01621542/]
  1515. NCT01622933: Multiple Antigen-Engineered DC Vaccine for Melanoma [https://clinicaltrials.gov/study/NCT01622933]
  1516. NCT01624701: [https://clinicaltrials.gov/show/NCT01624701/]
  1517. NCT01639612: [https://clinicaltrials.gov/show/NCT01639612/]
  1518. NCT01660529: [https://clinicaltrials.gov/ct2/show/NCT01660529?term=hTERT%2FSurvivin%2FCMV+Multipeptide+Vaccine&rank=1]
  1519. NCT01666782: [https://clinicaltrials.gov/ct2/show/NCT01666782]
  1520. NCT01666783: [https://clinicaltrials.gov/ct2/show/NCT01666783]
  1521. NCT01690377: [https://clinicaltrials.gov/ct2/show/NCT01690377]
  1522. NCT01697527: [https://clinicaltrials.gov/ct2/show/NCT01697527]
  1523. NCT01711970: [https://clinicaltrials.gov/ct2/show/NCT01711970]
  1524. NCT01718899: Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma [https://clinicaltrials.gov/ct2/show/NCT01718899]
  1525. NCT01744171: [https://clinicaltrials.gov/ct2/show/NCT01744171]
  1526. NCT01748747: [https://clinicaltrials.gov/ct2/show/NCT01748747]
  1527. NCT01759810: Proteome-based Personalized Immunotherapy of Glioblastoma [https://clinicaltrials.gov/study/NCT01759810]
  1528. NCT01766739: [https://clinicaltrials.gov/show/NCT01766739/]
  1529. NCT01767467: [https://clinicaltrials.gov/ct2/show/NCT01767467]
  1530. NCT01773395: GVAX vs. Placebo for MDS/​AML After Allo HSCT [https://clinicaltrials.gov/study/NCT01773395]
  1531. NCT01784913: [https://clinicaltrials.gov/show/NCT01784913/]
  1532. NCT01795313: [https://clinicaltrials.gov/ct2/show/NCT01795313?term=HLA-A2-Restricted+Synthetic+Glioma+Antigen+Peptides+Vaccine&rank=1]
  1533. NCT01800071: [https://clinicaltrials.gov/show/NCT01800071/]
  1534. NCT01823978: [https://clinicaltrials.gov/ct2/show/NCT01823978]
  1535. NCT01827137: [https://clinicaltrials.gov/show/NCT01827137/]
  1536. NCT01828762: [https://clinicaltrials.gov/ct2/show/NCT01828762]
  1537. NCT01836432: [https://clinicaltrials.gov/ct2/show/NCT01836432]
  1538. NCT01842139: [https://clinicaltrials.gov/show/NCT01842139/]
  1539. NCT01853878: [https://clinicaltrials.gov/ct2/show/NCT01853878]
  1540. NCT01854099: [https://clinicaltrials.gov/show/NCT01854099/]
  1541. NCT01861938: Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients [https://clinicaltrials.gov/study/NCT01861938]
  1542. NCT01863108: [https://clinicaltrials.gov/ct2/show/NCT01863108]
  1543. NCT01898039: Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients [https://clinicaltrials.gov/study/NCT01898039]
  1544. NCT01957956: [https://clinicaltrials.gov/ct2/show/NCT01957956]
  1545. NCT01961115: [https://clinicaltrials.gov/ct2/show/NCT01961115?term=MELITAC+12.1+Peptide+Vaccine&rank=1]
  1546. NCT01961882: [https://clinicaltrials.gov/show/NCT01961882/]
  1547. NCT01966289: [https://clinicaltrials.gov/ct2/show/NCT01966289]
  1548. NCT01967758: [https://clinicaltrials.gov/ct2/show/NCT01967758]
  1549. NCT01970358: A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma [https://clinicaltrials.gov/study/NCT01970358]
  1550. NCT01972737: [https://clinicaltrials.gov/show/NCT01972737]
  1551. NCT01972737, ClinicalTrials.gov: Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer [https://clinicaltrials.gov/show/NCT01972737]
  1552. NCT01994369: [https://clinicaltrials.gov/ct2/show/NCT01994369?term=EC17&rank=2]
  1553. NCT01995708: [https://clinicaltrials.gov/ct2/show/NCT01995708]
  1554. NCT02010203: [https://clinicaltrials.gov/ct2/show/NCT02010203]
  1555. NCT02015416: [https://clinicaltrials.gov/ct2/show/NCT02015416]
  1556. NCT02017678: [https://clinicaltrials.gov/show/NCT02017678/]
  1557. NCT02018458: Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer [https://clinicaltrials.gov/study/NCT02018458]
  1558. NCT02028442: [https://clinicaltrials.gov/ct2/show/NCT02028442]
  1559. NCT02033616: [https://clinicaltrials.gov/ct2/show/NCT02033616]
  1560. NCT02035358: [https://clinicaltrials.gov/ct2/show/NCT02035358]
  1561. NCT02040636: [https://clinicaltrials.gov/ct2/show/NCT02040636]
  1562. NCT02040637: [https://clinicaltrials.gov/ct2/show/NCT02040637]
  1563. NCT02045836: [https://clinicaltrials.gov/ct2/show/NCT02045836]
  1564. NCT02049489: [https://clinicaltrials.gov/ct2/show/NCT02049489]
  1565. NCT02058680: Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone Independent Patients (PSA) [https://clinicaltrials.gov/ct2/show/NCT02058680]
  1566. NCT02061423: [https://clinicaltrials.gov/ct2/show/NCT02061423]
  1567. NCT02063724: [https://clinicaltrials.gov/ct2/show/NCT02063724]
  1568. NCT02065973: [https://clinicaltrials.gov/ct2/show/NCT02065973?term=PDS0101&rank=1]
  1569. NCT02074046: Safety Study of Cancer Stem Cell Vaccine to Treat Pancreatic Cancer [https://clinicaltrials.gov/study/NCT02074046]
  1570. NCT02077114: Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma [https://clinicaltrials.gov/study/NCT02077114]
  1571. NCT02078648: [https://clinicaltrials.gov/ct2/show/NCT02078648]
  1572. NCT02079324: [https://clinicaltrials.gov/show/NCT02079324/]
  1573. NCT02103426: [https://clinicaltrials.gov/show/NCT02103426]
  1574. NCT02107404: [https://clinicaltrials.gov/ct2/show/NCT02107404]
  1575. NCT02107950: [https://clinicaltrials.gov/ct2/show/NCT02107950]
  1576. NCT02107963: A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors [https://clinicaltrials.gov/study/NCT02107963]
  1577. NCT02111577: Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (VIABLE) [https://clinicaltrials.gov/ct2/show/NCT02111577]
  1578. NCT02111941: [https://clinicaltrials.gov/ct2/show/NCT02111941]
  1579. NCT02115126: Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant [https://clinicaltrials.gov/study/NCT02115126]
  1580. NCT02122861: [https://clinicaltrials.gov/ct2/show/NCT02122861?term=Dendritic+Cell-targeting+Lentiviral+Vector+ID-LV305&rank=1]
  1581. NCT02126579: [https://clinicaltrials.gov/ct2/show/NCT02126579?term=LPV7&rank=1]
  1582. NCT02128126: [https://clinicaltrials.gov/show/NCT02128126/]
  1583. NCT02140996: [https://clinicaltrials.gov/ct2/show/NCT02140996]
  1584. NCT02149225: [https://clinicaltrials.gov/show/NCT02149225/]
  1585. NCT02157051: [https://clinicaltrials.gov/show/NCT02157051]
  1586. NCT02159950: [https://clinicaltrials.gov/ct2/show/NCT02159950]
  1587. NCT02170389: [https://clinicaltrials.gov/ct2/show/NCT02170389]
  1588. NCT02179515: [https://clinicaltrials.gov/show/NCT02179515/]
  1589. NCT02193347: [https://clinicaltrials.gov/ct2/show/NCT02193347?term=PEPIDH1M+Vaccine&rank=1]
  1590. NCT02203357: [https://clinicaltrials.gov/ct2/show/NCT02203357?term=Hepatitis+B+Vaccine&rank=1]
  1591. NCT02204085: [https://clinicaltrials.gov/ct2/show/NCT02204085?term=GO-203-2C&rank=1]
  1592. NCT02223312: [https://clinicaltrials.gov/ct2/show/NCT02223312]
  1593. NCT02237638: [https://clinicaltrials.gov/ct2/show/NCT02237638?term=hVEGF26-104%2FRFASE&rank=1]
  1594. NCT02241369: [https://clinicaltrials.gov/show/NCT02241369]
  1595. NCT02264236: [https://clinicaltrials.gov/ct2/show/NCT02264236?term=Mimotope-P10s-PADRE+Peptide+Vaccine&rank=1]
  1596. NCT02285816: [https://clinicaltrials.gov/ct2/show/NCT02285816?term=AdMA3&rank=1]
  1597. NCT02293707: [https://clinicaltrials.gov/ct2/show/NCT02293707?term=GX+301&rank=1]
  1598. NCT02293850: [https://clinicaltrials.gov/ct2/show/NCT02293850?term=OBP-301&rank=1]
  1599. NCT02310464: [https://clinicaltrials.gov/ct2/show/NCT02310464?term=Globo+H-DT+Vaccine+OBI-833&rank=1]
  1600. NCT02316457: [https://clinicaltrials.gov/ct2/show/NCT02316457]
  1601. NCT02323230: [https://clinicaltrials.gov/show/NCT02323230/]
  1602. NCT02327468: [https://clinicaltrials.gov/show/NCT02327468]
  1603. NCT02332889: Phase I/​II: Decitabine/​Vaccine Therapy in Relapsed/​Refractory Pediatric High Grade Gliomas/​Medulloblastomas/​CNS PNETs [https://clinicaltrials.gov/study/NCT02332889]
  1604. NCT02334865: [https://clinicaltrials.gov/show/NCT02334865/]
  1605. NCT02362464: Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139 [https://clinicaltrials.gov/ct2/show/NCT02362464]
  1606. NCT02390063: [https://clinicaltrials.gov/ct2/show/NCT02390063]
  1607. NCT02410733: [https://clinicaltrials.gov/ct2/show/NCT02410733]
  1608. NCT02411019: [https://clinicaltrials.gov/show/NCT02411019]
  1609. NCT02411786: [https://clinicaltrials.gov/show/NCT02411786]
  1610. NCT02419170: Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC) [https://clinicaltrials.gov/study/NCT02419170]
  1611. NCT02423928: [https://clinicaltrials.gov/ct2/show/NCT02423928]
  1612. NCT02427581: [https://clinicaltrials.gov/ct2/show/NCT02427581]
  1613. NCT02439450: [https://clinicaltrials.gov/ct2/show/NCT02439450]
  1614. NCT02454634: [https://clinicaltrials.gov/ct2/show/NCT02454634?term=IDH1R132H-specific+Peptide+Vaccine&rank=1]
  1615. NCT02460367: [https://clinicaltrials.gov/ct2/show/NCT02460367]
  1616. NCT02479230: [https://clinicaltrials.gov/ct2/show/NCT02479230]
  1617. NCT02493829: B7.1/​IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX) [https://clinicaltrials.gov/study/NCT02493829]
  1618. NCT02499835: [https://clinicaltrials.gov/show/NCT02499835]
  1619. NCT02501278: [https://clinicaltrials.gov/show/NCT02501278]
  1620. NCT02503150: [https://clinicaltrials.gov/ct2/show/NCT02503150]
  1621. NCT02506933: [https://clinicaltrials.gov/ct2/show/NCT02506933?term=CMV-MVA+Triplex+Vaccine&rank=1]
  1622. NCT02510950: Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma [https://clinicaltrials.gov/study/NCT02510950]
  1623. NCT02514213: [https://clinicaltrials.gov/show/NCT02514213]
  1624. NCT02528682: [https://clinicaltrials.gov/ct2/show/NCT02528682]
  1625. NCT02529930: [https://clinicaltrials.gov/show/NCT02529930]
  1626. NCT02550678: [https://clinicaltrials.gov/ct2/show/NCT02550678?term=Interferon-gamma-expressing+Adenovirus+Vaccine+ASN-002&rank=1]
  1627. NCT02555397: [https://clinicaltrials.gov/ct2/show/NCT02555397]
  1628. NCT02562755: Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone (PHOCUS) [https://clinicaltrials.gov/ct2/show/NCT02562755]
  1629. NCT02568566: [https://clinicaltrials.gov/ct2/show/NCT02568566?term=Recombinant+Human+Papillomavirus+Nonavalent+Vaccine&rank=1]
  1630. NCT02587520: [https://clinicaltrials.gov/ct2/show/NCT02587520?term=Bordetella+pertussis+Vaccine+Adsorbed&rank=1]
  1631. NCT02587520: [https://clinicaltrials.gov/ct2/show/NCT02587520?term=Diphtheria+Toxoid+Tetanus+Toxoid+Vaccine+Adsorbed&rank=1]
  1632. NCT02601040: [https://clinicaltrials.gov/show/NCT02601040]
  1633. NCT02615574: [https://clinicaltrials.gov/show/NCT02615574/]
  1634. NCT02625857: [https://clinicaltrials.gov/ct2/show/NCT02625857]
  1635. NCT02636582: [https://clinicaltrials.gov/ct2/show/NCT02636582?term=Nelipepimut-S+Plus+GM-CSF+Vaccine&rank=1]
  1636. NCT02636582: Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer [https://clinicaltrials.gov/ct2/show/NCT02636582]
  1637. NCT02648282: [https://clinicaltrials.gov/ct2/show/NCT02648282]
  1638. NCT02649439: [https://clinicaltrials.gov/show/NCT02649439/]
  1639. NCT02654587: [https://clinicaltrials.gov/ct2/show/NCT02654587]
  1640. NCT02688673: DC Vaccine Combined With CIK Cells in Patients With SCLC [https://clinicaltrials.gov/study/NCT02688673]
  1641. NCT02693236: [https://clinicaltrials.gov/show/NCT02693236/]
  1642. NCT02718443: [https://clinicaltrials.gov/show/NCT02718443]
  1643. NCT02728102: Dendritic Cell/​Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) [https://clinicaltrials.gov/study/NCT02728102]
  1644. NCT02745756: A Combined Cell Therapy Approach to the Treatment of Neuroblastoma [https://clinicaltrials.gov/study/NCT02745756]
  1645. NCT02750995: Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML (AZACTA) [https://clinicaltrials.gov/study/NCT02750995]
  1646. NCT02772562: [https://clinicaltrials.gov/show/NCT02772562/]
  1647. NCT02773849: [https://clinicaltrials.gov/ct2/show/NCT02773849?term=Instiladrin&rank=1]
  1648. NCT02780401: Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission (WOKVAC) [https://clinicaltrials.gov/study/NCT02780401]
  1649. NCT02795988: [https://clinicaltrials.gov/ct2/show/NCT02795988]
  1650. NCT02808416: Personalized Cellular Vaccine for Brain Metastases (PERCELLVAC3) (PerCellVac3) [https://clinicaltrials.gov/study/NCT02808416]
  1651. NCT02822079: [https://clinicaltrials.gov/show/NCT02822079]
  1652. NCT02826434: [https://clinicaltrials.gov/show/NCT02826434/]
  1653. NCT02848911: [https://clinicaltrials.gov/show/NCT02848911/]
  1654. NCT02851056: Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT) [https://clinicaltrials.gov/study/NCT02851056]
  1655. NCT02855892: A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH [https://clinicaltrials.gov/ct2/show/NCT02855892]
  1656. NCT02864368: Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens (PERFORMANCE) [https://clinicaltrials.gov/ct2/show/NCT02864368]
  1657. NCT02935790: [https://clinicaltrials.gov/show/NCT02935790/]
  1658. NCT02944357: Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery [https://clinicaltrials.gov/study/NCT02944357]
  1659. NCT02960594: hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse (TRT-001) [https://clinicaltrials.gov/ct2/show/NCT02960594]
  1660. NCT03042182: Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma (cholangio) [https://clinicaltrials.gov/study/NCT03042182]
  1661. NCT03042793: Vaccination With PD-L1 Peptide Against Multiple Myeloma [https://clinicaltrials.gov/study/NCT03042793]
  1662. NCT03047928: Combination Therapy With Nivolumab and PD-L1/​IDO Peptide Vaccine to Patients With Metastatic Melanoma [https://clinicaltrials.gov/study/NCT03047928]
  1663. NCT03059485: DC/​AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission [https://clinicaltrials.gov/study/NCT03059485]
  1664. NCT03092453: Dendritic Cell Vaccination in Patients With Advanced Melanoma [https://clinicaltrials.gov/study/NCT03092453]
  1665. NCT03121677: Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma [https://clinicaltrials.gov/study/NCT03121677]
  1666. NCT03141463: Vvax001 Cancer Vaccine in (Pre) Malignant Cervical Lesions [https://clinicaltrials.gov/study/NCT03141463]
  1667. NCT03166254: Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer [https://clinicaltrials.gov/study/NCT03166254]
  1668. NCT03226236: Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC (RENALVax-2) [https://clinicaltrials.gov/study/NCT03226236]
  1669. NCT03294564: Cognitive, Emotional, and Neural Responses to Acute Inflammation [https://clinicaltrials.gov/ct2/show/NCT03294564]
  1670. NCT03300817: MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer [https://clinicaltrials.gov/study/NCT03300817]
  1671. NCT03300843: Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer [https://clinicaltrials.gov/study/NCT03300843]
  1672. NCT03391232: PolyPEPI1018 Vaccine and CDx for the Treatment of Metastatic Colorectal Cancer (OBERTO) (OBERTO) [https://clinicaltrials.gov/study/NCT03391232]
  1673. NCT03396575: Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) (BRAVO) [https://clinicaltrials.gov/study/NCT03396575]
  1674. NCT03412786: Bcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node Metastases [https://clinicaltrials.gov/study/NCT03412786]
  1675. NCT03468244: Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms [https://clinicaltrials.gov/study/NCT03468244]
  1676. NCT03480152: Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer [https://clinicaltrials.gov/study/NCT03480152]
  1677. NCT03556566: Open Label Immunotherapy Trial for Ovarian Cancer (V3-OVA) [https://clinicaltrials.gov/study/NCT03556566]
  1678. NCT03558945: Clinical Trial on Personalized Neoantigen Vaccine for Pancreatic Tumor [https://clinicaltrials.gov/study/NCT03558945]
  1679. NCT03598816: PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/​Metastatic Renal Cell Carcinoma (PIVOT-RCC) [https://clinicaltrials.gov/study/NCT03598816]
  1680. NCT03674073: A Study Combining Personalized Neoantigen-based Dendritic Cell Vaccine With Microwave Ablation for the Treatment of Hepatocellular Carcinoma [https://clinicaltrials.gov/study/NCT03674073]
  1681. NCT03871205: Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer [https://clinicaltrials.gov/study/NCT03871205]
  1682. NCT03914768: Immune Modulatory DC Vaccine Against Brain Tumor [https://clinicaltrials.gov/study/NCT03914768]
  1683. NCT04079166: SCIB1 in Melanoma Patients Receiving Either Nivolumab With Ipilimumab or Pembrolizumab (The SCOPE Study) [https://clinicaltrials.gov/study/NCT04079166]
  1684. NCT04147078: Personalized DC Vaccine for Postoperative Cancer [https://clinicaltrials.gov/study/NCT04147078]
  1685. NCT04197687: TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery [https://clinicaltrials.gov/study/NCT04197687]
  1686. NCT04247282: Anti-PD-L1/​TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection [https://clinicaltrials.gov/study/NCT04247282]
  1687. NCT04270149: Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer [https://clinicaltrials.gov/study/NCT04270149]
  1688. NCT04317248: "Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma [https://clinicaltrials.gov/study/NCT04317248]
  1689. NCT04348747: Dendritic Cell Vaccines Against Her2/​Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer [https://clinicaltrials.gov/study/NCT04348747]
  1690. NCT04418219: Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer [https://clinicaltrials.gov/study/NCT04418219]
  1691. NCT04573140: A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM) (PNOC020) [https://clinicaltrials.gov/study/NCT04573140]
  1692. NCT04574583: Phase I/​II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/​PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) [https://clinicaltrials.gov/study/NCT04574583]
  1693. NCT04688385: Personalized Multi-peptide Vaccination in CLL Patients [https://clinicaltrials.gov/study/NCT04688385]
  1694. NCT04741984: Monocyte Antigen Carrier Cells for Newly Diagnosed GBM (DEMAND) [https://clinicaltrials.gov/study/NCT04741984]
  1695. NCT04749641: Neoantigen Vaccine Therapy Against H3.3-K27M Diffuse Intrinsic Pontine Glioma (ENACTING) [https://clinicaltrials.gov/study/NCT04749641]
  1696. NCT04912765: Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC [https://clinicaltrials.gov/study/NCT04912765]
  1697. NCT04998474: FRAME-001 Personalized Vaccine in NSCLC [https://clinicaltrials.gov/study/NCT04998474]
  1698. NCT05014607: Personalized Multi-peptide Vaccination in Combination With the TLR1/​2 Ligand XS15 in Cancer Patients (InHeVac01) [https://clinicaltrials.gov/study/NCT05014607]
  1699. NCT05023928: Tumor Antigen-sensitized DC Vaccine as an Adjuvant Therapy for Esophagus Cancer [https://clinicaltrials.gov/study/NCT05023928]
  1700. NCT05098210: Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer [https://clinicaltrials.gov/study/NCT05098210]
  1701. NCT05111353: Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery [https://clinicaltrials.gov/study/NCT05111353]
  1702. NCT05163223: Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer (Cornerstone001) [https://clinicaltrials.gov/ct2/show/NCT05163223]
  1703. NCT05195619: Autologous dendritic cell vaccine loaded with personalized peptides (PEP-DC vaccine) [https://clinicaltrials.gov/study/NCT05195619]
  1704. NCT05202561: A Study of RNA Tumor Vaccine in Patients With Advanced Solid Tumors [https://clinicaltrials.gov/study/NCT05202561]
  1705. NCT05227378: Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer [https://clinicaltrials.gov/study/NCT05227378]
  1706. NCT05235607: Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors [https://clinicaltrials.gov/study/NCT05235607]
  1707. NCT05264974: Novel RNA-nanoparticle Vaccine for the Treatment of Early Melanoma Recurrence Following Adjuvant Anti-PD-1 Antibody Therapy [https://clinicaltrials.gov/study/NCT05264974]
  1708. NCT05283109: ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM (ETAPA I) [https://clinicaltrials.gov/study/NCT05283109]
  1709. NCT05317325: A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC [https://clinicaltrials.gov/study/NCT05317325]
  1710. NCT05359354: Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Solid Tumors [https://clinicaltrials.gov/study/NCT05359354]
  1711. NCT05457959: Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/​or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant [https://clinicaltrials.gov/study/NCT05457959]
  1712. NCT05479045: A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients [https://clinicaltrials.gov/ct2/show/NCT05479045]
  1713. NCT05533203: Safety of Prodencel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC) [https://clinicaltrials.gov/study/NCT05533203]
  1714. NCT05559177: An Open, Dose-escalation Clinical Study of Chimeric Exosomal Tumor Vaccines for Recurrent or Metastatic Bladder Cancer [https://clinicaltrials.gov/study/NCT05559177]
  1715. NCT05638698: Tg01 Vaccine /​ Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer (TESLA) [https://clinicaltrials.gov/study/NCT05638698]
  1716. Nelson et al., 2016: Nelson HH, Pawlita M, Michaud DS, McClean M, Langevin SM, Eliot MN, Kelsey KT. Immune Response to HPV16 E6 and E7 Proteins and Patient Outcomes in Head and Neck Cancer. JAMA oncology. 2016; ; . [PubMed: 27930753].
  1717. Nemunaitis et al., 2006: Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, DeVol E, Maples PB, Liu L, Chamberlin T, Shawler DL, Fakhrai H. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006; 24(29); 4721-4730. [PubMed: 16966690].
  1718. Nemunaitis et al., 2009: Nemunaitis J, Nemunaitis M, Senzer N, Snitz P, Bedell C, Kumar P, Pappen B, Maples PB, Shawler D, Fakhrai H. Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer gene therapy. 2009; 16(8); 620-624. [PubMed: 19287371].
  1719. Nemunaitis, 2003: Nemunaitis J. GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer. Journal of controlled release : official journal of the Controlled Release Society. 2003; 91(1-2); 225-231. [PubMed: 12932654].
  1720. New et al., 1988: New JH, Eggleston AK, Fennewald M. Binding of the Tn3 transposase to the inverted repeats of Tn3. Journal of molecular biology. 1988; 201(3); 589-599. [PubMed: 2843651].
  1721. Nicholaou et al., 2009: Nicholaou T, Ebert LM, Davis ID, McArthur GA, Jackson H, Dimopoulos N, Tan B, Maraskovsky E, Miloradovic L, Hopkins W, Pan L, Venhaus R, Hoffman EW, Chen W, Cebon J. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009; 15(6); 2166-2173. [PubMed: 19276262].
  1722. Nicholson et al., 2003: Nicholson S, Guile K, John J, Clarke IA, Diffley J, Donnellan P, Michael A, Szlosarek P, Dalgleish AG. A randomized phase II trial of SRL172 (Mycobacterium vaccae) +/- low-dose interleukin-2 in the treatment of metastatic malignant melanoma. Melanoma research. 2003; 13(4); 389-393. [PubMed: 12883365].
  1723. Niethammer et al., 2002: Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nature medicine. 2002; 8(12); 1369-1375. [PubMed: 12415261].
  1724. Nigro et al., 2009: Nigro EA, Brini AT, Soprana E, Ambrosi A, Dombrowicz D, Siccardi AG, Vangelista L. Antitumor IgE adjuvanticity: key role of Fc epsilon RI. Journal of immunology (Baltimore, Md. : 1950). 2009; 183(7); 4530-4536. [PubMed: 19748979].
  1725. Nitschke et al., 2017: Nitschke NJ, Bjoern J, Iversen TZ, Andersen MH, Svane IM. Indoleamine 2,3-dioxygenase and survivin peptide vaccine combined with temozolomide in metastatic melanoma. Stem cell investigation. 2017; 4; 77. [PubMed: 29057249].
  1726. Nooka et al., 2018: Nooka AK, Wang ML, Yee AJ, Kaufman JL, Bae J, Peterkin D, Richardson PG, Raje NS. Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial. JAMA oncology. 2018; 4(12); e183267. [PubMed: 30128502].
  1727. Nothdurft, 2008: Nothdurft HD. Hepatitis A vaccines. Expert review of vaccines. 2008; 7(5); 535-545. [PubMed: 18564009].
  1728. Nowicki et al., 2019: Nowicki TS, Berent-Maoz B, Cheung-Lau G, Huang RR, Wang X, Tsoi J, Kaplan-Lefko P, Cabrera P, Tran J, Pang J, Macabali M, Garcilazo IP, Carretero IB, Kalbasi A, Cochran AJ, Grasso CS, Hu-Lieskovan S, Chmielowski B, Comin-Anduix B, Singh A, Ribas A. A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019; 25(7); 2096-2108. [PubMed: 30573690].
  1729. O'Connor et al., 1978: O'Connor TP, Labandter HP, Hiles RW, Bodenham DC. A clinical trial of BCG immunotherapy as an adjunct to surgery in the treatment of primary malignant melanoma. British journal of plastic surgery. 1978; 31(4); 317-322. [PubMed: 361132].
  1730. Ochiai et al., 2014: Ochiai RL, Khan MI, Soofi SB, Sur D, Kanungo S, You YA, Habib MA, Sahito SM, Manna B, Dutta S, Acosta CJ, Ali M, Bhattacharya SK, Bhutta ZA, Clemens JD. Immune responses to Vi capsular polysaccharide typhoid vaccine in children 2 to 16 years old in Karachi, Pakistan, and Kolkata, India. Clinical and vaccine immunology : CVI. 2014; 21(5); 661-666. [PubMed: 24599532].
  1731. Odin et al., 2001: Odin L, Favrot M, Poujol D, Michot JP, Moingeon P, Tartaglia J, Puisieux I. Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53. Cancer gene therapy. 2001; 8(2); 87-98. [PubMed: 11263530].
  1732. Odunsi et al., 2007: Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnjatic S. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(31); 12837-12842. [PubMed: 17652518].
  1733. Odunsi et al., 2012: Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, Beck A, Morrison CD, Ritter G, Godoy H, Lele S, duPont N, Edwards R, Shrikant P, Old LJ, Gnjatic S, Jäger E. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(15); 5797-5802. [PubMed: 22454499].
  1734. Oertli et al., 2002: Oertli D, Marti WR, Zajac P, Noppen C, Kocher T, Padovan E, Adamina M, Schumacher R, Harder F, Heberer M, Spagnoli GC. Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo. Human gene therapy. 2002; 13(4); 569-575. [PubMed: 11874634].
  1735. Oji et al., 2023: Oji Y, Kagawa N, Arita H, Naka N, Hamada KI, Outani H, Shintani Y, Takeda Y, Morii E, Shimazu K, Suzuki M, Nishida S, Nakata J, Tsuboi A, Iwai M, Hayashi S, Imanishi R, Ikejima S, Kanegae M, Iwamoto M, Ikeda M, Yagi K, Shimokado H, Nakajima H, Hasegawa K, Morimoto S, Fujiki F, Nagahara A, Tanemura A, Ueda Y, Mizushima T, Ohmi M, Ishida T, Fujimoto M, Nonomura N, Kimura T, Inohara H, Okada S, Kishima H, Hosen N, Kumanogoh A, Oka Y, Sugiyama H. WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1. Cancers. 2023; 15(2); . [PubMed: 36672344].
  1736. Oka et al., 2006: Oka Y, Tsuboi A, Kawakami M, Elisseeva OA, Nakajima H, Udaka K, Kawase I, Oji Y, Sugiyama H. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers. Current medicinal chemistry. 2006; 13(20); 2345-2352. [PubMed: 16918359].
  1737. Okada et al., 2011: Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, Zeh H, Holtzman MP, Reinhart TA, Whiteside TL, Butterfield LH, Hamilton RL, Potter DM, Pollack IF, Salazar AM, Lieberman FS. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011; 29(3); 330-336. [PubMed: 21149657].
  1738. Okur et al., 2011: Okur FV, Yvon E, Biagi E, Dotti G, Carrum G, Heslop H, Mims MP, Fratantoni JC, Peshwa MV, Li L, Brenner MK. Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia. Cytotherapy. 2011; 13(9); 1128-1139. [PubMed: 21745159].
  1739. Olin et al., 2014: Olin MR, Low W, McKenna DH, Haines SJ, Dahlheimer T, Nascene D, Gustafson MP, Dietz AB, Clark HB, Chen W, Blazar B, Ohlfest JR, Moertel C. Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response. Journal for immunotherapy of cancer. 2014; 2; 4. [PubMed: 24829761].
  1740. Olivares et al., 2011: Olivares J, Kumar P, Yu Y, Maples PB, Senzer N, Bedell C, Barve M, Tong A, Pappen BO, Kuhn J, Magee M, Wallraven G, Nemunaitis J. Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011; 17(1); 183-192. [PubMed: 21208907].
  1741. Onaitis et al., 2002: Onaitis M, Kalady MF, Pruitt S, Tyler DS. Dendritic cell gene therapy. Surgical oncology clinics of North America. 2002; 11(3); 645-660. [PubMed: 12487060].
  1742. Osanto, 1997: Osanto S. Vaccine Trials for the Clinician: Prospects for Tumor Antigens. The oncologist. 1997; 2(5); 284-299. [PubMed: 10388061].
  1743. Ott et al., 2017: Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017; 547(7662); 217-221. [PubMed: 28678778].
  1744. Ottensmeier et al., 2016: Ottensmeier C, Bowers M, Hamid D, Maishman T, Regan S, Wood W, Cazaly A, Stanton L. Wilms’ tumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a Phase II non-randomised clinical trial (WIN). NIHR Journals Library. 2016; ; . [PubMed: 27099895].
  1745. Overwijk et al., 1999: Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll MW, Moss B, Rosenberg SA, Restifo NP. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96(6); 2982-2987. [PubMed: 10077623].
  1746. Paff et al., 2014: Paff M, Alexandru-Abrams D, Hsu FP, Bota DA. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients. Human vaccines & immunotherapeutics. 2014; 10(11); 3322-3331. [PubMed: 25625931].
  1747. Pal et al., 2006: Pal R, Venzon D, Santra S, Kalyanaraman VS, Montefiori DC, Hocker L, Hudacik L, Rose N, Nacsa J, Edghill-Smith Y, Moniuszko M, Hel Z, Belyakov IM, Berzofsky JA, Parks RW, Markham PD, Letvin NL, Tartaglia J, Franchini G. Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. Journal of virology. 2006; 80(8); 3732-3742. [PubMed: 16571790].
  1748. Palefsky et al., 2006: Palefsky JM, Berry JM, Jay N, Krogstad M, Da Costa M, Darragh TM, Lee JY. A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. AIDS (London, England). 2006; 20(8); 1151-1155. [PubMed: 16691066].
  1749. Panelli et al., 2000: Panelli MC, Wunderlich J, Jeffries J, Wang E, Mixon A, Rosenberg SA, Marincola FM. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. Journal of immunotherapy (Hagerstown, Md. : 1997). 2000; 23(4); 487-498. [PubMed: 10916759].
  1750. Park et al., 2010: Park MY, Kim DR, Jung HW, Yoon HI, Lee JH, Lee CT. Genetic immunotherapy of lung cancer using conditionally replicating adenovirus and adenovirus-interferon-beta. Cancer gene therapy. 2010; 17(5); 356-364. [PubMed: 19893592].
  1751. Park et al., 2011: Park MH, Yang DH, Kim MH, Jang JH, Jang YY, Lee YK, Jin CJ, Pham TN, Thi TA, Lim MS, Lee HJ, Hong CY, Yoon JH, Lee JJ. Alpha-Type 1 Polarized Dendritic Cells Loaded with Apoptotic Allogeneic Breast Cancer Cells Can Induce Potent Cytotoxic T Lymphocytes against Breast Cancer. Cancer research and treatment : official journal of Korean Cancer Association. 2011; 43(1); 56-66. [PubMed: 21509164].
  1752. Parker et al., 2000: Parker LL, Do MT, Westwood JA, Wunderlich JR, Dudley ME, Rosenberg SA, Hwu P. Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Human gene therapy. 2000; 11(17); 2377-2387. [PubMed: 11096442].
  1753. Parkhurst et al., 2003: Parkhurst MR, DePan C, Riley JP, Rosenberg SA, Shu S. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. Journal of immunology (Baltimore, Md. : 1950). 2003; 170(10); 5317-5325. [PubMed: 12734382].
  1754. Parkhurst et al., 2011: Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, Restifo NP, Robbins PF, Laurencot CM, Rosenberg SA. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Molecular therapy : the journal of the American Society of Gene Therapy. 2011; 19(3); 620-626. [PubMed: 21157437].
  1755. Parkinson and Sznol, 1995: Parkinson DR, Sznol M. High-dose interleukin-2 in the therapy of metastatic renal-cell carcinoma. Seminars in oncology. 1995; 22(1); 61-66. [PubMed: 7855620].
  1756. Parmiani et al., 2014: Parmiani G, Pilla L, Corti A, Doglioni C, Cimminiello C, Bellone M, Parolini D, Russo V, Capocefalo F, Maccalli C. A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma. Oncoimmunology. 2014; 3(11); e963406. [PubMed: 25941591].
  1757. Parvanova et al., 2011: Parvanova I, Rettig L, Knuth A, Pascolo S. The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination. Vaccine. 2011; 29(22); 3832-3836. [PubMed: 21470580].
  1758. Patel et al., 2013: Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013; 31(34); 4349-4357. [PubMed: 24145346].
  1759. Pavlenko et al., 2004: Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, Bergman B, Egevad L, Hellström M, Kiessling R, Masucci G, Wersäll P, Nilsson S, Pisa P. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. British journal of cancer. 2004; 91(4); 688-694. [PubMed: 15280930].
  1760. Peethambaram et al., 2009: Peethambaram PP, Melisko ME, Rinn KJ, Alberts SR, Provost NM, Jones LA, Sims RB, Lin LR, Frohlich MW, Park JW. A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009; 15(18); 5937-5944. [PubMed: 19723649].
  1761. Pektor et al., 2018: Pektor S, Hilscher L, Walzer KC, Miederer I, Bausbacher N, Loquai C, Schreckenberger M, Sahin U, Diken M, Miederer M. In vivo imaging of the immune response upon systemic RNA cancer vaccination by FDG-PET. EJNMMI research. 2018; 8(1); 80. [PubMed: 30112704].
  1762. Pellegatta et al., 2015: Pellegatta S, Valletta L, Corbetta C, Patanè M, Zucca I, Riccardi Sirtori F, Bruzzone MG, Fogliatto G, Isacchi A, Pollo B, Finocchiaro G. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta neuropathologica communications. 2015; 3; 4. [PubMed: 25849072].
  1763. Perloff et al., 1977: Perloff M, Holland JF, Lumb GJ, Bekesi JG. Effects of methanol extraction residue of Bacillus calmette-Guérin in humans. Cancer research. 1977; 37(4); 1191-1196. [PubMed: 321117].
  1764. Perricone et al., 2004: Perricone MA, Smith KA, Claussen KA, Plog MS, Hempel DM, Roberts BL, St George JA, Kaplan JM. Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. Journal of immunotherapy (Hagerstown, Md. : 1997). 2004; 27(4); 273-281. [PubMed: 15235388].
  1765. Pertl et al., 2003: Pertl U, Wodrich H, Ruehlmann JM, Gillies SD, Lode HN, Reisfeld RA. Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma. Blood. 2003; 101(2); 649-654. [PubMed: 12393580].
  1766. Phan et al., 2003: Phan GQ, Touloukian CE, Yang JC, Restifo NP, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. Journal of immunotherapy (Hagerstown, Md. : 1997). 2003; 26(4); 349-356. [PubMed: 12843797].
  1767. Phuphanich et al., 2013: Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuño MA, Richardson JE, Fan X, Ji J, Chu RM, Bender JG, Hawkins ES, Patil CG, Black KL, Yu JS. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII. 2013; 62(1); 125-135. [PubMed: 22847020].
  1768. Pinto et al., 1999: Pinto LA, Berzofsky JA, Fowke KR, Little RF, Merced-Galindez F, Humphrey R, Ahlers J, Dunlop N, Cohen RB, Steinberg SM, Nara P, Shearer GM, Yarchoan R. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS (London, England). 1999; 13(15); 2003-2012. [PubMed: 10546852].
  1769. Pitel, 1988: Pitel ML. Use of a cantilevered acrylic splint in the autogenous transplantation of a third molar: report of case. Journal of the American Dental Association (1939). 1988; 117(2); 329-331. [PubMed: 3166476].
  1770. Plotkin and Bouveret-Le, 1995: Plotkin SA, Bouveret-Le Cam N. A new typhoid vaccine composed of the Vi capsular polysaccharide. Archives of internal medicine. 1995; 155(21); 2293-2299. [PubMed: 7487253].
  1771. Pol et al., 2014: Pol JG, Zhang L, Bridle BW, Stephenson KB, Rességuier J, Hanson S, Chen L, Kazdhan N, Bramson JL, Stojdl DF, Wan Y, Lichty BD. Maraba virus as a potent oncolytic vaccine vector. Molecular therapy : the journal of the American Society of Gene Therapy. 2014; 22(2); 420-429. [PubMed: 24322333].
  1772. Pol et al., 2019: Pol JG, Acuna SA, Yadollahi B, Tang N, Stephenson KB, Atherton MJ, Hanwell D, El-Warrak A, Goldstein A, Moloo B, Turner PV, Lopez R, LaFrance S, Evelegh C, Denisova G, Parsons R, Millar J, Stoll G, Martin CG, Pomoransky J, Breitbach CJ, Bramson JL, Bell JC, Wan Y, Stojdl DF, Lichty BD, McCart JA. Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. Oncoimmunology. 2019; 8(1); e1512329. [PubMed: 30546947].
  1773. Pollack et al., 2016: Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H. Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. Journal of neuro-oncology. 2016; 130(3); 517-527. [PubMed: 27624914].
  1774. Pope et al., 1994: Pope BL, Sigindere J, Chourmouzis E, MacIntyre P, Goodman MG. 7-Allyl-8-oxoguanosine (loxoribine) inhibits the metastasis of B16 melanoma cells and has adjuvant activity in mice immunized with a B16 tumor vaccine. Cancer immunology, immunotherapy : CII. 1994; 38(2); 83-91. [PubMed: 8306370].
  1775. Posner et al., 2008: Posner MC, Niedzwiecki D, Venook AP, Hollis DR, Kindler HL, Martin EW, Schilsky RL, Goldberg RM, Mayer RJ. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Annals of surgical oncology. 2008; 15(1); 158-164. [PubMed: 18008108].
  1776. Prabakaran et al., 2002: Prabakaran I, Menon C, Xu S, Gómez-Yafal A, Czerniecki BJ, Fraker DL. Mature CD83(+) dendritic cells infected with recombinant gp100 vaccinia virus stimulate potent antimelanoma T cells. Annals of surgical oncology. 2002; 9(4); 411-418. [PubMed: 11986195].
  1777. Prince et al., 2015: Prince HE, Seaton BL, Matud JL, Batterman HJ. Chikungunya virus RNA and antibody testing at a National Reference Laboratory since the emergence of Chikungunya virus in the Americas. Clinical and vaccine immunology : CVI. 2015; 22(3); 291-297. [PubMed: 25540275].
  1778. Prins et al., 2013: Prins RM, Wang X, Soto H, Young E, Lisiero DN, Fong B, Everson R, Yong WH, Lai A, Li G, Cloughesy TF, Liau LM. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. Journal of immunotherapy (Hagerstown, Md. : 1997). 2013; 36(2); 152-157. [PubMed: 23377664].
  1779. Procaccio et al., 2017: Procaccio L, Schirripa M, Fassan M, Vecchione L, Bergamo F, Prete AA, Intini R, Manai C, Dadduzio V, Boscolo A, Zagonel V, Lonardi S. Immunotherapy in Gastrointestinal Cancers. BioMed research international. 2017; 2017; 4346576. [PubMed: 28758114].
  1780. Pruitt et al., 2011: Pruitt SK, Boczkowski D, de Rosa N, Haley NR, Morse MA, Tyler DS, Dannull J, Nair S. Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. European journal of immunology. 2011; 41(12); 3553-3563. [PubMed: 22028176].
  1781. Pujol et al., 2016: Pujol JL, De Pas T, Rittmeyer A, Vallières E, Kubisa B, Levchenko E, Wiesemann S, Masters GA, Shen R, Tjulandin SA, Hofmann HS, Vanhoutte N, Salaun B, Debois M, Jarnjak S, De Sousa Alves PM, Louahed J, Brichard VG, Lehmann FF. Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016; 11(12); 2208-2217. [PubMed: 27544054].
  1782. Pullarkat et al., 2003: Pullarkat V, Lee PP, Scotland R, Rubio V, Groshen S, Gee C, Lau R, Snively J, Sian S, Woulfe SL, Wolfe RA, Weber JS. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003; 9(4); 1301-1312. [PubMed: 12684398].
  1783. Purner et al., 1994: Purner MB, Berens RL, Krug EC, Curiel TJ. Epstein-Barr virus-transformed B cells, a potentially convenient source of autologous antigen-presenting cells for the propagation of certain human cytotoxic T lymphocytes. Clinical and diagnostic laboratory immunology. 1994; 1(6); 696-700. [PubMed: 8556523].
  1784. Qazilbash et al., 2017: Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, Kanodia S, Ruisaard KE, Giralt SA, Estey EH, Cortes J, Komanduri KV, Clise-Dwyer K, Alatrash G, Ma Q, Champlin RE, Molldrem JJ. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia. 2017; 31(3); 697-704. [PubMed: 27654852].
  1785. Qi et al., 2006: Qi H, Li YH, Zheng SB. [Oral gene therapy via live attenuated Salmonella leads to tumor regression and survival prolongation in mice]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University. 2006; 26(12); 1738-1741. [PubMed: 17259109].
  1786. Qi et al., 2012: Qi CJ, Ning YL, Han YS, Min HY, Ye H, Zhu YL, Qian KQ. Autologous dendritic cell vaccine for estrogen receptor (ER)/progestin receptor (PR) double-negative breast cancer. Cancer immunology, immunotherapy : CII. 2012; 61(9); 1415-1424. [PubMed: 22290073].
  1787. Qiao et al., 2005: Qiao H, Qian XP, Zhang HG, Tian C, Chen WF. [Estimation of an NY-ESO-1 expressing HCC cell line by NY-ESO-1b specific CD8+T cells in vitro induced by HLA-A2 restricted NY-ESO-1b peptide]. Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences. 2005; 37(6); 565-568. [PubMed: 16378102].
  1788. Qin and Chatterjee, 1996: Qin H, Chatterjee SK. Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF. Human gene therapy. 1996; 7(15); 1853-1860. [PubMed: 8894677].
  1789. Qin et al., 2005: Qin H, Zhou C, Wang D, Ma W, Liang X, Lin C, Zhang Y, Zhang S. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens. Immunology letters. 2005; 99(1); 85-93. [PubMed: 15894116].
  1790. Qiu et al., 2018: Qiu J, Peng S, Ma Y, Yang A, Farmer E, Cheng MA, Roden RBS, Wu TC, Chang YN, Hung CF. Epithelial boost enhances antigen expression by vaccinia virus for the generation of potent CD8+ T cell-mediated antitumor immunity following DNA priming vaccination. Virology. 2018; 525; 205-215. [PubMed: 30296681].
  1791. Quandt et al., 2018: Quandt J, Schlude C, Bartoschek M, Will R, Cid-Arregui A, Schölch S, Reissfelder C, Weitz J, Schneider M, Wiemann S, Momburg F, Beckhove P. Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses. Oncoimmunology. 2018; 7(12); e1500671. [PubMed: 30524892].
  1792. Quirt et al., 1991: Quirt IC, Shelley WE, Pater JL, Bodurtha AJ, McCulloch PB, McPherson TA, Paterson AH, Prentice R, Silver HK, Willan AR. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991; 9(5); 729-735. [PubMed: 2016615].
  1793. Raez et al., 2003: Raez LE, Cassileth PA, Schlesselman JJ, Padmanabhan S, Fisher EZ, Baldie PA, Sridhar K, Podack ER. Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma. Cancer gene therapy. 2003; 10(11); 850-858. [PubMed: 14605671].
  1794. Raez et al., 2004: Raez LE, Cassileth PA, Schlesselman JJ, Sridhar K, Padmanabhan S, Fisher EZ, Baldie PA, Podack ER. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004; 22(14); 2800-2807. [PubMed: 15254047].
  1795. Ragupathi et al., 1998: Ragupathi G, Koganty RR, Qiu D, Lloyd KO, Livingston PO. A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm. Glycoconjugate journal. 1998; 15(3); 217-221. [PubMed: 9579798].
  1796. Ragupathi et al., 2000: Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. International journal of cancer. 2000; 85(5); 659-666. [PubMed: 10699946].
  1797. Ragupathi et al., 2009: Ragupathi G, Damani P, Srivastava G, Srivastava O, Sucheck SJ, Ichikawa Y, Livingston PO. Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine. Cancer immunology, immunotherapy : CII. 2009; 58(9); 1397-1405. [PubMed: 19190907].
  1798. Rahma et al., 2010: Rahma OE, Ashtar E, Ibrahim R, Toubaji A, Gause B, Herrin VE, Linehan WM, Steinberg SM, Grollman F, Grimes G, Bernstein SA, Berzofsky JA, Khleif SN. A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. Journal of translational medicine. 2010; 8; 8. [PubMed: 20109232].
  1799. Rakhmilevich et al., 2001: Rakhmilevich AL, Imboden M, Hao Z, Macklin MD, Roberts T, Wright KM, Albertini MR, Yang NS, Sondel PM. Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factor. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001; 7(4); 952-961. [PubMed: 11309346].
  1800. Ramesh et al., 2010: Ramesh R, Ioannides CG, Roth JA, Chada S. Adenovirus-mediated interleukin (IL)-24 immunotherapy for cancer. Methods in molecular biology (Clifton, N.J.). 2010; 651; 241-270. [PubMed: 20686970].
  1801. Rapoport et al., 2011: Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Fang HB, Cai L, Janofsky S, Chew A, Storek J, Akpek G, Badros A, Yanovich S, Tan MT, Veloso E, Pasetti MF, Cross A, Philip S, Murphy H, Bhagat R, Zheng Z, Milliron T, Cotte J, Cannon A, Levine BL, Vonderheide RH, June CH. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood. 2011; 117(3); 788-797. [PubMed: 21030558].
  1802. Rapoport et al., 2014: Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Xu YY, Kalos M, Cai L, Fang HB, Weiss BM, Badros A, Yanovich S, Akpek G, Tsao P, Cross A, Mann D, Philip S, Kerr N, Brennan A, Zheng Z, Ruehle K, Milliron T, Strome SE, Salazar AM, Levine BL, June CH. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014; 20(5); 1355-1365. [PubMed: 24520093].
  1803. Rapoport et al., 2015: Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nature medicine. 2015; 21(8); 914-921. [PubMed: 26193344].
  1804. Rappaport et al., 2024: Rappaport AR, Kyi C, Lane M, Hart MG, Johnson ML, Henick BS, Liao CY, Mahipal A, Shergill A, Spira AI, Goldman JW, Scallan CD, Schenk D, Palmer CD, Davis MJ, Kounlavouth S, Kemp L, Yang A, Li YJ, Likes M, Shen A, Boucher GR, Egorova M, Veres RL, Espinosa JA, Jaroslavsky JR, Kraemer Tardif LD, Acrebuche L, Puccia C, Sousa L, Zhou R, Bae K, Hecht JR, Carbone DP, Johnson B, Allen A, Ferguson AR, Jooss K. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nature medicine. 2024; 30(4); 1013-1022. [PubMed: 38538867].
  1805. Ravindranathan et al., 2018: Ravindranathan S, Nguyen KG, Kurtz SL, Frazier HN, Smith SG, Koppolu BP, Rajaram N, Zaharoff DA. Tumor-derived granulocyte colony-stimulating factor diminishes efficacy of breast tumor cell vaccines. Breast cancer research : BCR. 2018; 20(1); 126. [PubMed: 30348199].
  1806. Reali et al., 2001: Reali E, Greiner JW, Corti A, Gould HJ, Bottazzoli F, Paganelli G, Schlom J, Siccardi AG. IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines. Cancer research. 2001; 61(14); 5517-5522. [PubMed: 11454701].
  1807. Reali et al., 2005: Reali E, Canter D, Zeytin H, Schlom J, Greiner JW. Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms. Vaccine. 2005; 23(22); 2909-2921. [PubMed: 15780740].
  1808. Redman et al., 2008: Redman BG, Chang AE, Whitfield J, Esper P, Jiang G, Braun T, Roessler B, Mulé JJ. Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. Journal of immunotherapy (Hagerstown, Md. : 1997). 2008; 31(6); 591-598. [PubMed: 18528294].
  1809. Reed et al., 2015: Reed CM, Cresce ND, Mauldin IS, Slingluff CL Jr, Olson WC. Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015; 21(17); 3879-3887. [PubMed: 25967144].
  1810. Reid et al., 2004: Reid Y, Storts D, Riss T, Minor L. Authentication of Human Cell Lines by STR DNA Profiling Analysis. . 2004; ; . [PubMed: 23805434].
  1811. Reinartz et al., 2004: Reinartz S, Köhler S, Schlebusch H, Krista K, Giffels P, Renke K, Huober J, Möbus V, Kreienberg R, DuBois A, Sabbatini P, Wagner U. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clinical cancer research : an official journal of the American Association for Cancer Research. 2004; 10(5); 1580-1587. [PubMed: 15014007].
  1812. Reker et al., 2004: Reker S, Becker JC, Svane IM, Ralfkiaer E, Straten PT, Andersen MH. HLA-B35-restricted immune responses against survivin in cancer patients. International journal of cancer. 2004; 108(6); 937-941. [PubMed: 14712500].
  1813. Relitti et al., 2020: Relitti N, Saraswati AP, Federico S, Khan T, Brindisi M, Zisterer D, Brogi S, Gemma S, Butini S, Campiani G. Telomerase-based cancer therapeutics: a review on their clinical trials. Current topics in medicinal chemistry. 2020; ; . [PubMed: 31894749].
  1814. Reusch et al., 2015: Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, Eser M, McAleese F, Molkenthin V, Gall FL, Topp M, Little M, Zhukovsky EA. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. mAbs. 2015; 7(3); 584-604. [PubMed: 25875246].
  1815. Reuschenbach et al., 2016: Reuschenbach M, Pauligk C, Karbach J, Rafiyan MR, Kloor M, Prigge ES, Sauer M, Al-Batran SE, Kaufmann AM, Schneider A, Jäger E, von Knebel Doeberitz M. A phase 1/2a study to test the safety and immunogenicity of a p16(INK4a) peptide vaccine in patients with advanced human papillomavirus-associated cancers. Cancer. 2016; 122(9); 1425-1433. [PubMed: 26949913].
  1816. Ribas et al., 2010: Ribas A, Camacho LH, Lee SM, Hersh EM, Brown CK, Richards JM, Rodriguez MJ, Prieto VG, Glaspy JA, Oseguera DK, Hernandez J, Villanueva A, Chmielowski B, Mitsky P, Bercovici N, Wasserman E, Landais D, Ross MI. Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. Journal of translational medicine. 2010; 8; 89. [PubMed: 20875102].
  1817. Rice et al., 2004: Rice J, Buchan S, Dewchand H, Simpson E, Stevenson FK. DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire. Journal of immunology (Baltimore, Md. : 1950). 2004; 173(7); 4492-4499. [PubMed: 15383580].
  1818. Rice et al., 2008: Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nature reviews. Cancer. 2008; 8(2); 108-120. [PubMed: 18219306].
  1819. Ricupito et al., 2013: Ricupito A, Grioni M, Calcinotto A, Hess Michelini R, Longhi R, Mondino A, Bellone M. Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings. Cancer research. 2013; 73(12); 3545-3554. [PubMed: 23539449].
  1820. Ridolfi et al., 2018: Ridolfi L, de Rosa F, Fiammenghi L, Petrini M, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Bulgarelli J, Riccobon A, Gentili G, Nanni O, Framarini M, Tauceri F, Guidoboni M. Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial). BMJ open. 2018; 8(8); e021701. [PubMed: 30082356].
  1821. Rijavec et al., 2015: Rijavec E, Biello F, Genova C, Barletta G, Maggioni C, Dal Bello MG, Coco S, Truini A, Vanni I, Alama A, Beltramini S, Grassi MA, Boccardo F, Grossi F. Belagenpumatucel-L for the treatment of non-small cell lung cancer. Expert opinion on biological therapy. 2015; 15(9); 1371-1379. [PubMed: 26211534].
  1822. Rijnkels and Rosen, 2001: Rijnkels M, Rosen JM. Adenovirus-Cre-mediated recombination in mammary epithelial early progenitor cells. Journal of cell science. 2001; 114(Pt 17); 3147-3153. [PubMed: 11590241].
  1823. Rinaldi et al., 2008: Rinaldi M, Fioretti D, Iurescia S, Signori E, Pierimarchi P, Seripa D, Tonon G, Fazio VM. Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma model. Biochemical and biophysical research communications. 2008; 370(2); 279-284. [PubMed: 18364239].
  1824. Rini et al., 2016: Rini BI, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, Oudard S, Weikert S, Bracarda S, Crabb SJ, Bedke J, Ludwig J, Maurer D, Mendrzyk R, Wagner C, Mahr A, Fritsche J, Weinschenk T, Walter S, Kirner A, Singh-Jasuja H, Reinhardt C, Eisen T. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet. Oncology. 2016; 17(11); 1599-1611. [PubMed: 27720136].
  1825. Rivoltini et al., 1999: Rivoltini L, Squarcina P, Loftus DJ, Castelli C, Tarsini P, Mazzocchi A, Rini F, Viggiano V, Belli F, Parmiani G. A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy. Cancer research. 1999; 59(2); 301-306. [PubMed: 9927036].
  1826. Robbins et al., 2015: Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Li YF, El-Gamil M, Rosenberg SA. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015; 21(5); 1019-1027. [PubMed: 25538264].
  1827. Robert et al., 2013: Robert C, Schadendorf D, Messina M, Hodi FS, O'Day S. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013; 19(8); 2232-2239. [PubMed: 23444228].
  1828. Robins et al., 1991: Robins RA, Denton GW, Hardcastle JD, Austin EB, Baldwin RW, Durrant LG. Antitumor immune response and interleukin 2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody. Cancer research. 1991; 51(19); 5425-5429. [PubMed: 1913661].
  1829. Rochlitz et al., 2003: Rochlitz C, Figlin R, Squiban P, Salzberg M, Pless M, Herrmann R, Tartour E, Zhao Y, Bizouarne N, Baudin M, Acres B. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. The journal of gene medicine. 2003; 5(8); 690-699. [PubMed: 12898638].
  1830. Rodeberg et al., 2005: Rodeberg DA, Nuss RA, Heppelmann CJ, Celis E. Lack of effective T-lymphocyte response to the PAX3/FKHR translocation area in alveolar rhabdomyosarcoma. Cancer immunology, immunotherapy : CII. 2005; 54(6); 526-534. [PubMed: 15838707].
  1831. Rodriguez and Jungery, 1987: Rodriguez MH, Jungery M. Glycoprotein recognition mediates attachment of Plasmodium chabaudi to mouse erythrocytes. Infection and immunity. 1987; 55(1); 187-192. [PubMed: 3539801].
  1832. Roldão et al., 2010: Roldão A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM. Virus-like particles in vaccine development. Expert review of vaccines. 2010; 9(10); 1149-1176. [PubMed: 20923267].
  1833. Roohvand and Kossari, 2012: Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities. Expert opinion on therapeutic patents. 2012; 22(4); 391-415. [PubMed: 22455502].
  1834. Roos et al., 2005: Roos AK, Pavlenko M, Charo J, Egevad L, Pisa P. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. The Prostate. 2005; 62(3); 217-223. [PubMed: 15389792].
  1835. Rosenberg et al., 1998: Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature medicine. 1998; 4(3); 321-327. [PubMed: 9500606].
  1836. Rosenberg et al., 2003: Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Topalian SL, Sherry RM, Restifo NP, Wunderlich JR, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, Gritz L, Panicali DL, White DE. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003; 9(8); 2973-2980. [PubMed: 12912944].
  1837. Rosenblatt et al., 2011: Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, Wu Z, Joyce R, Levine JD, Dombagoda D, Yuan YE, Francoeur K, Fitzgerald D, Richardson P, Weller E, Anderson K, Kufe D, Munshi N, Avigan D. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood. 2011; 117(2); 393-402. [PubMed: 21030562].
  1838. Rosenblatt et al., 2013: Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T, Dey BR, Somaiya P, Mills H, Campigotto F, Weller E, Joyce R, Levine JD, Tzachanis D, Richardson P, Laubach J, Raje N, Boussiotis V, Yuan YE, Bisharat L, Held V, Rowe J, Anderson K, Kufe D, Avigan D. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013; 19(13); 3640-3648. [PubMed: 23685836].
  1839. Roth et al., 1996: Roth J, Dittmer D, Rea D, Tartaglia J, Paoletti E, Levine AJ. p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93(10); 4781-4786. [PubMed: 8643480].
  1840. Rousseau et al., 2006: Rousseau RF, Biagi E, Dutour A, Yvon ES, Brown MP, Lin T, Mei Z, Grilley B, Popek E, Heslop HE, Gee AP, Krance RA, Popat U, Carrum G, Margolin JF, Brenner MK. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood. 2006; 107(4); 1332-1341. [PubMed: 16249392].
  1841. Rouxel et al., 2016: Rouxel RN, Mérour E, Biacchesi S, Brémont M. Complete Protection against Influenza Virus H1N1 Strain A/PR/8/34 Challenge in Mice Immunized with Non-Adjuvanted Novirhabdovirus Vaccines. PloS one. 2016; 11(10); e0164245. [PubMed: 27711176].
  1842. Ruan et al., 2009: Ruan Z, Yang Z, Wang Y, Wang H, Chen Y, Shang X, Yang C, Guo S, Han J, Liang H, Wu Y. DNA vaccine against tumor endothelial marker 8 inhibits tumor angiogenesis and growth. Journal of immunotherapy (Hagerstown, Md. : 1997). 2009; 32(5); 486-491. [PubMed: 19609240].
  1843. Rubinstein et al., 2000: Rubinstein A, Mizrachi Y, Bernstein L, Shliozberg J, Golodner M, Liu GQ, Ochs HD. Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage phi X174 in asymptomatic HIV-1 infected patients. AIDS (London, England). 2000; 14(4); F55-62. [PubMed: 10770533].
  1844. Russo et al., 2007: Russo V, Cipponi A, Raccosta L, Rainelli C, Fontana R, Maggioni D, Lunghi F, Mukenge S, Ciceri F, Bregni M, Bordignon C, Traversari C. Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity. The Journal of clinical investigation. 2007; 117(10); 3087-3096. [PubMed: 17885685].
  1845. Russo et al., 2013: Russo V, Pilla L, Lunghi F, Crocchiolo R, Greco R, Ciceri F, Maggioni D, Fontana R, Mukenge S, Rivoltini L, Rigamonti G, Mercuri SR, Nicoletti R, Maschio AD, Gianolli L, Fazio F, Marchianò A, Florio AD, Maio M, Salomoni M, Gallo-Stampino C, Fiacco MD, Lambiase A, Coulie PG, Patuzzo R, Parmiani G, Traversari C, Bordignon C, Santinami M, Bregni M. Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes. International journal of cancer. Journal international du cancer. 2013; 132(11); 2557-2566. [PubMed: 23151995].
  1846. Sabbatini et al., 2006: Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, Hensley M, Livingston P, Iasonos A, Spriggs D, McGuire W, Reinartz S, Schneider S, Grande C, Lele S, Rodabaugh K, Kepner J, Ferrone S, Odunsi K. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006; 12(18); 5503-5510. [PubMed: 17000686].
  1847. Sabbatini et al., 2007: Sabbatini PJ, Ragupathi G, Hood C, Aghajanian CA, Juretzka M, Iasonos A, Hensley ML, Spassova MK, Ouerfelli O, Spriggs DR, Tew WP, Konner J, Clausen H, Abu Rustum N, Dansihefsky SJ, Livingston PO. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007; 13(14); 4170-4177. [PubMed: 17634545].
  1848. Saeki et al., 2004: Saeki A, Nakao K, Nagayama Y, Yanagi K, Matsumoto K, Hayashi T, Ishikawa H, Hamasaki K, Ishii N, Eguchi K. Diverse efficacy of vaccination therapy using the alpha-fetoprotein gene against mouse hepatocellular carcinoma. International journal of molecular medicine. 2004; 13(1); 111-116. [PubMed: 14654980].
  1849. Saenger et al., 2008: Saenger YM, Li Y, Chiou KC, Chan B, Rizzuto G, Terzulli SL, Merghoub T, Houghton AN, Wolchok JD. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. Cancer research. 2008; 68(23); 9884-9891. [PubMed: 19047169].
  1850. Saeterdal et al., 2001: Saeterdal I, Bjørheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, Nesland JM, Eriksen JA, Møller M, Lindblom A, Gaudernack G. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(23); 13255-13260. [PubMed: 11687624].
  1851. Saha et al., 2004: Saha A, Chatterjee SK, Foon KA, Primus FJ, Sreedharan S, Mohanty K, Bhattacharya-Chatterjee M. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice. Cancer research. 2004; 64(14); 4995-5003. [PubMed: 15256474].
  1852. Saha et al., 2006: Saha A, Baral RN, Chatterjee SK, Mohanty K, Pal S, Foon KA, Primus FJ, Krieg AM, Weiner GJ, Bhattacharya-Chatterjee M. CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice. Cancer immunology, immunotherapy : CII. 2006; 55(5); 515-527. [PubMed: 16044253].
  1853. Saito et al., 2017: Saito H, Kitagawa K, Yoneda T, Fukui Y, Fujsawa M, Bautista D, Shirakawa T. Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro. Cancer gene therapy. 2017; 24(7); 289-296. [PubMed: 28621316].
  1854. Salerno et al., 2013: Salerno EP, Shea SM, Olson WC, Petroni GR, Smolkin ME, McSkimming C, Chianese-Bullock KA, Slingluff CL Jr. Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide. Cancer immunology, immunotherapy : CII. 2013; 62(7); 1149-1159. [PubMed: 23657629].
  1855. Sampson et al., 2020: Sampson JH, Gunn MD, Fecci PE, Ashley DM. Brain immunology and immunotherapy in brain tumours. Nature reviews. Cancer. 2020; 20(1); 12-25. [PubMed: 31806885].
  1856. Sang et al., 2011: Sang M, Wang L, Ding C, Zhou X, Wang B, Wang L, Lian Y, Shan B. Melanoma-associated antigen genes - an update. Cancer letters. 2011; 302(2); 85-90. [PubMed: 21093980].
  1857. Sarivalasis et al., 2019: Sarivalasis A, Boudousquié C, Balint K, Stevenson BJ, Gannon PO, Iancu EM, Rossier L, Martin Lluesma S, Mathevet P, Sempoux C, Coukos G, Dafni U, Harari A, Bassani-Sternberg M, Kandalaft LE. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma. Journal of translational medicine. 2019; 17(1); 391. [PubMed: 31771601].
  1858. Sato et al., 1997: Sato T, Bullock TN, Eisenlohr LC, Mastrangelo MJ, Berd D. Dinitrophenyl-modified autologous melanoma vaccine induces a T cell response to hapten-modified, melanoma peptides. Clinical immunology and immunopathology. 1997; 85(3); 265-272. [PubMed: 9400626].
  1859. Sato-Dahlman et al., 2020: Sato-Dahlman M, LaRocca CJ, Yanagiba C, Yamamoto M. Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination. Cancers. 2020; 12(5); . [PubMed: 32455560].
  1860. SAUER and TUCKER, 1954: SAUER LW, TUCKER WH. Immune responses to diphtheria, tetanus, and pertussis, aluminum phosphate adsorbed. American journal of public health and the nation's health. 1954; 44(6); 784-788. [PubMed: 13158668].
  1861. Savvateeva et al., 2015: Savvateeva LV, Schwartz AM, Gorshkova LB, Gorokhovets NV, Makarov VA, Reddy VP, Aliev G, Zamyatnin AA Jr. Prophylactic Admission of an In Vitro Reconstructed Complexes of Human Recombinant Heat Shock Proteins and Melanoma Antigenic Peptides Activates Anti-Melanoma Responses in Mice. Current molecular medicine. 2015; 15(5); 462-468. [PubMed: 26122656].
  1862. Sawada et al., 2012: Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M, Nakagohri T, Takahashi S, Gotohda N, Takayama T, Yamao K, Uesaka K, Furuse J, Kinoshita T, Nakatsura T. Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012; 18(13); 3686-3696. [PubMed: 22577059].
  1863. Sawada et al., 2013: Sawada Y, Yoshikawa T, Fujii S, Mitsunaga S, Nobuoka D, Mizuno S, Takahashi M, Yamauchi C, Endo I, Nakatsura T. Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: an autopsy case. Human vaccines & immunotherapeutics. 2013; 9(6); 1228-1233. [PubMed: 23466818].
  1864. Saxena and Bhardwaj, 2018: Saxena M, Bhardwaj N. Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment. Trends in cancer. 2018; 4(2); 119-137. [PubMed: 29458962].
  1865. Schaller and Sampson, 2017: Schaller TH, Sampson JH. Advances and challenges: dendritic cell vaccination strategies for glioblastoma. Expert review of vaccines. 2017; 16(1); 27-36. [PubMed: 27500911].
  1866. Schütz et al., 2001: Schütz A, Oertli D, Marti WR, Noppen C, Padovan E, Spagnoli GC, Heberer M, Zajac P. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen. Cancer gene therapy. 2001; 8(9); 655-661. [PubMed: 11593334].
  1867. Schleiss, 2009: Schleiss MR. VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection. Current opinion in molecular therapeutics. 2009; 11(5); 572-578. [PubMed: 19806506].
  1868. Schmitz-Winnenthal et al., 2018: Schmitz-Winnenthal FH, Hohmann N, Schmidt T, Podola L, Friedrich T, Lubenau H, Springer M, Wieckowski S, Breiner KM, Mikus G, Büchler MW, Keller AV, Koc R, Springfeld C, Knebel P, Bucur M, Grenacher L, Haefeli WE, Beckhove P. A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer. Oncoimmunology. 2018; 7(4); e1303584. [PubMed: 29632710].
  1869. Schneble et al., 2014: Schneble EJ, Berry JS, Trappey FA, Clifton GT, Ponniah S, Mittendorf E, Peoples GE. The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy. 2014; 6(5); 519-531. [PubMed: 24896623].
  1870. Schoof et al., 1998: Schoof DD, Smith JW 2nd, Disis ML, Brant-Zawadski P, Wood W, Doran T, Johnson E, Urba WJ. Immunization of metastatic breast cancer patients with CD80-modified breast cancer cells and GM-CSF. Advances in experimental medicine and biology. 1998; 451; 511-518. [PubMed: 10026920].
  1871. Schuler et al., 2014: Schuler PJ, Harasymczuk M, Visus C, Deleo A, Trivedi S, Lei Y, Argiris A, Gooding W, Butterfield LH, Whiteside TL, Ferris RL. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014; 20(9); 2433-2444. [PubMed: 24583792].
  1872. Schwartzentruber et al., 2011: Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. The New England journal of medicine. 2011; 364(22); 2119-2127. [PubMed: 21631324].
  1873. Sears et al., 2011: Sears AK, Perez SA, Clifton GT, Benavides LC, Gates JD, Clive KS, Holmes JP, Shumway NM, Van Echo DC, Carmichael MG, Ponniah S, Baxevanis CN, Mittendorf EA, Papamichail M, Peoples GE. AE37: a novel T-cell-eliciting vaccine for breast cancer. Expert opinion on biological therapy. 2011; 11(11); 1543-1550. [PubMed: 21895539].
  1874. Seavey et al., 2009: Seavey MM, Maciag PC, Al-Rawi N, Sewell D, Paterson Y. An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model. Journal of immunology (Baltimore, Md. : 1950). 2009; 182(9); 5537-5546. [PubMed: 19380802].
  1875. Seino et al., 1997: Seino K, Kayagaki N, Okumura K, Yagita H. Antitumor effect of locally produced CD95 ligand. Nature medicine. 1997; 3(2); 165-170. [PubMed: 9018234].
  1876. Senzer et al., 2012: Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, Lifshitz S, Magee M, Oh J, Mill SW, Bedell C, Higgs C, Kumar P, Yu Y, Norvell F, Phalon C, Taquet N, Rao DD, Wang Z, Jay CM, Pappen BO, Wallraven G, Brunicardi FC, Shanahan DM, Maples PB, Nemunaitis J. Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. Molecular therapy : the journal of the American Society of Gene Therapy. 2012; 20(3); 679-686. [PubMed: 22186789].
  1877. Seo et al., 2011: Seo SH, Kim KS, Park SH, Suh YS, Kim SJ, Jeun SS, Sung YC. The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene therapy. 2011; 18(5); 488-495. [PubMed: 21228885].
  1878. Shang et al., 2004: Shang XY, Chen HS, Zhang HG, Pang XW, Qiao H, Peng JR, Qin LL, Fei R, Mei MH, Leng XS, Gnjatic S, Ritter G, Simpson AJ, Old LJ, Chen WF. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004; 10(20); 6946-6955. [PubMed: 15501973].
  1879. Shapiro et al., 1993: Shapiro DN, Sublett JE, Li B, Downing JR, Naeve CW. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer research. 1993; 53(21); 5108-5112. [PubMed: 8221646].
  1880. Sharma et al., 2012: Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Koski G, Czerniecki BJ. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer. 2012; 118(17); 4354-4362. [PubMed: 22252842].
  1881. Shore et al., 2017: Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb RL 3rd, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G, Sawutz DG, Yla-Herttuala S, Parker NR, Dinney CPN. Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017; 35(30); 3410-3416. [PubMed: 28834453].
  1882. Shore et al., 2020: Shore ND, Morrow MP, McMullan T, Kraynyak KA, Sylvester A, Bhatt K, Cheung J, Boyer JD, Liu L, Sacchetta B, Rosencranz S, Heath EI, Nordquist L, Cheng HH, Tagawa ST, Appleman LJ, Tutrone R, Garcia JA, Whang YE, Kelly WK, Weiner DB, Bagarazzi ML, Skolnik JM. CD8(+) T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens. Molecular therapy : the journal of the American Society of Gene Therapy. 2020; 28(5); 1238-1250. [PubMed: 32208168].
  1883. show: [https://clinicaltrials.gov/show/]
  1884. Siegel et al., 2001: Siegel F, Lu M, Roggendorf M. Coadministration of gamma interferon with DNA vaccine expressing woodchuck hepatitis virus (WHV) core antigen enhances the specific immune response and protects against WHV infection. Journal of virology. 2001; 75(11); 5036-5042. [PubMed: 11333883].
  1885. Simons and Sacks, 2006: Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urologic oncology. 2006; 24(5); 419-424. [PubMed: 16962494].
  1886. Sirisinha and Eisen, 1971: Sirisinha S, Eisen HN. Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proceedings of the National Academy of Sciences of the United States of America. 1971; 68(12); 3130-3135. [PubMed: 4108872].
  1887. Siurala et al., 2015: Siurala M, Bramante S, Vassilev L, Hirvinen M, Parviainen S, Tähtinen S, Guse K, Cerullo V, Kanerva A, Kipar A, Vähä-Koskela M, Hemminki A. Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma. International journal of cancer. 2015; 136(4); 945-954. [PubMed: 24975392].
  1888. Slingluff et al., 2003: Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EM, Wiernasz CJ, Merrill P, Gibson J, Ross M, Engelhard VH. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003; 21(21); 4016-4026. [PubMed: 14581425].
  1889. Slingluff et al., 2008: Slingluff CL Jr, Petroni GR, Olson W, Czarkowski A, Grosh WW, Smolkin M, Chianese-Bullock KA, Neese PY, Deacon DH, Nail C, Merrill P, Fink R, Patterson JW, Rehm PK. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008; 26(30); 4973-4980. [PubMed: 18809608].
  1890. Slingluff et al., 2011: Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Ross MI, Haas NB, von Mehren M, Grosh WW. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011; 29(21); 2924-2932. [PubMed: 21690475].
  1891. Slingluff et al., 2013: Slingluff CL Jr, Lee S, Zhao F, Chianese-Bullock KA, Olson WC, Butterfield LH, Whiteside TL, Leming PD, Kirkwood JM. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clinical cancer research : an official journal of the American Association for Cancer Research. 2013; 19(15); 4228-4238. [PubMed: 23653149].
  1892. Slovin et al., 2005: Slovin SF, Ragupathi G, Fernandez C, Jefferson MP, Diani M, Wilton AS, Powell S, Spassova M, Reis C, Clausen H, Danishefsky S, Livingston P, Scher HI. A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21. Vaccine. 2005; 23(24); 3114-3122. [PubMed: 15837210].
  1893. Small et al., 2014: Small EJ, Higano CS, Kantoff PW, Whitmore JB, Frohlich MW, Petrylak DP. Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T. Prostate cancer and prostatic diseases. 2014; 17(3); 259-264. [PubMed: 24957547].
  1894. Smith et al., 2005: Smith CL, Dunbar PR, Mirza F, Palmowski MJ, Shepherd D, Gilbert SC, Coulie P, Schneider J, Hoffman E, Hawkins R, Harris AL, Cerundolo V. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. International journal of cancer. Journal international du cancer. 2005; 113(2); 259-266. [PubMed: 15386406].
  1895. Smith et al., 2009: Smith FO, Klapper JA, Wunderlich JR, Rosenberg SA, Dudley ME. Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma. Journal of immunotherapy (Hagerstown, Md. : 1997). 2009; 32(8); 870-874. [PubMed: 19752747].
  1896. Snape et al., 2010: Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, Findlow J, Yu LM, Borrow R, Ypma E, Toneatto D, Pollard AJ. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. The Pediatric infectious disease journal. 2010; 29(11); 71-79. [PubMed: 20844462].
  1897. Snook et al., 2008: Snook AE, Stafford BJ, Li P, Tan G, Huang L, Birbe R, Schulz S, Schnell MJ, Thakur M, Rothstein JL, Eisenlohr LC, Waldman SA. Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. Journal of the National Cancer Institute. 2008; 100(13); 950-961. [PubMed: 18577748].
  1898. Soares et al., 2001: Soares MM, Mehta V, Finn OJ. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. Journal of immunology (Baltimore, Md. : 1950). 2001; 166(11); 6555-6563. [PubMed: 11359807].
  1899. Soliman et al., 2018: Soliman H, Khambati F, Han HS, Ismail-Khan R, Bui MM, Sullivan DM, Antonia S. A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer. Oncotarget. 2018; 9(11); 10110-10117. [PubMed: 29515795].
  1900. Sondak and Sosman, 2003: Sondak VK, Sosman JA. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. Seminars in cancer biology. 2003; 13(6); 409-415. [PubMed: 15001159].
  1901. Song et al., 2011: Song GY, Srivastava T, Ishizaki H, Lacey SF, Diamond DJ, Ellenhorn JD. Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion. Cancer investigation. 2011; 29(8); 501-510. [PubMed: 21843052].
  1902. Sonpavde et al., 2017: Sonpavde G, McMannis JD, Bai Y, Seethammagari MR, Bull JMC, Hawkins V, Dancsak TK, Lapteva N, Levitt JM, Moseley A, Spencer DM, Slawin KM. Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer. Cancer immunology, immunotherapy : CII. 2017; 66(10); 1345-1357. [PubMed: 28608115].
  1903. Sosman et al., 2008: Sosman JA, Carrillo C, Urba WJ, Flaherty L, Atkins MB, Clark JI, Dutcher J, Margolin KA, Mier J, Gollob J, Kirkwood JM, Panka DJ, Crosby NA, O'Boyle K, LaFleur B, Ernstoff MS. Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008; 26(14); 2292-2298. [PubMed: 18467720].
  1904. Speiser et al., 2010: Speiser DE, Schwarz K, Baumgaertner P, Manolova V, Devevre E, Sterry W, Walden P, Zippelius A, Conzett KB, Senti G, Voelter V, Cerottini JP, Guggisberg D, Willers J, Geldhof C, Romero P, Kündig T, Knuth A, Dummer R, Trefzer U, Bachmann MF. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. Journal of immunotherapy (Hagerstown, Md. : 1997). 2010; 33(8); 848-858. [PubMed: 20842051].
  1905. Stadtmauer et al., 2011: Stadtmauer EA, Vogl DT, Luning Prak E, Boyer J, Aqui NA, Rapoport AP, McDonald KR, Hou X, Murphy H, Bhagat R, Mangan PA, Chew A, Veloso EA, Levine BL, Vonderheide RH, Jawad AF, June CH, Sullivan KE. Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. Blood. 2011; 117(1); 63-71. [PubMed: 20864577].
  1906. Stahl et al., 1992: Stahl M, Wilke HJ, Seeber S, Schmoll HJ. Cytokines and cytotoxic agents in renal cell carcinoma: a review. Seminars in oncology. 1992; 19(2 Suppl 4); 70-79. [PubMed: 1553577].
  1907. Stebbing et al., 2012: Stebbing J, Dalgleish A, Gifford-Moore A, Martin A, Gleeson C, Wilson G, Brunet LR, Grange J, Mudan S. An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2012; 23(5); 1314-1319. [PubMed: 21930686].
  1908. Stegmann et al., 2023: Stegmann T, Wiekmeijer AS, Kwappenberg K, van Duikeren S, Bhoelan F, Bemelman D, Beenakker TJM, Krebber WJ, Arens R, Melief CJM. Enhanced HPV16 E6/E7(+) tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides. Cancer immunology, immunotherapy : CII. 2023; 72(8); 2851-2864. [PubMed: 37222770].
  1909. Steitz and Tüting, 2013: Steitz J, Tüting T. Biolistic DNA vaccination against melanoma. Methods in molecular biology (Clifton, N.J.). 2013; 940; 317-337. [PubMed: 23104352].
  1910. Stern and Wiley, 1994: Stern LJ, Wiley DC. Antigenic peptide binding by class I and class II histocompatibility proteins. Behring Institute Mitteilungen. 1994; (94); 1-10. [PubMed: 7998902].
  1911. Steuerwald et al., 2016: Steuerwald MT, Gabbard SR, Beauchamp GA, Riddle MK, Otten EJ. Administration of CroFab Antivenom by a Helicopter Emergency Medical Service Team. Air medical journal. 2016; 35(6); 371-373. [PubMed: 27894563].
  1912. Stevenson et al., 2004: Stevenson FK, Ottensmeier CH, Johnson P, Zhu D, Buchan SL, McCann KJ, Roddick JS, King AT, McNicholl F, Savelyeva N, Rice J. DNA vaccines to attack cancer. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101 Suppl 2; 14646-14652. [PubMed: 15292504].
  1913. Storm et al., 1979: Storm FK, Sparks FC, Morton DL. Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guérin and hyperthermic perfusion. Surgery, gynecology & obstetrics. 1979; 149(1); 17-21. [PubMed: 451822].
  1914. Sugiyama, 2005: Sugiyama H. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. Expert review of vaccines. 2005; 4(4); 503-512. [PubMed: 16117707].
  1915. Sugiyama, 2017: Sugiyama H. WT1 peptide cancer vaccine. Nihon rinsho. Japanese journal of clinical medicine. 2017; 75(2); 263-269. [PubMed: 30562862].
  1916. Sun et al., 2002: Sun X, Hodge LM, Jones HP, Tabor L, Simecka JW. Co-expression of granulocyte-macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination. Vaccine. 2002; 20(9-10); 1466-1474. [PubMed: 11818167].
  1917. <